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Abstract: 
 
This thesis focuses on the synthesis and analysis of novel chloride based platinum complexes derived 
from iminophosphine and phosphinoamide ligands, along with studies on their reactivity towards 
substitution and oxidation reactions. Also explored here are the potential applications of these 
complexes for biological and luminescent purposes.  
 
Chapter one provides an extensive overview of platinum coordination chemistry with examples of 
various mixed donor ligands along with the history of platinum anticancer therapy. It also looks at 
metals in medicine, both for biological functions as well as for therapeutic purposes and gives a 
background to some other applications for platinum complexes. 
 
Chapter two outlines the design and synthetic strategies employed for the development of novel 
platinum (II) chloride complexes from iminophosphine and phosphinoamide ligands. Also reported is 
the cyclometallation of these complexes to form stable tridentate mixed donor platinum (II) 
compounds. Crystal structures and a detailed analysis of the NMR spectroscopy for these complexes, 
as well as their ligands, are also included in this chapter.  
 
In Chapter three the development of a direct method for displacing a chloride from a platinum metal 
centre with a desired phosphine is reported. Numerous methods for successful oxidation of the 
platinum (II) complexes will also be explored, leading to novel platinum (IV) complexes being 
reported here also. The importance of stabilisation of the displaced anion, chloride, by the solvent 
system will also be discussed in this chapter.  
 
Chapter four investigates the reactivity of the platinum (II) complexes towards two different 
biomolecules to form novel platinum bio-adducts. The potential application of the platinum (II) 
cyclometallates as chemotherapeutics will also be explored here using in-vitro cancer cell testing. 
Finally, luminescence studies are also reported here for the ligands and platinum complexes reported 
in chapter two and three to investigate potential applications in this field also.  
 
Chapter five provides a final conclusion and an overall summary of the entire project as well as 
identifying key areas for future work.  
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1.1 Chapter 1 Background: 
 
 Since the discovery of the anti-cancer activity of Cisplatin cis-[PtCl2(NH3)2] by 
Rosenberg et al in the 1960’s the entire area of metallo-drugs has expanded rapidly.1 This is 
especially true for complexes associated with the group 10 transition metals, particularly 
platinum. This chapter aims to explore the current progress of platinum based drugs and any 
future potential which they may hold and their relevance to this research project. The role of 
metals in biological organisms is also detailed here along with the success of other metals in 
medicine. 
Emphasis is placed on the discovery of Cisplatin (and its analogues), which became 
the first and most successful platinum based anti-cancer drug and will be discussed in detail 
later in this chapter. Cisplatin works by binding to the DNA of fast developing cancer cells 
and suppresses the division of those cells.
2
 This biological interaction has stimulated the 
development of a vast range of other biologically active metal complexes. Both the 
mechanism of these biological interactions as well as the structure of all biologically active 
metal complexes will be discussed in detail in this chapter. 
This chapter also aims to introduce the concepts and principles of coordination 
chemistry that are utilised in the design, synthesis and applications of platinum complexes. 
The Hard Soft Acid Base (HSAB) theory and hemilability of various ligands will also be 
discussed along with the development of Cisplatin analogues.  
 
1.2 The Biological Role of Metal Ions: 
 
Living organisms do not employ the elements in accordance with their abundance in 
the Earth’s crust. Elements such as aluminium and silicon, which are in high abundance, are 
rarely found in mammals. But elements such as copper, zinc and selenium, some of which are 
only present in trace amounts in the Earth’s crust, play a crucial role in living organisms; 
such as cobalt in coenzyme B12.
3
 
The vitamin coenzyme B12, which involves a cobalt-carbon bond, is the only known 
organometallic compound found in nature. Its structure incorporates a cobalt ion as Co(III) 
into a corrin ring structure, 101, Figure 1.1. When the compound is isolated from natural 
sources the adenosine group is usually replaced by a cyanide group. It is in this form that the 
compound is used medicinally and is known as Vitamin B12. Coenzyme B12 is known to 
prevent anaemia and it has also been found to have some catalytic properties.
4
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In this structure, Figure 1.1, the cobalt can be counted at Co (III), as stated by 
Miessler et al, where the four corrin nitrogens contribute two electrons each and a charge of -
2 by delocalisation. The benzimidazole nitrogen contributes two electrons and the adenosine 
structure also contributes two electrons and a charge of -1. Therefore the octahedral complex 
contains six coordination bonds to cobalt which contribute 12 electrons in total, when added 
to the 6 valence electrons of Co (III) this gives a stable 18 electron complex.
4
  
 
5’-deoxyadenosine (red) 
 
 
 
 
101 
 
 
        Benzimidazole (green) 
 
Figure 1.1: The octahedral coenzyme B12 101 complex where the red section is 5’-
Deoxyadenosine and the green section is Benzimidazole. 
 
Many catalytic proteins, known as metallo-enzymes, already have naturally occurring 
metals such as Zn (II) or Cu (I)/(II) in their active sites. Around thirty percent of enzymes 
have a metal atom at the active site and facilitate a variety of reactions such as acid-catalysed 
hydrolysis, redox reactions and the rearrangement of carbon-carbon bonds.
5
 
Metal based proteins are also used in the binding and transport of oxygen, which is 
essential because of its role in respiration and its production in photosynthesis. They are 
commonly referred to as “oxygen carriers” and each of them make use of a metal atom or 
pair of metal atoms at an active site.
3
 
Two such proteins used by vertebrates are haemoglobin, 102, Figure 1.2, which is an 
oxygen carrier, and myoglobin, with is used for oxygen storage. A second type of oxygen 
carrier, hemocyanin, 103, Figure 1.2, is found in snails and crabs while a third type, 
hemerythrin, 104, Figure 1.2, is found in some sea worms. The O2 binding site in 
haemoglobin consists of a single Fe (II) ion while hemocyanin uses a pair of Cu (I) ions and 
hemerythrin consists of a pair of Fe
 
(II)
 
ions.
3
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Figure 1.2: Oxygen Carriers: A fragment of haemoglobin 102, hemocyanin 103 and 
hemerythrin 104 with an oxygen molecule bound to the active site.
3
 
 
As well as catalytic, transport and storage functions metal ions can play significant 
structural roles in biological systems, such as Ca
 
(II) ions which are involved in protein 
folding. In general metal ion containing molecules serve important functions within 
biological systems. The manner in which they act is also highly varied where some metal ions 
can exert an inductive effect by coordination to the site of reaction. These can serve as redox 
sites that function by either electron or atom transfer. Selectivity can also be achieved by 
using ions of the appropriate size, stereochemical preference, hard-soft character, or reduction 
potential to perform a given task.
3
 
 
1.3 Non Platinum-based Metallo-drugs: 
 
1.3.1 Background: 
 
The human body has tens of thousands of different proteins, all of which have 
significant roles with specific functions such as catalysis, transport and providing structure. 
Metal ions in the form of a metallo-drug can attach themselves to a part of a protein that is 
critical for its function. The addition of a metallo-drug to a protein of this kind can result in 
displacement of the natural metal ion with that of the metallo-drug using the same ligands on 
the protein as donor atoms. This can then inhibit the protein from fulfilling its biological 
function which sometimes can be enough to kill the cell.
5
  
As well as proteins, another important biomolecule that can be targeted by metallo-
drugs is deoxyribonucleic acid or DNA. This polymeric molecule is critical for cell division 
and therefore any disruption in its function can have a disastrous effect on the cell. DNA 
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contains all the genetic information for all the cells that make up the body and found wrapped 
around proteins called histones which together form a particle known as a nucleosome.
3,5
 
There are over ten million nucleosome particles in the human genome serving to 
organise the entire DNA into a relatively small nuclear space. The resulting protein-DNA 
complex is called chromatin. This complex is much less vulnerable to attack by metallo-
drugs, in comparison to purified DNA, due to the blocking effects of the histones. But when a 
DNA sequence is being read to transcribe a gene, segments of the DNA are exposed and 
therefore susceptible to attack by drugs, Figure 1.3.
5,6
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: DNA replication where segments of the strand are exposed to attack by various 
drugs.
6
  
 
DNA is made up of four different monomers called nucleotides which themselves 
consist of a heterocyclic base, a deoxyribose sugar and a phosphate group. There are donor 
groups on the DNA bases that can serve as nucleophiles towards metallo-drugs. They are also 
generally located on the exposed edges of the base pairs, making metal DNA binding easier. 
The most important metal binding sites that have been identified are N-7 positions of adenine 
and guanine, both of which are located in the major groove (elongated stretch) of double 
helical DNA.
5
 
The lone pairs on the nitrogen atoms of these bases are only weakly basic towards a 
proton, so competition between a proton and a metal ion for these sites at neutral pH is not a 
factor. For these reasons metallo-drugs are often bound quite easily to these donor atoms and 
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since these atoms are considered intermediate bases on the Hard Soft Acid Base (HSAB) 
scale, Table 1.1 and Table 1.2, they form the most favourable complexes with intermediate 
acids.
7
  
 
Hard Bases Borderline Bases Soft Bases 
  H
-
 
F
-
, Cl
-
 Br
-
 I
- 
H2O, OH
-
, O
2-
  H2S, HS
-
, S
2- 
ROH, RO
-
, R2O, CH3COO
-
  RSH, RS
-
, R2S 
NO3
-
, ClO4
-
 NO2
-, 
N3
- 
SCN
-
, CN
-
, RNC, CO 
CO3
2-
, SO4
2-
, PO4
3- 
SO3
2- 
S2O3
2-
 
NH3, RNH2, N2H4 C6H5NH2, C5H5N, N2 R3P, (RO)3, R3AsC2H4, C6H6 
Table 1.1: Examples of “Hard and Soft Bases”, adapted from R.G. Pearson.7 
Hard Acids Borderline Acids Soft Acids 
H
+
, Li
+
, Na
+
, K
+
   
Be
2+
, Mg
2+
, Ca
2+
, Sr
2
  
 
BF3, CCl3, B(OR)3 B(CH3)3 BH3, Tl
+
, Tl(CH3)3 
Al
3+
, Al(CH3)3, AlCl3, AlH3   
Cr
3+
, Mn
2+
, Fe
3+
, Co
3+ 
Fe
2+
, Co
2+
, Ni
2+
, Cu
2+
, Zn
2+
, 
Rh
3+
, Ir
3+
, Ru
3+
, Os
2+
 
Cu
+
,Ag
+
,Au
+
,Cd
2+
,Hg2
2+
, 
Hg
2+
,CH3Hg
+
, Pd
2+
, Pt
2+
, Pt
4+ 
Ions with oxidation states of 4 
or higher
 
SO3
2- 
Br2, I2 
Hydrogen-bonding molecules C6H5NH2, C5H5N, N2 Metals(0), π-acceptors 
Table 1.2: Examples of “Hard and Soft Acids”, adapted from R.G. Pearson.7 
 
1.3.2 Gold based Metallo-Drugs: 
 
Gold in its many forms has been used medicinally for hundreds of years for the 
treatment of various ailments, particularly arthritis. Elemental gold is relatively rare and 
chemically inert but can be easily extracted from the earth and shaped into a variety of forms. 
It has a long association with humans and found its way into nearly every culture in the form 
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of jewellery, ornaments and monetary exchange. Gold compounds on the other hand are 
much more chemically reactive and serve a variety of medicinal applications such as treating 
cancer, malaria and AIDS.
8,9
 
Rheumatoid arthritis is a systemic disorder that causes the immune system to attack 
joints of the body which ultimately results in the loss of the lubricating fluid causing the joint 
to swell and deform.
10
 The use of gold for treating rheumatoid arthritis was first described by 
Forestier in 1934 when he described the use of gold salts for the treatment of tuberculosis and 
arthritis.
11
 Since then numerous studies of gold compounds in biological media have raised 
the issue of stability in low pH environments, such as the stomach. Unfortunately this 
property reduces the effectiveness of the drugs towards treatment of arthritis. It has been 
found by some investigators that auranofin in particular, a popular gold based rheumatoid 
arthritis treatment, degrades in stomach acid; leaving only 25% of the oral dose to be 
absorbed through the intestine.
4,12
 Despite these stability problems, a wide range of gold 
compounds have approved for use for the treatment of rheumatoid arthritis, Figure 1.4.  
Gold compounds have also been investigated in connection with their activity as anti-
cancer agents.
8
 Some early work on auranofin, 108, Figure 1.4 and its analogues revealed 
that Au
 
(I) complexes which contained phosphine and thioglucose ligands were quite 
effective at killing melanoma and leukaemia cells in-vitro.
13,14
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Structure of gold-based drugs used for the treatment of arthritis; sodium 
aurothiomalate 105, aurothiosulphate 106, aurothioglucose 107, auranofin 108. 
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Unlike other metal based anti-cancer agents, such as Pt
 
(II); which are stable towards 
reduction, many Au
 
(III) complexes were found to be easily reduced by thiol based 
biomolecules. There has been however some initial success with organometallic type 
compounds which contained Au (III)-carbon bonds, 112, Figure 1.5, along with some 
compounds with bulky ligands. This bond strongly donates electrons to the metal ion via a σ 
bond, which makes the metal ion more difficult to reduce. Some of these complexes also 
contained two easily displaced ligands such as Cl
-
, SCN
-
 or OAc
-
 in cis configurations, which 
has been found to be very important for anti-cancer activity and will be discussed further in 
Section 1.6.
15
  
Work by Berners-Price and Sadler also found that the presence of five-membered 
chelate rings and phosphorus atoms with bulky phenyl groups can block nucleophiles from 
attacking the central gold ion.
16
 Further work by Che and co-workers resulted in the synthesis 
of the square planer Au(TPP)Cl complex, 111, Figure 1.5. This compound was designed 
with a tetraphenylporphyrin ligand bound to Au (III) giving a very stable complex in 
biological environments.
17,18
 Further in-vitro screening of the compound resulted in high anti-
cancer activity and good IC50 values against nasopharyngeal carcinoma.
19
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Structure of some gold-based anti-cancer drugs: sodium AuBr3(PEt3) 109, 
AuCl2(phen)Cl 110, Au(TPP)Cl 111, AuCl2(damp) 112. 
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The organometallic gold anti-cancer compounds went on to show activity against 
bladder and ovarian cancer cell lines and some analogues even exhibited activity comparable 
to cisplatin.
20
 The Au (III) ion in these and other compounds, 110, Figure 1.5, is an 
intermediate acid on the HSAB scale, therefore allowing it to bind to the intermediate bases 
on DNA. Work by Mirabelli et al has demonstrated that these complexes can clearly change 
the degree of supercoiling of DNA.
21
  
Currently specific cellular targets for the phosphine type compounds have not been 
identified, but some reports have shown the site of action to be the mitochondria within the 
cell.
22,23
 Other investigations gave indications that the complex [AuBr3(PEt3)] 109, Figure 
1.5 in particular binds to the N-7 position of guanine bases on double stranded DNA.
24,25
 
Also, more recent studies with triphenylphosphine type complexes have revealed inhibition 
of the enzyme lipoxygenase whose metabolites can regulate cellular proliferation or 
apoptosis.
26
  
 
1.3.3 Vanadium based Metallo-Drugs: 
 
 Vanadium has been used as a treatment for diabetes for over a hundred years. In 1899 
the French physician B. Lyonnett described the ability of sodium vanadate, Na3VO4, to lower 
the blood sugar levels of diabetic patients.
27,28
  
   
 
 
 
 
 
 
 
Figure 1.6: Structure of vanadocene dichloride 113, bis(4,7 – dimethyl-1, 10-phenanthroline) 
sulfatooxovanadium (IV) [metvan] 114, and VO[salmet)(dpg)] 115, all of which have anti-
tumour properties.  
Modern vanadium complexes, such as those in Figure 1.6, are insulin mimics in the 
forms of vanadate (which contains V
 
(V)) and vanadyl VO
2+
 (which contains V (IV)). The 
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vanadyl compounds currently exhibit very few side effects and certain complexes also help 
maintain proper glucose levels for individuals.
27
 
As well as having anti-diabetic properties, some vanadium complexes also have anti-
cancer effects, first reported by Kopf-Maier et al. During testing for anti-cancer activity, in 
particular for vanadocene dichloride 113, Figure 1.6, these vanadium based metallo drugs 
exhibited less toxicity and fewer side effects than cisplatin (the benchmark metallo anti-
cancer drug). Some of these complexes have also been found to bind to DNA and form 
similar adducts as those formed with cisplatin.
29
  
The planar oxovanadium (IV) compound bis(4,7 – dimethyl-1, 10-phenanthroline) 
sulfatooxovanadium (IV), metvan 114, Figure 1.6 has shown huge potential as an anti-cancer 
agent by inducing cell apoptosis in human leukemia cells, some myelomas and solid tumour 
cell lines.
30–32
 Other oxovanadium (IV) complexes such as VO[(salmet)(dpg)] 115, Figure 
1.6 which contain Schiff base ligands, have also been investigated by Chakravarty and 
coworkers in connection with photodynamic therapy (PDT).
33
 PDT is the use of light to 
destroy tumours in connection with a photosensitive anti-cancer drug and has been effective 
in connection with quite a few anti-cancer metallo drugs.
34
 It will be discussed further in 
Section 1.7. 
 
1.3.4 Ruthenium based Metallo-Drugs: 
  
Although the use of metals in medicine is largely overshadowed by platinum, 
ruthenium is sometimes seen as a very attractive alternative due to its rich synthetic chemistry 
and range of oxidation states (Ru (II), Ru (III) and Ru (IV)). These features are quite 
significant since the activities of most metal-based anti-cancer drugs rely heavily on their 
oxidation state.
35,36
  
For many years ruthenium complexes were used exclusively as metal catalysts for 
chemical transformations,
37
 but since the late 1980’s their anti-cancer activity has been the 
focus of considerable interest. Some of the anti-cancer active complexes kill the primary 
tumour cells while others prevent the tumour from spreading to other parts of the body.
36
 
Two compounds in particular, NAMI-A and KP1019 (both containing Ru (III)), are currently 
involved in clinical trials, Figure 1.7, as well as other complexes such as KP1339.
38–40
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Figure 1.7: Structure of NAMI-A 116 and KP1019 (FFC14A) 117, both of which contain Ru 
(III) and are currently undergoing clinical trials for anti-cancer activity. 
As well as various oxidation states, ruthenium is also well suited to medical use due to 
its ability to exchange ligands rapidly and mimic iron in binding to certain biological 
molecules such as transferrin. In rapid dividing cancer cells there is a greater demand for iron 
so the transferrin receptors are over-expressed, allowing ruthenium metallo-drugs to enter the 
cell with greater efficiency.
36,41
 
More recent work on organometallic based ruthenium complexes has also shown 
promising results against some cisplatin-resistant human ovarian cell lines.
42,43
 These 
complexes contain Ru (II) and represent an interesting class of mixed arene and phosphine 
based compounds with anti-cancer activity, Figure 1.8.
44,45
 Similar to platinum based anti-
cancer drugs, as part of their biological activity, these compounds have been reported to lose 
their bound ligands and react with target molecules in the cell.
46
  
 
 
 
 
 
 
 
Figure 1.8: Structure of DW12 118, [(η6-biphenyl)Ru(en)Cl]PF6 119 and [(η
6
-p-
cymeme)Ru(pta)Cl2] 120, all of which contain Ru (II) and have displayed significant anti-
cancer potential.
46
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1.3.5 Titanium and Gallium based Metallo-Drugs: 
 
 In 1979, one year after cisplatin was approved for use as a drug, Kopf and Kopf-
Maier reported a simple titanium based metallocene that exhibited potent antitumor 
properties, called titanocene dichloride.
47
  Titanocene dichloride, 121, Figure 1.9, was found 
to interact with DNA in a similar manner to cisplatin due to the two chloride leaving groups 
present. The compound was also found to accumulate in the nuclei of human tumours and 
bind to DNA in a similar manner to cisplatin.
48
 As well as this it was also found to have less 
toxicity than cisplatin and displayed no nephro- or myelotoxicity (which are commonly 
associated with cisplatin).
47
  
  
 
 
 
 
 
 
 
 
Figure 1.9: Structures of titanocene dichloride 121, budotitane 122 and a Schiff-base 
titanium complex 123, all of which have been confirmed to have anti-cancer activity.
49
   
 
This discovery prompted other research groups to investigate a wide range of titanium 
based metallo-drugs including β-diketonate complexes consisting of a Ti (IV) metal centre 
122, Figure 1.9, called budotitane. Titanocene dichloride on the other hand went on to 
become the first non-platinum metal complex to enter clinical trials along with various other 
complexes synthesised by Keppler and coworkers.
49
  
Studies with budotitane in particular reported that due to the presence of the phenyl 
groups on the β-diketonate ligands the compound may bind to DNA via intercalation; a 
method of biological interaction which has also become evident for some platinum 
complexes (further discussed in Section 1.4).
50
 Further clinical trials were later discontinued 
however due to hydrolytic instability of the complexes at physiological pH and difficulty in 
formulating a solution that could be used in chemotherapy.
51
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Recently however there has been some interest in the more stable titanium Schiff-base 
coordination complexes featuring a mixture of chelating nitrogen and oxygen donor atoms. A 
report from Obeid et al in particular has seen in-vitro antibacterial and antitumor activity via 
DNA cleavage from some novel Schiff-base titanium complexes, 123, Figure 1.9.
52
  
Chelating nitrogen and sulphur based ligands have also been investigated in 
connection with both titanium and in particular gallium metallo-drugs as anti-cancer agents. 
Recently Kowol and co-workers have reported the anti-cancer properties of a Ga (III) 
compound containing a thiosemicarbazone ligand. This tri-dentate five-coordinate distorted 
square-pyramidal complex is isolated from the reaction of GaCl3 with a pyridine-
dimethylthio-semicarbazone ligand 124, Figure 1.10. Through a proposed interaction with 
ribonucleotide reductase, it has exhibited potent toxicity towards human ovarian carcinoma 
(41M) and mammary carcinoma (SK-BR-3) cells in-vivo.
53
  
 
 
 
 
 
 
 
 
 
Figure 1.10: Structures of the anti-cancer active complex GaLCl2 124, and the octahedral 
complex cis, cis, cis-[GaL2]ClO4 125. 
 
Further work by Veriani and co-workers have also revealed anti-cancer properties 
with octahedral Ga
 
(III) complexes 125, Figure 1.10. The cytotoxicity of these tridentate N2O 
complexes have revealed strong activity towards human neuroblastoma (SK-N-Be(2)) cells 
and the mechanism of action is thought to target the proteasome in prostate cancer cell 
lines.
54
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1.4 Platinum-based Metallo-Drugs:  
 
1.4.1 Background:  
 
 Platinum and palladium have distinctly different properties than the 1
st
 row group 10 
transition element nickel.
 
Although nickel does exist in Ni
 
(III) and Ni
 
(IV)
 
oxidation states, 
the octahedral structures it forms tend to be distorted due to its small size so Ni (II) is the 
primary oxidation state. This is in contrast to palladium and platinum whose M (IV) 
oxidation states generally form regular octahedral complexes.
55
 
 
 Although four coordinate Ni (II) complexes can form both tetrahedral and square 
planar structures, Pt (II), which has the electronic configuration of 5d
8
 and is diamagnetic 
(S=0), only forms square planar complexes. In these square planar structures the dx
2
- y
2
 orbital 
is pushed higher in energy and the large energy difference between the dx
2
- y
2
 and the dxy 
orbitals results in only the dxy orbital being occupied, therefore only square planar complexes 
are formed. 
The common occurrence of square planar 4d
8
 and 5d
8
 complexes correlates with the 
high values of the ligand-field splitting parameter in these two series, which give rise to a 
high ligand-field stabilisation of the low-spin square-planar complexes. This is one of the 
primary distinguishing differences between nickel and the other group 10 metals in the d
8
 
configuration.
56
 
 Palladium, like platinum, also has a strong disposition to form coordination 
complexes. The distinguishing difference between palladium and platinum is that in the d
8
 
configuration Pd (II) complexes tend to be less stable (both kinetically and thermally) than 
their Pt (II) analogues.
56
 This chapter will primarily focus on platinum in the (II) and (IV) 
oxidation states and complexes with square planar and octahedral geometry respectively. 
 
1.4.2 Cisplatin Pharmacokinetics: 
 
 The bright yellow compound cis-diamminedichloroplatinum(II) was first reported by 
the Italian chemist Michele Peyrone in 1844 and was later named Peyrone’s Salt.57 The 
molecular structure of the compound, including its isomerism, was then determined by Alfred 
Werner as part of his 1913 Nobel Prize winning work.
58
 But it was not until 1965 that the 
biological activity of Peyrone’s Salt was discovered by Rosenberg, van Camp et al of 
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Michigan State University and the compound subsequently became known as cisplatin, 126, 
Figure 1.11.  
Rosenberg initially discovered that electrolysis of platinum electrodes generated a 
soluble complex which inhibited binary fission in E. coli bacteria. The bacterial growth 
actually continued but the cell division was stopped resulting in long filaments of bacterial 
growth. It was discovered that while the electric current was running it created a tiny 
concentration (~10 ppm) of the platinum complexes cis-dichlorodiammine-platinum (II) and 
cis-tetrachlorodiammine-platinum (IV).
59
 These cis complexes inhibited the cell division in 
bacteria, however the trans analogues were not found to be active and will be discussed in 
more detail in Section 1.3.2.  
When dissolved in water, cisplatin, cis-[PtCl2(NH3)2] slowly reacts losing its two 
chloride ligands to form the diaquated species, 128, Figure 1.11.
60
 When solvated, known as 
Platinol-AQ, it is stored in an aqueous solution containing sodium chloride at a pH that has 
been adjusted to between 3.5 and 4.5. The additional chloride ions push the equilibrium to the 
left in favour of the anti-cancer active dichloro form of the drug, 126.
61,60
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Speciation of cisplatin 126, in aqueous solution where the chloride ligands are 
substituted by water to form the diaquated species 128.
60
  
 
 The concentration of cisplatin in solution must be kept less than 105 mM in order to 
keep the concentration of chloride ions less that found naturally in blood. This is to prevent 
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unwanted hydrolysis prior to entering the body which reduces the uptake of cisplatin into the 
cell. When added into blood, Le Chatelier’s principle states that the system will move to the 
right in favour of the aquated species. Also the hydroxo form, 129, Figure 1.11, has been 
found to predominate at 37
o
C (body temperature) which may have detrimental effects on the 
activity of cisplatin due to the hydroxide ion being a poorer leaving group than water.
60,62
 
 
 1.4.3 Mechanism of Action of Cisplatin (DNA Binding): 
 
 Shortly after the discovery of the anti-cancer activity of Cisplatin, Rosenberg and 
coworkers
59
 along with Howle and Gale
63
 suggested that its cellular target was DNA, Figure 
1.12. Early research by Harder found that the platinum complexes were inhibiting the 
synthesis of DNA in cells. It was reported that although it prevented DNA replication it did 
not hinder RNA or protein synthesis. Evidence was also presented that the synthesis of 
precursors to DNA synthesis were not blocked. Therefore it was concluded that the platinum 
complex’s mode of action was most likely due to a primary lesion in DNA itself.64  
Interstrand crosslinking was initially ruled out since the distance between strands was 
greater than that which could be spanned by a single platinum metal complex ion (3.3 Å). 
Researchers therefore proposed that Cisplatin connected two adjacent purine bases on the 
same strand of DNA to form an intrastrand purine dimer (which are stacked 3.4 Å apart). 
Later studies supported this initial investigation and identified the major DNA adduct as Pt-
GG along with lesser amounts of the DNA adduct Pt-AG, both of which were found to be 1,2 
intrastrand crosslinks.
65,66
  
 
  
 
 
 
 
 
      132  133   134 
Figure 1.12: 1,2 intrastrand crosslinking 132, and 1,3 intrastrand crosslinking 133. Guanine 
with the N-7 position labelled 134.
2
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From these early studies it was also determined that Cisplatin could form 1,3 
intrastrand crosslinks with guanine bases in trinucleotide sequences along with interstrand 
crosslinks between both DNA strands again using guanines. It all cases it was found that the 
primary donor atom used for binding to Pt
 
(II) metal centres was the N-7 position of adenine 
or guanine, 134 Figure 1.12. Once formed Cisplatin-DNA adducts induce a variety of 
cellular responses such as replication arrest, transcription inhibition, cell cycle arrest, induces 
necrosis and apoptosis. 
Further studies by Hambley and co-workers determined the full mechanism of action 
for Cisplatin in the body, Figure 1.13. Once the Cisplatin complex enters the cell it is 
converted to the aqua form by losing its chloride leaving groups which can then displace its 
H2O ligands to coordinate to DNA easily. The aqua forms of the drug are in a proton 
equilibrium with their respective hydroxo (HO
-
) forms, but only the diaquated form can lose 
its ligands easily.
67
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: The reaction scheme for the binding of cisplatin to guanine base pairs on DNA 
strands (-GG-).
67
 
 
The initial in-vivo trials with cisplatin saw 95% of the induced tumours in animals 
achieve complete regression. The complex even cured animals which were within a few days 
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of death. However drawbacks to this form of therapy were identified. The drugs also inhibit 
the cell-division in normal human tissue and somatic cells as well the ones present in the 
tumours, especially fast dividing cells such as the intestinal wall, causing severe internal 
damage.
64,2
  
Although it is one of the world’s foremost anti-cancer drugs, it still has some severe 
side effects including kidney damage and neurotoxicity along with nausea and vomiting.
2
  
Its isomer, transplatin, on the other hand is not anti-cancer active due to its inability to 
form intrastrand crosslinks. Recent studies however has identified that isomers of transplatin 
are cytotoxic when photo-activated, using Photo Dynamic Therapy (PDT). By using lasers 
and fibre optics, site-specific activation of photo active chemotherapeutic agents is possible 
and will be discussed in more detail later in this chapter.
68
 
 
1.4.4 Mechanism of Action of Other Platinum Anti-cancer Agents (Intercalation and 
Non-DNA interactions): 
 
   
 
 
 
 
 
 
 
 
Figure 1.14: Schematic representation of double stranded DNA without (left) and with 
(shaded area, right) a bound intercalator.
69
  
Another interesting feature of double-stranded DNA is that flat planar molecules 
(usually containing aromatic groups) that are hydrophobic, can insert themselves between the 
base pairs of DNA through a process known as intercalation. By doing this, the spacing 
between the base pairs of DNA must increase in order to accept the intercalating molecule, 
Figure 1.14. This also increases the length of the DNA helix, which will affect the template 
function of DNA in terms of replicating.
5,69
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 Therefore, aside from simply binding a metal centre to a donor atom on a DNA 
strand, certain metal complexes that contain flat aromatic residues can also bind to DNA by 
intercalation. The driving force for this interaction is the association of the hydrophobic DNA 
base pairs with the hydrophobic region of the drug molecule.
5,36
  
 Some investigators have found that ruthenium compounds which contain an arene 
residue have the ability to intercalate between base pairs, as well as forming direct 
Ruthenium-DNA adducts to the N7 position of guanine (through mono-functional binding) 
such as those previously discussed in Figure 1.8, Section 1.3.4.
70,71
 Further work by Nair et 
al on chromium (III) complexes has also shown bifunctional mechanisms with intercalation 
and binding in the major groove of a DNA double helix.
72
  
As well as ruthenium and chromium complexes, bifunctional metallointercalator 
compounds have been identified for a variety of other metals but here the focus will be on 
platinum compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15: An intercalating Pt (II) bipyridyl complex with diphenylthiourea, [Pt(pipy)(ph2-
tu)2]Cl2 135,
73
 and the cyclometallated Pt (II) complex [Pt(CNN)(4-dpt)]PF6 136 identifying 
the intercalating and non-intercalating portions of the complex.
74
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Lippard et al pioneered studies on DNA-metallointercalators using square-planar Pt 
(II) complexes with ligands containing aromatic groups,
75
 while Barton et al subsequently 
extended the scope to various octahedral metal complexes with aromatic di-imine ligands.
76
 
As well as hydrophobic similarities, these metallointercalators also bind to DNA through π-π 
and electrostatic interactions. Extensive reports by Mingos et al advocate design studies 
based on metal complexes with nitrogen-donor ligands that can participate in both hydrogen 
bonding and π-π interactions.77 Two such cationic platinum based complexes are presented in 
Figure 1.15. 
 Pt (II) square planar complexes containing aromatic ligands in particular are very 
suitable for intercalation with DNA, as they often possess the appropriate geometry for the 
interaction. It is also possible to tune to a large extent their electronic and steric properties by 
suitable choice of the ligands. As seen in work by Frassineti et al on bifunctional platinum 
intercalating anti-cancer complexes, they have revealed that the bipyridyl complex with 
diphenylthiourea, [Pt(pipy)(ph2-tu)2]Cl2 135, shown in Figure 1.15 is active towards both 
cisplatin sensitive and resistant human ovarian cell lines.
73
   
Also for the cyclometallated Pt (II) complex [Pt(CNN)(4-dpt)]PF6 136 in Figure 1.15, 
a mixed DNA binding mode is observed with the Pt(CNN) moiety intercalating into the 
helical stack and the 4-dpt ligand protruding into the minor groove of the double helix.
74
 
New monobinding cyclometallated Pt (II) complexes have recently presented high 
cytotoxicity with only one leaving group present. This is in contrast to the traditional view of 
needing bifunctional lesions for good activity (double binding to DNA), like those present in 
cisplatin and most second generation platinum metallo-drugs, Section 1.4.5. However, many 
monobinding platinum complexes presented to date have been charged, like those in Figure 
1.15. This raises other issues such as membrane permeability which may influence the 
biological activity of these complexes adversely.
78
  
Extensive work by Edwards et al,
79
 Kodaka et al 
80
 and Navarro-Ranninger et al 
81
 on 
the other hand has demonstrated a new range of highly cytotoxic neutral platinum anti-cancer 
drugs with new biological functionality in comparison to cisplatin and its analogues. As well 
as singly binding to DNA and intercalating, some charged platinum cyclometallated 
complexes have shown anti-cancer activity by preferentially accumulating in the cytoplasmic 
structures of the cells instead of covalently binding to nuclear DNA (137, Figure 1.16).
82
  
The platinum carbon bond(s) have been reported as being quite strong, therefore 
rendering the Pt (II) cyclometallated complexes to display unique photophysical properties 
Chapter 1  General Introduction  
 
23 | P a g e  
 
(discussed further in Section 1.7) and enhanced stability against biological reduction and 
ligand exchange reactions.
79
  
 
 
 
 
 
 
 
 
 
Figure 1.16: The structure of a pyrophosphate Pt (II) complex which is cytotoxic and doesn’t 
bind to DNA 137,
83
 and a charged cyclometallated Pt (II) complex 138 which  inhibits 
tumour growth by accumulating in cytoplasmic structures.
82
  
 
Milton et al have also reported a class of Pt (II) and Pt (IV) pyrophosphato complexes 
(138, Figure 1.16) that exhibit cytotoxicity comparable with and, in some cases, better than 
cisplatin in some ovarian cell lines, yet no evidence of covalent binding to DNA was 
observed. They propose numerous alternative cytotoxic mechanisms for their mode of action 
including a pathway that involves an interaction with fas ligand proteins and two 
antiapoptotic genes.
83
  
 
1.4.5 Second Generation Platinum Drugs: 
 
1.4.5.1 Carboplatin: 
 
Since 1971, second and third generation platinum analogues have been investigated in 
an attempt to broaden the spectrum of activity, fight rising resistance and overcome toxic 
side-effects. Figure 1.17 shows the first analogue to obtain approval for clinical use by the 
US Food and Drug Administration (FDA) in the United States, called carboplatin.  
Carboplatin was first reported by Cleare and Hoeschele in 1973 and later obtained 
approval by the FDA under the brand name Paraplatin in 1978.
84
 As stated by Edwards et al, 
active platinum agents require two kinetically inert ligands to form the non-leaving group, for 
example primary amines or ammonia, and two labile anionic ligands in a cis configuration, 
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such as that seen in cisplatin with chlorides, to enable bifunctional binding to the heterocyclic 
bases of the target DNA (the leaving group).
79
 Carboplatin does possess these structural 
features, but the key difference between the structures of carboplatin and cisplatin is that the 
former possess a six-membered dicarboxylate ring, which, because of the chelate effect, 
makes it much less chemically reactive than cisplatin.
85
  
 
 
 
 
 
 
 
   139a      139b 
Figure 1.17: Carboplatin [Pt(cbdca-O,O’)(NH3)2] 139a, where cbdca is cyclobutane-1,1-
dicarboxylate and O and O’ are the ligand donor atoms. The single-crystal x-ray structure of 
carboplatin 139b, where the cbdca ligand is orientated perpendicular to the plane.
85
  
  
Although carboplatin is much less chemically reactive than cisplatin, it still possesses 
potent anti-cancer properties, which has prompted many investigators to focus on ways to 
enhance its activity. Studies on the bio-activity of carboplatin have shown that most of the 
drug is eliminated in the urine as the unreacted starting material, with the remainder bound to 
proteins and forming small-molecule biotransformation products. The free ligand, cbdca, is 
found in the urine of patients receiving the drug, indicating that biological nucleophiles may 
have attacked the metal centre and displaced the dicarboxylate ligand.
86
 
Extensive work by Sadler and co-workers on carboplatin’s activity towards various 
biomolecules (found naturally in the body) showed that the presence of the cbdca chelate ring 
makes a dramatic difference in the reactivity of platinum compounds towards thiols. N-
acetyl-cysteine, N-acetyl-L-cysteine and the tripeptide, Glutathione, all displayed unusually 
low reactivity towards the drug despite the Pt (II) being a soft acid and the thiol a soft base.
87
  
 Further studies on carboplatin’s interaction with cellular targets have revealed, like 
cisplatin, that DNA is the most important target.
88,89
 It was determined that carboplatin, like 
cisplatin, forms intrastrand DNA crosslinks as a difunctional platinum-DNA adduct. 
However, since the concentration of carboplatin required to reach a DNA-unwinding state 
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comparable to that of cisplatin was 100 times greater, carboplatin is much less reactive 
toward DNA than cisplatin.
90
 
Carboplatin by itself or in combination with other drugs is still in worldwide clinical 
uses today for the treatment of a variety of different cancers, including head and neck cancer, 
along with ovarian, breast, small cell lung, testicular, bladder and brain tumours. Although 
carboplatin is much less nephro- and ototoxic than cisplatin, it is myelosuppressive, which 
leads to a reduction in the white cell count in the blood, thus exposing the patient to infection 
by various organisms.
91
  
 
1.4.5.2 Oxaliplatin: 
 
[Oxalate(2-)-O,O’][1R,2R-cyclohexanediamine-N,N’] platinum (II) (Figure 1.18) was 
the first platinum anti-cancer drug approved that was capable of overcoming cisplatin 
resistance. It was found to be especially effective when used in combination with 5-
fluorouracil against colorectal cancer (the first anti-cancer drug to see effectiveness against 
this particular cancer). It was also found to be much less nephro- and ototoxic than cisplatin 
as well as being less myelosuppressive than cisplatin.
92
  
 
 
 
 
 
  
  140a       140b 
Figure 1.18: Oxaliplatin [Pt(1R,2R-dach-N,N’)oxalate] 140a, where dach is 
cyclohexanediame and N, N’ are the ligand donor atoms. The single-crystal x-ray structure 
of oxaliplatin 140b, where the dach ligand is in a chair-shaped confirmation.
93
  
 
In oxaliplatin the two ammine ligands (present in both cisplatin and carboplatin) have 
been replaced by a single bidentate ligand, (1R,2R)-cyclohexane-1,2-diamine (R,R-dach) 
which act as the non-leaving group.
93
 The synthesis of oxaliplatin and determination of its 
anti-cancer properties were first reported by Yoshinori Kidanin et al in 1976.
94
 It gained 
approval for clinical use in the European Union in 1999 (France in 1996) and in the United 
States in 2002, followed by Japan in 2005.
95,96
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Similarly to the other clinically approved platinum based anti-cancer drugs, the major 
cellular target for oxaliplatin is DNA. Extensive work by Claney and coworkers determined 
that the DNA adducts formed by oxaliplatin resemble those formed by cisplatin but with 
significant differences between the two structures.
97
 Further work has revealed that the 
oxaliplatin-GG structure has a narrow minor groove and the adduct forces a bend in the helix 
that is around 30
o
, while the cisplatin-GG adduct produces a wide minor groove and a helix 
bend of 60-80
o
.
98
 It is these differences in the structure of the DNA adducts that provide 
oxaliplatin with the ability to overcome cisplatin resistance by preventing the DNA damage 
repair proteins from doing their job.   
 
1.4.5.3 Other Second Generation Platinum Drugs: 
 
As well as cisplatin, carboplatin and oxaliplatin, there are numerous platinum based 
anti-cancer drugs currently approved for use in certain regions of the world. The structures of 
nedaplatin 141, lobaplatin 142, and heptaplatin 143 are given in Figure 1.19. 
Diammine[hydroxyacetato(2 )-O,O’]platinum (II) or nedaplatin 141 is currently approved for 
clinical use in Japan for the treatment of ovarian and cervix carcinomas as well as head/neck 
tumours, oesophageal and bladder cancer.
99
 It is structurally quite similar to carboplatin with 
the same cis-ammonia non-leaving groups, but contains a dianionic form of glycolic acid as 
its leaving group.
100
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19: Nedaplatin 141 (approved for use in Japan), lobaplatin 142 (approved for use 
in China) and heptaplatin 143 (approved for use in the Republic of Korea).
99
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The stability and low toxicity of the leaving group is quite often seen as integral to the 
ongoing success of new platinum anti-cancer compounds. [2-hydroxypropanoato(2-)-
O1,O2][1, 2-cyclobutanedimethanamine-N,N’]platinum (II) or lobaplatin 142 (Figure 1.19) 
has been approved for use as a drug in China and is generally found as a mixture of two 
diastereomeric compounds. Its leaving group takes the form of a naturally occurring 
optically-active form of lactic acid while its non-leaving group is a stable metal-nitrogen 
bound seven-membered chelate ring. Lobaplatin is used to treat non-small-cell-lung cancer, 
breast tumours, certain forms of leukaemia and more recently cholangiocarcinoma. Ongoing 
investigations and clinical trials have found it to be less nephro-, neuro- or ototoxic than 
cisplatin.
101,102
  
 In South Korea, heptaplatin 143 (Figure 1.19) has been approved for use as a drug to 
treat gastric cancer and, in combination with Paclitaxel, head and neck squamous cancers.
103
 
The non-leaving group is a chiral form of a seven-membered diamine with a fused five-
membered diether, while the leaving group is a dianion of malonic acid.
104
 The drug has, 
however, been found to cause mild hepatoxicity and myelosuppression as well as 
nephrotoxicity. Recently, further investigations have reported a water soluble analogue of 
heptaplatin with more activity and less toxicity.
105
  
 
 
 
 
 
 
 
144       145 
Figure 1.20: Picoplatin 144 (currently in phase II clinical trials), an x-ray crystal structure 
of a Pt (IV) analogue of picoplatin 145, showing the pyridine ring sitting nearly 
perpendicular to the metal centre. 
106
 
 
Further evolution of second-generation platinum anti-cancer complexes has led to 
new structural innovations to provide stability, increased activity and less toxicity. Picoplatin 
(cis-amminedichlorido(2-methylpyridine)platinum (II)) Figure 1.20 for instance was 
designed primarily to circumvent glutathione-mediated drug resistance. The presence of a 2-
methyl pyridine ligand perpendicular to the coordination plane of the metal ion reduces the 
Pt
Cl
Cl
N
NH3
H3C
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possibility of substitution reactions with biomolecules which require a five-coordinate 
transition state which is discussed in further detail in Chapter 3. 
107
  
The methyl group’s position over the metal centre in both picoplatin and its Pt (IV) 
analogue (Figure 1.20) provides steric hindrance to the attack of the drug by nucleophiles, 
particularly thiols.
108,106
 In-vitro studies of picoplatin have demonstrated that it has some 
ability to overcome some drug resistance, showing anti-cancer activity in cisplatin, 
carboplatin and oxaliplatin resistant cell lines. In-vivo studies have shown that it possesses 
little or no neuro- or nephro- toxicity and it is currently being investigated as an effective 
anti-cancer agent in combination with other drugs.
109,110
 
 
1.4.6 Third Generation Platinum Drugs: 
 
 As well as 16 electron square planar complexes, platinum can also form stable 18 
electron octahedral compounds with a variety of ligands. These Pt (IV) complexes can be 
synthesised through two different routes, oxidation of a Pt (II) complex and direct synthesis. 
Both routes are explored in this project and are further discussed in Chapter 3.  
 
 
 
 
 
 
 
   146       147 
Figure 1.21: Tetraplatin 146 and Iproplatin 147, both Pt (IV) octahedral complexes which 
reached Phase I clinical trials but later discontinued due to high toxicity.
111
 
 
 As seen in Figure 1.21, the Pt (IV) complexes contain additional functional groups 
(compared to their Pt (II) analogues) above and below the plane of the traditional equatorial 
leaving and non-leaving groups. These additional functional groups are normally referred to 
as the “axial groups”. One of the primary advantages identified by Hall et al that Pt (IV) 
complexes present is the large number of chemical and biological variations that can be 
achieved by substituting different groups on the axial positions.
112
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The axial and equatorial ligands determine a large array of anti-tumour mechanisms, 
unfortunately the full extent of these mechanisms have yet to be studied in extensive detail. In 
studies carried out by Choi et al it was been found that Pt (IV) compounds are generally inert 
towards ligand substitution reactions relative to their Pt (II) analogues. In order to bind to 
DNA it has been proposed that they must first be reduced to their Pt (II) analogue. It was also 
found that they are reduced by both extracellular and intracellular agents such as ascorbate, 
glutathione and other protein sulfhydryls.
113,114
 The proposed mechanism for the reduction of 
Pt (IV) complexes is illustrated in Figure 1.22. 
Figure 1.22 shows the fate of a typical Pt (IV) chloride complex in-vivo. The extra 
cellular chloride concentration outside the cell (left hand side) (100 mM) is much higher than 
the concentration inside the cell, intracellular (4 mM). The molecule passes into the cell in 
response to the chloride concentration gradient through a process similar to osmosis.
115
 
Because the Pt (IV) drugs need to be reduced prior to binding to the target DNA, these 
complexes are therefore often called prodrugs.
116
 
 
           
             
 
           
                   Reduced 
 
 
 
                  Hydrolysed 
Can’t leave the cell 
 
Figure 1.22: The mechanism of Pt (IV) reduction in-vivo of a typical chloride based 
octahedral complex, the cell membrane is shown in the middle in blue.
115
  
 
Further work by Choi et al on cyclometallated Pt (IV) complexes has shown that the 
platinum complexes with hydroxo axial ligands reduced very slowly while those with chloro 
axial ligands reduced very fast. Acetate ligands generally show a moderate reduction rate, 
while certain complexes reported were not reduced under the conditions investigated.  
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It was also noted that reduction is favoured by the presence of electron withdrawing 
axial ligands and bulky axial ligands. Electronegative axial ligands, such as chlorides, 
increased the reduction rate by promoting destabilisation of the Pt (IV) state, due to electron-
withdrawing effects. Complexes with bulky axial ligands also promote destabilisation of the 
Pt (IV) state, which results in a faster reduction to the more stable Pt (II) state.
113
 
 In the presence of reducing agents such as glutathione and ascorbate, Pt (IV) 
complexes generally show enhanced reactivity towards DNA. This supports the proposal that 
the Pt (IV) complexes need to be reduced to their active Pt (II) analogue in order to have anti-
cancer activity.
112
 However, in certain cases the parent Pt (IV) complex is actually more 
active than its analogous Pt (II) complex. Choi et al and Galanski et al have both reported 
some examples of Pt (IV) complexes which can bind to DNA and RNA fragments without 
being reduced (Figure 1.23).
113,117
  
 
 
 
 
 
 
   148      149 
Figure 1.23: The structure of the Pt (IV) complex [enPt(OCOCH3)4]  148 and the GMP 
disodium salt 149 used to form the platinum bio-adduct.
117
 
 Galanski and Bernhard have created a Pt (IV)-5’-GMP bio-adduct species in their 
studies from the above salt 148 and Pt (IV) complex 149, Figure 1.23. They have also 
confirmed the stability of the species over several weeks by (
1
H and 
15
N) NMR spectroscopy. 
Interestingly, the analogous Pt (II) reduced species was not detected in the final products.
117
 
 One particular Pt (IV) complex which has attracted quite a lot of interest in the past 
number of years is “satraplatin” (bis-aceto-ammine-dichloro-cyclohexylamine platinum (IV)) 
or JM-216, first reported by Kelland et al in 1993, Figure 1.24.
118
 Initial in-vitro studies on 
Satraplatin found it to be around 3 fold more potent than cisplatin in some cell lines and it 
had 4.2 fold better intracellular accumulation compared to cisplatin.
118
 Also, in Phase I and II 
clinical trials it was observed to have no cardiac, renal, heptatic, or neurologic toxicity.
119
 
More recently it has proceeded to Phase III trials in combination with other therapies such as 
Docetaxel where moderate success has been achieved.
120
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Although satraplatin is not vastly beneficial over existing treatments, in all the clinical 
trials one feature has made it very attractive; it is orally active.
119,120
 The traditional platinum 
agents, cisplatin, carboplatin, and oxaliplatin are all administered intravenously and are 
associated in varying degrees with neurotoxicity, nephrotoxicity, myelosuppression, and oto-
toxicity. As an oral based drug, Satraplatin has convenient dosing and so far has not been 
associated with the same level of toxicity as the currently approved platinum based anti-
cancer compounds. Currently it remains in clinical trials in the United States but given the 
lack of an overall survival benefit, satraplatin has not yet received approval by any regulatory 
authority.
121
 
 
 
 
 
 
 
 
150 
Figure 1.24: The structure of Satraplatin 150, a Pt (IV) complex that has reached phase III 
clinical trials and will be discussed further in Chapter 3.  
 
1.4.7 New Second and Third Generation Platinum Drug Design: 
 
Current investigations into drug design for second and third generation Pt (II) anti-
cancer complexes are primarily concerned with providing structural stability for the non-
leaving groups and reducing the toxicity of the leaving groups. An important feature of active 
Pt (II)  complexes, which has been frequently identified, is the strong relationship between 
the halide leaving groups and the overall biological activity of the complex. Studies between 
Pt-Cl and Pt-Br complexes have concluded that the heavier bulkier halides lead to more 
active complexes - which is in accordance with the relative metal-halide bond strengths.
79 
Edwards et al have investigated the role of the non-leaving groups of platinum 
complexes. It was shown that these ligands were not involved in the biological action of the 
complex per se, however, the introduction of steric crowding around the metal centre leads to 
greatly increased biological activity. Edwards et al achieved this by the introduction of 
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successive  -substituent’s on the non-leaving groups. For good activity to be achieved, it was 
identified that these bulky ligands must remain coordinated to the metal centre while in the 
body. In-vivo testing has confirmed this through stability studies of certain complexes 
towards biomolecules which will be discussed further in Chapter 4.
79
 
 The potential of Pt (II) complexes still remains much higher than its Pd (II) analogues, 
even through the coordination chemistry of Pt (II) and Pd (II) are very similar. Edwards et al 
have confirmed that the anti-cancer activity of palladium complexes in-vivo was only 
moderate at best, while further studies of the newest analogues of the platinum complexes 
show continuing success. This was explained by way of the slightly nucleophilic behaviour of 
the platinum complexes in comparison to the purely electrophilic behaviour of palladium, 
along with solubility and stability issues within Pd (II) complexes. The palladium complexes 
also react too quickly to achieve their aim due to their high lability relative to platinum 
analogues.
79
  
 The use of hemilabile Schiff base bidentate and tridentate ligands as non-leaving 
groups has been investigated by Crouse et al (S-benzyldithiocarbazates) and Smith et al 
(thiosemicarbazones) among others. Tridentate cycloplatinated thiosemicarbazone 
complexes, 151, Figure 1.25 were seen to have both antitumour and antiparasitic properties, 
while tridentate S-benzyldithiocarbazates compounds, 152, Figure 1.25 were also reported to 
have strong cytotoxicity against human ovarian cancer cell lines.
122,123
  
 
 
 
 
 
 
 
Figure 1.25: The structure of the tridentate Pt (II) complex [Pt(mpasme)Cl] 151 and the 
thiosemicarbazone platinum complex 152.
117
 
Further work by Edwards et al on iminophosphine type ligands has also shown 
cytotoxic activity against cancer cell lines. It was seen that in general the compounds reported 
affect growth inhibition at low concentrations and form stable complexes where the ligands 
are not readily displaced.
79
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Edwards et al also reported that palladium complexes incorporating a phosphorus 
donor moiety have lower biological activity than analogous platinum complexes because of 
the greater lability of the palladium to phosphorus bond. This greater lability means that the 
phosphine based ligands are released too quickly from the complex and the metal centre 
reacts before reaching its intended target. In addition to this, this would also result in 
unwanted side effects from the palladium based drugs.
79
 
 
1.5 Hemilabile Mixed Donor ligands as Non-Leaving Groups:  
 
1.5.1 Hemilability Overview: 
 
 Coordination ligands which have the ability to both stabilise a metal centre and create 
an empty coordination site for further reaction, are becoming an increasingly studied area. 
Ligands which have this ability are termed as being “hemilabile”. This concept was 
introduced in terms of phosphine-amine and phosphine-ether bifunctional ligands in 1979 by 
Jeffrey and Rauchfuss.
124
 Hemilability arises from the mixed bonding characteristics of 
hybrid ligands such as iminophosphines (further details in Section 1.6.1).
125
  
 
 
 
 
 
 
 
 
   153      154 
Figure 1.26: Types of hemilabile ligands 153. Homo functional ligands can join to form 
mixed donor ligands 154.
126
  
 Hemilabile ligands are usually found to be “polydentate” because they consist of 
mixed donor moieties (153, Figure 1.26). These type of ligands contain two or more different 
functional sites on the same ligand which are all capable of coordinating to the metal in their 
own specific way (154, Figure 1.26). 
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Specific functionalities of a donor moiety will influence the bonding and/or reactivity 
of other ligands or substrates to the metal in particular this is determined by whether the 
group is hard or soft as defined by the HSAB theory.
126
 Hard Soft Acid Base theory (HSAB) 
plays an important role in the properties of these ligands. Acids and bases are defined as 
being hard or soft by the stability of the complexes they form (see Table 1.1 and 1.2, Section 
1.2). As a general rule, “like binds like”. Pt (II) (a “soft” acid) binds to the phosphine (a 
“soft” base) of the ligand in Figure 1.27 below, followed by subsequent binding to the “har-
soft” nitrogen.127 
 
 
 
 
 
 
 
 
 
Figure 1.27: A mixed donor iminophosphine ligand 155. Platinum bound chelating bidentate 
iminophosphine complex 156 (an example of the HSAB theory and hemilability).
128
  
 For a lewis acid/base to be defined as being soft or hard, the concept depends on the 
size and electro-negativity of the atom. In this way oxygen is a small, highly electro-negative, 
donor base, so it is therefore defined as being “hard” in nature. Hard base components such as 
oxygen (nitrogen is defined as “borderline” meaning it is between soft and hard, Table 1.1, 
Section 1.2) do not bind as strongly to the “soft” platinum centre, hence the primary criteria 
for hemilabile behaviour is satisfied in the above structure because one of the defining 
features of a hemilabile ligand is to have at least one substitutionally labile donor functional 
group (also “Z” in Figure 1.28).126,127 
The HSAB theory also explains the properties of the metal centre, since metals tend to 
get softer as they get heavier. This is one of the defining characteristics between analogous Pt 
(II) and Pd (II) complexes. For example, platinum is heavier than palladium and is therefore 
“softer” so it binds more strongly to “soft” bases such as phosphines. This also explains the 
previously discussed observation that similar palladium complexes are too labile for anti-
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cancer activity because they react too fast in-vivo and subsequently decompose, Section 
1.4.7.
127
  
 
 
 
 
 
 
Figure 1.28: An example of mixed donor ligands and formation of coordination sites.
126
 
In Figure 1.28 the “D” functional group remains bound to the metal centre while the 
other functional group “Z” disconnects to leave a coordination site open. In this way the “Z” 
donor group “swings” away from the metal in a “wind-screen wiper” type analogy.126 This 
process involves a dynamic equilibrium that can be observed at lower temperatures as in 
Figure 1.29 where the metal centre is a copper atom and the exchanging group can be seen 
on the left of the complex.
129
 
 
 
 
 
 
 
 
 
 
 157       158 
Figure 1.29: An example of dynamic equilibrium that can be observed at lower temperatures 
where the exchanging group is shown on the left of each structure.
129
  
 The most useful consequence of hemilabile ligands in a complex is that they 
significantly influence the coordination of incoming substrates, therefore allowing 
transformations in the complex that would not normally occur. This may also happen faster 
or slower depending on the nature of the coordination sphere.
126
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1.5.2 Types of Hemilability: 
 
 There are three specific types of hemilability characterised by the way in which the 
labile donor group coordinates i.e. whether it is easily displaced or not.  
 
1.5.2.1 Type I: Spontaneous opening: 
 
 This is observed by the DZ (Figure 1.30) chelate opening of its own accord without 
any external help. This may occur in both mononuclear and polynuclear (DZ bridge) systems. 
Type I is usually seen in metals which can easily vary their coordination numbers and more 
relevant to this research d
8
 ML4/ML3 (4 3) and d
8
 ML5/ML4 (5 4), where “M” is a Metal 
centre and “L” is a coordinating ligand.  
 
 
 
 
 
 
 
Figure 1.30: A schematic of spontaneous opening, leaving an empty coordination site.
126
 
 
1.5.2.2 Type II: Intramolecular competition: 
 
 This is characterised by competition within the same metal-ligand complex usually 
between two or more hybrid ligands. The competition between two donor functional groups 
causes a switching from one group to the other, which joins to the metal with loss of the first. 
There are two main types as illustrated in Figure 1.31; there are also many other examples of 
this but they are not relevant to this research and as a result will not be discussed here. 
Intramolecular competition will be explored further in Chapter 2 where competition between 
the formation of a tridentate (P,N,O) complex and a tridentate (P,N,C) complex of the same 
ligand will be investigated. Examples of P,N,O complexes studied within this research group 
can be observed in Figure 1.34. 
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 Another type of intramolecular competition within a single ligand is a fluxional “tick 
tock” process where the “D, Z” ligand can connect/disconnect frequently illustrated in Figure 
1.31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.31: A schematic of intramolecular fluxional competition.
126
 
1.5.2.3 Type III: Coordination by an external reagent: 
 
 In this type, the DZ hybrid ligand is attacked by an external substrate (B) which 
displaces the weakest donor group, “Z” in Figure 1.32. The new substrate will then 
coordinate to the metal, causing the hybrid ligand to swing away while still attached to the 
metal centre through the D donor group.
126 
  
 
 
 
 
 
 
Figure 1.32: A schematic of coordination by an external reagent.
126
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This type of hemilability is an intermolecular process rather than an intramolecular 
process; which is prominent for Type I and Type II. The introduction of an external ligand 
results in displacement of one of the coordinated donor moieties of the hemilabile 
polydentate ligand in favour of coordinating the newly introduced external ligand in its place. 
Substitution reactions similar to this will be discussed further in Chapter 3, where 
displacement of a halide ligand from a metal centre by an external phosphine will be 
attempted.  
 
1.4.3 Hemilabile Functional Phosphines and Their Complexes: 
  
 As we have already seen, early work on hemilability with Jeffrey and Rauchfuss 
involved phosphine based ligands. From their work, the P,O based ligands were found to 
function as asymmetric bidentate chelates with metal centres. Other research groups have 
also reported similar metal chelates with P,N and P,C based ligands, Figure 1.33.
124,130,131
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.33: The structures of some P,N and P,C type metal complexes: A Pd (II) 
iminophosphine complex 159,
132
a Pt (II) iminophosphine complex 160,
130
 a Pt (II) 
cyclometallated phosphine complex 161,
133
and an iridium P,N complex 162.
134
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Phosphorus-oxygen (P,O) and phosphorus-nitrogen (P,N) based hybrid ligands, have 
both “soft” (phosphine), “hard” (oxygen) donor groups or “hard/soft” (Nitrogen) donor 
groups. Again these characteristics are essential properties of a hemilabile ligand which are 
especially useful in the current research involving coordinating the ligand to the platinum 
centre (see Table 1.1 and 1.2, Section 1.2) for HSAB acids and bases.  
These hybrid ligands are among the most widely used hemilabile ligands in 
coordination and organometallic chemistry. Their late transition metal complexes can adopt 
several coordination (P monodentate, N monodentate, P,N bridging and P,N chelate) 
depending on the ligand bite and the hardness of the metal atoms.
130 
 Phosphorus based ligands have been described as being one of the most stabilising 
and common ligands towards a variety of transition metal centres. The bond strengths 
provided by the phosphorus and nitrogen/oxygen bonds are specific to the hard/soft nature of 
the metal centre involved. The phosphorus as previously explained will bind very well to Pt 
(II) metal centres as they are both “soft” in nature. But if say Fe (III) was the metal centre, 
this would produce a weak M-P bond due to the “hard” nature of Fe (III).127 
 
 
 
 
 
 
 
 
 
Figure 1.34: The structures of a Pd (II) 163 and Pt (II) 164 P,N,O type complexes 
One of the well documented properties about analogous Pd (II) complexes is that the 
covalent Pd-O bond in the Pd (P,O ligand) complex does not display any lability, unlike the 
other donor ligands. This also appears in the chemistry of Pt-O in the same or similar 
complex (See Figure 1.34 where both complexes have been made in our research group). 
The HSAB theory therefore does not apply here, as it does for other donor ligands, since 
oxygen uses its extra lone pair of electrons to donate into the metal centre which 
demonstrates the limitations of the HSAB theory. This makes the Pd/Pt-O bond very useful to 
stabilize the complex for oxidation and substitution reactions.
135
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1.6       The Types of Platinum Complexes in this Work: 
 
1.6.1 Platinum Complexes From Iminophosphines: 
 
As previously mentioned phosphine based ligands are favourable for platinum 
complex formation because of the stable complexes they form. Mixed donor ligands are also 
attractive, particularly iminophosphine P, N type ligands, due to the weak π-accepting nature 
of the imine C=N bond and the σ-donor ability of the phosphine. In comparison to analogous 
amines, imines are harder to displace/cleave under acidic conditions as they form stronger 
metal to nitrogen bonds which are less labile than equivalent metal to amine bonds. 
Furthermore, the lability of the imino-group can also be influenced by substituents present 
within the ligand.
136
 
 On coordination to transition metals the soft/hard nature of P,N ligands creates 
asymmetry in the metal orbitals, which then affects the reactivity of the complexes. This can 
be easily illustrated by the difference in the trans influence of the phosphorus donor atom 
compared to the nitrogen. In iminophosphine complexes the bond trans to the phosphorus is 
longer than that trans to the nitrogen, indicating the greater trans influence of phosphorus 
compared to the imine functionality.
137,138
 
  
 
 
 
 
 
 
 
 
 
Figure 1.35: The structures of a tridentate iminophosphine P, N, C type Pt (II) complex 167 
formed alongside its bidentate analogue 166, both from a Pt (IV) iminophosphine 
complex 165.   
The vast majority of iminophosphine metal complexes reported to date are bidentate 
chelates between phosphorus and nitrogen donor moieties. Tridentate complexes of the form 
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P, N, C are not as common, particularly cyclometallated iminophosphine based complexes. 
Work by Balana et al on an iminophosphine Pt (IV) complexes have revealed the possibility 
of stabilising the platinum metal centre for C-H activation and subsequent cyclometallation to 
form a Pt (II) iminophosphine tridentate complex 167,  as well as a Pt (II) phosphinoamine 
bidentate complex, 166 Figure 1.35.
139
  
 
1.6.2 Platinum Complexes From Phosphinoamines: 
 
 Chiral phosphinoamine and phosphinoamide ligands are generally used in conjunction 
with palladium or rhodium, as metal complexes, as catalysts for asymmetric allylic 
alkylation.
140,141
 Phosphinoamide ligands can easily form chelate complexes with 5 or 6 
membered rings. This is usually facilitated via hemilability with insertion of the metal centre 
into the N-H bond assisted by chelation to the phosphorus anchor.
134
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.36: Scheme of the platinum phosphinoamide complex 168, ring opening 169 and 
coordination with guanine through the N1 or N7 position (X) 170.
142
   
From a biological point of view, some phosphinoamide Pt (II) complexes have shown 
to be cytotoxic against cancer cells with potency close to that of cisplatin, while others have 
been reported as active against cisplatin resistant cell lines also.
143,144
 The ability of Pt (II) 
phosphinoamine as well as phosphinoamide complexes to undergo reversible ring opening in 
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aqueous media (Figure 1.36) has also been reported by numerous research groups similar to 
the hemilabile example given in Figure 1.27.
144,142
 These properties have made Pt (II) 
phosphinoamine and analogous phosphinoamide complexes a popular choice for ongoing 
anti-cancer drug design.  
 
1.6.3 Biologically Active Cyclometallated Complexes: 
  
 Cyclometallated Pt (II) complexes have been studied extensively for activity against 
cancerous cells. The relatively strong Pt-C bond(s) means that many complexes display 
unique photophysical properties (more detail in Section 1.7) and enhanced stability in 
biological systems e.g. against reduction or ligand exchange.
82
  
As previously mentioned in Section 1.3.3, work undertaken by Edwards et al has 
reported that tridentate cyclometallated Pt (II) complexes with only one labile ligand could 
act as monofunctional DNA binding agents. In the low chloride concentration of intracellular 
fluid, aquation would lead to a reactive cationic species which may bind directly to DNA as 
well as interacting via intercalation of the planar chromophore into the DNA double helix.
79
  
 
 
 
 
 
 
 
 
 
 
Figure 1.37: The structure of the biologically active cyclometallated N, N, C type Pt (II) 
complex 171 which intercalates with and binds to DNA.
145
  
There has been some success for cyclometallated complexes in terms of biological 
activity. N, N, C type complexes reported by Che et al bind to the major groove of DNA 
along with behaving as DNA intercalators. One of their complexes 171, Figure 1.37 also 
suppressed the activity of CREB (a cAMP response element-binding protein) which normally 
regulates cell cycle regulatory genes such as cyclin A1 and cyclin D2. It did this by 
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selectively blocking the CREB/DNA interaction site by binding to the major groove of 
DNA.
145
  
Other successful biologically active cyclometallates include those with Schiff base type 
ligands, particularly those of thiosemicarbazones. First described by Vázquez-Garcia et al,
146
 
these S, N, C type complexes, Figure 1.38, have shown good cytotoxicity in recent work 
carried out by Smith et al. Compound 172, Figure 1.38, showed the highest activity out of all 
the compounds reported against cisplatin sensitive and cisplatin resistant ovarian cell lines. 
Interestingly the compounds with the single platinum metal centre did not show an overall 
advantage over the bimetallic species, 173, Figure 1.38, which was also active against both 
cell types but only where the diphosphine bridge was bis(diphenylphosphino)ferrocene.
123
  
 
 
 
 
 
 
 
 
 
 
Figure 1.38: The structure of two biologically active S, N, C type thiosemicarbazone 
complexes as a mono-platinum compound 172 and a bimetallic species 173 .
123
  
Cyclometallated phosphine type complexes such as 161, Figure 1.33, Section 1.4.3, are 
relatively common due to the stabilising ability of the strong Pt-P bond.
133
 Tridentate 
cyclometallated complexes of the type P, N, C on the other hand are much less common with 
reports by Balana et al 167, Figure 1.35, Section 1.5.1 being the only available structures at 
the time of writing.
139
 Other P, N bidentate structures like 166, Figure 1.35, Section 1.5.1 
have the potential to form cyclometallated complexes of the type P, N, C, but there are no 
reports of this to date.
130
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1.7       Photophysical Properties of Platinum complexes 
 
1.7.1 Inorganic Complexes in Photodynamic Therapy (PDT) 
 
Photodynamic Therapy (PDT) is a clinically used cancer treatment that utilizes a sensitizing 
agent (an anti-cancer complex for instance), biological molecular oxygen and light to generate a 
reactive chemical species that kills cancer cells. Usually the anti-cancer complex is nontoxic and 
unreactive in its injected form. Once the patient is administered the drug it can be localised and 
activated to the site of the tumour due to pH variations and then irradiated using high intensity light 
on the cancerous area. For tumours on exposed portions of the body this irradiation of light can be 
done externally to the body but fibre optics can also be used to target internal tumours.
147,148
  
Porphyrins have been identified as the most effective class of sensitizing agents for use in 
photodynamic therapy (PDT). These macrocyclic structures are naturally occurring, nontoxic and 
have relatively strong absorptions in the red and near-infrared region of the spectrum and can be 
stimulated by light (Figure 1.39).
149
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.39: The structure of a porphyrin coordinated to a metal centre 174 and a Jablonski 
diagram to illustrate the photoactivation process.
149
  
These photosensitizers use oxygen in their mechanism of action which can be explained by a 
“Jablonski diagram”, Figure 1.39. The compound (with or without a metal centre) absorbs light and is 
converted from its ground state, S0, to a higher, excited singlet state, S1. This process is very fast and 
promotes an electron from a bonding molecular orbital to a higher vibrational level.  
Normally this excited state, S1, is not stable very long and it decays very quickly back to the 
ground state, S0, through a process called “fluorescence”. This process releases a photon (hv) which is 
lower in energy than the excited photon. However, if oxygen is near the excited sensitizer the energy 
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in the excited S1 state can be transferred through a process know as an “intersystem crossing” to the 
oxygen molecule to form a “triplet state” T in the sensitizer molecule.150  
Since the singlet state of oxygen is lower in energy than the triplet (T) state of the 
sensitizer molecule, the collision of an oxygen molecule with an excited sensitizer molecule 
can result in the transfer of energy from the triplet (T) state of the sensitizer to the singlet (S) 
state of oxygen. Singlet oxygen is quite reactive and can attack biological molecule near the 
sensitizer. This can then cause damage to certain biomolecules which can result in the cell 
entering apoptosis and dying. However, the requirement for oxygen is a major drawback as 
many malignant and aggressive cancer cells are hypoxic.
150,151
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.40: The structure of the Pt (IV) diazido complex trans,trans,trans-[Pt-
(N3)2(OH)2(pyridine)2] 175, which is unreactive in the dark but is cytotoxic when 
photoactivated by UVA and visible light (hv) and binds strongly to guanine nucleotides 
(GMP) on DNA strands 176-177.
152
  
One of the primary advantages of PDT over conventional forms of therapy is that 
since light is the activation agent, the area of irradiation can be carefully controlled. This has 
resulted in the development of photoactivatable prodrugs of platinum-based antitumor agents 
aimed at increasing the selectivity and hence lowering the toxicity. These drugs could find 
use in treating localised tumours accessible to laser-based fibre-optic devices. So far Pt (IV) 
complexes have appeared the most attractive as candidates for PDT because they are usually 
substitution inert and require reduction to the Pt (II) species to become cytotoxic (as 
discussed in Section 1.3.5).
151
 
Recently Pracharova et al have reported a Pt (IV) diazido complex that is stable and non-
cytotoxic in the dark but can exhibit significant toxicity in cancer cells upon irradiation with short 
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wavelengths (365 nm) (Figure 1.40). Its activation with UVA irradiation to produce cytotoxic and 
reactive Pt (II) analogues does not require oxygen, which is a huge advantage over conventional 
photosensitizers currently in clinical use for PDT. It was also reported that the selective 
photoactivation of these Pt (IV) complexes in cancer cells may help overcome limitations normally 
connected with toxic side effects of antitumour platinum drugs.
152
   
It was reported that this Pt (IV) diazido complex, upon irradiation, did bind to DNA in 
a number of human cancer cell lines. Importantly it was also noted that no platinum was 
found to be bound to DNA if the cells were treated with the Pt (IV) complex in the dark. 
Measurements of DNA-bound platinum after exposure to the photoactivatable platinum drug 
under irradiation revealed that the amount of platination by the Pt (IV) diazido complex was 
16 fold higher compared to that determined after the treatment with the same dose of cisplatin 
in the dark for the same length of time.
152
  
 
1.7.2 Luminescence of Platinum Based Complexes 
 
Since the late 1980’s square planar Pt (II) complexes have gained significant interest 
outside of biological applications because of their interesting excited state properties and their 
suitability for a number of advanced technological applications. The photochemical and 
photophysical properties of cyclometallated complexes in particular have received the 
majority of attention due to fact that many of these complexes have been successfully applied 
as phosphorescent dopants in the manufacture of highly efficient organic light-emitting 
devices (OLEDs).
153,154
   
Various studies have revealed how the excited state energies and hence colour in several 
classes of Pt (II) complexes can be controlled through rational ligand design. Concepts such 
as rigidity of the complex and assessment of ligand-field strengths can provide a qualitative 
prediction of the extent of luminescence (via decay from an excited state). There are two 
types of decay from an excited state under which Pt (II) complexes may undergo; radiative 
and non-radiative.
155
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Figure 1.41: The Crystal field Ligand Splitting Energies of various geometries. The dx
2
- y
2
 
orbital is the highest in energy for square planar complexes.  
Radiative decay is the release of observable luminescence from an emission of a photon 
due to the decay of energy from an excited state to the ground state. The extent to which this 
occurs depends on the contribution of metal orbitals to the lowest energy triplet excited state. 
Non-radiative decay is also due to the decay of energy from an excited state to the ground 
state but with no emission of a photon and therefore no luminescence.
156
  
The strong preference of Pt (II) complexes to be square planar owing to ligand field 
stabilisation, results in the unoccupied dx
2
- y
2
 orbital being strongly anti-bonding (Figure 
1.41). Population of this orbital will be accompanied by elongation of Pt-L bonds and severe 
distortion which promotes non-radiative decay of metal centred excited states to the ground 
state (known as d-d states). In order to promote radiative decay over non-radiative decay it is 
nessessary that the lowest lying excited state is not a metal centred one (d-d state).
155
  
Ligand centred (LC) or charge-transfer (CT) states are much more favourable for 
radiative decay. A large energy gap is also desired, between the lowest lying excited state and 
the highest lying metal centred d-d state. By increasing the ligand field splitting energy for 
square planar complexes, the dx
2
- y
2
 orbital is also raised in energy, resulting in a larger 
energy gap. This can be achieved using strong-field ligands or co-ligands and/or substitution 
of weak field ligands such as halides with strong field ligands such as imines and 
phosphines.
155
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Figure 1.42: The structure of a CNN type complex 178, a CNC type complex 179 and a CN 
bidentate complex 180, all of which are luminescent.
157–159
 
Cyclometallated tridentate ligands of the type NNC, NCN and CNC coordination types 
have all been explored extensively, as well as C, N bidentate complexes.  Many of these 
compounds have been reported to produce very high luminescence along with providing the 
ability to tune the colours across the visible spectrum by making small changes to the ligands. 
However there have been no reports found at the time of writing of luminescent PNC type 
platinum complexes or mixed donor iminophosphine ligands.
157–159
  
  
 
 
 
 
 
 
 
 
 
 
Figure 1.43: The normalised excitation and emission spectra of a cyclometallated CNN type 
complex, inset (concentration 10
-5
M).
157
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1.8 Summary and Objectives 
 
 The uses of mixed-donor or hemilabile ligands to stabilise and generate complexes 
with potential medicinal applications, specifically with anti-cancer activity, are numerous and 
well studied. The interest in the medicinal applications of metal complexes stems from the 
success of the anti-cancer complex cisplatin. The use of mixed-donor, or hemilabile, ligands 
has been identified as an effective way of stabilising a metal centre and allowing substitution 
by another external ligand.  
 The nature of these coordination complexes is influenced primarily by the Hard Soft 
Acid Base theory (i.e. like binds to like). The most useful ligands have been identified to 
contain phosphorus and nitrogen donor moieties and demonstrate the potential to generate 
stable metal complexes with reversible binding in the presence of other donor 
substrates/ligands. Mixed donor hemilabile ligands have been reported to be very effective 
for platinum complexes designed for medicinal applications, such as iminophosphines. 
 The wide-scale use of cisplatin as an anti-cancer therapeutic drug has generated huge 
interest in developing other effective metal complexes with equal or increased potency as 
anti-cancer agents. Cisplatin, despite its continued use in the clinic, exhibits high toxicity and 
undesirable side effects as well as an acquired resistance by way of repair to damaged 
cancerous DNA caused by cisplatin. Second generation analogues were therefore developed 
in the hope of reducing side-effects and increasing resistance like that found for carboplatin 
and oxaliplatin, both of which are FDA approved and used in the clinic worldwide. Many of 
the other analogues developed were found to have greater toxicities than that of cisplatin and 
so further research into third generation platinum complexes are ongoing. 
 The third generation platinum drugs to be developed were Pt (IV) type complexes 
such as satraplatin, which is currently in phase III clinical trials as the first orally active 
platinum drug. These inorganic prodrugs, with reduced lability, can be reduced in-vivo to 
generate active Pt (II) complexes, which can then act as anti-cancer agents by binding to 
DNA. It has been postulated that the identity of the axial ligands (and their associated 
reduction potentials) correlates directly with their biological activity. 
 With the potential of complexes with mixed-donor (hemilabile) ligands to exhibit 
anti-tumour activity, it is the aim of this project to develop novel tridentate P,N,C and P,N,O 
ligands containing iminophosphine and phosphinoamide functional groups derived from 2-
diphenylphosphinoaniline and to investigate the coordination behaviour and reactivity of 
these ligands towards a platinum metal centre in both +2 and +4 oxidation states in an 
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attempt to generate a novel series of Pt (II) and Pt (IV) cycloplatinated complexes which 
would potentially exhibit biological activity. The platinum complexes studied in this report 
will be of the chloro type, similar to already FDA approved platinum anti-cancer drugs, as 
opposed to the previously reported iodo-complexes from this research group.  
 The advantage of chlorides over iodides for platinum complexes, deemed potentially 
active for an anti-cancer drug, will also be explored. The reactivity of the chloro 
cycloplatinated species formed towards monophosphine substitutions will be investigated in 
an attempt to develop stable complexes with potential biological activity, and investigate the 
lability of the Pt-Cl bond which is reported as an important functionality for successful anti-
cancer activity.   
 Further applications of iminophosphine and phosphinoamide platinum complexes 
will also be explored in the form of luminescence studies to investigate if the rigid 
cyclometallated compounds correlate in regards to intensity with already known Pt (II) 
cyclometallated luminescence complexes.  
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2.1 Chapter 2 Background: 
 
It is the intention of this chapter to extend the investigation of this research group into 
novel cycloplatinated Pt (II) chloro complexes. The process of cycloplatination contained in 
this chapter involves the coordination of an organic ligand containing three potential 
coordination sites to a Pt (II) metal centre. The chelating organic iminophosphine and 
phosphinoamide ligands used in this chapter are derived from the reaction of the 
aminophosphine; 2-diphenylphosphinoaniline 201, Figure 2.1, with the appropriate aldehyde 
202 or acyl chloride 203.  
 
 
 
 
 
201    202    203 
Figure 2.1: The structure of 2-diphenylphosphinoaniline 201, and the general structure of 
the aldehyde used to make the iminophosphine ligands, 202, and the acyl chlorides 
used to make the phosphinoamides, 203.  
Cyclometallation is the process where a metal centre can be cyclised by a ligand with 
the formation of a carbon-metal bond. The iminophosphine ligands used in this study are 
synthesised via a condensation reaction with an appropriate aldehyde (202, Figure 2.1). The 
phosphinoamide ligands are synthesised via loss of HCl by reacting 2-
diphenylphosphinoaniline with the appropriate acyl chloride (203, Figure 2.1).  
Both ligands undergo coordination to the Pt (II) metal centre in a variety of ways, 
which will be explored in this chapter.  Previous work within this research group has 
investigated the effect of substituents on the ligand towards the cyclometallation of Pd (II) 
chloro and Pt (II) iodo complexes (as well as the formation of PNO type complexes). 
1,2
  
Focus for this current work is therefore the synthesis of a series of 
novelcyclometallated Pt (II) chloro complexes from iminophosphine and phosphinoamide 
ligands. Also investigated will be the factors affecting C-H bond activation as well as solvent 
effects. Subsequent oxidation and substitution type reactions will be explored in Chapter 3, 
while studies on the potential applications of these complexes will be discussed and reported 
in Chapter 4.  
PPh2
NH2
O
H
R
O
Cl
R
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2.2 Phosphine and Nitrogen as Donor Ligands 
 
2.2.1 PN Complexes: 
 
 Phosphines can be very effective coordination ligands, particularly for platinum metal 
complexes. The σ-donor ability and π-acceptor ability of phosphines can vary widely 
depending on the substituents present. In a comparison of IR (infra-red) stretching bands for a 
carbonyl group on a molybdenum complex, it can clearly be seen how the phosphine 
substituents can influence the other ligand on the complex (Table 2.1). PF3 for instance is the 
weakest σ-donor as a consequence of the highly electronegative fluorides, but is also the 
strongest π-acceptor. PMe3 on the other hand is the strongest σ-donor and weakest π-
acceptor.
3
  
 
Complex ν (CO), cm-1 
Fac-Mo(CO)3(PF3)3 2090, 2055 
Fac-Mo(CO)3(PCl3)3 2040, 1991 
Fac-Mo(CO)3(PClPh2)3 1977, 1885 
Fac-Mo(CO)3(PMe3)3 1945, 1854 
Table 2.1: Examples of carbonyl IR stretching bands for a range of molybdenum complexes.
3
 
 As a result, the molybdenum in Mo(CO)3(PMe3)3 carries the greatest electron density 
and is therefore most able to donate electron density to the π* orbitals of the CO ligands. This 
back bonding to CO lowers the energy of the carbonyl stretching vibrations. As a result of 
this, the CO ligands in Mo(CO)3(PMe3)3 have the weakest C-O bonds of these set of 
complexes and the lowest energy stretching bands. Similar correlations between a metal 
environment and a variety of other ligands can be shown using IR spectroscopy and is 
therefore used throughout this work as a method of characterisation.
3
  
 Some types of phosphine ligands when coordinated to platinum metal centres promote 
C-H activation and hence favour the formation of cycloplatinated complexes, Figure 2.2. A 
large number of studies have indicated that to achieve C-H bond activation (and subsequent 
cyclometallation), a stable, soluble Pt (II) complex with a labile ligand is desirable. The labile 
ligand allows for a substitution reaction wherein the carbon can bind to the metal centre. C-H 
activation and cyclometallation will be further discussed in Section 2.3. 
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     204       205 
 
 
 
Figure 2.2: Examples of platinum phosphine cyclometallated complexes.
4
.  
Nitrogen has been used as a donor ligand for all of the currently approved platinum 
anti-cancer complexes including cisplatin, carboplatin and oxaliplatin. Nitrogen donor groups 
generally form part of the non-leaving group due to the stability of the complexes they form 
with platinum. But, all of the currently approved anti-cancer complexes are homo-donor 
chelate ligands. Hetero-donor ligands on the other hand (such as P, N donor chelates) have a 
distinct trans effect which can play an important role in controlling selectivity and activity of 
the complex.
5,6
 
 
NMe3 > NHMe2 > NH2Me > NH3 
Figure 2.3: Some substitutions with alkyl groups instead of hydrogen on nitrogen based 
ligands can increase its donor ability by increasing its negative character, with the above 
giving us the order of base strength for difference nitrogen based substituents.
7
  
As already seen for phosphines, the presence of electronegative substituents on a 
donor ligand can decrease the ability of the donor moiety to coordinate to the acid (metal 
centre).  This also holds true for nitrogen based donor ligands also, but for imines in 
particular there is the added effect of increased electron density from the double bond which 
can actually contribute negative character to the nitrogen donor atom. Other methods for 
increasing the coordination ability of a nitrogen donor moiety include adding alkyl groups in 
the place of hydrogen which can actually increase its negative character making nitrogen a 
stronger donor moiety, Figure 2.3.
7
  
Nitrogen is also a popular coordination ligand used for metal complex formation and 
C-H activation. Most C-H bond activation studies have involved chelating nitrogen donor 
ligands like those found in Figure 2.4. The stability provided by the strong phosphine-
N
P
Pt
SMe2
Me
P
Pt
SMe2
Me
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platinum bond results in rapid C-H activation for the complexes shown in Figure 2.2. As 
previously discussed in Chapter 1 and displayed in Table 1.1, Section 1.3.1, nitrogen type 
ligands are generally neither hard nor soft bases according to the HSAB theory (they are 
referred to as borderline). Imines, including Schiff bases in particular, which are employed 
for this project, are also very important intermediates in many metabolic pathways and 
organic synthetic routes.
8
 
  
 
 
 
 
 
 
206         207 
Figure 2.4: The structure of two platinum complexes coordinated to an aromatic N-donor 
ligand, showing a chloro bridged dimer 206 and the DMSO substitute 207.
9
 
Aromatic N-donor ligands are also sometimes employed for coordination, particularly 
for platinum coordination, due to the possible anti-cancer activity they produce with platinum 
metal centres (Figure 2.4). These aromatic N-donor ligands can form very stable complexes 
due to the large electron density from the ring structure, which give the donor atom increased 
negative character.
9
  
Successful platinum coordination to bulky di-imine ligands has also been reported, 
showing their success as coordinating ligands even under difficult sterically crowded 
conditions. The resulting complexes (Figure 2.5) can be subsequently cyclometallated in a 
variety of ways, forming mono-cyclometallated and doubly cyclometallated complexes. 
These will be discussed further under the context of cyclometallation in Section 2.2.
10
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208 
 
Figure 2.5: The structure of a bidentate di-imine coordinated Pt (II) complex with a bulky 
ligand, prior to cyclometallation.
10
 
 
2.2.2 Iminophosphine Ligands: 
 
 A number of research groups have reported successful palladium and platinum 
coordination studies on a multitude of P, N mixed donor ligands. Early interest in these 
systems was driven by the possibilities of forming new catalysts (particularly with palladium) 
and generally focussed on bidentate ligands as seen in Figure 2.6.
11–13
  
 
 
 
 
 
 
   
 
209       210 
 
Figure 2.6: The structure of two bidentate palladium complexes coordinated to a P, N mixed 
donor ligand. Both complex 209
11
 (iminophosphine) and 210
12
 are used as catalysts. 
 
On coordination to transition metals, the hard/soft combination of the P, N donor 
ligands creates asymmetry in the metal orbitals which then affects the reactivity of the 
complex. This property of palladium and platinum type complexes in particular has been 
widely reported with respect to other iminophosphine type ligands.
5
  
Hetero-donor ligands like iminophosphines have a distinct trans effect which can play 
a role in controlling the selectivity/activity, particularly for catalytic processes. The trans 
Pd
P
N
Ph
Ph
R
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P
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influence of the phosphorus donor moiety is significantly different to that of the nitrogen 
donor moiety. In an iminophosphine complex the bond trans to the phosphorus is longer than 
that trans to the nitrogen, indicating the greater trans influence of phosphorus compared to 
the imine donor functionality.
14–16
  
This, as well as the hard/soft combination, lends itself to a versatile coordination 
behaviour with metal centres in different oxidation states and provides hemilabile 
functionality (as discussed in Chapter 1, Section 1.5). Moreover, these types of ligands 
allow modulation of the steric crowding around the metal centre though simple variation of 
the substituents on the imine and phosphine groups.
17
  
Numerous transition metal complexes of iminophosphines have been reported 
(particularly palladium based), but only a limited amount of those containing platinum. Also 
most of the platinum complexes reported are designed for catalysis Figure 2.7.    
 
 
 
 
 
 
 
   211      212 
Figure 2.7: The structure of two Pt (II) iminophosphine complexes. The bidentate complex 
211 is used as a catalyst
18
 while complex 212 is a rare example of a tridentate 
cyclometallated platinum P, N, C type iminophosphine complex.
19
(both feature an unusually 
large P, N bite angle). 
 
 In terms of catalysis, an important property of these ligands is that they stabilise metal 
ions in a variety of oxidation states and geometries, which normally occur during a catalytic 
cycle. Similar ideas can be applied to anti-cancer activity where stability of the non-leaving 
group ligand is crucial to the development of new analogues of platinum based anti-cancer 
complexes.
20
 
The π-acceptor ability of the phosphine, previously mentioned in Section 2.1, can also 
stabilise a metal centre, while the nitrogen σ-donor ability makes the metal centre more 
susceptible to oxidative addition reactions. For example, binding a phosphorus moiety 
directly to a more electronegative atom such as an oxygen or nitrogen will reduce its electron 
donating capability while also enhancing its π-acceptor capacity. On the other hand, the 
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presence of an imino rather than an amino group will result in a nitrogen donor atom of 
greater σ-donating capabilities.21,6,22  
 As previously mentioned, studies which involve ligands containing mixed phosphorus 
and nitrogen atoms have generally focussed on bidentate type coordination. However, multi-
dentate ligands such as that contained in complex 212, Figure 2.7 (P, N, C type) have 
recently become more popular due to their stability for catalysis and potential for anti-cancer 
activity.
23
 Tridentate ligands involving platinum and palladium metal centres of the type “P, 
N, O” have been extensively studied by this research group and others, Figure 2.8.1,24 
 
 
 
 
 
 
    213       214 
Figure 2.8: The structure of two tridentate P, N, O, type group 10 iminophosphine 
complexes. The palladium complex 213 is used as a catalyst
24
 while complex 214 is a 
tridentate platinum iminophosphine complex previously reported by our research group.
1
  
 
 The reactivity of palladium versus platinum towards hemilabile P,N,O type tridentate 
ligands has also been reported with palladium coordinating to the hard oxygen ligand much 
more easily due to its higher reactivity over platinum.  
 
 
 
 
 
 
 
 
 
 215     216     217 
Figure 2.9: Examples of a P,N,N copper complex 215,
25
 a platinum based P,P, N 
iminophosphine type complex 216
23
 and a P,N,S type complex, also with platinum as the 
metal centre 217.
26
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The strong phosphorus-metal bond along with the phosphine ligands’ strong trans 
influence and the chelate effect (discussed further in Chapter 3) also allow for P,N,O 
tridentate coordination in the above complexes.
24
 Other tridentate iminophosphine complexes 
reported to date include P,N,N 
27
 types, P,P, N 
23
 types and C,N,S 
26
 types (with P outside of 
the chelate ring) as seen in Figure 2.9.  
 
2.2.3 Phosphinoamide Ligands 
 
 Phosphinoamide type ligands have similar, but more versatile, coordination behaviour 
to iminophosphines with the same mixed donor atoms of phosphine and nitrogen as seen in 
Figure 2.10, however, the amide donor ligand has less donating ability (and hence negative 
character) than the equivalent imine ligand. This can lead to different hemilability and 
coordination behaviour towards certain metals. The coordination behaviour and hemilability 
of phosphinoamides has been exploited in several ways to bring about good stereoselectivity 
as catalytic complexes, like those featured in Figure 2.10.
28
 
 
  
 
 
 
 
 
 
   218      219 
Figure 2.10: Examples of a platinum phosphinoamide complex which has been reported as a very 
useful catalyst 218,
29
 and a palladium phosphinoamide complex which interestingly coordinates to the 
harder oxygen ligand over the amide 219.
30
  
 
 These functionalised phosphinoamides are generally used where it is desirable to have 
a hinging chelate arm ready for substitution as discussed in terms of hemilability in Chapter 
1, Section 1.5.2. With this functionality in mind these ligands (coordinated to palladium in 
particular) have been reported to be efficient chirality sources for allylic alkylation as 
catalysts. As well as platinum and palladium other phosphinoamide complexes of rhodium (I) 
and iridium (I) have also been reported to be effective catalysts.
28,29
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2.3 Organometallic Compounds, C-H Bond Activation and Cyclometallation: 
 
2.3.1  Main-Group Organometallic Chemistry: 
 
Cyclometallation is core to the formation and development of the newest analogues of 
platinum anti-cancer complexes and the primary concept that will be explored over the course 
of the rest of this chapter. Cyclometallation involves surrounding a metal centre (platinum in 
the present case) with various ligands in a coordinated structure to produce at least one 
platinum-carbon bond via C-H bond activation.  
For a long time it was assumed that transition metal-carbon bonds were too weak to 
yield stable metal alkyl complexes. Compounds such as TiEt4 are very reactive, decomposing 
at temperatures above minus 50
o
C. Main-group organometallic compounds on the other hand 
have long been reported and features such as the role of steric congestion around the central 
atom have been studied by various scientists as far back as the mid 19
th
 century. One of the 
pioneers of main-group organometallic chemistry was the English chemist E.C. Frankland, 
who became the first person to synthesise dimethylzinc in 1848.
31
 
In terms of stability, the trend for compounds of p-block elements is that methyl 
compounds of the light elements of groups 13 and 15 are tend to react exothermically with 
this character decreasing down the group, and the compounds of the heaviest elements react 
endothermically. The relative instability of the heavy members of the group is a consequence 
of the decrease in metal-carbon bond strength where compounds such as Pb(CH3)4 can 
undergo homolytic cleavage to produce CH3 radicals when heated in the gas phase. Similarly, 
dimethylcadmium can decompose explosively.
31
 
 
 
 
 
 
 
    220   221   222 
Figure 2.11: Examples of s-block 220 and p-block 221, 222 organometallic compounds.
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The alkyl compounds of s-block elements contain a highly polar Metal
δ+
 - Carbon
δ-
 bond. 
Some analyses of the bonding in these compounds indicate about 90% ionic character for the 
Li-CH3 interaction, 220, Figure 2.11. Methyllithium is both strongly basic and 
highly nucleophilic due to the partial negative charge on carbon and is therefore particularly 
reactive towards electron acceptors and proton donors. Methyllithium in non-polar solvents 
consists of a tetrahedron of Li atoms with each face bridged by a methyl group, 220, Figure 
2.11. Therefore operations involving methyllithium require anhydrous conditions, because 
the compound is highly reactive toward water, oxygen and carbon dioxide.
31,32
  
The first isolated organometallic compounds of any transition metal on the other hand 
were (CH3)3PtI, (CH3)3PtNO, (CH3)3PtOH and (CH3)3PtCl in 1907 by Pope and Peachy. It 
was noted at the 1907 proceedings of the Chemical Society of London that the authors of the 
report were congratulated on “having opened an entirely new branch of investigation which 
might indeed be said to be a wonderful find”. Since then there has been enormous interest in 
transition metal organometallic compounds, with particular interest given to platinum based 
ones due to their stability, their relative inertness to air and water along with the wide range 
of possible applications.
33
 
 
2.3.2  Formation of Cyclometallated Complexes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  224      223 
Figure 2.12: NaOAc assisted C-H bond activation and subsequent cyclometallation.
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Much of the basic organometallic chemistry of the s- and p-block metals was 
understood by the early part of the twentieth century, but that of the d- and f-blocks has only 
been developed more recently. Early methods of transition metal organometallic synthesis 
used thermal C-H activation to generate the metal-carbon bond. This involved using high 
temperature boiling point solvents (and more recently, solid state heating) to induce the C-H 
bond activation for subsequent binding to the metal centre.
34,35
 
But it was soon discovered that thermolysis and low yields restricted the use of this 
method. Insolubility in high boiling point solvents such as toluene was also cited by Crespo et 
al as another possible reason for failure. However, in time, reagent assisted cyclometallation 
began to emerge as a creditable alternative to achieve metal-carbon bond formation, such as 
that displayed in Figure 2.12. This involves NaOAc acting as a nucleophile towards the 
metal centre followed by loss of one of the coordinated X ligands (where X = Cl, I, Br etc.). 
An intermediate of the type 223 shown in Figure 2.12, has been previously reported by 
Crespo et al.
36–38
 
It has been well reported in the literature that C-H bonds are very strong and generally 
quite difficult to cleave, whether heterolytically or homolytically. Transition metal complexes 
on the other hand offer not only C-H bond activation, but also chemo- and regioselectivity for 
catalytic purposes by tweaking the properties of the complex through choice of metal and 
ligand design (as discussed in Section 2.1). Second and third row transition metals in 
particular offer relatively strong metal-carbon bonds. Pt (II) complexes have been reported to 
form the strongest metal-hydrogen bonds known as well as some of the strongest metal-
carbon bonds for analogous systems.
39,40
    
 
 
225     226 
 
 
 
 
 
Figure 2.13: Cyclometallated pincer-type N,N,C platinum complexes where C-H activation 
was achieved by thermal means.
41
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 Direct thermal C-H bond activation, though, remains the most desired approach to 
synthesising cyclometallates since it requires the least amount of substrates and synthetic 
steps to form the desired product i.e. C-H activation without the use of NaOAc in Figure 
2.12. Limited success has been achieved within this area with various methods employed to 
achieve the desired result. Ka-Wen Chiu et al have achieved direct cyclometallation of 
‘‘pincer’’-type N,N,C Pt (II) chloride complexes interestingly using acetic acid as the solvent 
medium. Square planar geometry, as expected, was achieved for the complexes as identified 
by x-ray crystallographic studies. Figure 2.13.
41
 
N,N,C platinum cyclometallates have also been studied by Vila et al, again 
synthesised by direct thermal cyclometallation but in this instance with toluene as the solvent, 
227, Figure 2.14. They also reported bi-metallic complexes (228, Figure 2.14) with each 
metal centre coordinated in a N,N,C type coordination, also achieved via thermal 
cyclometallation.
42
  
 
 
 
 
 
 
   227      228 
Figure 2.14: Cyclometallated Schiff-Base N,N,C type platinum complexes where C-H 
activation was achieved by thermal means using high boiling point solvents.
42
  
The importance of solvent choice has been shown by Crespo et al,
 
where they have 
discovered a protic solvent such as methanol assists cyclometallation. Although this method 
works well, it still requires the use of an external coordinating base such as NaOAc and a two 
step reaction mechanism. The role of solvent is highlighted further by Wong-Foy et al where 
they have proposed the inclusion of a solvent molecule in the C-H bond activation 
mechanism for the formation of cyclometallated complexes Figure 2.15.
43,44
 
Wong-Foy et al have proposed two pathways for the cyclometallation described in 
Figure 2.15, either direct displacement or by a solvent-assisted pathway to give intermediate 
A. From intermediate A, the actual breaking of the C-H bond can proceed via an oxidative 
addition mechanism (Path I) to generate a Pt (IV) hydride which can then be deprotonated by 
a base in solution, or alternatively via direct deprotonation of the agostic complex (Path II). 
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The evidence they propose supports the formation of Pt(IV) hydrides as important 
intermediates in C-H bond activation and subsequent cyclometallation.
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15: Solvent assisted cyclometallation of a tridentate N,N,N type platinum complex, 
where no external base was used (the reverse arrows are removed for clarity).
44
  
 Direct one-step cyclometallation of palladium complexes with no solvent or base 
assistance has been reported and discussed further in Section 2.5.3. The ability of the 
methoxy group to be ortho, para directing and delocalise its unshared electron pairs is crucial 
in stabilising the proposed arenium ion intermediate. NaOAc is not required for this 
palladium cyclometallation reaction but increased yields can be achieved using NaOAc in 
methanol. This type of C-H bond activation will be explored further in this current research 
using analogous chloro platinum complexes.
45
  
Recently Crespo et al have also reported successful direct C-H bond activation (and 
subsequent cyclometallation) of platinum based bulky di-imine complexes. They report that 
compound 230, Figure 2.16 is very stable, but when refluxed in a high boiling point solvent 
(toluene) for about one hour, metallation of one of the anthryl substituents was achieved with 
loss of a single methane molecule (231, Figure 2.16). When the reaction time was increased 
to four hours, formation of compound 232, Figure 2.16 was also reported, in which both 
anthryl groups were metallated.
10
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 230        231 
 
 
 
 
 
      232 
Figure 2.16: Direct cyclometallation of a bulky platinum diimine complex 230 using a 
variety of methods to form complex 231 and 232.
10
 
 Double metallation of compound 230, Figure 2.16 was also achieved, unexpectedly, 
using acetyl chloride in a dichloromethane-methanol solution. The purpose of this reaction 
originally was to study the protonation of the compound using acetyl chloride as a source of 
anhydrous HCl. Crespo et al however found that it led to a good yield of 232, Figure 2.16 
after ten minutes at room temperature. They propose that the acetyl chloride may be replacing 
the methyl groups on the platinum metal centre with chloride ligands, making it easier for 
metallation of the anthryl groups. Further work using a chloride analogue of 230, Figure 
2.16, displayed as 233, Figure 2.17, resulted in metallation occurring at room temperature in 
dichloromethane.
10
  
 
 
 
 
 
 
    233      234 
Figure 2.17: Direct cyclometallation of a platinum chloride diimine complex at room 
temperature in dichloromethane or chloroform.
10
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Crespo et al found that when compound 233, Figure 2.17 was left in dichloromethane 
or in deuterated chloroform for a few hours, a new compound, 234, Figure 2.17, was formed. 
After 24 hours the major product was compound 234, Figure 2.17 where the release of HCl 
was noted from the reaction solution. Interestingly though, attempts to achieve complete 
transformation of compound 234 into the doubly metalated compound 232, Figure 2.16 using 
a variety of solvents and external reagents such as toluene and sodium acetate, proved to be 
unsuccessful.
10
  
Crespo et al also report that the cyclometallation reaction is quite fast in chlorinated 
solvents, particularly for the chloride complexes, and view Z to E isomerisation as the cause 
for preventing conversion to compound 232, Figure 2.16.
10
  
Further work by Mamtora et al into the stabilisation of the liberated chloride ion by 
solvents, has reported that this may assist coordination of the platinum metal centre to the 
carbon of an aryl ring.
 
In contrast to other solvents such as toluene, methanol or acetic acid 
previously reported by Crespo et al and Ka-Wen Chiu et al, Mamtora et al specifically cite 
the use of chlorinated solvents as having the ability to stabilise the liberated chloride ion via a 
hydrogen bond type of interaction. Chloroform in particular can allow direct cyclometallation 
without the use of NaOAc or other external reagents due to its stabilising effects.
46
  
They propose that this stabilisation of the liberated chloride ion lowers the activation 
energy and hence increases the rate of reaction for a one step concerted cyclometallated 
mechanism. They therefore propose that the loss of the chloride is the rate determining step 
for the reaction. The stabilisation of chloride ions and solvent interactions into 
cyclometallation will be discussed further in Section 2.2.4.
43,44,41
 
 
2.3.3 Cyclometallated Complexes: 
 
 Cyclometallated complexes represent an important class of metal based compounds 
and are widely encountered in modern organometallic and coordination chemistry. Various 
examples of C-H activated (sp
2
 and sp
3
) achiral
47
 or chiral
48
 metal complexes have been 
reported and find numerous applications ranging from organic transformations, directed self-
assembly, catalysis, chemical sensing and more recently as luminescent materials.
49,50
  
The most common form of cyclometallation is “ortho-metallation”. This is an 
oxidative addition in which the ortho position of an aromatic ring becomes attached to the 
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metal (235, Figure 2.18). The other type of cyclometallation occurs by the process of 
reductive elimination, shown as 236 in Figure 2.18.
51
  
 
 
235          236 
 
 
 
 
 
 
237          238  
 
 
 
 
 
Figure 2.18: Cyclometallation reactions by oxidative addition 235 and by reductive 
elimination 237, which is the opposite of an oxidative addition.
51
   
Initial coordination of a metal to donor moieties, such as phosphorus or nitrogen as 
previously discussed in Section 2.2, stabilises the metal centre to allow C-H bond activation 
on the aryl ring of the ligand and hence cyclometallation of the complex with the formation 
of a metal-carbon bond as seen in 237, Figure 2.18.
37
 
 Following on from previous work
 
with cyclopalladation reactions, Crespo et al have 
completed further study on cycloplatinated species using N-benzlidenebenzylamines and the 
platinum substrate [Pt2Me4( -SMe2)2]. The study identifies a possible nucleophilic behaviour 
in the platinum substrates not identified in the palladium complexes. In the palladium 
analogues the reaction occurs solely as an intramolecular electrophilic attack of the Pd at the 
carbon atom.
 
However it has been proposed that the platinum centre possesses the ability to 
attack carbon as an electrophile or as a nucleophile.  C-H bond activation allows 
intramolecular oxidative addition to take place, hence generating the cyclometallate.
37,52
 
 Another specific feature of these reactions identified by Crespo et al is that 
substituents bound to the carbon adjacent to the metallation position (i.e. the alpha positon) 
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hinder the reaction.
 
It was found that the reactivity of the carbon centre depends on the 
specific substituents attached to the alpha position for example chloride or methyl groups. 
One particular example of this interaction is shown  in Figure 2.19.
37
 
 
 
 
 
 
  
   
   239       240 
Figure 2.19: Example of an interaction within a molecule between a CH3 group and a Cl 
group, complex 239 and a H to a Cl group in complex 240.
37
 
In the case of compound 239, cyclometallation was achieved due to the electron 
withdrawing ability of the chloride centre at the 5 position and its interaction with the methyl 
group coordinated to the metal centre, confirmed by 
1
H NMR studies. In compound 240, the 
hydrogen interaction with the chloride on the aryl ring also influenced the cyclometallation 
outcome. NMR studies of compound 240 showed that the iminic resonance was shifted 
slightly downfield in comparison to other analogous complexes. It was concluded that this 
was due to the interaction between the imine proton and the chloride centre at the 2 position 
in 240. The effect of substituents on a ligand towards cyclometallation and C-H bond 
activation will be discussed further in Section 2.2.5.
37
  
 As mentioned previously, nitrogen donor groups on the ligand also play an important 
role as they enhance the nucleophilic nature of the platinum metal centre. Crespo et al have 
performed much of their studies on Pt (II) 241 and Pt (IV) 242 N,N,C type complexes, like 
those in Figure 2.20.
52
  
 In the cyclic voltammetry tests performed by Crespo et al some interesting properties 
about the reductive effects of the Pt (IV) aromatic complexes 242 were identified. It was 
confirmed that the reduction of Pt (IV) complexes is mainly centred on the aromatic ring 
system, like that present in Figure 2.20. From this evidence it was documented that one of 
the driving forces for the formation of a Pt (II) metallacycle involves the filled d-orbitals and 
the fused endo metallacycle with the aryl ring.
52
  
 
Chapter 2  Coordination and Cyclometallation 
 
81 | P a g e  
 
 
 
 
 
 
 
 
   241      242 
Figure 2.20: Example of two N, N, C cyclometallated platinum complexes studied by Crespo 
et al, a Pt (II) type 241 and a Pt (IV) type 242.
52
  
It was seen that during the cyclometallation of the Pt (II) complex 241, Figure 2.20, 
not only does it lead to the formation of a Pt-Caryl bond, but it also leads to an extension of the 
 system to form a “platina-isoindole” system. This is proposed to be a major contributor to 
the stabilisation of the extra electron obtained from the electric current during the 
voltammetry experiment carried out by Crespo et al.
52
 
 The majority of platinum cyclometallates reported to date are from nitrogen based 
ligands, imines in particular. Phosphorus based compounds on the other hand such as tertiary 
phosphines, phosphinites, phosphites, iminophosphoranes and PCP-pincer ligands have not 
been as widely studied for their C-H activation processes, with only a few exceptions as seen 
in Figure 2.21.  
 
 
 
  243 
 
 
Figure 2.21: A doubly cyclometallated (phosphino)amine platinum complex with five 
membered metallacycles.
53
  
It has been well reported however by Gaw et al and others that a general feature of 
phosphinoamine chemistry is the air/moisture sensitivity of these ligands due to the reactive 
nature of the heterolytic P-N bond.
54,55
 However, phosphinoamines have been shown to 
undergo thermally induced orthometallation at Pt (II) and Rh (III) metal centres giving rare 
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examples of thermally stable metal-P-N-Carene-Carene five-membered metallacycles, 243, 
Figure 2.21.
53
  
Very recently successful thermal cyclometallation was also achieved for another 
phosphinoamine type ligand, again trans to a phosphine moiety, using a protic solvent 
(methanol) for the reaction at room temperature, Figure 2.22. For this complex a rare 
thermally stable metal-P-N-Carene-Carene five-membered metallacycle is also formed.
54
  
 
 
 
 
 
 
 
 
 
  244    245    246 
Figure 2.22: Cyclometallation of a (Phosphino)amine complex in a protic solvent at room 
temperature, with C-H activation para to an electron donating group.
54
  
Interestingly, the C-H activation for this complex is also para to an electron-donating 
substituent on the aryl ring (-H and –COOMe). The influence of electron donating and 
electron withdrawing substituents on C-H activation will be discussed further in Section 
2.3.5.  
 
2.3.4  Stabilisation of Liberated Chloride Anions: 
 
 To understand how stabilisation of the chloride ion can assist in facilitating 
cyclometallation, we must first look at hydrogen bonding interactions of the free chloride 
anion and how different solvents influence the overall reaction. Recently, in a comparison of 
solvents by López et al and Narayan Biswas et al for platinum and palladium 
cyclometallation reactions, the polarity and nature of the solvent was cited as playing a key 
role in the stabilisation of C-H activation and subsequent cyclometallation reactions.
56,57
 
Pedzisa and Hay have recently completed extensive studies using electronic structure 
calculations, MP2/aug-cc-pVDZ, into energies of hydrogen bonds with chloride anions (C-H· 
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· · Cl
-
) for a series of X-CH3 donor groups and common organic solvents in which the 
electron-withdrawing ability of X is varied over a wide range of values Figure 2.23.
58
 
Worth noting about this study is the difference between chloroform and methanol in 
binding energies (-19.6 vs -16.6 kcal/mol). Chloroform has a stronger affinity for the 
liberated chloride ion in comparison to methanol (a protic solvent), which has been used 
extensively to facilitate C-H bond activation by a variety of research groups.
58
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23: All stable geometries located, at the computational method MP2/aug-cc-pVDZ 
level of theory, for Cl- interactions to common organic solvents. Note chloroform 
CHCl3 has the shortest bond length with the chloride anion at 2.07Å.
58
  
 The three chlorides in the chloroform molecule cause an electron withdrawing effect 
leaving a δ-positive charge on the hydrogen of the solvent molecule. This results in a stronger 
hydrogen bond with the free chloride anion, than that of any other solvent listed above, even 
the O-H donor solvents such as methanol. Chloroform is therefore ideal for stabilising the 
liberated chloride ion from a platinum cyclometallation reaction.  
The results obtained by Pedizsa and Hay are supported by a study conducted by 
Kryacho et al where chloroform was also found to have the strongest interaction with free 
chloride ions.
 
Figure 2.24 shows anion binding abilities of chloroform in comparison to other 
solvents.
59
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Figure 2.24: Comparison of withdrawing groups on different solvents and their influence on 
anion binding.
59
 
Work by Mamtora et al has shown rapid oxidations and C-H activation at low 
temperatures for Pt (II) complexes in chlorinated solvents (chloroform in particular) as 
discussed previously in Section 2.3.2. Reaction of compound 247, Figure 2.25 with PhICl2 in 
chloroform gives a clean and rapid conversion to the Pt (IV) species 248 through a C-H 
activation and oxidation with the addition of a chloride ligand. Further details on oxidation 
reactions and Pt (IV) complexes will be discussed in Chapter 3.
46
  
 
 
 
 
 
 
 
 
    247     248 
Figure 2.25: Oxidation and C-H activation at low temperatures for a nitrogen based 
heterocyclic complex in chloroform.
46
  
During the oxidation of compound 245, Figure 2.25, C-H activation was also 
observed to form a cyclometallated Pt (IV) complex 248. The oxidation reactions in 
chloroform were complete in 5 mins, whereas comparable reactions in acetone did not go to 
CH4 (Methane) H-Cl (~2.7Å) 
 
 
 
 
CH2Cl2 (Dichloromethane) H-Cl (~2.3Å) 
 
 
 
 
 
 
CHCl3 (Chloroform) H-Cl (~2.1Å) 
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completion, even after an hour and increased temperature. Interestingly, in the oxidation of a 
second complex, compound 249, Figure 2.26, the researchers also got an isomeric by-
product (250, Figure 2.26) when the reaction was completed in acetone. However, only one 
product (compound 251, Figure 2.26) is observed when compound 249 is reacted under the 
same conditions in chloroform.
46
  
 
 
 
 
 
 
 
 
249        251 
 
 
 
 
    250    
Figure 2.26: Oxidation of a nitrogen based heterocyclic complex in chloroform and acetone. 
A secondary by-product was  formed in acetone, but not chloroform.
46
  
Based on previous work by Kryacho et al and Slater et al they report that 
chloroform’s ability to solubilise chloride anions through hydrogen bonding would allow the 
liberated chloride from PhICl2 to move more freely in solution. Therefore only the 
thermodynamic product 251 is formed when chloroform is used as a solvent. This hydrogen-
bonding type of stabilisation of the chloride ion is also used to explain the more rapid 
reaction in chloroform compared to acetone for these complexes.
46,59,60
  
It is also worth noting that they suggest an SN2 type attack on the PhICl3, giving a 
five-coordinate cationic intermediate during the oxidation reaction. This intermediate would 
exist as a tight ion-pair in acetone, resulting in two products formed.
46
 The hydrogen bonding 
interactions between a chloroform molecule and the chlorides on the platinum metal centre of 
compound 251 are shown in Figure 2.27.  
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251 
 
 
 
Figure 2.27: H-bonding interactions between the chloroform solvate and the platinum 
chlorides in the X-ray crystal structure of 251, Figure 2.25.
46
  
 
2.3.5  Influence of the Ligand Substituents on Cyclometallation: 
 
 As previously mentioned, P,N-Donor bidentate ligands are among the most used 
hemilabile ligands in coordination and organometallic chemistry.
 
In general, the rigid and 
short-bite P,N-ligands coordinate to metal atoms in the bridging mode, whereas a non-rigid 
ligand can easily form a five- or six-membered chelate ring as previously seen within this 
research group and others.
61,2,45
 
The ligand substituents at or near the cyclometallation site (or C-H activation site) can 
also influence the outcome of the reaction, as seen in Figure 2.22 earlier. These substituent 
effects have been studied by a variety of research groups, including ours. As discussed earlier 
in Section 2.2.4, the presence of an aromatic ring at the C-H activation position allows for 
resonance delocalisation, stabilising the possible arenium ion intermediate via electron 
donation from the substituent para to the activation position.
61
 
 As previously seen, Vila et al and Crespo et al have both used methoxy and methyl-
substituted aryl groups in tridentate and tetradentate type ligands to form cyclometallated 
complexes using high boiling point solvents such as toluene. It was found that Caryl-H bond 
activation was achievable under relatively mild conditions for C-3 methyl and methoxy group 
substituted rings, Figure 2.28.
42,62
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  252       253 
Figure 2.28: Examples of cyclometallated aryl substituted platinum complexes. 252 is a C, N, 
N type complex
42
 and 253 is a benzylidenebenzylaime type complex.
37
  
The effect of electron withdrawing groups such as chlorides and bromides on the 
other hand can vary depending on their position on the aryl ring. Some reports suggest that 
the presence of chloro substituents adjacent to the activated ortho position does not affect the 
formation of cycloplatinates. On the other hand, other studies suggest that the presence of a 
chloro substituent adjacent to the site of cycloplatination does influence the ability, and hence 
regioselectivity, of cycloplatination.
63,62
  
 
 
 
 
 
  254      255 
Figure 2.29: Examples of electron withdrawing aryl substituted compounds. Compound 254 
is a C, N, N type complex cyclometallated under severe conditions
42
 and 255 is a 
benzylidenebenzylaime type ligand that does not allow cyclometallation even under 
severe conditions.
63
  
Compound 254, Figure 2.29 is formed after the reagents have been heated to reflux 
for 16 hours at reflux in toluene. This is in contrast to the reactivity of ligands with electron 
donating substituents like those shown in Figure 2.28, which can achieve cyclometallation 
under mild conditions at room temperature. Sometimes chloro substituents adjacent to the C-
H bond to be activated can inhibit cyclometallation of the complex. Compound 255, Figure 
2.29 on the other hand does not allow cyclometallation with platinum due to the unfavourable 
electronic effects present within the ligand.
63,62
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Heterocyclic ligands have also been shown to influence the formation of 
cyclometallated metal complexes. Work by Anderson et al has focused on complexes with 
multi ring systems and the behaviour of thienyl imines towards metal centres in particular. It 
was reported that C-H bond activation is achieved exclusively at the carbon alpha (α) to the 
sulphur moiety. It was also noted that after 15 minutes only the nitrogen coordinated complex 
existed (257, Figure 2.30) while further stirring at room temperature for 16 hours resulted in 
the formation of the cyclometallated product 258 without the need for heat or an external 
reagent.
64
 
       257 
 
 
 
 
256  
        258 
Figure 2.30: Direct cyclometallation of a thienyl imine 256, is achieved by stirring at room 
temperature for 16 hours in acetone to form compound 258 from 257.
64
  
The proximity of the metal centre to the C-H bond to be activated is also an important 
consideration in terms of ligand design. Song et al have used tridentate P,N,C type ligands 
with a large P,N, bite angle for this purpose, Figure 2.31. The advantage of these type of 
ligands is their hemilability as discussed in Section 2.1. For Pd (II) and Pt (II) complexes the 
soft phosphorus moiety binds strongly to the metal centre followed by the harder (borderline) 
nitrogen donor moiety which binds more weakly to Pt (II) and Pd (II) metal centres. This sets 
up the metal centre into a bidentate chelating environment such as that seen for compound 
260, Figure 2.31. The proximity of a carbon near the metal centre then allows 
cyclometallation to subsequently occur.
61
 
 
 
 
  259        260 
Figure 2.31: Example of a P,N ligand 259 and bidentate platinum compound 260, with a C-
H bond in close proximity for activation and subsequent cyclometallation.
61
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2.4 Conclusions: 
 
In conclusion, it can be seen that the solvent used along with the nature of the 
coordinating ligand can influence whether or not the cycloplatinated species are formed. The 
location of the substituent can also facilitate activation of the desired C-H bond or the 
presence of a heterocyclic system can assist in achieving one-step cyclometallation under 
mild conditions.  
In order to achieve one-step cyclometallation, the solvent used must not only facilitate 
C-H activation but also stabilise the liberated chloride anion. Chloroform is ideally suited to 
this task, rather than methanol which was previously used along with NaOAc by both this 
research group and others, thus it will be the solvent of choice for this current work.  
Studies into the influence of electron donating substituents, like methyl and methoxy 
groups, will also be undertaken as well as the effects of electron withdrawing substituents. 
However, these factors alone will not ensure the successful synthesis of a cycloplatinated 
species. Other factors investigated will include the influence of the steric bulk of a ligand as 
well as the reaction conditions. 
In contrast to the previously studied iodo platinum complexes, the smaller chloride 
ligands attached to the platinum metal centre should allow the halide to move closer to the 
metal and metal to be in closer proximity to the C-H bond to be activated. The 
thermodynamically stable side product which will be formed from the cyclometallation 
reaction, HCl, may also drive the reaction i.e. increasing entropy.  
 
 
 
 
 
 
 
 
 
 
 
For clarity: A summary of all the complexes and ligands discussed in the results and 
discussion section of this chapter. 
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2.5 Syntheses 
 
2.5.1  Synthesis of the iminophosphine ligands HL
1-4
 
 
 
 
 
 
 
 
 
 
 
Figure 2.32: A Schiff base condensation reaction based on a variation of previously reported 
methods to generate the iminophosphine ligands used for coordination.  
The o-diphenylphosphinoaniline (2-DPPA) starting material was synthesised from a 
variation of a literature method.
65
 Toluene was used instead of benzene where required, liquid 
nitrogen was used to cool the intermediate napthalenide solution instead of solid CO2 and the 
product was purified on a silica gel rather than alumina. Fluffy white crystals of the 
analytically pure starting material (2-DPPA) were formed on cooling in a solution of ethanol 
in a freezer overnight with a yield of 17.8g (89% from the starting nickel complex). The 
mixture was stored in a freezer until required due to previously reported light sensitivity of 
the intermediates and noted light sensitivity of final product 2-DPPA.
65
  
Synthesis of the iminophosphine ligands HL
1-4
 261, 262, 263, 264 was achieved by a 
variation on three different methods previously reported.
1,24,66
 This involved a Schiff base 
condensation of o-diphenylphosphinoaniline (2-DPPA) with one equivalent of the 
appropriate aldehyde (3-H, 3-Br, 3-Cl, 2,3-(OMe)2) in a minimum amount of protic solvent, 
methanol in this case, Figure 2.33. One drop of formic acid was also added to catalyse the 
condensation reaction (Figure 2.33) as it has been reported that imines are formed at an 
optimum pH of ca. 4 to 4.5.
66
 
After stirring the mixture at 50
o
C for 20h, the resulting yellow solution was reduced 
to dryness in vacuo and the residue taken up in dichloromethane. The organic solution was 
then washed three times with distilled water to remove any excess acid and any remaining 
PPh2
NH2
H
O
R
+
PPh2
N
R
+
H2O
R = H
R = 3-Br
R = 3-Cl
R = 2,3-(OMe)2
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R = H
R = 3-Br
R = 3-Cl
R = 2,3-(OMe)2
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MeOH
50oC
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starting materials that may be present. After separation, the organic layer was then dried over 
MgSO4, filtered and reduced to dryness in vacuo. The resulting oil was then crystallised from 
hot distilled methanol yielding the crystallised product. The physical appearances and yields 
of the ligands are shown in Table 2.2.  
Attempts were made to synthesise other novel imine ligands using other aldehydes. 
Both 3-(diethoxymethyl)-benzaldehyde and 3-(4-methoxyphenoxy)-benzaldehyde were used 
with variations of previously reported methods, but only trace amounts of the desired imine 
were detected by NMR and IR characterisation possibly due to hydrolysis. It was therefore 
decided that they were not viable as ligands for further study in this project at this time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.33: Acid catalysed formation of the imine functional group.
67
 
Ligand R Physical appearance Yield 
HL
1
 261 H White powder 56% 
HL
2
 262 3-Br Yellow needles 54% 
HL
3
 263 3-Cl White needles 61% 
HL
4
 264 2,3-(OMe)2 Yellow powder 88% 
Table 2.2: Physical appearances and yields for the successfully formed iminophosphine 
ligands 261, 262, 263 and 264 
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2.5.2  Synthesis of the phosphinoamide ligands HL
5-7
 
 
 
 
 
 
 
 
 
 
 
Figure 2.34: A condensation reaction based on a variation of previously reported methods to 
generate the phosphinoamide ligands with the loss of a HCl molecule as a salt.  
As previously mentioned for the iminophosphine ligands in Section 2.4.1, the o-
diphenylphosphinoaniline (2-DPPA) starting material was synthesised using a variation of a 
literature method.
65
  
Synthesis of the phosphinoamide ligands HL
5-7
 265, 266, 267 was achieved by a 
variation of a previously reported method.
29,68
 This involved the condensation of o-
diphenylphosphinoaniline (2-DPPA) with one equivalent of the appropriate acyl chloride (3-
OMe, 2,4-(OMe)2, 3-Br) in a minimum amount of THF, Figure 2.35. Two equivalents of 
DABCO (1,4-diazabicyclo[2.2.2]octane) were also added to the reaction mixture to neutralise 
the unwanted HCl formed during the reaction.  
After stirring the mixture for 5 hours at room temperature, a white precipitate of 
DABCO.HCl was formed from the reaction of DABCO with the HCl formed. This was 
filtered to leave a light yellow solution which was then reduced to dryness in vacuo and the 
residue taken up in dichloromethane. The organic solution was then washed three times with 
distilled water to remove any traces of HCl or DABCO.HCl along with any remaining 
starting materials that may be present also.  
After separation, the organic layer was dried over MgSO4, filtered and reduced to 
dryness in vacuo. The resulting oil was then crystallised from distilled dichloromethane-
hexane yielding the crystallised product. The physical appearances and yields of the ligands 
are shown in Table 2.3.  
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Figure 2.35: The formation of the phosphinoamide ligands from a primary amine and an 
acyl chloride with the loss of a HCl molecule using an external base.  
Ligand R Physical appearance Yield 
HL
5
 265 3-OMe White powder 75% 
HL
6
 266 2,4-(OMe)2 White needles 61% 
HL
7
 267 3-Br White needles 58% 
Table 2.3: Physical appearances and yields for the successfully formed phosphinoamide 
ligands 265, 266, and 267 
2.5.3  Synthesis of the bidentate iminophosphine complexes with the general formula 
[Pt (η3-PN-L1-3) Cl] 271-273 METHOD A: 
 
As seen in Section 2.2.5 the formation of cyclopalladated and cycloplatinated 
complexes is affected by substituents on the aryl ring of the ligand which contains the C-H 
bond to be activated. Previous work with iminophosphine ligands in our research group has 
found that one-step cyclopalladation did not occur when electron withdrawing substituents 
(such as chloride or bromide) were present in meta positions on the aryl ring (i.e. C2 and C4). 
Neither did it occur if the aryl ring was unsubstituted. In both cases, a η2-P, N bidentate 
complex was formed rather than the η3-P, N, C tridentate complex i.e. there was no C-H 
activation.
45
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In further work carried out by our research group into analogous iodo platinum 
iminophosphine complexes, similar results were seen to occur for both chloride and iodo 
based metal centres. Cycloplatination of the initially formed η2-P, N bidentate iodo 
complexes was only achieved by using an external coordinating base, sodium acetate, in a 
protic solvent such as methanol in a variation of a method described by Crespo et al.
37,2
 
However when an electron donating substituent such as a methoxy group was present 
in the C3 position on the aryl ring, both Lennon and Maguire identified that cyclometallated 
complexes were formed in a single step, regardless of solvent choice.  The proposed 
mechanism of this cyclometallation involves resonance delocalisation, generating a highly 
reactive arenium ion intermediate, Figure 2.36. It was proposed that in order to generate this 
intermediate, an electron donating group must be present at the 3-position of the aryl ring. 
The arenium ion is then formed by resonance delocalisation at the C-6 position of the aryl 
ring as seen in Figure 2.36.
2,45
  
 
 
 
 
 
 
268        
        269 
 
 
 
 
 
 
 
 
270 
 
Figure 2.36: Mechanism of cyclometallation via generation of an arenium ion intermediate 
with the loss of a HCl molecule, proposed by Lennon.
45
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It is the intention of this section to investigate whether analogous chloro platinum 
complexes will produce similar results to iodo cycloplatinated complexes previously 
synthesised by our research group and whether direct cyclometallation is possible with 
electron withdrawing substituents on the aryl ring. To this end a slight excess of the 
appropriate iminophosphine ligand HL
1-3
 261, 262 and 263 was reacted with one equivalent 
of platinum chloride [PtCl2], Figure 2.37. 
 
 
 
 
 
 
 
 
 
Figure 2.37: Reaction of PtCl2 with the iminophosphine ligands HL
1-3
 261, 262 and 263 
using a variety of solvents including acetonitrile, dichloromethane, chloroform, methanol, 
tetrahydrofuran and toluene.  
To a heated and stirred solution of PtCl2 in acetonitrile a 1.1 equivalent of the 
appropriate ligand HL
1-3
 261, 262 or 263 was added as a solid. Previously in our research 
group, acetonitrile was used when working with PtCl2 due to its limited solubility in other 
solvents. The solubility of PtCl2 is primarily limited to acetonitrile with only trace amounts 
being soluble in chlorinated and protic solvents. Acetonitrile on the other hand does have a 
high boiling point however, allowing for possible thermal cyclometallation.  
Getting the platinum chloride into solution, prior to adding the ligand, proved to be 
crucial for coordination and cyclometallation. The PtCl2 was therefore refluxed in acetonitrile 
for 30mins prior to the addition of the ligand. After the ligand was added slowly over an hour 
the resulting mixture was heated at reflux for up to 10 hours. Incompletion was noted at 
shorter reaction times where traces of a brown solid, proposed to be platinum chloride – 
PtCl2, was found in the final product.  
As the reaction proceeded, HCl gas was noted from the reaction mixture using a pH 
probe and litmus paper. After refluxing for 10 hours a cloudy yellow/orange precipitate was 
formed with some black material evident at the bottom of the flask. The solution was filtered 
N
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and the filtrate was found to be a mixture of insoluble materials later identified as the 
bidentate complexes 271-273 using dichloromethane in place of acetonitrile.  
The mother liquor was reduced down to dryness in vacuo and the residue was then 
taken up in dichloromethane and washed with 2 portions of de-ionised water before being 
dried over MgSO4. The solution was then reduced to dryness again in vacuo and crystallised 
from dichloromethane-hexane to produce the cyclometallated complexes 281, 282 and 283 in 
very low yields, Table 2.4.  
 
Compound Coordination Physical appearance Yield 
281 η
3
-PNC-L
1
 Yellow powder 8% 
282 η
3
-PNC-L
2
 Dark Yellow powder 1% 
283 η
3
-PNC-L
3
 Orange powder 5% 
Table 2.4: Physical appearances and yields for the successfully formed cyclometallated 
complexes 281, 282, and 283 from PtCl2 in CH3CN 
The reactions were repeated with the same quantities in dichloromethane which has a 
lower boiling point in comparison to acetonitrile in order to prevent formation of the 
insoluble black material. The PtCl2 was refluxed in a large excess of dichloromethane for an 
hour in order to achieve solubility. HCl gas was not evident for the reaction of PtCl2 with the 
iminophosphine ligands 261-264 and there was no evidence of cyclometallation by NMR or 
IR spectroscopy even after 48 hours at reflux. There was also no evidence of the black 
material found previously but instead a large amount insoluble yellow powder was isolated.  
 
 
 
 
 
 
 
 
 
Figure 2.38: Bidentate complexes are formed in low boiling point solvents which are also 
intermediates in the overall cyclometallation reaction and susceptible to dimerisation. 
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Identification of the yellow powders (271-273) proved to be especially difficult due to 
their insolubility in all available deuterated NMR solvents. Accurate yields were also difficult 
to access due to uncertainty about the purity of the products. However, IR spectroscopy 
identified a shift in the imine stretching frequency in comparison to the uncoordinated ligands 
suggesting coordination with the metal centre (discussed further in Section 2.6.1). Also, 
elemental analysis confirmed the presence of a bidentate Pt (II) complex with a small amount 
of solvent of crystallisation present. It is therefore proposed that these compounds are 
bidentate complexes which have formed insoluble dimers due to the chlorides bring very 
good bridging ligands, Figure 2.39.
69
  
 
    SnCl3
-
 < RSO2
-
 < Cl
-
 < Br
-
 < I
-
 < R2PO
-
 < SR
-
 < PR2
-
 
Figure 2.39: The bridge tendencies for ligands associated with Pt (II) complexes.
70
 
Bidentate halo-bridging platinum dimers have also been reported by numerous 
research groups
69,71,72
 and most of which have been found to be quite insoluble in all common 
solvents.
42,58,41
 The first halo-bridged binuclear compound was first isolated as far back as 
1870; the platinum carbonyl compound [Pt2Cl2(µ-Cl2)CO2],
73
 but more recently halo-bridged 
derivatives have been identified as key intermediates in platinum coordination and 
cyclometallation chemistry. They have also become especially useful in allowing preparation 
of complexes containing two different types of neutral ligands.
69
  
Cotton and Wilkinson have identified three types of bridged d
8
 complexes, Figure 
2.40. The structure of the first two types (a) and (b) are most often found when the bridging 
ligand (µ-X) is a halogen, an S
2-
 or an SR type ligand. The type (c) shown in Figure 2.40 on 
the other hand is usually confined to PR2 and has shorter metal to metal distances in 
comparison to type (a) and (b). The π-donor ability of the bridging ligand can also be 
influential in the adoption of a particular geometry.
70
  
 
 
 
 
 
Figure 2.40: The three types of bridged complexes formed with d
8
metal complexes.
70
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Platinum and palladium bridged complexes have been studied extensively but other d
8
 
metal complexes can also adopt similar structures, for example Rh2Cl2(CO)4 is an (a) type, 
Figure 2.40 and Ir2(µ-PPh2)2(CO)2(PMe3)2 forms a (c) type dimer, Figure 2.40. For Pt (II) 
complexes the bridge tendencies are in the order shown in Figure 2.39, where chloride can 
be seen as having the highest tendency to form bridged structures of all the halides.
70
  
Based on previous work in our research group by Maguire it is proposed that the 
cyclometallated complexes, 281-283, occur with the initial formation of a bidentate species, 
Figure 2.38. But there is also a competing dimerisation reaction occurring also which then 
prevents cyclometallation due to the high tendency for chloride ligands to form bridges.
2
  
Analogous di-iodo bidentate complexes, synthesised by Maguire, were isolated and 
characterised by IR and elemental analysis but direct cyclometallation was not seen to occur 
which these complexes. In Maguire’s research, sodium acetate was used to break the bridged 
ligands and induce cyclometallation. The chloride ligands however, as can be seen in Figure 
2.39, are two orders of magnitude higher in tendency to form bridges than iodide and all 
attempts to use sodium acetate in the present work failed to produce cyclometallates.
2
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.41: The proposed possible structures of the bridged bidentate platinum 
iminophosphine complexes by Maguire.
2
  
These dimeric complexes are proposed to contain a penta-coordinate Pt (II) metal 
centre, Figure 2.41, similar to the previously proposed structures of the iodo platinum dimers 
reported by Maguire and type (a) as described by Cotton and Wilkinson in Figure 2.40. 
Further to the proposed structures in Figure 2.41, it can be seen that the steric and energetic 
constraints of a syn structure (a) would favour the formation of an anti structure (b). However 
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without further characterisation, the complete structure of these complexes cannot be 
confirmed. Attempts to break these dimers by solid state and solvent mediated thermal 
reactions failed along with additions of pyridine which was found to form further 
unidentifiable insoluble complexes at this time. 
 
2.5.4  Synthesis of platinum complexes of the HL
4
 (264) ligand with the general 
formula [Pt (η3-PNO-L4) Cl] 285 METHOD A: 
 
Reaction of the HL
4
 264 ligand with PtCl2 under identical conditions used for the 
synthesis of [Pt(η3-PNC-L1-3)Cl] 281-283 reported for method A described in section 2.4.3 
initially produced only one identifiable product, a PNO type complex 285, Figure 2.42. Also 
an insoluble yellow bidentate dimer, similar to those found for [Pt(η3-PNC-L1-3)Cl] 271-273, 
was again found for this reaction which reduced the yields for the formation of a tridentate 
product due to the high tendency for chlorides to form bridges as discussed earlier.  
 
 
 
 
 
 
 
 
Figure 2.42: The PNO complex formed from the HL
4
 ligand with the loss of a MeCl. 
  A cyclometallated product was not observed for this reaction, despite the presence of 
an electron donating group at the para position to the C-H bond to be activated. Interestingly 
the reaction prefers to form the PNO product 285 over the cyclometallated product even 
though the oxygen ligand is defined as hard by the HSAB theory and platinum is defined as 
soft as discussed in Chapter 1. Also, diluting the solution by adding more acetonitrile to 
reduce the possibility of bidentate dimer formation increased the yields by about 10% to 
43%. 
Attempts to form a cyclometallated product using polar protic solvents such as 
methanol and increasing the refluxing time were not successful. The use of an external 
coordinating base such as NaOAc as previously employed by our research group, Maguire, to 
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achieve cyclometallation also failed.
2
 Reactions of the HL
4
 ligand 264 with alternative 
platinum starting materials such as K2[PtCl4] and PtCl2(dmso)2 also produced the PNO 
complex 285, but in vastly reduced yields of 10 to 15 % in comparison to the reaction with 
PtCl2 and also gave no evidence of the cyclometallated product 284 even in chlorinated 
solvents.   
 
 
 
 
 
 
 
Figure 2.43: The PNO complex formed from a hydroxyl ligand in yields of 77% by Lennon.
45
 
This PNO complex, 285, Figure 2.42, has been previously reported by this research 
group but synthesised from an alternative ligand, Figure 2.43.
45
 Work by Maguire also 
previously reported an analogous iodo PNO complex with the same ligand using in this 
research, HL
4
 264, but also reported equal amounts of the PNC cyclometallated complex 
without the use of an external coordinating base, NaOAc.
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.44: The overall reaction of the HL
4
ligand with PtCl2 in chlorinated solvents. 
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When the reaction in Figure 2.42 was repeated again under the same conditions as for 
the [Pt(η3-PNC-L1-3)Cl] 271-273 complexes but with a chlorinated solvent instead of 
acetonitrile, trace amounts of a cyclometallated product, complex 284, was identified by 
NMR and IR spectroscopy, Figure 2.44. The interesting coordination behaviour of the HL
4
 
ligand 264 with platinum chloride reagents will be discussed further in Section 2.5.6. 
 
2.5.5 Synthesis of cyclometallated tridentate iminophosphine complexes with the 
general formula [Pt (η3-PNC-L1-3) Cl] 281-283 METHOD B: 
 
Due to the insolubility of PtCl2 in polar protic and chlorinated solvents, both of which 
(as previously discussed) have been identified as important for successful cyclometallation, 
alternative platinum starting materials were investigated. Initial work centred on K2[PtCl4] 
(potassium tetrachloroplatinate) and PtCl2(dmso)2 (dimethyl sulfoxide dichloroplatinate) 
which have been used by other research groups as starting materials for coordination and 
cyclometallation.
34,74,75,10
  
K2[PtCl4] has a similar solubility profile to PtCl2 except that it is also soluble in water 
so unfortunately it is of no benefit to this research. It also is readily reduced to platinum metal 
in the presence of alcohols and bases. It was therefore decided not to proceed any further with 
it and instead it was used to synthesise PtCl2(dmso)2 by reacting with dimethyl sulfoxide 
(dmso) in a minimum amount of water giving a 90% yield of the desired product.  
 
 
 
 
 
 
 
 
 
Figure 2.45: Attempted reactions of the HL
1-3
 ligands with PtCl2(dmso)2 produced the 
desired cyclometallated complexes but again, like PtCl2, in very low yields. 
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Reactions with ligands HL
1-3
 261, 262, and 263 in acetonitrile were attempted with 
PtCl2(dmso)2, Figure 2.45, but yields and results were almost identical to those reactions 
completed with PtCl2 and reported in Section 2.5.3 (Method A).  
Previous work carried out by our research group into cyclometallated iodo complexes 
used [PtI2(cod)] ((1,5-cyclooctadiene)di-iodoplatinum) as a starting material for coordination 
to the iminophosphine ligands.
2
 It was noted that its solubility in a large amount of solvents, 
particularly methanol and dichloromethane, was beneficial for coordination and increased 
yields. Other research groups have also found success with (1,5-cyclooctadiene) 
dichloroplatinum (II) [PtCl2(cod)] as their starting material for platinum chloride complex 
formation.
76,22
  
  [PtCl2(cod)] was therefore synthesised using a variation of two literature methods.
77,78
 
The starting material used was PtCl2 instead of the more usual K2[PtCl4], Na2[PtCl4] or 
platinum. The product was isolated in average yields of 50-60% as a white crystalline 
powder. It was characterised by NMR, IR and elemental analysis.  
 
 
 
 
  
 
 
 
Figure 2.46: Direct cyclometallation of the iminophosphine ligands HL
1-3
 261, 262 and 263 
using PtCl2(cod) in chloroform. 
A stirred solution of (1,5-cyclooctadiene) dichloroplatinum (II) [PtCl2(cod)] dissolved in 
chloroform (20ml) was reacted with 1.1 equivalents of the appropriate ligand 261-263, which 
was also dissolved in chloroform (10ml). The ligand was added dropwise from an addition 
funnel over 4 hours to the solution, after which the reaction mixture was heated at reflux for 
an additional 4 hours. After 2 hours of reflux the solution changed colour from a pale yellow 
to dark orange with TLC analysis noting the formation of the desired cyclometallate with an 
Rf value of 0.83, while the previously identified bidentate intermediates 271-273 displayed an Rf 
value of 0.08, primarily due to insolubility.  
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After 8 hours at reflux, the orange/yellow solution was reduced to dryness in vacuo 
and the residue was taken up in 20ml of singly distilled dichloromethane to which silica gel 
was added. This is similar to an analogous literature procedure and is employed here to 
remove any unwanted bidentate material and hydrolysed products.
79,70
 Celite was also 
attempted initially but proved to be unsuccessful for achieving a high yield of the 
cyclometallate from the separation.    
The silica gel was then filtered off and washed with two portions of dichloromethane. 
The yellow filtrate was again reduced to dryness in vacuo and crystallised from doubly 
distilled dichloromethane-hexane to yield cyclometallates 281-283, Table 2.5.  
 
Compound Coordination Physical appearance Yield 
281 η
3
-PNC-L
1
 Yellow, metallic powder 73% 
282 η
3
-PNC-L
2
 Yellow, crystalline powder 7% 
283 η
3
-PNC-L
3
 Orange, metallic powder 45% 
Table 2.5: The physical appearances and yields obtained for the PNC cyclometallated 
complexes 281-283 synthesised from PtCl2(cod), Method B. 
Shorter reaction times resulted in a reduced yield; longer reaction times also saw a 
slightly reduced yield primarily due to hydrolysis of the iminophosphine ligand by the HCl 
side product which is formed from the cyclometallation step. Acid catalysed hydrolysis of 
imines have been reported by a wide range of research groups and studied in depth by 
Madrigal et al in particular, Figure 2.47.
80
  
 
 
 
 
 
 
 
Figure 2.47: The hydrolysis of sasrin-like resin bound imines 279, as monitored by 
fluorescence spectroscopy, reforms the aldehyde starting material 280 which was used to synthesis 
the imines initially.
80 
 
Hydrolysis was confirmed by the appearance of an aldehyde peak in 
1
H NMR spectra 
in reactions that were refluxed for more than 10 hours. This corresponded to the aldehyde that 
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was used to synthesis the iminophosphine ligands as seen in Figure 2.32 previously 
discussed in Section 2.5.1. In tests carried out on the isolated cyclometallated products 281-
283 with HCl, hydrolysis was not observed to occur indicating that the cyclometallates are 
stable towards hydrolysis. However, in tests carried out with HCl on the free iminophosphine 
ligands HL
1-4
 261-264, hydrolysis was observed to occur and the appearance of an aldehyde 
peak was also observed in the 
1
H NMR 
The hydrolysis indicates that the reaction did not go to completion as there are also 
indications of other platinum coordinated complexes, which could be the non dimerised 
bidentate intermediates. The extensive NMR studies on all the reactions will be discussed 
further in Section 2.7. 
Microanalytical data obtained agreed with the proposed empirical formula (within 
experimental error). Most of the complexes were isolated with the presence of crystallisation 
solvent (CH2Cl2) which was also identified in the 
1
H NMR spectra of these complexes. 
As previously discussed in Section 2.5.3 we propose that the cyclometallated 
complexes, 281-283, occur via the initial formation of a bidentate species (which are not 
isolated here) which then have three possible routes within the reaction, Figure 2.48.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.48: The various routes that the bidentate complex could take after formation. The 
possibility of Route 1 and 3 can be reduced though, resulting in the formation of the desired 
cyclometallate via Route 2.  
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In order to increase the possibility of Route 2 occurring in Figure 2.48, the possibility 
of the other two routes occurring must be reduced. The use of molecular sieves can reduce 
Route 1 quite effectively and adding the ligands HL
1-3
 drop wise as a solution over 4 hours 
reduces the possibility of Route 3 occurring. By adding the ligands slowly to a dilute solution 
of PtCl2(cod) it allows the intra-molecular oxidative addition of the bidentate intermediate to 
occur in order to form the cyclometallates 281-283 which we propose is the rate determining 
step, Figure 2.49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.49: The intramolecular oxidative addition of the bidentate complexes to generate 
the cycloplatinated Caryl-Pt bond, which is also the rate determining step of the overall 
reaction.  
As discussed in the introduction to this chapter, early methods of achieving platinum 
cyclometallation used thermal activation to generate the metal-carbon bond and it was seen 
that higher boiling point solvents would assist in increasing the yields of these 
cyclometallates.  
Synthesis of the cyclometallates 281-283 in dichloromethane with PtCl2(cod) gave 
average yields but even better yields were achieved in the higher boiling point solvent 
chloroform (61
o
C). It is proposed that chlorinated solvents assist in the cyclometallation 
procedure and C-H bond activation, the higher boiling point of chloroform in comparison to 
dichloromethane also assists with thermal cyclometallation. 
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However, attempts to improve the yields of the cyclometallated complexes further by 
refluxing the HL
1-4
 ligands 261-263 with PtCl2(Cod) in toluene (110
o
C) for 4 hours produced 
a black precipitate which may be platinum metal. 
1
H NMR studies on the black precipitate 
showed the presence of an aldehyde peak indicating that hydrolysis of the ligand had again 
occurred.  
Work by Crespo et al and others have also found that the use of toluene gave no 
reaction at all for Pt (II) cyclometallation. They cited extreme insolubility as a possible cause 
for failure, which is what is also proposed for this work along with thermal decomposition of 
the ligands, intermediates and starting materials at high temperatures.
43,44
 
Other solvents were also studied in this work, however, as previously seen in Section 
2.5.3 high-boiling point solvents such as acetonitrile (81
o
C) only produced the 
cyclometallates in very small quantities. Protic solvents such as methanol gave reduced 
yields, in contrast to work by Crespo et al
 
where they have identified the usefulness for a 
protic solvent in order to facilitate activation of the Caryl-H bond.
43
  
 
 
 
 
 
 
 
 
Figure 2.50: Solvent assisted cyclometallation with an aryl ring adapted from a proposed 
mechanism by Wong-Foy et al and previous work completed by Crespo et al.
43,44
 
Therefore from these studies it can be seen that cyclometallation is not solely 
dependent on thermal conditions. Solvent dependent direct cyclometallation has been 
identified by Wong-Foy et al, where they have proposed the inclusion of the solvent in the 
mechanism for C-H activation, Figure 2.50. The displaced halide acts as a nucleophile to 
remove the aryl hydrogen in a concerted mechanism. The mechanism in Figure 2.50 closely 
follows that proposed by Lennon in Figure 2.36 for direct cyclometallation using palladium 
where a highly reactive arenium ion intermediate is formed by resonance delocalisation at the 
C-6 position of the aryl ring, Step (c), Figure 2.50.  
M
N
P X
X
M
N
P X
Solv
Solv
X
M
N
P X
X
H
+
Solv
M
N
P X
HX
Arenium Ion Intermediate
(a) (b) (c) (d)
Chapter 2  Coordination and Cyclometallation 
 
107 | P a g e  
 
As is apparent for Step (c), Figure 2.50, the platinum metal centre becomes five-
coordinate. Further mechanistic investigations have been reported in the literature where C-H 
activation and subsequent cyclometallation has been identified to proceed in two steps. 
Therefore it seems quite likely that the reactions reported here follow a similar mechanism. 
Figure 2.51 gives a more detailed look at Step (a) to Step (b) from Figure 2.50 where a five-
coordinate intermediate is also formed.   
 
 
 
 
 
 
 
 
 
Figure 2.51: Proposed mechanism of trans effect substitution of the bidentate complexes 
adapted from a proposed mechanism by Wong-Foy et al and previous work completed by 
Crespo et al.
43,44
 
The proposed mechanism in Figure 2.51 involves coordination of a solvent molecule 
to the metal centre perpendicular to the square planar complex. The solvent molecule acts as 
a nucleophile towards the soft, electron poor metal centre. This generates a five coordinate 
intermediate as noted in the mechanism which follows the well established associative 
substitution mechanism which square planar complexes have been shown to follow.
74
  
The substituents then rotate around the metal centre, resulting in incorporation of the 
solvent molecule trans to the strongest trans-effect ligand, the diphenylphosphino group in 
the present case. This then results in the substituent X being projected perpendicular to the 
square planar complex. X is then lost generating the four-coordinate complex (b) allowing the 
X to act as a nucleophile and cause C-H bond activation, resulting in metal-carbon bond 
formation.  
The subsequent proposed reductive elimination generates hydrochloric acid which has 
been identified during the reaction using universal indicator paper. The result is the formation 
of the cyclometallated, square planar (four coordinate) tri-dentate complexes 281, 282 and 
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283. Evidence for the generation of a five-coordinate intermediate has been reported by 
Crespo et al where an acetate group was present instead of a solvent molecule.
43
 
As previously discussed in Section 2.2.4, Mamtora et al have completed extensive 
studies into C-H activation in chlorinated solvents and have found that chloroform was able 
to solubilise chloride anions via a hydrogen bond type of interaction, Figure 2.27, thus 
stabilising the liberated chloride anion in solution. This results in it being able to remove the 
hydrogen from the aryl ring as proposed in Figure 2.50 and 2.51.
46
 This hydrogen-bonding 
type of stabilisation of the chloride anion in chloroform can be invoked to explain the more 
efficient reaction compared with similar reactions in acetonitrile or toluene studied over the 
course of this research.
46
  
Attempted solid state reactions with the bidentate dimer complexes using heat over a 
number of hours initially found that HCl gas was being released from the solid sample. After 
approximately half an hour however it was no longer observed and upon analysis no 
cyclometallated complexes were found. This would imply also that the cyclometallation of 
these bidentate complexes is in fact solvent dependent, Figure 2.51, but further work is 
required to confirm this. 
 
 
 
 
 
 
 
 
 
 
Figure 2.52: Showing the free rotation around the labelled C1 and C7 bond with the large 
bromine substituent causing steric crowding at a potential C-H activation site (in comparison 
to chloride and hydrogen for HL
1
 and HL
3
). 
The yields produced from the direct cyclometallation during the course of this 
research, 7% for the 3-Br complex 282, 43% for the 3-Cl complex 283 and 73% for the 
unsubstituted 3-H complex 281, identify a trend associated with the substituents present at the 
C3 position of the ligands. Physical properties such as steric factors due to the free rotation of 
PPh2
N
C7
C1
C2
C3
C6
C5
C4
Br
PPh2
N
C7
C1
C4
C5
C6
C3
C2 Br
HL2 262Ligand conf ig A Ligand conf ig B
Chapter 2  Coordination and Cyclometallation 
 
109 | P a g e  
 
the C7-C2 bond in the ligand, indicated in Figure 2.52, significantly influence the yield of 
the reaction depending on the substitute present at the C3 position. 
The unsubstituted HL
1
 ligand 261 gives a much higher yield for cyclometallation 
since the bond rotation results in the same structure for both configurations opening up two 
possible sites for C-H activation. This means there are two sites (C2 and C4) at which the 
chloride anion can remove a hydrogen. This supports the proposed solvent assisted pathway 
shown in Figure 2.50 and 2.51. If the solvent displaces the chloride from the metal centre it 
would require a less sterically hindered environment, especially if ligand configuration B is 
taken into account Figure 2.53. 
 
 
 
 
 
 
 
 
 
 
Figure 2.53: Cyclometallation in Config B is more difficult so only Config A reacts to form 
the desired product which results in a reduced yield for complex 282. For the unsubstituted 
complex 281 despite the same rotation, only one configuration exists, which results in a much 
higher yield.  
The substituents present at the C3 position of the ligand can also affect the stability of 
the arenium ion intermediate, proposed in Figure 2.50. Electron withdrawing substitutions 
such as chloride and bromide in ligands HL
2
 and HL
3
 (262 and 263) pull electron density 
away from the aryl ring, resulting in a less stable arenium ion intermediate. Electron donating 
groups such as methoxy groups can have the opposite effect where the electron donating 
ability of the substituents can in fact stabilise the arenium ion intermediate which will be 
discussed further in the next section, Section 2.5.6.
45
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2.5.6 Synthesis of platinum complexes of the HL
4
 (264) ligand with the general 
formula [Pt (η3-PNC-L4) Cl] and [Pt (η3-PNO-L4) Cl]  284-285 METHOD B: 
 
Reaction of the HL
4
 ligand 264 with [PtCl2(cod)] under the same conditions used for 
the synthesis of [Pt(η3-PNC-L1-3)Cl] 281-283 discussed in Section 2.5.5 produced two 
products. Crystallisation of the residue from dichloromethane-hexane yielded orange-red 
crystals. These crystals were identified to be a mixture of two products by TLC, firstly the 
cyclometallate [Pt(η3-PNC-L4)Cl] 284 and the tridentate [P, N, O] complex [Pt(η3-PNO-
L
4
)Cl] 285 as confirmed by IR and NMR analysis (see Sections 2.6 and 2.7). As previously 
mentioned in Section 2.5.4 the chloro P,N,O complex was synthesised previously by this 
research group using an alternative method and ligand, Figure 2.43.  
TLC analysis gave three spots from the solution where one was at Rf=0.83 (Fraction 
A), another at Rf=0.33 (Fraction B) and one which stayed on the line with an Rf=0 (Fraction 
C), Figure 2.54. The two complexes (Fraction A and B) were separated using wet-flash 
chromatography on silica gel, eluting from chloroform:methanol (98:2) which gave the best 
separation as noted by TLC. The third fraction (Fraction C) stayed on the column despite 
various attempts with a number of solvents to remove it.  
 
 
 
 
 
 
Figure 2.54: Illustration of a TLC with the two primary products of the reaction (Fraction A 
and B) eluting from 98:2 CHCl3:MeOH while Fraction C remains on the column. 
Both products (Fraction A and B) were separated from 15 fractions and crystallised 
individually from dichloromethane-hexane. Product A, eluting first, was identified as the 
cyclometallated species [Pt(η3-PNC-L4)Cl] 284 while Product B, eluting second, was 
identified as the previously reported tridentate chloro PNO complex [Pt(η3-PNO-L4)Cl]  285.  
The material which stayed on the column (Fraction C) was found to be very insoluble 
and is again proposed to be a mixture of the bichloro bidentate complex and its proposed 
dimer. The yields and physical appearances of both products can be found in Table 2.6. 
 
Fraction A
Rf = 0.83
Fraction B
Rf = 0.33Fraction C
Rf = 0.0
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Compound Coordination Physical appearance Yield 
284 η
3
-PNC-L
4
 Orange, metallic powder 62% 
285 η
3
-PNO-L
4
 Orange, crystalline powder 12% 
Table 2.6: The yields and physical appearances of the complexes 284 and 285 
Unlike the reactions with PtCl2, Method A as reported in Section 2.5.4, the 
cyclometallated complex [Pt(η3-PNC-L4)Cl]  284 formed in good yields here as well as the 
previously reported PNO complex [Pt(η3-PNO-L4)Cl] 285. Similar to the reactions discussed 
in Section 2.5.5 for the cyclometallated complexes 281-283, the cyclometallated complex 
[Pt(η3-PNC-L4)Cl] 284 is formed here via the same proposed mechanisms by analogy with 
the use of the HL
4
 ligand 264 via the bidentate intermediate, Figure 2.55. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.55: The two tridentate products formed from the HL
4
 ligand 264 formed via the 
bidentate intermediate in chloroform.  
The ability to form two products from the HL
4
 ligand 264 stems from the fact 
discussed in Section 2.4.5 with the bond rotation around C7-C2 as seen in Figure 2.52. But 
instead of the methoxy group preventing coordination like that seen for the HL
2
 and HL
3
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ligands, a methyl group is displaced in order to coordinate to the oxygen heteroatom directly 
forming the PNO product 285. Also the electron donating ability of the methoxy group para 
to the C-H bond to be activated helps to stabilise the arenium ion intermediate from the 
proposed cyclometallation mechanism in Figure 2.50. 
In order to investigate the role of the solvent in the reaction of HL
4
 264 with 
PtCl2(cod) was repeated using acetonitrile rather than chloroform. The largest product from 
this reaction was the tridentate PNO complex 285 with only a trace amount of the 
cyclometallated Pt  (II) PNC complex 284 formed. This is in contrast to the results from the 
reaction in chloroform where the cyclometallated complex 284 is the major product. These 
observations provide additional evidence for a solvent assisted pathway in cyclometallate 
formation.  
It is also worth noting that unlike work completed with the analogous iodo complexes 
reported previously by our research group, an external base (NaOAc) was not required to 
form the cyclometallated complex 284. Instead a one step solvent assisted cyclometallation 
was seen via the mechanisms discussed in Section 2.5.5. 
 
2.5.7 Synthesis of cyclometallated tridentate phosphinoiminol complexes with the 
general formula [Pt (η3-PNC-L5-7) Cl] and [Pt (η3-PNO-L6) Cl] 286-289: 
 
 As discussed in Section 2.1.2 phosphinoamide type ligands have similar coordination 
behaviour to iminophosphines with the same mixed donor atoms of phosphine and nitrogen. 
However, the nitrogen group of the amide donor ligand has less donating ability (and hence 
negative character) than the equivalent imine ligand described already which can lead to 
different hemilability and coordination behaviour. 
Previous work in this research group on phosphinoamide ligands with platinum iodo 
starting materials [PtI2(cod)] reported extensive difficulties attempting to form tridentate 
complexes. Initial work resulted in the formation of insoluble monodentate iodide bridged 
dimers (µ-I) with coordination taking place solely through the diphenylphosphine group. This 
is due to the amide/nitrogen group having less donating ability in comparison to the 
analogous imine group on the iminophosphine ligands.  
 Additional refluxing for a number of days and the addition of a large excess of 
sodium acetate was required to form the bidentate complexes with coordination through both 
the phosphine and iminol. It was found by NMR spectroscopy that although the iminol group 
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possess similar coordination properties to imines described earlier, due to the presence of the 
hydroxyl moiety the ligands are more susceptible to hydrolysis.
81
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.56: The phosphinoamide ligands exist as two forms. In the solid state they take the 
amide form while in solvents they tautomerise to form an iminol giving two possible isomers.  
 In order to achieve cyclometallation of the phosphinoamide complexes, an external 
base to induce tautomerism and assist in cyclometallation was required. The base-induced 
tautomerism of phosphine amides has also been reported by other research groups as well as 
their complexation to metal centres.
29,68,82
  
The methodology for the synthesis of the platinum chloride cyclometallated 
complexes 286-288 is based on a combination of previously reported methods
29,2
 and that 
which was successful for the iminophosphine complexes in Section 2.4.5. Initially the 
reactions with PtCl2(cod) and the HL
5-7
 ligands 265-267 were attempted in chloroform using 
the same conditions as that found to be successful the iminophosphine complexes, Section 
2.5.5. HCl was again generated (as detected by litmus paper and a pH meter), suggesting that 
cyclometallation had occurred. However yields of the products remained very low and NMR 
studies suggested extensive hydrolysis has taken place.  
The reactions were therefore repeated using an external base to remove the HCl. 
Initially triethylamine was used to form Et3N.HCl, however multiple products were found 
upon completion of the reaction which suggested possible coordination between the metal 
centre and the external base. Therefore DABCO was used instead as its bulky molecular 
nature reduces any potential coordination with Pt (II) metal centres, Figure 2.57.  
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To a stirred refluxing dilute solution of PtCl2(cod) in chloroform with an excess of 
sodium carbonate (to maintain basic conditions) and DABCO added, the HL
5-7
 ligands 265, 
266 and 267 were added as a solution of chloroform from a drop-funnel over four hours. The 
solution was then refluxed for a further two hours to assist thermal cyclometallation. 
Immediately after adding the ligand the reaction became cloudy white with the formation of 
the DABCO.HCl.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.57: Synthesis of the cyclometallated platinum iminol complexes from the E-isomer 
of the tautomerised phosphinoamide ligands HL
5-7
265, 266 and 267. The Z-isomer of the 
iminol version of the ligand cannot form cyclometallated products. 
  
Compound Coordination Physical appearance Yield 
286 η
3
-PNC-L
5
 Pale yellow, metallic powder 42% 
287 η
3
-PNC-L
6
 Yellow, crystalline powder 51% 
288 η
3
-PNC-L
7
 Yellow, crystalline powder 12% 
Table 2.7: The physical properties and yields for the cyclometallated platinum iminol 
complexes 286, 287 and 288 
After six hours the bright yellow cloudy solution was filtered to remove the 
DABCO.HCl formed. The filtrate was then reduced to dryness in vacuo, taken up in 
dichloromethane, washed three times with de-ionised water and dried over MgSO4. The 
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solution was then reduced to dryness again in vacuo and crystallised from dichloromethane-
hexane to produce the cyclometallated complexes 286, 287 and 288 in average yields, Table 
2.7. Each complex was identified by elemental analysis, IR and NMR spectroscopy, Section 
2.6 and 2.7.  
The DABCO serves three possible roles in this reaction in order to achieve 
coordination and subsequently cyclometallation of the complexes 286-288 in good yields. 
Role A, Figure 2.58; Role B, Figure 2.59 and Role C, Figure 2.60.
2,43
 Firstly, the DABCO 
can assist in the formation of the iminol by forming an “external base-stabilised polar iminol 
form” which then allows the nitrogen donor moiety to increase its negative character, Figure 
2.58.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.58: Role A: Base induced tautomerism of the amide ligands into their iminol form 
in solution, adapted from Crespo et al.
43
 
In Figure 2.58 the tautomerisation step is achieved by deprotonation of the amide N-
H bond which results in resonance delocalisation and formation of the iminol. This polar 
form, as illustrated in Figure 2.58, has been identified as stabilised by external bases by 
Crespo et al where triethylamine was used as the external base.
43
 From this step, reaction of 
PtCl2(cod) with the HL
5-7
 ligands resulted in the formation of the bidentate intermediate 
through coordination though the phosphorus and nitrogen donor moieties, previously seen for 
complexes 281-285.   
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The second role for DABCO is to form an ion-pair with the HCl formed from the 
cyclometallation procedure. The phosphinoamide ligands, particularly in the iminol form, are 
more sensitive to hydrolysis over the analogous iminophosphines and so an ion-pair base is 
necessary; Role B, Figure 2.59.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.59: Role B: Cyclometallation of the E-isomer iminol Pt (II) complexes by removing 
the HCl formed from the reaction. 
In Role B, Figure 2.59, the cyclometallate is formed from the E-isomer of the 
bidentate intermediate via intramolecular oxidative addition and by a solvent assisted 
mechanism as previously discussed in the context of the iminophosphine complexes in 
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Section 2.4.5. The Z-isomer cannot form cyclometallates and both bidentate intermediates 
form dimers with each other and themselves. 
Finally, work by Crespo et al has reported a third role for DABCO (and other external 
bases such as triethylamine) which is that it can also assist in cyclometallation, Role C, 
Figure 2.60. In their work they also report that the process is solvent dependent and in order 
to facilitate the formation of a metal-Caryl bond, a carbanion is generated by transfer of a 
proton to the external base.
43
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 2.60: Role C: The proposed ion-pair cyclometallation of the (E-isomer) iminol 
platinum complexes via assistance by an external base, DABCO.
43
 
The anionic carbon attacks the electrophilic Pt (II) metal centre with simultaneous 
elimination of a chloride, thus generating an ion-pair with the protonated external base 
(DABCO hydrochloric acid), Figure 2.60. Work by Crespo et al has found that this 
mechanism is most prominent in polar, non-protic solvents such as chloroform as used here. 
This further facilitates the transition state, Figure 2.60, which results in formation of the Pt-
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Caryl bond formation. In the presence of solvents such as methanol, ion-pairs do not 
significantly influence the cyclometallation process due to the solvents’ own participation in 
the cyclometallation process.  
Attempts were made to increase the yields by refluxing for longer periods of time (up 
to 72 hours). However, the reactions involving ligands HL
5
 265 and HL
7
 267 in particular 
resulted in extensive hydrolysis of the complexes, ligands and intermediates which as a result 
produced lower yields of the cyclometallates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.61: The formation of a secondary PNO product 289 from the E-isomer of the HL
6
 
ligand as well as the cyclometallated PNC complex 287 in a similar manner to that which 
was seen for the iminophosphine ligand HL
4
 and its multiple products. 
For the dimethoxy ligand HL
6
 266 after 48 hours reflux the yield of the previously 
identified cyclometallate [Pt(η3-PNC-L6)Cl]  287 was reduced like that found for the other 
two ligands HL
5
 and HL
7
. However, a secondary tridentate PNO type product [Pt(η3-PNO-
L
6
)Cl] was identified in very low yields, Figure 2.61. Efforts to increase the yield of this 
PNO complex 289 were unsuccessful despite using different solvents (such as acetonitrile) 
and increasing the reflux time. Isolation of this compound from the cyclometallated product 
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287 was also very difficult as it was found to be sensitive to the slight acidic nature of silica 
gel, which caused hydrolysis.  
Using a variety of solvent systems and a more neutral alumina column also failed but 
recrystallisation techniques with dichloromethane and hexane did reduce the amount of the 
cyclometallated complex 287. This left the PNO product as the majority compound which 
was then identified by IR and NMR spectroscopy. The product is proposed to be formed in a 
similar way to the iminophosphine PNO complex identified earlier in Sections 2.5.4 and 2.5.6 
with ligand bond rotation bringing the methoxy group nearer to the metal centre, Figure 2.61.  
The reaction mechanism for all the phosphinoiminol complexes is proposed to take 
place via numerous intermediates previously isolated for the analogous iodo complexes but 
not characterised here due to insolubility. The bidentate intermediate is again proposed as 
seen for the iminophosphine complexes along with a monodentate intermediate with 
coordination solely through the phosphine.  
 
2.6 Infra-red spectroscopic studies 
 
2.6.1 Iminophosphine ligands HL
1-4
 (261-264) and their Pt (II) complexes [Pt(η2-PN-
L
1-3
)Cl] (271-273), [Pt(η3-PNC-L1-4)Cl] (281-284) and [Pt(η3-PNO-L4)Cl] (285): 
 
In the iminophosphine ligands and their complexes the most informative peak given 
by IR spectroscopy is the stretching band of the imine bond, υ(C=N). The uncoordinated 
ligands typically exhibit a strong stretching band at ca. 1600 cm
-1
 for this bond. The υ(C=N) 
values for ligands HL
1-4
 261-264 along with their corresponding bidentate and tridentate 
iminophosphine chloride complexes as synthesised from PtCl2 (Method A) or PtCl2(cod) 
(Method B) are displayed in Table 2.8 and Table 2.9.  
 
Ligand 
HL
1-3 
υ(C=N) 
cm
-1
 
[Pt(η2-PN-L1-4)Cl2] υ(C=N) 
cm
-1
 
[Pt(η3-PNC-L1-3)Cl] υ(C=N) 
cm
-1
 
HL
1
 261 1626 271 1595 281 1585 
HL
2
 262 1621 272 1591 282 1587 
HL
3
 263 1622 273 1584 283 1575 
Table 2.8: The υ(C=N) values for ligands HL1-3 along with their analogous bidentate and 
tridentate complexes from the PtCl2 starting material (METHOD A).  
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Ligand 
HL
4
 
υ(C=N) 
cm
-1
 
[Pt(η2-PN-L4)Cl2] υ(C=N) 
cm
-1
 
[Pt(η3-PNC-L4)Cl] 
[Pt(η3-PNO-L4)Cl] 
υ(C=N) 
cm
-1
 
HL
4
 264 1615 274 1589 284 1578 
HL
4
 264 1615 274 1589 285 1606 
Table 2.9: The υ(C=N) values for the ligand HL4 along its analogous bidentate and 
tridentate PNO complex from the PtCl2(cod) starting material (METHOD B). 
Successful coordination of the imino-nitrogen to the platinum metal centre results in a 
reduction in the stretching frequency of the imine functionality from ca. 1620cm
-1
 for the free 
ligands to ca. 1590cm
-1
 for the bidentate intermediates, 271-274, Figure 2.62. There is then a 
further reduction upon cyclometallation to the tridentate species to ca. 1580cm
-1
 for 
complexes 281-283, Figure 2.62. This confirms the presence of an imine-Pt bond in all of 
these complexes. Multiple aromatic stretching bands were also observed for the free ligands 
and the complexes at ca. 1450cm
-1
 corresponding to aromatic carbon stretches. 
The reduction in stretching frequency of the C=N bond in the complexes is due to the 
weakening and stretching of the C=N imine bond as a result of Pt-N bond formation which 
pulls electron density from the nitrogen interaction into the empty d-orbitals of the Pt (II) 
metal centre,.
83,84
 The large reduction in the stretching frequency for the tridentate 
cyclometallates, 281-284, compared to that for the bidentate complexes, can be attributed to 
the formation of a sterically rigid, fixed  geometry composed of two five-membered rings, 
around the electrophilic Pt(II) metal centre resulting in additional lengthening, and hence 
weakening, of the imine bond Figure 2.62.  
The 2,3-(OMe)2 iminophosphine complexes 274, 284 and 285 also display the same 
trend of reduction in stretching frequency of the imine functionality in comparison with the 
free ligand HL
4
 264, Table 2.9. However, there is significant difference in the imine 
stretching frequencies between the cyclometallated complex 284 and the PNO complex 285 
which are both formed from the same ligand.  
In the case of the PNO type complex [Pt(η3-PNO-L4)Cl] 285, we see a higher υ(C=N) 
than that of the cyclometallated PNC complex  [Pt(η3-PNC-L4)Cl] 284. This would indicate 
that the imine bond of the PNO complex 285 is stronger than that of the cyclometallated 
complex 284. For the PNO tridentate complex 285 a mixture of a five-membered ring and a 
six-membered ring are formed instead upon cycloplatination, Figure 2.62, resulting in a less 
sterically rigid complex and therefore causing less weakening of the imine bond which can be 
seen in Table 2.9. 
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Figure 2.62: The range of complexes described in this section with the types of rings formed 
upon coordination and cyclometallation highlighted.  
 
This concept will be discussed further on in this chapter and it is also worth noting 
that the stretching frequency of the C=N bond for the PNO complex [Pt(η3-PNO-L4)Cl] 285 
matches that obtained previously by this research group in the alternative synthesis of this 
compound.
1,45
 However, the stretching frequencies for the cyclometallated complexes of this 
research are significantly higher than that previously reported for similar iodo 
cyclometallated Pt (II) complexes which would suggest that the C=N imine bond in the 
chloro cyclometallates is stronger than that found in the iodo counterparts, implying 
increased stability.
2
 
 
2.6.2 Phosphinoamide ligands HL
5-7
 (265-267) and their Pt (II) iminol complexes 
[Pt(η3-PNC-L5-7)Cl] (286-288): 
 
As previously discussed in Section 2.4.7, the phosphinoamide ligands HL
5-7
 265, 266 
and 267 tautomerise in solution to the iminol form. This makes a direct comparison between 
the solid amide ligands and the Pt (II) iminol complexes 286-288 impossible using IR 
spectroscopy.  
IR data for the phosphinoamide ligands HL
5-7
 and the cyclometallated Pt (II) iminol 
complexes are given in Table 2.10. The amide ligands show the presence of ν(C=O) and ν(N-
H) stretching bands and N-H bending frequencies along with various ν(C=C) bands 
confirming that they exist as the amide tautomer in the solid state.  
PPh2
N
N
Pt
PPh2
Cl
R = 3-H 261
3-Br 262
3-Cl 263
2,3 (OMe)2 264
Cyclometallated
PNC Complexes
R
Iminophosphine Ligands
R
R = 3-H 271
3-Br 272
3-Cl 273
2,3 (OMe)2 274
Ph2
P
N
R
Pt
Cl
Cl
Bi-dentate complexes
Bi-dentate Dimers
R = 3-H 281
3-Br 282
3-Cl 283
2,3 (OMe)2 284
Cyclometallated
PNO Complex 285
N Pt
PPh2
O
Cl
OMe
5
5
5
6
5
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The platinum iminol cyclometallates 286-288 on the other hand show the presence of 
ν(C=N) and broad ν(O-H) stretches along with various ν(C=C) bands as well confirming that 
coordination of the iminol tautomer has occurred. Multiple aromatic stretching bands were 
also observed for the free ligands and the complexes at ca. 1450cm
-1
 corresponding to 
aromatic carbon stretches. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.64: The range of compounds described in this section with the types of rings formed 
upon coordination highlighted. The notable stretching bands for each structure are given in 
Table 2.10 and Table 2.11. 
 
 
Ligand 
HL
5-7 
υ(C=O)  
cm
-1
 
υ(N-H)  
cm
-1
 
[Pt(η3-PNC-L5-7)Cl] υ(C=N)  
cm
-1
 
υ(O-H)  
cm
-1
 
HL
5
 265 1678 3362 286 1582 3330 
HL
6
 266 1649 3275 287 1575 3323 
HL
7
 267 1675 3366 288 1579 3328 
Table 2.10: The υ(C=O ) and υ(N-H) values for ligands HL5-7 along with the υ(C=N) and 
υ(O-H) values for their analogous cyclometallated complexes 286-288. 
Ligand 
HL
6 
υ(C=O)  
cm
-1
 
υ(N-H)  
cm
-1
 
[Pt(η3-PNO-L5-7)Cl] υ(C=N)  
cm
-1
 
υ(O-H)  
cm
-1
 
HL
6
 266 1678 3362 289 1606 3331 
Table 2.11: The υ(C=O ) and υ(N-H) values for the ligand HL6 266 along with the υ(C=N) 
and υ(O-H) values for the PNO minor product 289. 
PPh2
NH
N
Pt
PPh2
Cl
R = 3-OMe 265
3,4-(OMe)2 266
3-Br 267
Cyclometallated Iminol
PNC Complexes
R
Phosphinoamide Ligands
R
R = 3-OMe 286
3,4-(OMe)2 287
3-Br 288
Proposed Tridentate
PNO Complex 289
N
Pt
PPh2
O
Cl5
5
5
6
O
HO
HO
OMe
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There is a significant difference in the imine stretching frequencies between the 
cyclometallated complex 287 and the PNO complex 289, both of which are formed from the 
same ligand and bidentate intermediate. This is similar to the 2,3-(OMe)2 iminophosphine 
ligand, HL
4
 264, where the HL
6
 ligand 266 is also seen to act in the same way with a PNC 
complex 287 forming as well as a PNO complex 289, Figure 2.61.  
In the case of [Pt(η3-PNO-L6)Cl] 289, we see a higher υ(C=N) and υ(O-H) than that 
of the cyclometallate  [Pt(η3-PNC-L6)Cl] 287 which would again indicate that the imine bond 
of the PNO complex 289 is also stronger than that of its analogous cyclometallated complex 
287 like that seen for the iminophosphine complexes in Section 2.6.1. The difference in the 
rings formed during coordination can influence the imine stretching frequencies as 
highlighted in Figure 2.64. 
 
2.7 NMR spectroscopic studies 
 
2.7.1 NMR data for the Iminophosphine ligands HL
1-4
 (261-264): 
 
1
H and
 31
P{
1
H} spectroscopic data was obtained for all the iminophosphine ligands 
261-264. 
13
C, [
1
H-
1
H] COSY plots and [
13
C DEPT 45-
1
H] HETCOR plots were carried out 
on the HL
4
 ligand as a comparison for the cyclometallated complex 284 which is the most 
soluble of all the complexes reported and thus the only one for which it was possible to 
obtain 
13
C NMR spectra.  
 
 
 
 
 
 
 
 
 
 
Figure 2.64: The iminophosphine ligands with a comparison of the E and Z possible isomers 
and the HL
4
 ligand which has electron donating substituents unlike the other iminophosphine 
ligands. 
 
PPh2
N
PPh2
N
H
H
MeO
OMeR = 3-H 261
3-Br 262
3-Cl 263
R
Ligand HL4 [2,3-(OMe)2] 264
E-isomer
N
H
R
Ph2P
The proposed Z-Isomer
R = 3-H 261
3-Br 262
3-Cl 263
2,3-(OMe)2 264
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The 
1
H NMR and 
31
P{
1
H} data of the iminophosphine ligands are summarised in 
Table 2.12. All the spectra exhibit a singlet, integrating for one proton, in the range of δ 8.07-
8.61 ppm which corresponds to the azomethine signal, H-C=N, Figure 2.65.  
For the ligands 261 (3-H), 262 (3-Br) and 263 (3-Cl), a higher field azomethine signal 
is observed in comparison with the ligand 264 (2,3-(OMe)2) which contains two electron 
donating groups. The presence of the methoxy groups results in a significant deshielding 
effect and hence causes a further downfield shift of the azomethine signal. From this, it can 
be concluded that an inductive effect must enhance the strength of the imine C=N bond in the 
case of 264 in Figure 2.54, resulting in a further downfield shift of the azomethine signal.  
 
Ligand 
 δ (H-C=N) δ (H-Ar) δ (R=OCH3) δ (
31
P{
1
H}) 
HL
1
 261 8.14 (1H, s) 7.00-7.50 (19H, t,q,m,dd,m) _ -14.2 (s) 
HL
2
 262 8.07 (1H, s) 6.62-7.75 (18H, t,q,m,dd,d) _ -13.7 (s) 
HL
3
 263 8.08 (1H, s) 6.83-7.86 (18H, dd,t,m,q,d) _ -13.8 (s) 
HL
4
 264 8.54 (1H, s) 6.52-7.86 (17, dd,t,m,t,q,m) 3.70 (3H, s) 
3.85 (3H, s) 
-14.5 (s) 
1. Chemical shift values (δ) are expressed in ppm relative to the TMS standard for 1H and H3PO4 
for 
31
P. 
2. s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet.  
3. Coupling constants (J) are measured in Hz 
Table 2.12:  
1
H and 
31
P{
1
H} NMR data
1, 2, 3
 for the iminophosphine ligands HL
1-4
 261-264 in 
CDCl3 at 300 MHz and 121.5 MHz respectively. 
The 
1
H NMR spectra of the HL
4
 ligand 264 also displays two singlet resonances at δ 
3.70 and δ 3.85 ppm respectively. These correspond to the two methoxy (-OCH3) substituents 
present at the C-3 and C-2 position of the lower aryl ring and integrate for 3 hydrogens each. 
The aromatic signals for the iminophosphine ligands HL
1-4
 are found with significant 
overlapping in the range of δ 6.45-7.81 ppm. [1H-1H] COSY plots, Figure 2.65, along with 
[
13
C DEPT 45-
1
H] HETCOR plots, Figure 2.66, were required to fully characterise the 
relative positions of the aromatic protons on the ligand.  
The integrations of these aromatic protons were 19H (261), 18H (262 and 263) and 
17H (264) respectively as expected. It was found to be very difficult to fully assign these 
signals for all the iminophosphine ligands due to signal overlaps. Only the HL
4
 ligand gave 
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observable differences between the aromatic signals with only some overlapping signals 
observed. This allowed for a full characterisation of the individual aromatic proton signals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.65: The [
1
H-
1
H] COSY NMR plot of the HL
4
 ligand 264 showing the interactions 
between the aromatic hydrogens as well as the position of the methoxy groups OCH3 and 
azomethine group He-C=N run at 300 MHz.  
 
δ(1H) ppm Peak Assignment Observed Correlations 
6.88 m (Ha) (Hb, Hc) 
6.92 dd (Hh) (Hg, Hf) 
7.05 d,q (Hd, Hg) (Hc,Hh) 
7.14 t (Hb) (Ha, Hc, Hd) 
7.20-7.35 m Phosphinophenyl Phosphinophenyl 
7.37, t (Hc) (Ha, Hb, Hd) 
7.53, dd (Hf) (Hg, Hh) 
Table 2.13: Measured [
1
H-
1
H] COSY NMR correlations for the HL
4
 ligand 264. 
PPh2
N
He
MeO
OMe
Ligand HL4 [2,3-(OMe)2] 264
Ha
Hb
Hc
Hd
Hf
Hg
Hh
Ha Hf 
Hc 
Hb 
Hd He 
Hg,h OMe 
OMe 
O
M
e
 
O
M
e
 
H
e
 
H
c
 
H
f 
H
b
 
H
a
 
H
g
,h
 
H
d
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From the [
1
H-
1
H] COSY plot in Figure 2.65 of the HL
4
 ligand 264, the aromatic 
protons in the region of 7.24-7.35 ppm can be assigned to the aromatic protons (10H) on the 
PPh3 group which only couple to each other. The other aromatic protons (7H) along with the 
azomethine and methoxy signals are assigned individually in Figure 2.65. The signal that 
resonated as a series of four doublets in the region 6.88 ppm with a coupling value (J) of 7.62 
Hz is due to the coupling to the phosphorus atom as well as the neighbouring aryl protons on 
the upper aryl ring. 
For the corresponding (3-Br) HL
2
 262 and (3-Cl) HL
3
 263 ligands, the aromatic 
regions also showed three sets of signals in the range of 7.87-7.45 ppm corresponding to the 
protons on the aryl ring (4H) where the PPh2 substituent is attached. More aromatic signals at 
7.45-7.10 ppm correspond to the PPh2 protons (10H) and finally at 6.85-7.20 ppm which 
correspond to the aryl protons of the salicyladimine (4H) ring. The multiplet signals for the 
aromatic region of these ligands though were much more complicated in comparison to the 
HL
4
 ligand 264 which meant it was impossible to assign the individual aromatic hydrogens 
with certainty for 261-263.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.66: The [
13
C DEPT 45 -
1
H] HETCOR NMR plot of the HL
4
 ligand 264 showing the 
relationship between the carbons and protons present in the compound run at 300 MHz.  
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13
C NMR data was also obtained for the HL
4
 ligand in order to compare the spectra 
with its coordinated platinum cyclometallated complex 284, Section 2.6.3. In addition to 
various 
13
C and DEPT NMR experiments, a [
13
C DEPT 45-
1
H] HETCOR plot, Figure 2.66, 
was also obtained in order to better associate the individual aromatic CH signals with the 
1
H 
NMR spectra obtained for the HL
4
 ligand 264.  
In the 
13
C NMR spectra the doublet signal at 155.88 ppm was attributed to the carbon 
atom of the imine bond (HC=N) which was also supported by the [
13
C DEPT 45-
1
H] 
HETCOR plot, Figure 2.66. It appears as a doublet due to 
4
J (1.51 Hz) coupling to the 
phosphorus donor moiety. The signals at 61.93 and 55.85 ppm were assigned to each carbon 
atom of the two methoxy substituent groups –OCH3. Interestingly, the methoxy signals were 
found to be doublets, which may be tentative evidence for the existence of E/Z isomers in the 
iminophosphine ligands, similar to that found for the phosphinoamide ligands HL
5-7
 265-267, 
which is discussed in detail in Section 2.7.2. However, this is the only spectroscopic evidence 
for the iminophosphine Z-isomer at this time and will be discussed further in Section 2.7.3.  
Strong multiple overlapping signals at 134.05-134.32 ppm and 128.28-128.50 ppm 
were assigned to the phosphinophenyl carbons as per the [
13
C DEPT 45-
1
H] HETCOR plot. 
Individual signals found from 114.80 ppm to 124.18 ppm were assigned to the salicyladimine 
ring while the remaining signals at 128.37-132.55 ppm were assigned to the aromatic 
hydrogens on the aryl ring with the PPh2 substituent using the results from the [
1
H-
1
H] COSY 
plot as a reference, Figure 2.65.  
The phosphorus NMR spectra, 
31
P {
1
H}, of each ligand HL
1-4
 , displays a singlet 
resonance in the range of δ -12.6 to -14.0 ppm which corresponds to the single phosphorus 
environment in the ligand. The starting material (2-diphenylphosphinoaniline) displays a 
peak at δ -21 ppm not present in the final spectra of the ligand, indicating a shift of δ 6 – 8 
ppm upon formation of the ligand. Also no evidence of the aldehyde was seen in the 
1
H NMR 
where a peak at ca. 10ppm would normally occur, indicating successful formation of the 
imine ligand.  
 
2.7.2 NMR data for the Phosphinoamide ligands HL
5-7
 (265-267) 
 
1
H and
 31
P{
1
H} spectroscopic data was obtained for the phosphinoamide ligands 265-
267. 
13
C, [
1
H-
1
H] COSY plots and [
13
C DEPT 45-
1
H] HETCOR plots were also undertaken 
on the HL
6
 ligand as a comparison for its analogous cyclometallated complex 288 which is 
the most soluble of all the phosphinoamide complexes reported and thus the only one for 
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which it was possible to obtain 
13
C data. Interestingly none of the synthesised 
phosphinoamide ligands exhibited the characteristic amido proton, N-H, signal indicating that 
the amide tautomer is not present in solution, in contrast to that found for the solid state by IR 
in Section 2.6.2. 
Instead, all the spectra exhibit a broad doublet, integrating for one proton, in the range 
of δ 9.51-10.48 ppm which corresponds to an iminol signal, H-O, Figure 2.67. Thus for these 
phosphinoamide ligands it is proposed that they exist as an iminol tautomeric form in 
solution. The 
1
H NMR and 
31
P{
1
H} data of the phosphinoamide ligands are summarised in 
Table 2.14.  
 
 
 
 
 
 
 
 
 
 
Figure 2.67: Tautomers of the phosphinoamide ligands also showing the E and Z isomers of 
the iminol form. 
 
For the dimethoxy ligand HL
6
 266 a higher field hydroxyl signal is observed in 
comparison with the other two ligands HL
5
 265 and HL
7
 267 due to the two methoxy groups. 
These are electron donating which results in a significant deshielding effect and causes a 
downfield shift of the hydroxyl signal. From this, it can be concluded that an inductive effect 
must enhance the strength of the imine C=N bond in the case of 265, resulting in a further 
downfield shift of the hydroxyl signal. 
The hydroxyl signals for the HL
5-7
 ligands appear as doublets and there are two 
possibilities for this. The first one is proposed to be due to the presence of two isomers, 
anti(E)/syn(Z) in the solution, Figure 2.67, while the second could be due to coupling 
between the iminol hydroxyl proton and the phosphine donor moiety as 
6
JH-P ω-coupling 
(omega). However, the coupling constant appears to be influenced by the nature and positions 
of the substituents in the aryl ring system which would imply an isomeric reason, Table 2.14. 
PPh2
NH
PPh2
N
O
HO
R = 3-OMe 265
2,4-(OMe)2 266
3-Br 267
R
Iminol Tautomer in Solution
The E-Isomer
N
HO
R
Ph2P
Iminol Tautomer in Solution
The Z-Isomer
Amide Tautomer (Solid State)
R
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The integrations of these aromatic hydrogens were 18H (265 and 267) and 17H (264) 
respectively as expected for the proposed structure for the ligands in solution. It was found to 
be very difficult to fully resolve these signals for all the phosphinoamide ligands because of 
the overlapping signals. For the HL
5
 265 and HL
7
 267 ligands, the aromatic regions showed 
three sets of signals in the range of 8.43-7.48 ppm corresponding to the hydrogens on the 
phosphine and nitrogen substituted aryl ring (4H), 7.48-7.20 ppm corresponding to the 
phosphinophenyl protons (10H) and finally 7.20-6.95 ppm which correspond to the aryl 
protons of the salicyladimine (4H) roughly.  
The multiple overlapping signals for these ligands meant it was impossible to assign 
the individual aromatic hydrogens with certainty. Only the HL
6
 ligand 266 gave identifiable 
differences between the aromatic signals with just some overlapping observed in the spectra. 
This allowed for a full characterisation of the individual aromatic hydrogen signals using a 
[
1
H-
1
H] COSY plot, Figure 2.68, along with a [
13
C DEPT 45-
1
H] HETCOR plot, Figure 
2.69, and identified the different isomers present as seen in Figure 2.67. 
 
Ligand 
 δ (HO-C=N) δ (H-Ar) δ (R=OCH3) δ (
31
P{
1
H}) 
HL
5
 265 8.84 (1H, d) 
6
JP-H=8 
6.96-8.43 (18H, t,q,m,dd,m) 3.81 (3H, s) -19.8 (s) 
HL
6
 265 10.50 (1H, d) 
6
JP-H=6 
6.43-8.47 (17H, dd,t,m,t,m) 3.86 (3H, s) 
3.79 (3H, s) 
-17.7 (s) 
HL
7
 267 8.60 (1H, d) 
6
JP-H=8 
6.95-8.34 (18H, dd,t,m,q,d) _ -18.7 (s) 
1. Chemical shift values (δ) are expressed in ppm relative to the TMS standard for 1H and H3PO4 
for 
31
P. 
2. s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet.  
3. Coupling constants (J) are measured in Hz 
Table 2.14: The 
1
H and 
31
P{
1
H} NMR spectra
1, 2, 3
 recorded for the phosphinoamide ligands 
HL
5-7
 265-267 in CDCl3 at 300 MHz and 121.5 MHz respectively. 
The 
1
H NMR spectra of the HL
6
 ligand 266 also displays two singlet resonances at δ 
3.84 and δ 3.79 ppm respectively corresponding to the major E-isomer (due to the relative 
intensities of the signals and thermodynamically favourable structure). The spectra of the HL
5
 
ligand 265 on the other hand display a single resonance at δ 3.81 ppm, also corresponding to 
the E-isomer. These are assigned to the electron donating methoxy (-OCH3) substituents 
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present at the C-2 and C-4 position of the aryl ring system for the HL
6
 ligand and at the C-3 
position for the HL
5
 ligand, all of which integrate for 3 hydrogens each. For the HL
6
 ligand 
there are also a second set of methoxy signals at δ 3.68 and 3.71 ppm corresponding to the 
methoxy groups on the Z-isomer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.68: The [
1
H-
1
H] COSY NMR plot of the HL
6
 ligand 266 showing the interactions 
between the aromatic hydrogens as well as the position of the methoxy groups OCH3 and 
hydroxyl group HO-C=N run at 300 Mhz.  
 
δ(1H) ppm Peak Assignment Observed Correlations 
6.42 dd (Hf) (Hg) 
6.42-6.51 m (Hg) (Hf, Hh) 
7.85 q (Ha) (Hb,Hc) 
7.19 t (Hb) (Ha, Hc, Hd) 
7.24-7.38 m Phosphinophenyl Phosphinophenyl 
7.43, t (Hc) (Ha, Hb, Hd) 
8.21, dd (Hf) (Hg) 
8.47, m (Hd) (Hc, Hb) 
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Table 2.15: Measured [
1
H-
1
H] COSY NMR correlations for the HL
6
 ligand 266. 
The aromatic protons in the region of 7.24-7.38 ppm are attributed to the 
phosphinophenyl protons (10H) which only couple to each other. The rest of the aromatic 
hydrogens (7H) along with the hydroxyl and methoxy signals are assigned individually in 
Figure 2.68 as per their correlations outlined in Table 2.17. 
13
C NMR data was also collected for the HL
6
 ligand in order to compare the spectra 
with its coordinated platinum cyclometallated complex 288, Section 2.7.4. The 
cyclometallated 2,4-(OMe)2 complex 288 was the only phosphinoamide complex sufficiently 
soluble to enable 
13
C spectra to be obtained.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.69: The [
13
C DEPT 45 -
1
H] HETCOR NMR plot of the HL
6
 ligand 266 showing the 
relationship between the carbons and protons present in the compound run at 300 
MHz/75.5MHz.  
 
In addition to various 
13
C and DEPT NMR data, a [
13
C DEPT 45-
1
H] HETCOR plot, 
Figure 2.69, was also obtained in order to better associate the individual aromatic CH signals 
with the 
1
H NMR spectra obtained for the HL
6
 ligand 266. This was also completed in order 
to later compare it to the analogous spectra obtained for the platinum coordinated complex 
288 which is synthesised from the HL
6
 ligand in Section 2.6.3. 
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From the [
13
C DEPT 45-
1
H] HETCOR plot, strong multiple overlapping signals at 
135.23-133.48 ppm and 128.95-128.67 ppm were assigned to the phosphinophenyl carbons. 
Individual signals found from 98.65 ppm to 124.40 ppm were assigned to the salicyladimine 
ring of each isomer while the remaining signals at 128.37-135.58 ppm were assigned to the 
aromatic hydrogens on the phosphino-imine aryl ring using the results from the [
1
H-
1
H] 
COSY plot as a further reference, Figure 2.68.  
Interestingly, there were two carbon signals corresponding to some aromatic 
hydrogens according to the [
13
C DEPT 45-
1
H] HETCOR plot, Figure 2.69. The signals at 
55.56, 55.80, 55.85 and 56.63 ppm were assigned to each carbon atom of two sets of the two 
methoxy substituent groups –OCH3. There were also two carbon signals for each aromatic 
hydrogen on the salicyladimine ring (Hf, Hg and Hh, Figure 2.69), but not for the phosphine 
and nitrogen substituted ring. It is therefore proposed that there are two different 
salicyladimine ring environments present which would indicate the presence of the E/Z 
isomers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.70: An expansion of the 
1
H NMR spectra of the HL
6
 ligand 266 showing the 
aromatic signals and inset: the structures of the isomers with the hydrogens removed for 
clarity, run at 300 MHz.  
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Further NMR studies run at 600 MHz to confirm the existence of the two isomers 
include a DEPTQ (a comparison of 
13
C quaternary signals with CH, CH2 and CH3 signals), a 
HSQC (similar to a HETCOR plot except for neighbouring carbons), a HMBC (a 2D plot 
showing the relationship between the 
13
C DEPTQ spectra and 
1
H NMR up to 2-3 bonds 
away) and a NOESY plot (showing protons that have a relationship through space up to 5Å). 
From these studies and the 
1
H NMR it was determined that the isomers are in a 3:1 ratio with 
the preferred E-isomer in the majority as determined by the relative intensities of the signals 
and taking the E-isomer as the more thermodynamically stable structure.  
In the Z-isomer no relationship between the Hf and Hd aromatic hydrogens was 
identified by the NOESY plot, indicating that the salicyladimine ring is in fact twisted where 
the Hd proton is pointing into the centre of the salicyladimine ring. Efforts to separate the 
isomers by various chromatographic methods were unsuccessful at the present time.  
The phosphorus NMR spectra, 
31
P {
1
H}, of each ligand HL
1-4
 , displays a singlet 
resonance in the range of δ -17.7 to -18.8 which corresponds to the single phosphine present 
in the ligand. Interestingly only one signal was seen for both isomers, further proving that the 
change in the salicyladimine environment is the only observable spectrographic difference 
between the two isomers.  
The starting material (2-diphenylphosphinoaniline) displays a peak at -21ppm, which 
is not present in the spectra of the ligand, indicating that the reaction of the starting materials 
has gone to completion. Also no evidence of the acyl chloride was seen in the 
1
H NMR where 
a peak at ca. 10ppm would normally occur, again indicating completion of the ligand 
reactions.  
 
2.7.3 NMR spectra for the tridentate Pt(II) iminophosphine complexes [Pt(η3-PNC-L1-
4
)Cl] 281-284 and [Pt(η3-PNO-L4)Cl] 285: 
 
1
H and
 31
P{
1
H} spectroscopic data was obtained for all the cyclometallated complexes 
[Pt(η3-PNC-L1-4)Cl] 281-284 and the PNO complex [Pt(η3-PNO-L4)Cl] 285. 13C, [1H-1H] 
COSY plots and [
13
C DEPT 45-
1
H] HETCOR plots were also completed for the dimethoxy 
cyclometallated complex 284 which is the most soluble of all the platinum complexes 
reported. A downfield shift in the 
1
H NMR spectra of the azomethine resonance frequency 
from ca. 8.20 ppm for the free ligands HL
1-4
 261-264 to ca. 9.40ppm for the cyclometallated 
complexes 281-284. The downfield shift observed indicates successful coordination of the 
imino-nitrogen to the Pt (II) metal centre.  
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Coordination of the imino-nitrogen to the metal centre, electron density is pulled 
towards the coordination bond (Pt-N), weakening the H-C bonds. This observed trend 
correlates also with a similar trend seen in the IR data for these complexes, Section 2.6.1. 
The 
1
H NMR and 
31
P{
1
H} data of all the iminophosphine complexes (PNC and PNO) are 
summarised in Table 2.16.  
 
Complex 
 δ (H-C=N) δ (H-Ar) δ (R=OCH3) δ (
31
P{
1
H}) 
3-H  
281 
9.40 (1H, s) 
JPt-H = 123 Hz 
7.41-8.21 (18H, q,dd,d,m) - 25.3 
JPt-P = 2083 Hz 
3-Br  
282 
9.40 (1H, s) 
JPt-H = 123 Hz 
7.40-8.13 (17H, q,m) - 25.6 
JPt-P = 2100 Hz 
3-Cl  
283 
9.41 (1H, s) 
JPt-H = 123 Hz 
7.34-8.15 (17H, m,m) - 25.5 
JPt-P = 2123 Hz 
2,3-(OMe)2  
284 
9.72 (1H, s) 
JPt-H = 126 Hz 
7.27-8.17 (16H, dd,q,m) 3.88 (3H, s) 
4.02 (3H, s) 
25.2 
JPt-P = 2102 Hz 
PNO 3-OMe  
285 
9.15 (1H, s) 
JPt-H = 76 Hz 
6.59-7.90 (16H, d,q,m) 3.89 (3H, s) 13.1 
JPt-P = 3816 Hz 
4. Chemical shift values (δ) are expressed in ppm relative to the TMS standard for 1H and H3PO4 
for 
31
P. 
5. s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet.  
6. Coupling constants (J) are measured in Hz 
Table 2.16: The 
1
H and 
31
P{
1
H} NMR spectra
1, 2, 3
 recorded for the iminophosphine tridentate 
complexes 281-285, all ran in CDCl3 at 300 MHz and 121.5 MHz respectively. 
It is also worth noting that the downfield shift of the azomethine signals for the chloro 
cycloplatinated complexes are ca. 0.1 ppm less than the analogous iodo complexes previously 
reported by this research group, indicating a slightly stronger azomethine bond for the 
chloride complexes.
2
 The smaller, more electronegative chloride in comparison with the 
larger, less electronegative, iodide (electronegativity values: 3.16 for chloride, 2.66 for 
iodide) pulls electron density away from the platinum metal centre and creates a stronger Pt-
Cl bond than the analogous Pt-I bond.  
It is proposed that this induces a δ positive charge on the metal centre, inducing a δ 
negative charge on the imino nitrogen increasing the electron density in the H-C=N system 
relative to that seen in the analogous iodo complexes previously reported. This trend is also 
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noticed in the IR spectroscopy of these same complexes where the stretching frequency of the 
C=N bonds are also higher than their iodo counterparts section 2.5.1. A summary of this 
change in the azomethine chemical shift for each of the iminophosphine tridentate complexes 
281-285 compared with their free ligands are displayed in Table 2.17. 
 
Ligand δ(H-C=N) 
ppm 
[Pt(η3-PNC-L1-4)Cl] 
[Pt(η3-PNO-L4)Cl] 
δ(H-C=N) 
ppm 
Δδ 
ppm 
HL
1
 261 8.14 3-H 281 9.40 1.26 
HL
2
 262 8.07 3-Br 282 9.40 1.33 
HL
3
 263 8.11 3-Cl 283 9.41 1.30 
HL
4
 264 8.54 2,3-(OMe)2 284 9.72 1.18 
HL
4
 264 8.54 PNO 3-OMe 285 9.15 0.61 
Table 2.17: A comparison of the azomethine signal between  the free ligands 261-264 and 
their analogous tridentate complexes 281-285 from the 
1
H NMR spectra. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.71: The range of complexes described in this section with the types of rings formed 
upon coordination and cyclometallation highlighted along with the azomethine hydrogen 
indicated in red for the ligands 261-264 and complexes 281-285.  
 
Platinum satellites are also observed for the H-C=N azomethine signals of all the 
tridentate complexes shown in Figure 2.71. This further confirms the successful coordination 
of the imino-nitrogen moiety to the Pt (II) metal centre. The 
3
JH-Pt coupling constants for all 
the iminophosphine Pt (II) complexes are given in Table 2.16.  
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Figure 2.72: The azomethine peak with 
195
Pt satellite peaks corresponding to the relative 
abundances of the NMR active 
195
Pt isotope (34% abundant) in the cyclometallated complex 
284 run at 300 MHz. 
 
In the case of the PNO complex 285, we see a smaller downfield shift of the 
azomethine signal to that of the cyclometallated complexes on comparison to the free ligands 
HL
1-4
. However, there is a much smaller 
3
JH-Pt coupling constant (76 Hz) in comparison with 
that seen for the cyclometallated complexes (123 Hz), Table 2.16. We can therefore propose 
that the PNO complex 285 has a stronger imine-Pt bond than that of the cyclometallated 
complexes 281-284 which is also supported by the IR data obtained and reported in Section 
2.6.1. This also correlates with the data previously obtained for this complex (from a 
alternative synthesis method) by our research group.
1
  
 
 
 
 
 
 
 
 
 
 
Figure 2.73: The azomethine peak with 
195
Pt satellite peaks corresponding to the relative 
abundances of the NMR active 
195
Pt isotope (34% abundant) in the PNO complex 285 run at 
300 MHz. 
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This difference in chemical shift and coupling constant on formation of the 
cyclometallated complexes 281-284 is due to the 5-5 fused ring system of these PNC 
complexes which would be more sterically restricted and strained in comparison to the 5-6 
fused ring system of the PNO complex 285. This in turn could result in subsequent 
weakening of the C=N bond for the cyclometallated complexes 281-284 which is reflected in 
the 
1
H NMR data, Table 2.18. 
The aromatic region for the cyclometallated complexes 281-284 show multiple 
overlapping signals making it very difficult to fully resolve these signals for all the 
complexes. However the signals integrate as expected for 18H (281), 17H (282 and 283) and 
16H (284 and 285). There is also a noticeable downfield shift of the aromatic signals on 
comparison with the free ligands.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.74: The [
1
H-
1
H] COSY NMR plot of the cyclometallated complex 284 showing the 
interactions between the aromatic hydrogens as well as the position of the methoxy groups 
(OCH3) and azomethine group H-C=N run at 300 MHz.  
 
To more fully assign the aromatic region, a [
1
H-
1
H] COSY plot, Figure 2.74, of the 
2,3-(OMe)2 cyclometallated complex 284 was obtained. The aromatic protons in the region of 
7.35-7.28 ppm and 7.68-7.77 ppm can be attributable to the phosphinophenyl protons (PPh2) 
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(10H) which only couple to each other. The rest of the aromatic hydrogens (6H) are assigned 
based on their [
1
H-
1
H] COSY plot correlations in Table 2.18. The cyclometallated complex 
284 has the least overlapping aromatic signals of the iminophosphine complexes reported, 
allowing for successful assignment but it can be used as a model for the other cyclometallated 
complexes also 281-283. However, there are still some overlapping signals which make this a 
tentative assignment. The azomethine signal (He) and the two methoxy signals are easily 
assigned and reported previously in Table 2.16.  
Unfortunately, due to the large shift in the signals for all the aromatic hydrogens, 
making a direct comparison with the free ligand HL
4
 264 is difficult. However, the most 
significant difference is the absence of any signal for Hf which previously corresponded to 
the aromatic proton of the carbon α to the imine substituent on the free ligand HL4 264. This 
is further evidence for the presence of a Pt-C bond formed due to cyclometallation.  
 
δ(1H) ppm Peak Assignment Observed Correlations 
7.25 d (Hh) (Hg) 
7.38 m (Hc), Phosphinophenyl (Hb, Hd) 
7.57 t (Hb) (Hc,Ha) 
7.65-7.79 m (Hd), (Hg), Phosphinophenyl (Hc), (Hh), Phosphinophenyl 
7.94, q of d (Ha) (Hb, Hc) 
Table 2.18: Measured [
1
H-
1
H] COSY NMR correlations for the 2,3-(OMe)2 cyclometallated 
complex 284. 
At δ 7.94 ppm a signal resonates as a quartet of doublets due to coupling to the 
phosphorus donor moiety as well as the neighbouring aryl protons on the phosphorus and 
nitrogen containing aryl ring. It is proposed to be the proton α to the phosphorus donor 
moiety (Ha, Figure 2.74). This signal has shifted dramatically downfield with respect to the 
corresponding signal observed for the proton α to the phosphorus group in the free ligand 
HL
4
 264 (δ 6.88 ppm). This is due to donation of electron density into the metal centre from 
the phosphorus donor moiety and gives further evidence for coordination of the metal centre 
to the phosphine group.  
For the corresponding unsubstituted complex 281 and the halide substituted ligands 
complexes 282 and 263, the aromatic regions show complicated overlapping sets of signals in 
the range of δ 7.45-7.56 ppm and δ 7.62-7.77 ppm corresponding to the phosphinophenyl 
Chapter 2  Coordination and Cyclometallation 
 
139 | P a g e  
 
protons (10H) (PPh2). In addition there are some signals in the range δ 7.45-7.92 ppm 
corresponding to the remaining aromatic hydrogens. Because of significant signal overlap for 
some of these signals, it is not possible to assign these any further at this time.  
The 
1
H NMR spectra of [Pt(η3-PNC-L4)Cl] 284 and [Pt(η3-PNO-L4)Cl] 285 display 
resonances for the methoxy groups present, as seen in Table 2.16. The cyclometallated 
complex 284 displays two singlet resonances at δ 3.88 and δ 4.02 ppm while the PNO 
complex 285 displays a singlet resonance at δ 3.89 ppm. These correspond to the two electron 
donating methoxy (-OCH3) substituents present at the C-3 and C-2 position of the lower aryl 
ring and integrate for 3 hydrogens each for the PNC complex 284.  
For the PNO complex 285 only one methoxy signal indicates the loss of one of the 
methoxy groups in comparison to the free ligand HL
4
 264, further confirming coordination  
of the platinum to the oxygen heteroatom. Along with the presence of the two methoxy 
groups in the cycloplatinate PNC complex 284, this helps to distinguish between the two 
different tridentate complexes from the HL
4
 ligand 264 spectroscopically. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.75: The [
13
C DEPT 45 -
1
H] HETCOR NMR plot of the 2,3-(OMe)2 complex 284 
showing the relationship between the carbons and protons present in the compound run at 
300 MHz/75.5 MHz.  
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It was hoped to obtain 
13
C NMR data for all the Pt (II) cyclometallated complexes in 
order to confirm that a Pt-C bond has indeed formed. However only the 2,3-(OMe)2 
cyclometallated complex [Pt(η3-PNC-L4)Cl] 284 was soluble enough to enable 13C spectra to 
be obtained. In addition to obtaining various 
13
C and DEPT NMR spectra, a [
13
C DEPT 45-
1
H] HETCOR plot, Figure 2.75, was also obtained in order to better associate the individual 
aromatic CH signals with the 
1
H NMR spectra obtained for the 2,3-(OMe)2 complex 284.  
In the 
13
C NMR spectra the doublet signal at 165.78 ppm was attributed to the carbon 
atom of the imine bond (HC=N) which was also supported by the [
13
C DEPT 45-
1
H] 
HETCOR plot, Figure 2.75. This represents a 10 ppm shift downfield in comparison to the 
free ligand HL
4
 264, due to coordination of the platinum metal centre to the nitrogen donor 
moiety on the imine bond. This also indicates weakening of the C=N bond since the electron 
density is being donated into the metal centre which was also reported for the 
1
H NMR and 
IR spectra. Like the free ligand HL
4
 the iminic carbon is also coupling to the phosphorus 
donor moiety giving a coupling value of 
4
J = 6 Hz which is an increase of 4.5 Hz over the 
free ligand due to the rigidity of the complex formed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.76: The 
13
C NMR spectra of the 2,3-(OMe)2 complex 284 showing the iminic carbon 
at 164.78 ppm as a doublet due to coupling to the phosphorus moiety and the new quaternary 
metallic carbon at 142.53 ppm, run at 75.5 MHz.  
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For the cyclometallated complex, the signals for the aromatic carbons have also 
shifted by circa 12 ppm with respect to the free ligand HL
4
 integrating for 16H in comparison 
to 17H for the ligand. Unfortunately these signals could not be assigned individually using 
the [
13
C DEPT 45-
1
H] HETCOR plot because of the limited solubility of the 2,3-(OMe)2 
complex 284. It was however possible to assign the other aromatic carbon signals with strong 
overlapping signals at 133.71-133.54 ppm and 128.94-128.80 ppm assigned to the 
phosphinophenyl (PPh2) carbons. The individual signals that remained in the 
13
C DEPT 45 
NMR spectra belong to the 6 aromatic hydrogens on the rest of the complex.  
A new signal for a quaternary carbon was found in the 
13
C NMR spectra at 142.53 
ppm which was not present in the spectra for the free HL
4
 ligand 264, Figure 2.76. It was 
assigned as the carbon of the Pt-C bond formed as a result of cyclometallation. The position 
of this signal also corresponds well with previous 
13
C NMR studies on other platinum and 
palladium cyclometallates by our research group, as well as others.
45,85
 
The signals at 61.93 and 55.85 ppm seen in both the 
13
C NMR and the 
13
C DEPT 45 
NMR spectra were assigned to each carbon atom of the two methoxy substituent groups –
OCH3 and represent almost no shift in comparison to the free ligand HL
4
 264 which also had 
methoxy signals at 61.92 and 55.85 ppm.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.77: The 
13
C NMR spectra of the free ligand HL
4 
264 has a doublet for the methoxy 
versus a singlet for the methoxy signals in the complex due to only one isomer present. 
 
However, the methoxy signals found for the free ligand HL
4
 264, as discussed in 
Section 2.7.1 were found to be doublets, unlike the cyclometallated complex [Pt(η3-PNC-
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)Cl]   284 which are observed to be singlets. This is proposed to be further evidence for the 
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existence of E/Z isomers in the iminophosphine ligands, similar to that seen for the 
phosphinoamide ligands HL
5-7
 265-267. But again the spectroscopic evidence for confirming 
the iminophosphine Z-isomer at this time is still too limited to confirm, Figure 2.77.  
31
P{
1
H} NMR spectroscopy of the complexes show a singlet resonance for each of the 
cyclometallated complexes 281-284 in the range of δ 25.1-25.3 ppm. On comparison with the 
free ligands, this represents a large downfield shift of around δ 40 ppm compared to the 
coordinated platinum complexes. For the PNO complex 285 on the other hand a singlet is 
observed at δ 13.1 ppm which represents a significantly different downfield shift, δ 28 ppm, 
in comparison with the cyclometallated complex 284 which is also formed from the same 
ligand HL
4
 264. The 
31
P{
1
H} NMR data are given in Table 2.16. 
This dramatic downfield shift found in the phosphorus NMR also confirms 
coordination of the phosphine donor moiety to the Pt (II) centre  for all the complexes and a 
comparison with the free ligands is given in Table 2.19. 
 
Ligand δ 31P{1H} 
ppm 
[Pt(η3-PNC-L1-4)Cl] 
[Pt(η3-PNO-L4)Cl] 
δ 31P{1H} 
ppm 
Δδ 
ppm 
HL
1
 261 -14.2 3-H 281 25.3 39.5 
HL
2
 262 -13.7 3-Br 282 25.6 39.3 
HL
3
 263 -13.8 3-Cl 283 25.5 40.0 
HL
4
 264 -14.5 2,3-(OMe)2 284 25.2 39.7 
HL
4
 264 -14.5 PNO 3-OMe 285 13.1 27.6 
 
Table 2.19: Comparison of the 
31
P{
1
H} signals between the free iminophosphine ligands 261-
264 with the tridentate platinum complexes 281-285. 
 
The phosphorus NMR data for all the complexes also show 
195
Pt satellites, Figure 
2.78. The 
1
J coupling constants for all the cyclometallated complexes 281-284 are in the 
range of 2080-2183 Hz, Table 2.18. These values are slightly higher than the analogous 
platinum iodo complexes previously reported by this research group but are still consistent 
with that expected for a P-Pt coupling trans to an aryl carbon group. The coupling is slightly 
smaller for the unsubstituted complex 281 at 2080 Hz, than the 3-Br/Cl 282/283 complexes 
(2099 Hz and 2123 Hz respectively) which may be influenced by the presence of an electron-
withdrawing substituent in the C3 position of the aryl ring (para to the Pt-C bond).  
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The PNO complex 285 on the other hand gives a significantly different coupling 
constant of 3816 Hz as seen in Table 2.18. The data for the PNO complex 285 is also 
identical to that previously reported by our research group for this complex and is typical of a 
P-Pt coupling interaction trans to an O-Pt bond. From these J-values we can state that the Pt-
O bond is stronger than that of the Pt-Caryl bond, due to the two different bonding 
heteroatom’s (O and Caryl), coordinative (availability of free lone pairs) ability and the 
subsequent fused ring size produced on successful coordination. 
 
 
 
 
 
 
 
 
 
 
Figure 2.78: The single phosphorus peak with Pt
195
 satellite peaks corresponding to the 
relative abundances of the NMR active Pt
195
 isotope (34% abundant) in the cyclometallated 
complexes 281-284 run at 300 Mhz 
 
As discussed in Section 2.5.3, owing to extensive solubility problems with the 
proposed bidentate intermediate complexes, NMR spectra could not be obtained. However in 
some 
1
H NMR spectra of the unsubstituted platinum cyclometallated complex 281, prior to 
filtration through silica gel, multiple possible azomethine signals were observed as well as 
evidence of hydrolysis, Figure 2.79. 
Crude 
1
H NMR data for [Pt(η3-PNC-L1)Cl]  281 show 4 signals in the region 9.12 to 
10.03 ppm. One of the peaks, 9.42 ppm, corresponds to the azomethine signal for the 
tridentate cyclometallated complex 281, while the other two peaks have not been reported 
previously for these complexes. The broad peak at 9.69 ppm displays 
195
Pt satellite peaks 
indicates coordination to the metal centre with a coupling of 39 Hz. The peak at 10.03 ppm 
represents hydrolysis of the ligand reforming the free benzaldehyde used to synthesis the 
ligand, Section 2.5.1.  
N
Pt
Ph2
P Cl
R = 3-H 271, 281
3-Br 272, 282
3-Cl 273, 283
2,3 (OMe)2 274, 284
R
17% 17% 
Chapter 2  Coordination and Cyclometallation 
  
 
144 | P a g e  
 
The final peak observed at 9.12 ppm may be proposed to be the bidentate 
unsubstituted complex 271 that has not undergone dimerisation. Unfortunately again due to 
the poor solubility of this complex, it cannot be confirmed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.79: Multiple azomethine peaks found when the reaction was taken off after 2 hours 
for the unsubstituted complex 284, run at 300 Mhz 
 
2.7.4 NMR spectroscopy for the tridentate Pt (II) phosphinoiminol complexes [Pt(η3-
PNC-L
5-7
)Cl] 286-288 and [Pt(η3-PNO-L6)Cl] 289: 
 
1
H and
 31
P{
1
H} spectroscopic data were obtained for the phosphinoiminol complexes 
286-289. 
13
C, [
1
H-
1
H] COSY plots and [
13
C DEPT 45-
1
H] HETCOR plots were also 
attempted for the 2,4-(OMe)2 cyclometallated complex [Pt(η
3
-PNC-L
6
)Cl] 287 which is the 
most soluble of all the phosphinoiminol complexes reported.  
All the cyclometallated phosphinoiminol complexes show a signal at circa δ 9.50 ppm 
corresponding to the iminol proton on the ligand. For complexes [Pt(η3-PNC-L5)Cl] 286 and 
[Pt(η3-PNC-L7)Cl] 288, this signal is shifted downfield from that of the corresponding 
ligands HL
5
 265 and HL
7
 267 (circa δ 8.50 ppm). The iminol signal for the HL6 ligand is 
further downfield than that of the other ligands at circa δ 10.50 ppm, perhaps due to the 
presence of the methoxy substituents. These do not appear to affect the relative position of 
Proposed 
Bidentate 
Complex 
Tridentate 
Cyclometallated  
Complex 281 Unknown  
Platinum Complex 
Benzaldehyde due 
to Hydrolysis 
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the iminol signal in the coordinated Pt (II) complex 287 in comparison to the other complexes 
formed.  
The iminol resonance for the PNO complex 289, [Pt(η3-PNO-L6)Cl], is further upfield 
than that of the cyclometallated complexes at δ 8.50 ppm, perhaps due to the nature of the 
structure sterically rigid structure that is formed, Figure 2.80. Also, in comparison with the 
free ligands HL
5-7
, where the iminol signal appear as a doublet (Section 2.7.2), the 
cyclometallated PNC and PNO complexes display a doublet of doublets. The observed shift 
in the signal and the formation of a doublet of doublets indicate successful coordination of 
the imino-nitrogen to the Pt (II) metal centre.  
 
Complex 
 δ (H-C=N) δ (H-Ar) δ (R=OCH3) δ (
31
P{
1
H}) 
3-OMe  
286 
9.45 (1H, dd) 
JH-P = 12 Hz 
JH-H = 3 Hz 
6.92-7.95 (17H, m,t,t,m) 3.87 (3H, s) 24.3 
JPt-P = 1928 Hz 
2,4-(OMe)2  
287 
9.49 (1H, dd) 
JH-P = 12 Hz 
JH-H = 3 Hz  
6.10-7.86 (16H, m, q,m) 3.89 (3H, s) 
3.74 (3H, s) 
22.9 
JPt-P = 1928 Hz 
3-Br  
288 
9.45 (1H, dd) 
JH-P = 12 Hz 
JH-H = 3 Hz  
6.77-8.10 (17H, m,m) - 25.1 
JPt-P = 2041 Hz 
PNO 4-OMe  
289 
8.01 (1H, dd) 
JH-P = 15 Hz 
JH-H = 6 Hz  
6.59-7.87 (16H, d,q,m) 3.46 (3H, s) 7.9 
JPt-P = 3340 Hz 
1. Chemical shift values (δ) are expressed in ppm relative to the TMS standard for 1H and H3PO4 
for 
31
P. 
2. s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet.  
3. Coupling constants (J) are measured in Hz 
Table 2.20: The 
1
H and 
31
P{
1
H} NMR spectra
1, 2, 3
 recorded for the phosphinoiminol 
tridentate complexes 286-289. All ran in CDCl3 at 300MHz and 121.5 MHz respectively. 
On donation of the lone pair of electrons on the imino-nitrogen into the metal centre, 
electron density is pulled towards the coordination bond (Pt-N), weakening the HO-C=N 
bonds. The observed shift in the NMR spectra correlates with this reduction in bond strength 
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also seen in the IR data for these complexes, Section 2.5.2. The 
1
H NMR and 
31
P{
1
H} data of 
all the phosphinoiminol complexes are summarised in Table 2.22.  
In the case of the PNO complex 289, we see a larger shift of the iminol signal than 
that seen for the cyclometallated complex 287 on comparison with their free ligand HL
6
 266, 
as well as a larger 
6
JH-H and 
6
JH-P coupling constant, Table 2.20. We can therefore propose 
that the PNO complex 289 has a stronger imine-Pt bond than that of the cyclometallated 
complexes 286-288 formed from the phosphinoiminol ligands which is also supported by the 
IR data obtained and reported in Section 2.6.2.  
This difference in chemical shift and coupling constant on formation of the 
cyclometallated complexes 287-288 is due to the 5-5 fused ring system of these PNC 
complexes which would be more sterically restricted and strained in comparison to the 5-6 
fused ring system of the PNO complex 289, similar to that which was reported for the 
iminophosphine complexes in Section 2.7.3. This in turn could result in subsequent 
weakening of the C=N bond for the cyclometallated complexes 286-288 which is reflected in 
the 
1
H NMR data, Table 2.20. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.80: The range of complexes described in this section with the types of rings formed 
upon coordination and cyclometallation highlighted along with the iminol hydrogen 
indicated in red with, complexes 286-289.  
 
In comparison to the free ligands HL
5-7
 265-267, the tridentate phosphinoiminol 
complexes are also more sterically rigid in a fixed position, thus long-range coupling is 
possible. The observed doublet of doublets signal can be attributed to coupling to an aryl 
proton and the phosphorus donor moiety of the coordinating phosphine, Figure 2.81, 
PPh2
N
N
Pt
PPh2
Cl
R = 3-OMe 265
2,4-(OMe)2 266
3-Br 267
Cyclometallated
PNC Complexes
R
Phosphinoamide Ligands
R
R = 3-OMe 286
2,4-(OMe)2 287
3-Br 288
Tridentate
PNO Complex 289
N
Pt
PPh2
O
Cl5
5
5
6
HO
HOHO
OMe
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incomparison to the doublet observed for the free ligands HL
5-7
 265-267 which corresponds 
to the E/Z-isomers present.  
 
 
 
 
 
 
 
 
 
 
Figure 2.81: An example of the doublet of doublets for the iminol signal in the 
1
H NMR 
spectra for the cyclometallated complex 286. The 
6
J ω-coupling responsible is highlighted in 
the structure of the rigid conjugated complex. 
 
A summary of shift in the iminol signal for each of the phosphinoiminol tridentate 
complexes 286-289 compared with their free ligands HL
5-7
 265-267 are given in Table 2.21. 
Ligand δ(H-C=N) 
ppm 
[Pt(η3-PNC-L5-7)Cl] 
[Pt(η3-PNO-L6)Cl] 
δ(H-C=N) 
ppm 
Δδ 
ppm 
HL
5
 261 8.84 (1H, d) 
6
JP-H=8 
3-OMe 286 9.45 (1H, dd) 
6
JH-P = 12 Hz 
6
JH-H = 3 Hz 
0.61 
HL
6
 264 10.50 (1H, d) 
6
JP-H=6 
2,4-(OMe)2 287 9.49 (1H, dd) 
6
JH-P = 12 Hz 
6
JH-H = 3 Hz  
1.01 
HL
7
 262 8.60 (1H, d) 
6
JP-H=8 
3-Br 288 9.45 (1H, dd) 
6
JH-P = 12 Hz 
6
JH-H = 3 Hz  
0.85 
HL
6
 264 10.50 (1H, d) 
6
JP-H=6 
PNO 3-OMe 289 8.01 (1H, dd) 
6
JH-P = 15 Hz 
6
JH-H = 6 Hz  
2.49 
Table 2.21: A comparison of the iminol signal between  the free ligands 265-267 and their 
analogous tridentate complexes 286-289 from the 
1
H NMR spectra. 
N
Pt
PPh2
Cl
O
H
H
OMe
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Generally coupling is found to occur up to a maximum of 4 bonds, 
4
J. However, long-
range coupling has been reported for “zig-zag” type, highly conjugated systems.86 It is 
described as omega (ω) coupling where the “zig-zag” structure can allow 6J coupling to 
occur. Because of this, the iminol proton has the ability to couple to distant NMR active 
nuclei via resonance, Figure 2.82. Because of the structure of the phosphinoiminol 
complexes, the result is two 
6
J coupling interactions that give a doublet of doublets in the 
1
H 
NMR spectra, Figure 2.81. We attribute the lower J-values (Table 2.20) to the iminol proton-
aromatic proton interaction, (red path, Figure 2.82) and the greater J-value to the iminol 
proton-phosphorus coupling (green path, Figure 2.82). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.82: The 
6
J ω-coupling between the iminol proton (H) and the two other NMR active 
nuclei in the rigid cyclometallated complexes. The resonance structure paths are illustrated 
in Red and Green. 
 
Unfortunately because of extensive overlapping of the aromatic signals in the spectra 
of the platinum phosphinoiminol complexes, complete assignment of each aromatic signal is 
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Pt
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P Cl
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H
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impossible. However the aromatic signals integrate for the expected number of protons for 
each complex i.e. 17H for 286, 16H for 287 and 289, and 17H for 288. The cyclometallated 
complex 287 is the only complex with minimal overlapping aromatic signals, allowing for 
some assignment but it can be also used as a model for the other phosphinoiminol complexes 
286-289.  
A large shift in the equivalent signals for all the aromatic protons was also found in 
comparison to the free ligands, making a direct comparison with HL
5-7
 265-267 difficult, 
Table 2.20. However, there is no equivalent signal for Hf which was found for the free ligand 
HL
6
 due to the platinum carbon bond formation in complex 287. The C-H activation of Hf is 
further evidence of the successful cyclometallation of the 2,3-(OMe)2 platinum complex. 
Only a limited number of other comparisons can be made at this time for the aromatic signals 
due to overlapping. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.83: The [
1
H-
1
H] COSY NMR plot of the cyclometallated phosphinoiminol complex 
287 showing the interactions between the aromatic hydrogens as well as the position of the 
methoxy groups (OCH3) and iminol group HO-C=N run at 300 MHz.  
 
As per the [
1
H-
1
H] COSY plot in Figure 2.83 of the 2,3-(OMe)2 cyclometallated 
complex 287, the aromatic protons in the region of 7.23-7.48 ppm and 7.62-7.79 ppm can be 
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attributable to the phosphinophenyl protons (10H) which only couple to themselves. The rest 
of the aromatic hydrogens (6H) are overlapping significantly. The azomethine signal (He) 
and the two methoxy signals are easily assigned and reported previously in Table 2.20. 
Further evidence for omega (ω) coupling can also be found in the [1H-1H] COSY plot where 
interaction between the iminol proton and an aromatic proton on the phosphine/imine ring 
system is immediately evident, Figure 2.83.  
For the other phosphinoiminol tridentate complexes 286, 288 and 289 the aromatic 
regions show complicated overlapping sets of signals in the range of 6.81-7.79 ppm 
corresponding to the phosphinophenyl protons (10H) and some signals overlapping between 
6.11 ppm and 7.98 ppm corresponding to the remaining aromatic hydrogens. The multiplet 
signals for the aromatic region of these complexes though were much more complicated, with 
overlapping spectra structures, than the 2,4-(OMe)2 complex 287 which meant it was 
impossible to assign the individual aromatic hydrogens with any certainty.  
The 
1
H NMR data for the 3-OMe cyclometallated complex [Pt(η3-PNC-L5)Cl] 286 also 
displays a singlet at δ 3.87 ppm integrating for 3 protons, corresponding to the methoxy 
substituent present. The cyclometallated complex [Pt(η3-PNC-L6)Cl] 287 on the other hand 
displays two singlet resonances at δ 3.89 and δ 3.74 ppm while the PNO complex [Pt(η3-
PNO-L
6
)Cl] 289 from the same ligand (HL
6
 ligand 266) also displays a singlet resonance at δ 
3.46 ppm, integrating for 3 protons.  
For the PNO complex [Pt(η3-PNO-L6)Cl] 289 only one methoxy signal indicates the 
loss of one of the methoxy groups to form a PNO complex, further confirming coordination 
to the oxygen heteroatom. Along with the presence of the two methoxy groups in the 
cycloplatinate PNC complex 287, this helps to distinguish between the two different 
tridentate complexes from the HL
6
 ligand 266 spectroscopically. 
It was desirable to get 
13
C NMR data for the phosphinoiminol platinum complexes 
286-289, with the goal being a comparison with the free ligands 265-267. However, the 
tridentate phosphinoiminol complexes have very limited solubility so only tentative 
13
C data 
was found for the 2,4-(OMe)2 cyclometallated complex [Pt(η
3
-PNC-L
6
)Cl]  287, which was 
the most soluble phosphinoiminol complex. 
In the 
13
C NMR spectra of 287, the singlet at 165.73 ppm was attributed to the carbon 
atom of the iminol bond (HO-C=N) following on from previous work with the 
iminophosphine complexes 281-285. This represents a 2 ppm shift downfield in comparison 
to the free ligand HL
6
 266, due to coordination of the platinum metal centre to the nitrogen 
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donor moiety on the imine bond. Unfortunately the aromatic carbon signals could not be 
assigned individually using the [
13
C DEPT 45-
1
H] HETCOR plot as the correlations are 
incomplete due to the limited solubility of the 2,4-(OMe)2 complex 287.  
However, strong multiple overlapping signals at 133.71-133.37 ppm and 128.68-
128.25 ppm were assigned to the phosphinophenyl carbons and signals at 56.07 and 54.68 
ppm seen in both the 
13
C NMR and the 
13
C DEPT 45 NMR spectra were assigned to each 
carbon atom of the two methoxy substituent groups (OCH3). There were no isomers found for 
the platinum cyclometallated complex as only the E-isomer of the ligand can form the 
cyclometallated complex as discussed earlier. 
31
P{
1
H} NMR spectroscopy of the complexes show a singlet resonance for each of the 
cyclometallated complexes 287-289 in the range of δ 22.9-25.1 ppm. On comparison with the 
free ligands, this represents a large downfield shift of around δ 42 ppm. For the PNO 
complex 289 on the other hand a singlet is observed at δ 7.9 ppm which represents a 
significantly different downfield shift, δ 25.6 ppm, in comparison with the cyclometallated 
complex 287 which is also formed from the same ligand HL
6
 266.  
The full list of the 
31
P{
1
H} NMR signals along with their platinum coupling 
frequencies for each complex are given in Table 2.20. This dramatic downfield shift found in 
the phosphorus NMR also confirms coordination of the phosphine donor moiety to the Pt (II) 
centre  for all the complexes and a comparison with the free ligands is given in Table 2.22. 
 
Ligand δ 31P{1H} 
ppm 
[Pt(η3-PNC-L5-7)Cl] 
[Pt(η3-PNO-L6)Cl] 
δ 31P{1H} 
ppm 
Δδ 
ppm 
HL
5
 265 -19.8 3-OMe 286 24.3 44.1 
HL
6
 266 -17.7 2,4-(OMe)2 287 22.9 40.6 
HL
7
 267 -18.7 3-Br 288 25.1 43.8 
HL
6
 266 -17.7 PNO 4-OMe 289 7.9 25.6 
 
Table 2.22: Comparison of the 
31
P{
1
H} signals between the free phosphinoamide ligands 
265-267 with the tridentate phosphinoiminol complexes 286-289. 
 
The phosphorus NMR data for all the complexes also show 
195
Pt satellites like that 
seen for the iminophosphine complexes. The 
1
J coupling constants for all the cyclometallated 
complexes 286-288 are in the range of 1928-2041 Hz, Table 2.22. These values are slightly 
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lower than the iminophosphine complexes 281-284 but are still consistent with that expected 
for a P-Pt coupling trans to an aryl carbon group.  
The PNO complex 289 on the other hand gives a significantly different coupling 
frequency of 3340 Hz as seen in Table 2.22. The data for this PNO complex is also quite 
similar to the previously reported iminophosphine complex 285 and is typical of a P-Pt 
coupling interaction trans to an O-Pt bond. From these J-values we can state that the Pt-O 
bond is stronger than that of the Pt-Caryl bond, due to the two different bonding heteroatom’s 
(O and Caryl), coordinative (availability of free lone pairs) ability and the subsequent fused 
ring size produced on successful coordination. 
 
2.8 X-Ray Crystallography: 
 
2.8.1 Crystal and molecular structures of [Pt(η3-PNC-L2-3)Cl] 282 and 283: 
 
Suitable crystals for X-ray analysis were grown by a slow evaporation of a CHCl3 
solution of 282 and 283 respectively. The single crystal analyses of these complexes were 
carried out by Dr. Curtis J. Elcoate and Dr. Simon E. Lawrence. Crystal data and relevant 
structure solution data for these complexes are given in the experimental Section 2.10. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.84: A view of [Pt(η3-PNC-L2)Cl] 282, showing the structure and stereochemistry of 
the solid state compound. Ellipsoids are shown with 50% probability. 
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The X-ray structures of both complexes 282 and 283 are illustrated in Figures 2.84 
and 2.85 respectively. Both complexes contain central platinum atoms which are in a four 
coordinate distorted square planar environment. In compound 282, the platinum metal centre 
coordinates to the P3, N18 and C10 moieties of the tridentate ligand and to the chloro ligand 
(Cl2), which is located trans to the nitrogen (N18) moiety in compound 282, Figure 2.84. 
The bonding environment is mirrored in the analogous complex 283, Figure 2.85 and the C-
Pt and the N-Pt bond distances established for both complexes were found to be consistent 
with each other. 
The distortions from the idealised square-planar geometry about the metal centre may 
be due to the bulk of the phosphine group and to the bite angle of the P, N chelate as well as 
the 5-membered ring formed on cyclometallation. Similar distorted square-planar geometry 
about the metal centre was also observed by our research group previously for PNO type 
platinum and palladium complexes as well as iodo platinum cyclometallates.
1,2
 Other 
research groups have also reported distorted square planar geometry for palladium PNO 
complexes of the type [Pd(η3-PNO-L)Cl].87  
 
Figure 2.85: A view of [Pt(η3-PNC-L3)Cl] 283, showing the structure and stereochemistry of 
the solid state compound. Ellipsoids are shown with 50% probability. 
 
The bond angles around the platinum centre deviate from the expected 90º angle 
within a perfect square planar geometry, Table 2.23. The trans P-Pt-C [166.74(7)-165.76(9)
o
] 
and trans N-Pt-Cl [175.47(6)-175.36(7)
o
] axes are found to be less than 180º for both 
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complexes, Table 2.23. The cis P-Pt-N and cis N-Pt-C angles are also dependant upon the 
sizes of the P,N and N,C rings, which in for these complexes are both 5-membered. Previous 
work in our research group into PNO type palladium and platinum iminophosphine 
complexes have found that systems with mixed 5 and 6 membered fused ring systems give 
different bond angles for each ring.  
Although the ring sizes are the same here, we also observed that the bond angles in 
each of the rings are different. The P-Pt-N angles for the P,N chelate ring are 85.46(6)
o
 for 
282 and 85.12(7)
o
 for 283, while the N-Pt-C angles for the N,C chelate ring are 81.27(10)
o
 for 
282 and 80.89(11)
o
 for 283. The bite angle of the platinum metal centre is therefore less for 
the N-Pt-C chelate ring primarily due to the P-Pt bond being stretched to accommodate the 
cyclometallation.  
There is also large difference in the angles between the platinum metal centre and the 
tridentate ligand (P,N,C) and the angles between the Pt-P, Pt-Cl and Pt-C bonds (P-Pt-Cl and 
Cl-Pt-C), Figure 2.86. This is again due to the presence of the two 5-memberd fused ring 
system. 
 
 
 
 
 
 
 
Figure 2.85: Complexes [Pt(η3-PNC-L2)Cl] 282 and [Pt(η3-PNC-L3)Cl] 283, showing the 
angles around the metal centre. 
 
[Pt(η3-PNC-L2)Cl] 282 [Pt(η3-PNC-L3)Cl] 283 
Angle Degree (º) Angle Degree (º) 
C(10)-Pt(1)-Cl(2) 94.54(7) C(12)-Pt(1)-Cl(1) 94.48(9) 
P(3)-Pt(1)-Cl(2) 98.72(2) P(1)-Pt(1)-Cl(1) 99.48(3) 
N(18)-Pt(1)-Cl(2) 175.47(6) N(1)-Pt(1)-Cl(1) 175.36(7) 
N(18)-Pt(1)-C(10) 81.27(10) N(1)-Pt(1)-C(12) 80.89(11) 
N(18)-Pt(1)-P(3) 85.46(6) N(1)-Pt(1)-P(1) 85.12(7) 
C(10)-Pt(1)-P(3) 166.74(7) C(12)-Pt(1)-P(1) 165.76(9) 
Table 2.23: A comparison of the inter-atomic bond angles around the metal centre for both 
complexes 282 and 283. 
N
Pt
Ph3
P Cl
Br
282
N
Pt
Ph3
P Cl
Cl
283
81.27
85.46 94.54
98.72
85.12
80.89
94.48
99.48
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All the metal-ligand bond distances around the platinum metal centre are within 
expected ranges. The observed similarities between the bond lengths of the two complexes 
(282 and 283) would suggest as expected that the substitution of a chloride for a bromide on 
the salicylic ring has little overall effect on the observed bond lengths around the metal 
centre.  
Table 2.24 compares all the bond distances around the metal centre are compared for 
each complex as well as the previously reported analogous iodo complex [Pt(η3-PNC-L1)I] 
220, Table 2.24. It can be seen that the Pt-nitrogen and Pt-phosphorus bonds for both the 
chloro complexes and the analogous iodo complex are quite similar. However the platinum-
carbon bonds are shorter in the chloro complexes than the iodo one, indicating increased 
bond strength for both 282 and 283 when compared with the iodo complex 220. 
 
Table 2.24: A comparison of the inter-atomic bond distances (Å) around the distorted square 
metal centre for both chloro complexes 282 and 283 and the previously reported analogous 
iodo complex 224 
 
2.9  Summary and Conclusion 
 
The iminophosphine ligands HL
1-4
, 261-264, were also prepared by an alternative 
method to that which was reported previously and characterised using NMR, 2D NMR plots, 
IR and elemental analysis. The preparation of the iminophosphine ligands HL
1-4
 261-264 
involved the reaction of a methanolic solution of 2-diphenylphosphinoaniline with one 
equivalent of the appropriate benzaldehyde with a drop of formic acid to catalyse the Schiff 
base condensation producing the iminophosphine ligands HL
1-4
 261-264 in good yields.  
The complexation of all four iminophosphine ligands HL
1-4
 261-264 towards a Pt (II) 
metal centre was investigated with PtCl2 and PtCl2(cod) as starting materials. PtCl2 proved to 
be insoluble in most common solvents, reducing the possibility of successful coordination 
and cyclometallation (Method A). It did however establish the methods and products that 
Bond 282 
Distance (Å) 
283 
Distance (Å) 
224
 
Distance (Å) 
Pt-Nitrogen 1.997(2) 2.002(3) 2.018(5) 
Pt-Phosphorus 2.271(7) 2.289(7) 2.280(16) 
Pt-Carbon 2.026(2) 2.031(8) 2.050(6) 
Pt-X(Halide) 2.296(9) 2.305(3) 2.5826(5) 
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could be formed from the iminophosphine ligands HL
1-4
. The more versatile PtCl2(cod) was 
found to be much more successful for coordination and cyclometallation to form the Pt (II) 
tridentate cyclometallates 281-284 in good yields (Method B).  
In method A, the reaction of PtCl2 for up to 48 hours with the iminophosphine ligands 
HL
1-4
 yielded an insoluble yellow powder and some of the cyclometallated complexes 281-
284 in very low yields. The insoluble complexes are proposed to be dimers of the bidentate 
intermediates 271-274 formed prior to cyclometallation and could only be characterised 
effectively by IR spectroscopy and elemental analysis. Also a refluxing acetonitrile solution 
of PtCl2 and the HL
4
 ligand 264 gave primarily the previously reported tridentate P,N,O 
complex 285. 
Several novel Pt (II) Schiff base complexes of the general formula [Pt(η3-PNC-L1-
4
)Cl] (L = 3-H L
1
 281, 3-Br L
2
 282, 3-Cl L
3
 283, 2,3-(OMe)2 L
4
 284) were synthesised from 
PtCl2(cod) and characterised by IR, NMR, elemental and X-ray crystallography (in selected 
cases). The previously reported PNO complex [Pt(η3-PNO-L4)Cl] 285 was also prepared 
from PtCl2(cod) in chloroform.  
The method to synthesis the cyclometallated complexes [Pt(η3-PNC-L1-4)Cl]  281-284 
involved a slow addition of the appropriate iminophosphine ligand (HL
1-4
 261-264) in 
chloroform over 6 hours to a refluxing chloroform solution of PtCl2(cod). Yields of the 
cyclometallated complexes from this method (Method B) improved significantly over those 
found for Method A with PtCl2.  
The coordination behaviour of the HL
4
 ligand 264 towards PtCl2(cod) was found to be 
different to that established for its coordination to Pd (II), but analogous to its coordination to 
the previously reported iodo-platinum complexes.
2
 Reaction of the HL
4
 ligand 264 with PtCl2 
in acetonitrile (Method A) generated primarily the tridentate PNO complex [Pt(η3-PNO-
L
4
)Cl] 274, whereas the same reaction with ligand HL
4
 264 with PtCl2(cod) formed primarily 
the novel 2,3-(OMe)2 cyclometallated complex [Pt(η
3
-PNC-L
4
)Cl] 284 in chloroform, via 
stabilisation of the liberated chloride anion. 
The previously reported phosphinoamide ligands, 265-267, were synthesised by an 
alternative method and fully characterised using NMR, 2D NMR plots, IR and elemental 
analysis. The preparation of the phosphinoamide ligands HL
5-7
 265-267 involved the reaction 
of a thf solution of 2-diphenylphosphinoaniline with one equivalent of the appropriate 
benzoyl chloride with an excess of DABCO to prevent build up the HCl by-product. This was 
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then stirred at room temperature to produce the phosphinoamide ligands HL
5-7
 265-267 in 
very good yields. 
Characterisation of the phosphinoamide ligands HL
5-7
 265-267 by IR spectroscopy 
identified the presence of the N-H signal, however in solution the ligands were found to 
tautomerise into an iminol form, as identified by 
1
H NMR. Further characterisation with 
13
C 
and 2D NMR plots also found that due to the tautomerisation in solution, two inseparable 
isomers are formed (E and Z). The desired E-isomer is in a 3:1 majority ratio to the Z-isomer 
but the presence of the other isomer reduces the chances of cyclometallation of the platinum 
complexes from the insoluble bidentate dimer intermediates.  
Several novel Pt (II) phosphinoiminol complexes of the general formula [Pt(η3-PNC-
L
5-7
)Cl] (L = 3-OMe L
5
 286, 2,4-(OMe)2 L
6
 287, 3-Br L
7
 288) were also synthesised from 
PtCl2(cod) and the phosphinoamide ligands HL
5-7
. A novel PNO complex [Pt(η3-PNO-L6)Cl] 
289 was also prepared and characterised from the HL
6
 ligand 266, but it was not possible to 
fully characterise it at this time.  
Synthesis of cyclometallated platinum phosphinoamide complexes 286-289 involved 
adding the ligands dropwise to a refluxing solution of PtCl2(cod) in chloroform with DABCO 
and sodium carbonate for up to 8 hours. A white precipitate was formed from the reaction of 
DABCO with the HCl formed from the cyclometallation reaction. Similar to the 
iminophosphine platinum complexes, insoluble compounds were also formed and are 
proposed to be dimers of bidentate complexes. Also a second novel tridentate P,N,O complex 
289 was formed from the reaction of PtCl2(cod) and the HL
6
 266 ligand but it proved to be 
very sensitive to hydrolysis.  
 In the IR spectra of all the prepared ligands HL
1-7
 the characteristic C=N imine/ HO-
C=N iminol stretch was observed in the region of 1615-1678 cm
-1
. For all of the platinum 
complexes 271-274 and 281-289 however there was a distinct shift of this stretch to lower 
wavenumbers of between 9 and 48 cm
-1
, which is typical for Schiff base transition metal 
complexes in which the nitrogen of the imine is involved in coordination to the metal 
centre.
87,88
 Other major peaks observed in the IR spectra of these complexes included 
aromatic C-H stretching in the 3000-3100 cm
-1
 region, C=C ring stretching in the 1400-1500 
cm
-1
 region and in the case of the phosphinoiminol complexes 286-289, broad O-H stretching 
in the 3100-3300 cm
-1
 region.  
1
H NMR data for the azomethine proton for all the iminophosphine complexes 281-
285 showed the typical downfield shift in the spectra relative to that of the free ligands HL
1-4
 
261-264 confirming coordination of the platinum to the nitrogen donor moiety. 
195
Pt satellite 
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signals were also observed for all the complexes with coupling frequencies of 123-126 Hz for 
the cyclometallates 281-284 and 76 Hz for the PNO complex 285. 
In the tridentate phosphinoiminol platinum complexes [Pt(η3-PNC-L5-7)Cl] and 
[Pt(η3-PNO-L6)Cl]   286-289, the iminol signal becomes a doublet of doublets in comparison 
to a doublet found for the free ligands HL
5-7
 265-267. This is observed because of the rigidity 
of the platinum phosphinoiminols. Omega coupling also appears to be occurring between one 
of the aromatic hydrogens on the P,N aryl ring and the iminol proton as indicated by a [
1
H-
1
H] COSY NMR plot where a correlation is observed.  
13
C NMR data and a [
1
H-
13
C DEPT 45] HETCOR plot confirmed the shift in the 
equivalent azomethine signal of the iminophosphine platinum complex [Pt(η3-PNC-L4)Cl]  
284 relative to its free ligand HL
4
 264. The new platinum-carbon bond formed as a result of 
cyclometallation was also identified as a new quaternary carbon not present in the free ligand. 
Also the Pt (II) complex 284 was found to have one less aromatic signal in comparison to the 
free ligand HL
4
 264, giving further evidence for the formation of a platinum-carbon bond.  
The 
31
P NMR data for all the complexes 281-289 showed a significant downfield shift 
of between 27.6 and 40.0 ppm on complexation of the ligands to the platinum metal centre as 
expected, indicating that the phosphorus donor moiety is coordinated to the metal.
88
 The 
presence of platinum satellites with coupling frequencies of 1950 – 2100 Hz for the 
cyclometallated complexes and 3140-3380 Hz for the PNO complexes is further evidence of 
successful coordination of the phosphorus donor moiety to the metal centre. 
X-ray crystal structures were obtained for complexes 282 and 283, confirming their 
structures as deduced from IR, NMR and elemental evidence. Both of these cycloplatinated 
complexes show the ligand coordinated in a tridentate manner to the platinum metal centre 
and both structures identify the complexes to have a distorted, square planar geometry, 
identical to previously reported iodo-platinum complexes. 
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2.10 Chapter 2 Experimental: 
 
2.10.1 Background: 
  
All reaction solvents were distilled prior to use, unless purchased as analytical grade 
(all from Sigma Aldrich Chemical Co. Ltd.). Toluene and thf were distilled directly before 
use from sodium-benzophenone. Methanol was distilled over magnesium/iodine according to 
Armarego et al
89 
and hexane was distilled over phosphorus pentoxide. O-
diphenylphosphinoaniline was synthesized according to a variation of a method by M. K. 
Cooper et al.
65
  
The following reagents were used as supplied; 2,3-dimethoxybenzaldehyde, 
benzaldehyde, 3-bromobenzaldehyde, 3-chlorobenzaldehyde, formic acid (all Aldrich 
Chemical Co. Ltd). Elemental analyses (Perkin-Elmer 2400 CHN elemental analyser) were 
performed by the microanalytical laboratory, University College Cork.  
The 
1
H and 
31
P{
1
H} NMR spectra were recorded on a Bruker Advance 300 MHz, 400 
MHz or 600 MHz NMR spectrometer (where specified). Chemical shifts (δ) are expressed in 
parts per million (ppm) and referenced to external tetramethylsilane (δ0) for 1H and 85% 
phosphoric acid (δ0) for 31P{1H} NMR using the high frequency positive convention.  
Infrared spectra were recorded as KBr disks on a Perkin-Elmer Paragon 1000 FT 
spectrometer. Relative intensities are designated (s), strong; (m), medium; (w), weak; (b), 
broad. Mass Spectra were recorded on a Waters/Micromass LCT Premier time of flight 
spectrometer (ESI). Single crystal X-ray diffraction studies of compounds 282 and 283 were 
performed by Dr. Curtis Elcoate, Dr Kevin Eccles and Dr Simon Lawrence, Department of 
Chemistry, UCC. Data was measured with Mo Kα radiation on a Bruker APEX DUO 
diffractometer as described previously.
90
 All calculations and refinements were made using 
the APEX software,
91,92
 and the diagrams prepared using Mercury.
93
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2.10.2  Preparation of the Iminophosphine ligands HL
1-4
 261-264: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.86: Synthesis of the iminophosphine ligands HL
1-4
 261-264  from 2-
diphenylphosphinoaniline and substituted benzaldehydes. 
 
 2-(diphenylphosphino)-aniline (2-DPPA) was dissolved with one equivalent of the 
required benzaldehyde in 20 ml of methanol along with one drop of formic acid and stirred 
for 20 hours at 50
o
C under N2. The resulting yellow solution was then reduced to dryness in 
vacuo and the residue taken up in 20 ml of dichloromethane.  
It was then washed with distilled water three times to remove any excess acid and any 
remaining starting materials that may be present. After separation, the organic layer was then 
dried over MgSO4, filtered and reduced to dryness in vacuo. The resulting oil was then 
crystallised from hot distilled methanol yielding the finely divided products HL
1-4
 261-264. 
 
HL
1
 261: Benzaldehyde (0.37 ml, 3.60 mmol) and 2-
(diphenylphosphino) aniline (1.000 g, 3.60 mmol) gave HL
1
 261 
as a pale yellow crystalline solid. Yield: 0.609 g (46.3 %) 
Found (required for C25H20NP): C, 81.88 (82.17); H, 5.40 (5.52); 
N, 3.88 (3.83). 
IR  max (KBr): 3054 (H2O)(w), 3012 (s), 3027 (s), 2886 (s), 1626 
(C=N)(s), 1574 (m), 1560 (w), 1492 (m), 1475 (Ar C=C)(s), 1460 
(Ar C=C)(s), 1433 (Ar C=C)(s), 1369 (m), 1305 (m), 1268 (m), 1194 (w), 1166 (w), 1116 (s), 
1090 (w), 1069 (m), 1025 (w), 995 (w), 999 (w), 981 (w), 974 (w), 885 (w), 859 (w), 828 
(w), 766 (s), 694 (s) 687 (s), 506 (s). 
1
H NMR δ ppm: 8.14 (1H, s), 7.00-7.50 (19H, m). 31P NMR δ ppm: -14.2 (s) 
m/z (ESI) [(M+H)
+
]: 366.20 
PPh2
N
PPh2
NPPh2
NH2
H
O
+ H2O
MeOH
R
R
R = 3-H 261
3-Br 262
3-Cl 263
2,3 (OMe)2 264
2-DPPA
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HL
2
 262: 3-Bromobenzaldehyde (0.420 ml, 3.60 mmol) and 2-
(diphenylphosphino) aniline (1.000 g, 3.60 mmol) gave HL
2
 262 as 
a yellow crystalline solid. Yield: 0.854 g (53.4 %) 
Found (required for C25H19BrNP): C, 67.53 (67.58); H, 4.39 
(4.31); Br, 17.66 (17.98); N, 3.24 (3.15). 
IR  max (KBr): 3649 (H2O)(w), 3250 (s), 3055 (s), 2362 (s), 1621 
(C=N)(s), 1592 (Ar C-C)(s), 1560 (Ar)(s), 1507 (Ar)(m), 1474 (Ar 
C=C)(s), 1448 (Ar C=C)(s), 1434 (Ar C=C)(s), 1356 (m), 1305 (m), 1268 (m), 1174 (s), 1138 
(m), 1116 (s), 1068 (m), 995 (w), 915 (w). 
1
H NMR δ ppm: 8.07 (1H, s), 6.62-7.50 (18H, m). 31P NMR δ ppm: -13.7 (s) 
m/z (ESI) [(M+H)
+
]: 446.10 
 
HL
3
 263: 3-Chlorobenzaldehyde (0.410 ml, 3.60 mmol) and 2-
(diphenylphosphino) aniline (1.000 g, 3.60 mmol) gave HL
3
 263 as 
a yellow crystalline solid. Yield: 0.957 g (61.4 %) 
Found (required for C25H19ClNP): C, 75.00 (75.09); H, 4.72 (4.79); 
N, 3.07 (3.50). 
IR  max (KBr): 3700 (b), 3056 (m), 2925 (m), 2855 (m), 1622 
(C=N)(s), 1563 (m), 1476 (Ar C=C)(s), 1434 (Ar C=C)(s), 1369 
(w), 1307 (w), 1270 (w), 1239 (w), 1193 (m), 1093 (w), 1076 (m), 1027 (w), 999 (w), 981 
(w), 889 (w), 843 (w), 791 (w), 749 (s), 696 (s), 681 (m), 544 (w), 528 (w), 505, (m), 470 (w) 
1
H NMR δ ppm: 8.11 (1H, s), 6.83-7.86 (18H, m). 31P NMR δ ppm: -13.8 (s) 
m/z (ESI) [(M+H)
+
]: 400.20 
 
HL
4
 264: 2,3-dimethoxybenzaldehyde (0.604 g, 3.60 mmol) and 
2-(diphenylphosphino) aniline (1.000 g, 3.60 mmol) gave HL
4
 
264 as a fluffy yellow crystalline solid. Yield: 1.343 g (87.7 %) 
Found (required for C27H24NO2P): C, 76.10 (76.22); H, 5.80 
(5.69); N, 3.55 (3.29). 
IR  max (KBr): 4244 (w), 3901 (w), 3056 (m), 2936 (C-H)(m), 
1616(C=N)(s), 1576(s), 1561(s), 1477(Ar C-C)(s), 1430(s), 1356 
(m), 1308 (m), 1270 (s), 1228 (m), 1207 (m), 1168 (m), 1072 (s), 
996 (s), 930 (w), 864 (w), 790 (s), 764 (m), 742 (s), 697 (s), 591 (w), 547 (m), 506 (s). 
PPh2
N
MeO
OMe
PPh2
N
Br
PPh2
N
Cl
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1
H NMR δ ppm: 8.54 (1H, s), 6.52-7.86 (18H, m), 3.70 (3H, s), 3.85 (3H, s).  
31P NMR δ ppm: -14.5 (s) 
m/z (ESI) [(M+H)
+
]: 426.20 
 
2.10.3  Preparation of the Phosphinoamide ligands HL
5-7
 261-264: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.86: Synthesis of the phosphinoamide ligands HL
5-7
 265-267 from 2-
diphenylphosphinoaniline and substituted benzoyl chlorides. 
 
To a solution of 2-diphenylphosphinoaniline (2-DPPA) in THF, one equivalent of the 
appropriate acyl chloride (3-OMe HL
5
 265, 2,4-(OMe)2 HL
6
 266, 3-Br HL
7
267) and 2 
equivalents of DABCO (1,4-diazabicyclo[2.2.2]octane) were added and stirred for 5 hours at 
room temperature.  
A white precipitate of DABCO.HCl was formed which was filtered off to leave a light 
yellow solution. This was then reduced to dryness in vacuo and taken up in 20ml of 
dichloromethane. This organic solution was then washed three times with distilled water to 
remove any excess acid or salts along with any remaining starting materials.  
After separation, the organic layer was then dried over MgSO4, filtered and reduced to 
dryness in vacuo. The resulting oil was then crystallised from distilled dichloromethane-
hexane yielding the finely separated products, ligands HL
5-7 
265-267.  
 
 
 
PPh2
NH2
Cl
O
R
+
PPh2
NH
R
265
266
267
R = 3-OMe
R = 2,3-(OMe)2
R = 3-Br
2-DPPA
Dabco
THF
+ Dabco.HCl
R = 3-OMe
R = 2,3-(OMe)2
R = 3-Br
O
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HL
5
 265: Anisoyl Chloride (0.49 ml, 3.60 mmol) and 2-
(diphenylphosphino) aniline (1.000 g, 3.60 mmol) gave HL
5
 265 
as a white crystalline solid. Yield: 1.112 g (75.1 %) 
Found (required for C26H22NO2P.(CH2)4O): C, 74.41 (74.52); H, 
5.40 (6.20); N, 2.90 (2.69). 
IR  max (KBr): 3362 (N-H)(s), 3054 (s), 3007 (w), 2956 (m), 2934 
(w), 2833 (w), 1783 (w), 1677 (C=O)(s), 1600 (w), 1572 (m), 
1511 (m), 1487 (Ar C=C)(s), 1433 (Ar C=C)(s), 1306 (s), 1290 
(s), 1275 (s), 1260 (s), 1217 (m), 1180 (w), 1132 (m), 1120 (w), 1096 (m), 1069 (w), 1042 
(m), 991 (w), 945 (w), 919 (w), 870 (w), 857 (w), 870 (w), 799 (w), 787 (s), 751 (s), 713 (w), 
696 (s) 683 (s), 596 (s), 569 (m), 506 (m). 
1
H NMR δ ppm: 8.84 (1H, d), 6.96-8.43 (18H, t,q,m,dd,m), 3.81 (3H, s).  
31P NMR δ ppm: -19.8 (s) 
m/z (ESI) [(M+H)
+
]: 412.20 
 
HL
6
 266: 2,4-dimethoxybenzoyl chloride (0.72 g, 3.60 
mmol) and 2-(diphenylphosphino) aniline (1.000 g, 3.60 
mmol) gave HL
6
 266 as a white crystalline solid. Yield: 
0.964 g (60.6 %) 
Found (required for C27H24BrO3P): C, 73.65 (73.76), H, 5.41 
(5.48), N, 3.10 (3.17).  
IR  max (KBr): 3275 (N-H)(w), 2936 (s), 2835 (s), 2362 (s), 
1720 (s), 1649 (C=N)(s), 1610, (s) 1573 (Ar C=C)(s), 1531 (Ar)(s), 1501 (Ar)(m), 1453 (Ar 
C=C)(s), 1433 (Ar C=C)(s), 1329 (m), 1305 (w), 1299 (m), 1260 (m), 1241 (m), 1212 (s), 
1164 (s), 1117 (m), 1086 (m), 1033 (m), 945 (w), 829 (w), 812 (w), 766 (m), 746 (m), 699 
(m), 671 (m), 546 (w), 512 (m), 473 (m). 
1
H NMR δ ppm: 10.50 (1H, d), 6.43-8.47 (17H, dd, t, m, t, m), 3.86 (3H, s), 3.79 (3H, s). 
 
31P NMR δ ppm: -17.7 (s) 
m/z (ESI) [(M+H)
+
]: 442.30 
 
 
PPh2
NH
O
MeO OMe
PPh2
NH
O
OMe
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HL
7
 267: 3-Bromobenzoyl chloride (0.48 ml, 3.60 mmol) and 2-
(diphenylphosphino) aniline (1.000 g, 3.60 mmol) gave HL
7
 267 as 
a yellow crystalline solid. Yield: 0.957 g (57.8 %) 
Found (required for C25H19ClNP): C, 65.10 (65.23), H, 3.95 (4.16), 
N, 2.94 (3.04).  
IR  max (KBr): 3366 (N-H)(s), 3057 (m), 1964 (w), 1923 (w), 1785 
(w), 1721 (w), 1675 (C=O)(s), 1576 (m), 1522 (m), 1473 (Ar 
C=C)(s), 1433 (Ar C=C)(s), 1305 (m), 1242 (m), 1174 (m), 1090 (w), 1068 (m), 1024 (w), 
997 (w), 942 (w), 921 (w), 903 (w), 892 (w), 852 (w), 864 (w), 794 (w), 752 (s), 732 (s), 697 
(s), 669 (s), 590 (w), 565 (w), 548 (m), 503 (m), 470 (w). 
1
H NMR δ ppm: 8.60 (1H, d), 6.95-8.34 (18H, dd, t, m, q, d). 31P NMR δ ppm: -18.7 (s) 
m/z (ESI) [(M+H)
+
]: 462.10 
 
2.10.4  Synthesis of Iminophosphine complexes [Pt( 2–PN–L1-3)Cl] 271-273 and [Pt( 3–
PNO–L4)Cl] 285  (Method A): 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.87: METHOD A: Synthesis of the platinum iminophosphine bidentate complexes 
271-273 (as dimers) and the PNO tridentate complex 285. 
 
PtCl2 was first refluxed in acetonitrile for 30mins prior to the addition of the ligand in 
order to ensure it was in solution. To the refluxing solution of PtCl2 in acetonitrile a 1.1 
equivalent of the appropriate ligand HL
1-4
 261-264 was added as a solid over an hour. The 
resulting mixture was then heated at reflux for 10 hours. A cloudy yellow/orange solution 
was produced and filtered to give a yellow solid which was washed with dichloromethane to 
produce the bidentate products 271-273. 
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Br
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N
PtCl2
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N
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Cl
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The bidentate complexes 271-273 proved to be too insoluble for NMR analysis so 
only IR spectroscopy and elemental analysis is presented here. 
For the PNO complex 285, the solution turned bright orange after reflux which was 
reduced to dryness in vacuo. The residue was then taken up in dichloromethane and washed 
with 2 portions of distilled water before being dried over MgSO4. The solution was then 
reduced to dryness again in vacuo and crystallised from dichloromethane-hexane to produce 
the PNO complex 285. 
 
271: HL
1 
(0.088 g, 0.24 mmol) 261 and PtCl2 (0.059 g, 0.22 
mmol) gave [Pt( 2–PN-L1)Cl] 271 as a yellow powder.  
Yield: 0.119 g (85.7%) 
Found (required for C25H20Cl2NPPt.0.5CH2Cl2): C, 45.90 
(45.85); H, 3.20 (3.15); N, 2.44 (2.21) 
IR  max (KBr): 3430 (w), 3058 (w), 2924 (w), 1595 (C=N)(s), 
1566 (m), 14.81 (Ar C=C)(s), 1437 (Ar C=C)(m), 1303 (w), 
1274 (w), 1227 (m), 1187 (m), 1175 (w), 1104 (m), 1066 (m), 
1028 (w), 998 (w), 972 (w), 924 (w) 828 (s), 783 (s), 768 (s), 756 (m), 720 (m), 692 (s), 592 
(s), 567 (s), 549 (m), 542 (m), 512 (s), 499 (m), 458 (w). 
 
272: HL
2 
(0.107 g, 0.24 mmol) 262 and PtCl2 (0.059 g, 0.22 
mmol) gave  [Pt( 2–PNC-L1)Cl] 292 as a yellow powder.  
Yield: 0.098 g (62.7%) 
Found (required for C25H19BrCl2NPPt.2.5CH2Cl2): C, 36.53 
(36.77); H, 3.89 (3.82); N, 3.30 (3.21) 
IR  max (KBr): 3329 (w), 2969 (w), 2920 (w), 2334 (m), 1683 
(w), 1591 (C=N)(s), 1519 (m), 1480 (Ar C=C)(m), 1436 (Ar 
C=C)(m), 1319 (w), 1158 (w), 1118 (s), 1098 (m), 1069 (s), 1026 
(w), 996 (w), 823 (w), 751 (m), 734 (s), 709 (s), 667 (s), 573 (s), 520 (m). 
 
 
 
 
 
Ph2
P
N
Pt
Cl
Cl
Ph2
P
N
Br
Pt
Cl
Cl
Chapter 2  Coordination and Cyclometallation 
  
 
166 | P a g e  
 
 
273: HL
3 
(0.088 g, 0.24 mmol) 263 and PtCl2 (0.059 g, 0.22 
mmol) gave [Pt( 2–PN–L3)Cl] 293 as a yellow powder.  
Yield: 0.087 g (59.4 %) 
Found (required for C25H19Cl3NPPt): C, 43.85 (43.96); H, 2.75 
(2.86); N 1.94, (2.03). 
IR  max (KBr): 3432 (H2O)(br)(m), 3171 (w), 2924 (w), 2851 (w), 
2353 (w), 2008 (w), 1703 (w), 1584 (C=N)(s), 1557 (m), 1475 (s), 
1436 (Ar C=C)(m), 1336 (s), 1287 (w), 1230 (w), 1181 (m), 1101 
(s), 1078 (m), 1068 (w), 1028 (w), 998 (w), 877 (m), 826 (s), 779 (s), 751 (m), 742 (m), 733 
(m), 715 (m), 692 (s), 625 (w), 572 (m), 527 (s), 500 (s), 456 (w). 
 
285: HL
4
 (0.102 g, 0.24 mmol) 264 and PtCl2 (0.059 g, 0.22 
mmol) gave [Pt( 3–PNO-L4)Cl] 275 as an orange crystalline 
powder.  
Yield PNO: 0.006g (4.9%) 
Found (required for C26H21ClNO2PPt.0.2CH2Cl2): C, 47.56 
(47.83); H, 3.14 (3.28); N, 2.12 (2.13); Cl, 7.23 (7.54). 
IR  max (KBr): 3854(w), 3806(w), 3751(w), 3427(m,b), 1654(w), 
1607 (C=N)(s), 1590(s), 1570(s), 1540(s), 1478(w), 1458(w), 1436(s), 1387(m), 1333(m), 
1249(s), 1231(s), 1174(s), 1101(m), 986(w), 876(w), 741(s), 714(m), 691(s), 564(s), 509(s), 
476(w), 467(w), 458(w). 
1
H NMR δ ppm: 9.15 (1H, s) (3JPt-H 76 hz), 6.59-7.90 (16H, d, q, d, m), 3.89 (3H, s).  
31P NMR δ ppm: 13.1 (s) (1JPt-P 3816 Hz) 
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2.10.5  Synthesis of the platinum iminophosphine complexes [Pt( 3–PNC–L1-3)Cl] 281-
283 and [Pt( 3–PNO–L4)Cl] 285  (Method B): 
 
 
 
 
 
 
 
 
 
Figure 2.88: METHOD B: Synthesis of the platinum iminophosphine cyclometallated 
complexes 281-283 via thermal and solvent assisted C-H activation.  
 
A stirred solution of (1,5-cyclooctadiene) dichloroplatinum (II) [PtCl2(cod)] in chloroform 
(20ml) was reacted with 1.1 equivalents of the appropriate ligand 261-263, which was also 
dissolved in chloroform (10ml). 4Å molecular sieves were added to the solution to ensure the 
absence of moisture. The ligand was added drop wise from an addition funnel over 4 hours, 
after which the reaction mixture was heated at reflux for an additional 4 hours.  
The resulting orange/yellow solution was then reduced to dryness in vacuo. The 
residue was taken up in 20ml of singly distilled dichloromethane to which silica gel was 
added to remove unwanted bidentate dimer complexes and hydrolysed ligand material. The 
silica gel was then filtered off and washed with two portions of dichloromethane. The filtrate 
was reduced to dryness in vacuo and crystallised from doubly distilled dichloromethane-
hexane to yield cyclometallates 281-283. 
 
281: HL
1 
(0.080 g, 0.22 mmol) 261 and PtCl2(cod) (0.076 g, 0.20 
mmol) gave  [Pt( 3–PNC-L1)Cl] 281 as a yellow metallic 
crystalline powder. Yield: 0.088 g (73.9 %) 
Found (required for C25H19ClNPPt.0.1CH2Cl2): C, 49.92 (49.96); 
H, 3.17 (3.21); N, 2.68 (2.32); Cl, 6.75 (7.05). 
IR  max (KBr): 3434 (w), 3047 (w), 3031 (w), 1585 (C=N)(s), 
1560 (m), 1527 (s), 1478 (Ar C=C)(m), 1467 (Ar C=C)(m), 1438 
N
Pt
PPh2
Cl
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(Ar C=C)(s), 1301 (w), 1269 (w), 1238 (m), 1186 (m), 1098 (s), 997 (w), 948 (w), 768 (s), 
751 (s), 719 (s), 692 (s), 572 (s), 526 (s), 506 (s), 498 (s). 
1
H NMR δ ppm: 9.40 (1H, s) (3JPt-H 123 Hz), 7.41-8.21 (18H, q,dd, d, m).  
31P NMR δ ppm: 25.3 (s) (1JPt-P 2083 Hz) 
 
282: HL
2 
(0.097 g, 0.22 mmol) 262 and PtCl2(cod) (0.076 g, 
0.20 mmol) gave  [Pt( 3–PNC-L1)Cl] 282 as a metallic 
yellow crystalline powder. Yield: 0.009g (6.7%) 
Found (required for C25H18BrClNPPt): C, 44.45 (44.56); H, 
2.65 (2.69); N, 1.92 (2.08). 
IR  max (KBr): 3422 (b), 3048 (w), 1587 (C=N)(s), 1556 
(m), 1518 (s), 1479 (Ar C=C)(m), 1471 (Ar C=C)(m), 1435 
(Ar C=C)(s), 1335 (w), 1287 (w), 1229 (m), 1180 (m), 1100 
(s), 998 (w), 922 (w), 823 (m), 766 (m), 743 (s), 691 (s), 572 (s), 527 (m), 499 (s). 
1
H NMR δ ppm: 9.40 (1H, s) (3JPt-H 123 Hz), 7.40-8.13 (17H, q, m).  
31P NMR δ ppm: 25.6 (s) (1JPt-P 2100 Hz) 
X-Ray: Crystals of [Pt( 3–PNC–L2)Cl] 282, suitable for X-ray analysis, were grown from the 
slow evaporation of a CHCl3 solution: 
Formula: [Pt
II
( 3–PNC–L2)Cl] Volume (Å3) 2162.7(7) 
Empirical Formula: C25H18BrClNPPt Z Z=4, Z’=0 
Weight: 629.36 Abs. coeff., µ 8.545 
Space Group P 21/n Reflections Total 5417 
Crystal System Monoclinic Radiation Type MoK\α (0.71073cm
-1
) 
a (Å) 9.5692(18) Reflections unique 5028 
b (Å) 12.410(3) Parameters 271 
c (Å) 18.326(4) R factor 1.68% 
α (o) 90 R1 >2σI 
β (o) 96.394(4) Crystal Colour Brown-yellow 
γ (o) 90 
Crystal Description pyramid 
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283: HL
3 
(0.088 g, 0.22 mmol) 263 and PtCl2(cod) (0.076 g, 0.20 
mmol) gave  [Pt( 3–PNC–L3)Cl] 283 as an orange metallic 
crystalline powder. Yield: 0.047g (37.1%) 
Found (required for C25H18Cl2NPPt): C, 47.31 (47.71); H, 2.85 
(2.88); N, 1.89 (2.23); Cl, 11.38 (11.27). 
IR  max (KBr): 3479 (w), 3185 (w), 3050 (w), 2921 (w), 2851 
(w), 1742 (w), 1576 (C=N)(s), 1557 (m), 1523 (s), 1474 (Ar 
C=C)(m), 1436 (Ar C=C)(m), 1384 (s), 1336 (w), 1287 (w), 
1230 (m), 1181 (m), 1101 (s), 1078 (m), 1068 (w), 1029 (w), 927 (w), 877 (m), 826 (s), 779 
(s), 693 (s), 625 (w), 572 (m), 527 (s), 499 (s). 
1
H NMR δ ppm: 9.40 (1H, s) (3JPt-H 123 Hz), 7.34-8.15 (17H, m, m).  
31P NMR δ ppm: 25.5 (s) (1JPt-P 2123 Hz) 
X-Ray: Crystals of [Pt
II
( 3–PNC–L3)Cl] 283, suitable for X-ray analysis, were grown from 
the slow evaporation of a CHCl3 solution: 
Formula: [Pt
II
( 3–PNC–L3)Cl] Volume (Å3) 2178.84 
Empirical Formula: C25H18Cl2NPPt Z Z=4, Z’=0 
Weight: 629.36 Abs. coeff., µ 6.771 
Space Group P 21/n Reflections Total 5295 
Crystal System Monoclinic Radiation Type MoK\α (0.71073cm
-1
) 
a (Å) 10.1435(11) Reflections unique 4620 
b (Å) 17.491(2) Parameters 271 
c (Å) 12.2865(14) R factor 1.97% 
α (o) 90 R1 >2σI 
β (o) 91.725(2) 
γ (o) 90 
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2.10.6  Synthesis of the platinum iminophosphine complexes [Pt( 3–PNC–L4)Cl] 284 
and [Pt( 3–PNO–L4)Cl] 285  (Method B): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.89: METHOD B: Synthesis of the platinum iminophosphine cyclometallated 
complex 284 as well as the previously reported PNO complex 285. 
 
A stirred solution of (1,5-cyclooctadiene) dichloroplatinum (II) [PtCl2(cod)] in 
chloroform (20ml) was reacted with 1.1 equivalents of the HL
4
 ligand 264, which was also 
dissolved in chloroform (10ml). 4Å molecular sieves were added to the solution to ensure the 
absence of moisture. The ligand was added dropwise from an addition funnel over 4 hours, 
after which the reaction mixture was heated at reflux for an additional 4 hours.  
The resulting orange/yellow solution was found to be a mixture of products identified 
by TLC and was then reduced to dryness in vacuo. The two tridentate complexes were 
separated using wet-flash chromatography on silica gel, eluting from chloroform:methanol 
(98:2). Visualisation under UV light using TLC gave 3 spots from the column where one was 
at Rf=0.83, another at Rf=0.33 and one which stayed on the line with an Rf=0.  
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The 2 soluble products were crystallised from dicheloromethane-hexane to give the 
cyclometallated complex [Pt( 3–PNC–L4)Cl] 284 and the previously reported PNO complex 
[Pt( 3–PNO–L4)Cl] 285. The insoluble material that stayed on the silica column is tentatively 
proposed to be the proposed bidentate complex 274. 
 
284: HL
4 
(0.095 g, 0.22 mmol) 264 and PtCl2(cod) (0.076 g, 0.20 
mmol) gave  [Pt( 3–PNC–L4)Cl] 284 as a metallic orange 
crystalline powder. Yield PNC: 0.083 g (63.1 %) 
Found (required for C27H23ClNO2PPt.0.2CH2Cl2): C, 48.27 
(48.62); H, 3.46 (3.51); N, 1.79 (2.08); Cl, 7.41 (7.39). 
IR  max (KBr): 3379 (w), 3053 (w), 2924 (m), 2853 (w), 1658 
(w), 1578 (C=N)(s), 1529 (m), 1474 (Ar C=C )(m), 1462 (s), 
1436 (Ar C=C)(m), 1424 (s), 1330 (w), 1264 (s), 1242 (m), 1203 
(m), 1183 (s), 1130 (m), 1099 (w), 1076 (w), 1013 (m), 955 (m), 824 (s), 755 (s), 694 (s), 662 
(w), 588 (m), 565 (s), 525 (s). 
1
H NMR δ ppm: 9.72 (1H, s) (3JPt-H 126 Hz), 7.27-8.17 (17H, m), 3.88 (3H, s), 4.02 (3H, s).  
31P NMR δ ppm: 25.2 (s) (1JPt-P 2102 Hz) 
 
285: HL
4
 (0.095 g, 0.22 mmol) 264 and PtCl2(cod) (0.076 g, 0.20 
mmol) gave [Pt( 3–PNO-L4)Cl] 285 as a orange crystalline 
powder. Yield PNO: 0.015 g (12 %) 
Found (required for C26H21ClNO2PPt.0.4CHCl3): C, 45.85 
(46.04); H, 3.27 (3.13); N, 2.20 (2.03). 
IR  max (KBr): 3443 (w), 3051 (w), 1607 (C=N)(s), 1590 (s), 
1540(s), 1477 (w), 1437 (w), 1395 (m), 1331 (m), 1279 (s), 1251 
(s), 1231 (m), 1178 (s), 1158 (m), 1102 (s), 1066 (m), 986 (w), 879 (w), 856 (w), 742 (s), 716 
(m), 691 (s), 583 (w), 566 (s), 583 (m), 509 (s), 459 (w). 
1
H NMR δ ppm: 9.15 (1H, s) (3JPt-H 76 Hz), 6.59-7.90 (16H, d, q, d, m), 3.89 (3H, s).  
31P NMR δ ppm: 13.1 (s) (1JPt-P 3816 Hz) 
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2.10.7  Synthesis of the platinum phosphinoiminol cyclometallated complexes [Pt( 3–
PNC–L5-7)Cl] 286-288: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.90: Synthesis of the platinum phosphinoiminol cyclometallated complex 286-288. 
 
To a stirred refluxing solution of PtCl2(cod) in 30ml of chloroform with an excess of 
sodium carbonate (0.04 g) and DABCO (0.05 ml) added, the HL
5-7
 ligands 265-267 were 
added as a solution of chloroform from a drop funnel over four hours. The solution was then 
refluxed for a further two hours to assist thermal cyclometallation. Immediately after adding 
the ligand the reaction became cloudy white with the formation of the DABCO hydrochloric 
salt. After six hours the bright yellow cloudy solution was reduced to dryness in vacuo, taken 
up in dichloromethane, washed three times with de-ionised water and dried over MgSO4. The 
solution was then reduced to dryness again in vacuo and crystallised from dichloromethane-
hexane to produce the cyclometallated complexes 286, 287 and 288. 
 
286: HL
5 
(0.091 g, 0.22 mmol) 265 and PtCl2(cod) (0.076 g, 0.20 
mmol) gave  [Pt( 3–PNC-L5)Cl] 286 as a pale yellow crystalline 
powder. Yield: 0.054 g (42.2 %) 
Found (required for C26H21ClNO2PPt.CH2Cl2):  C, 44.83 
(44.67); H, 3.27 (3.19); N, 2.10 (1.93). 
IR  max (KBr): 3329 (w), 3053 (w), 2932 (w), 1678 (w), 1582 
(C=N)(s), 1503 (m), 1484 (s) (Ar C=C)(s), 1458 (Ar C=C)(m), 
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1437 (Ar C=C)(m), 1321 (w), 1296 (m), 1264 (m), 1211 (m), 1181 (w), 1160 (w), 1098 (w), 
1039 (w), 998 (w), 870 (w), 796 (s), 780 (s), 748 (s), 694 (s), 533 (s), 492 (s), 508 (s). 
1
H NMR δ ppm: 9.45 (1H, dd) (6JH-P 12 hz, 
6
JH-H 3 Hz), 7.92-7.95 (17H, m), 3.87 (3H, s).  
31P NMR δ ppm: 24.3 (s) (1JPt-P 1928 Hz) 
 
287: HL
6 
(0.097 g, 0.22 mmol) 266 and PtCl2(cod) (0.076 
g, 0.20 mmol) gave  [Pt( 3–PNC-L6)Cl] 287 as a dark 
yellow crystalline powder. Yield: 0.068 g (51 %) 
Found (required for C27H23ClNO3PPt.0.5CH2Cl2): C, 
46.15 (46.30); H, 3.38 (3.39); N, 2.07 (1.96). 
IR  max (KBr): 3052 (w), 2929 (w), 1575 (C=N)(s), 1482 
(Ar C=C)(m), 1457 (Ar C=C)(m), 1436 (Ar C=C)(s), 
1260 (s), 1209 (w), 1157 (m), 1137 (m), 1099 (s), 1062 
(w), 1037 (m), 999 (w), 943 (w), 833 (m), 748 (m), 694 (s), 656 (s), 536 (m), 505 (s). 
1
H NMR δ ppm: 9.49 (1H, dd) (6JH-P 12 hz, 
6
JH-H 3 Hz), 6.10-7.86 (16H, m), 3.89 (3H, s), 
3.74 (3H,s).  
31P NMR δ ppm: 22.9 (s) (1JPt-P 1928 Hz) 
 
288: HL
7 
(0.101 g, 0.22 mmol) 267 and PtCl2(cod) (0.076 g, 
0.20 mmol) gave  [Pt( 3–PNC–L3)Cl] 288 as a pale yellow 
crystalline powder. Yield: 0.017 g (11.9 %) 
Found (required for C25H18BrClNOPPt.CH2Cl2) C, 42.36 
(42.15); H, 3.72 (3.62); N, 2.05 (1.94). 
IR  max (KBr): 3328 (w), 3052 (w), 2920 (m), 1677 (m), 1615 
(m), 1579 (C=N)(s), 1501 (m), 1457 (Ar C=C)(m), 1436 (Ar 
C=C)(m), 1392 (s), 1313 (w), 1261 (w), 1183 (m), 1159 (s), 
1100 (m), 1063 (s), 998 (m), 940 (w), 863 (w), 795 (w), 777 (s), 745 (s), 693 (s), 608 (w), 
534 (m), 505 (s). 
1
H NMR δ ppm: 9.45 (1H, dd) (6JH-P 12 hz, 
6
JH-H 3 Hz), 6.77-8.10 (17H, m).  
31P NMR δ ppm: 25.1 (s) (1JPt-P 2041 Hz) 
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3.1 Chapter 3 Background: 
 
The influence of phosphines as part of the tridentate iminophosphine ligand of the Pt 
(II) complexes and their properties have been highlighted extensively in Chapter 1 and 
Chapter 2. This chapter on the other hand aims to focus on synthetic routes to generate 
phosphine substitutions of the tridentate Pt (II) complexes 281-289 reported in Chapter 2, 
specifically via displacement of halide group.   
Phosphine substitutions can be of two different types, monophosphine substitution 
and polyphosphine substitution. The reactivity of multi-dentate platinum complexes with 
tertiary monodentate phosphines, such as triphenylphosphine, will be explored in this chapter 
as will the paths towards successful coordination of the phosphines with the platinum by 
displacement of a halide from the metal centre.  
The HSAB theory and the trans-effect will be employed throughout this chapter by 
way of explaining the results obtained. The soft-acid/soft-base interaction proposed by the 
HSAB theory is classed as a favourable process i.e. “soft base” phosphine –“soft acid” Pt (II). 
Phosphine moieties are also known to be strong trans-effect ligands, as a result we see an 
effect on the already coordinated tridentate iminophosphine ligand of the complex on 
introduction of new phosphine moieties trans across the metal centre which will be an 
important consequence for analysis and identification of these complexes by IR and NMR 
techniques.
1
  
This chapter also intends to discuss and compare synthetic routes and practical aspects 
encountered in the preparation of Pt (IV) chloro iminophosphine complexes. The biological 
implications and uses of these platinum complexes were discussed in detail in Chapter 1. 
Previously within this research group, preparation of Pt (IV) complexes of analogous iodo 
complexes were seen to be quite cumbersome and their reaction products difficult to predict; 
most of the time producing mixtures of products along with unreacted starting materials. 
The work undertaken in this chapter reports the substitution and oxidation of both the 
tridentate cycloplatinated species [Pt(η3-PNC-L1-7)Cl] 281-284, 286-288 and the previously 
reported tridentate P,N,O complex [Pt(η3-PNO-L4)Cl] 285. Their reactivity towards tertiary, 
monophosphine substitution and chloride based oxidising agents to produce two series of 
novel platinum complexes will be investigated. 
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3.2 Substitution Reactions of Platinum Complexes: 
 
3.2.1 The Trans-Effect in Platinum Complexes: 
 
 Chernyaev introduced the concept of the trans-effect in 1926 for platinum chemistry.  
He discovered that after synthesising many square planar Pt (II) complexes that the presence 
of certain ligands attached to the metal ion had the ability to cause the loss of the group that 
was in the position directly trans to it.
2
  
In reactions of square planar Pt (II) compounds, ligands trans to chloride in particular 
are more easily replaced than those trans to ligands such as ammonia.
3
 Therefore the chloride 
ligand is said to have a stronger trans-effect than ammonia. In the simplest terms, Dabrowiak 
describes the trans-effect as the following: the trans-effect pertains to the ability of a ligand 
in a complex to direct substitution opposite, or trans, to itself.
4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: The commercial synthesis of cisplatin 306 via the Dhara Synthesis, which 
demonstrates the trans-effect with the formation of the intermediate 303.  
 
The synthesis of the world’s number one platinum based anti-cancer drug, cisplatin, 
which forms two isomers (transplatin and cisplatin), is a great illustration of how the trans-
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effect works. Known as the “Dhara Synthesis”, potassium tetrachloroplatinate, K2[PtCl2] 301, 
is reacted with excess potassium iodide in an associative mechanism, Figure 3.1, until all the 
chloride ligands are replaced by iodides 302.  
[PtI4] is reacted with two equivalents of ammonia but only substitutes the iodides in a 
cis-manner due to the trans-effect of the iodide ligands 304. This is the most interesting 
feature of this synthesis since two geometric isomers are possible, cis and trans, and the cis 
would be less thermodynamically stable than the trans, but only the cis isomer is formed in 
the reaction.  
When a second equivalent of ammonia is added to the key intermediate, indicated in 
Figure 3.1, it only substitutes the iodide trans to another iodide rather than trans to the amine 
group already present. In this synthesis only the cis product is isolated, showing the ability of 
iodide to direct substitution trans to itself being greater than that of ammonia to direct 
substitution trans to itself.
5
  
Also of interest is the last part of the “Dhara Synthesis”, Figure 3.1, which involves 
the replacement of both iodides with two water molecules using two equivalents of AgNO3. 
This results in the formation of the insoluble salt AgI, with the metal complex staying as an 
equilibrium in the aqueous solution 305. This phenomenon is called a phase change, which 
involves the formation of insoluble AgI and NO3
-
 acting as a spectator ion due to the large 
concentration of water molecules. KCl is then used in excess to displace the water molecules 
and drive the equilibrium to the formation of cisplatin which precipitates from solution. This 
method of substitution has been used by our research group in the past as the primary method 
for substituting the Pt-X bond in platinum iminophosphine complexes.
6–8
  
 Not all ligands however share the same strength in what has been called the “trans 
directing ability” and as a result a series was created to rank the most common ligands by 
their ability to direct an incoming nucleophile to the coordination site trans to themselves, 
Figure 3.2.  
 
CN
- 
~ CO ~ C2H4 > PH3 ~ SH2 >NO2
- 
> I
-
 > Br
-
 > Cl
-
 > NH3 ~ py > OH
-
 > H2O 
 
Figure 3.2: The “Tran-Effect Series” which orders common ligands in relation to their trans 
directing ability. As can be seen, CN
-
 is the strongest trans directing ligand and water is the 
weakest.  
 
 A number of models have been proposed to explain the trans-effect and why a given 
ligand is where it is in the series as described in Figure 3.2. Early models focussed on the 
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structure of the reactants along with thermodynamic arguments which assumed that if a bond 
was slightly longer in the starting complex then it would be the bond broken in the 
substitution reaction.
4
  
Other models, based on transition state theory, addressed the structure of the transition 
state or activated complex in the reaction thus providing a kinetic focus to the theory. While 
these models address the trans-effect from a kinetic perspective, difficulties in estimating the 
electronegativities of some groups and a lack of knowledge of the structure of the transition 
state make it difficult to use. Some of this model will be discussed in Section 3.1.1.
4
 
 Recently however, two factors have been put forward to explain the trans-effect; 
weakening of the Pt-X bond and stabilisation of the five-coordinate intermediate (which was 
previously encountered as part of the mechanism proposed for cyclometallation in Chapter 
2). Both of these concepts will be discussed separately and in more detail in the following 
Sections 3.2.1 and 3.2.2 respectively.  
 
3.2.2 The Pt-X Bond; Sigma and Pi Bonding Effects: 
 
 The Pt-X bond is influenced by the Pt-T bond in 307, Figure 3.3, because both use 
the px and dx
2
-y
2
 orbitals on the platinum metal centre. When the Pt-T bond is strong, it uses a 
larger part of these orbitals and therefore leaves less for the Pt-X bond. As a result, the Pt-X 
bond is weaker and its ground state (sigma-bonding orbital) is higher in energy, leading to a 
small activation energy required for the breaking of this bond.  
 
 
 
 
 
   307     308 
Figure 3.3: Sigma-bonging effects, 1 and Pi-bonding effects in the Pt-T bond, 2. A strong σ 
bond between the Pt and T weakens the Pt-X bond, leading to a small activation energy for 
this bond. Further orbital structures are omitted for clarity.  
 
 This ground state effect is sometimes called the trans-influence and primarily applies 
to the leaving group. It is a thermodynamic effect and can partly predict the order for the 
trans-effect series based on the relative σ-donor properties of the ligands. However an 
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additional factor is needed to fully explain the order of the trans-effect series in Figure 3.2; 
π-bonding.3  
 The formation of a strong π-bond in the Pt-T bond, 308, Figure 3.3, results in charge 
being removed from the platinum metal centre and the entrance of another ligand to form a 5-
coordinate intermediate is more likely. In addition to the charge effect, the dx
2
-y
2
 orbital, 
which as previously mentioned is also involved in σ-bonding for square planar geometry, and 
both the dxz and dyz orbitals can contribute to π-bonding in the trigonal-bipyramidal 5-
coordinate transition state (discussed further in Section 3.1.2).
9
  
 The full trans-effect series, Figure 3.2, is therefore as a result of the combination of 
the two effects where ligands highest in the series are strong π-acceptors, followed by strong 
σ-donors. Ligands at the low end of the series therefore have neither strong σ-donor nor π-
acceptor abilities.
9
 
 
3.2.3 Nucleophilic Ligand Replacements (The 5-Coordinate Intermediate): 
 
It is generally accepted that substitution reactions of square-planar compounds are 
associative where an incoming ligand (Y, Figure 3.4) approaches along the z-axis. There is 
also a general agreement that the reactions involve nucleophilic attack of the entering ligand 
(Y) at the metal centre, with the resulting 5-coordinate intermediate passing through a square 
pyramidal and trigonal-bipyramidal stages, Figure 3.4.  
 
 
 
 
    Trigonal-Pyramidal    Square-pyramidal 
     5-Coordinate Intermediates 
Figure 3.4: Direct substitution of the platinum square-planar complex by the Y ligand, 
resulting in the loss of the X ligand.
9
  
 
As the X leaves, Figure 3.4, the new Y ligand moves down into the plane of T, Pt, 
and the two L ligands to form the trigonal-bipyramidal structure 308. The evidence for the 5-
coodinate intermediate (308, 309 Figure 3.4) is very strong with numerous reports detailing 
its existence. Several 5-coodinate complexes with trigonal-bipyramidal geometry, 308 such 
as [Pt(SnCl3)5]
3-
 have been isolated as discussed in Chapter 2, Section 2.3.2.  
Pt
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A second argument has also been put forward proposing the existence of a 6-
coodinate intermediate, with assistance from a solvent molecule, but the subsequent 
replacement of the co-ordinated solvent molecule (S) by the entering ligand (Y) is fast, 
making it difficult to isolate and confirm so a 5-coordinate mechanism is used, Figure 
3.5.
10,11 
 
The trigonal-bipyramidal complex of Figure 3.4 and 3.5 has been regarded as a 
reaction intermediate by both this research group and others, with the two square-pyramidal 
species (with the X ligand on the top or bottom of the plane) as transition states 309.
 
 
 
 
 
Figure 3.5: Solvent-assisted substitution of the platinum square-planar complex by the Y 
ligand, resulting in the loss of the X ligand.
9
 
 
 This mechanism explains the effect of the incoming ligand in both cases. A strong 
Lewis base is likely to react readily, but the hard-soft nature of the base (the incoming ligand) 
has an even large effect. Pt (II) is generally regarded as a soft acid, so soft ligands react more 
readily with it but it also depends on the trans-effect.  
 For substitution reactions involving Pt-Cl bonds in a methanolic solution, a 
relationship has been founds for certain ligands (excluding the influence of the trans-effect), 
Figure 3.6. Soft Lewis bases such as phosphine ligands (PR3) are the highest on the list while 
hard ligands such as Cl
-
 are the most difficult to use a substituting ligand. 
 
PR3 > CN
-
 > SCN
-
 > I
-
 > Br
-
 > N3
-
 > NO2
-
 > Py > NH3 ~ Cl
-
 > CH3OH 
 
Figure 3.6: The order of ligand reactivity for substituting a platinum metal centre.
9
 
 
 By the same argument, the leaving group (X, Figure 3.4 and 3.5), should also have a 
significant influence on the rate, and it does. The order of good leaving groups from a 
platinum metal centre is nearly the reverse of the list given in Figure 3.6, with hard ligands 
such as Cl
-
, NH3 and NO3
-
 leaving quickly. Soft ligands such as CN
-
, I
-
 and NO2
-
 are very 
reluctant to leave which is what was observed for the previously reported iodo platinum 
complexes reported by our research group.
6
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3.3 Phosphine Substitutions of Pt-Halide Bonds: 
 
3.3.1 Phosphine Substitutions Involving Halide Scavengers: 
 
 Previous reports by our research group undertaken by Maguire and Lennon have 
revealed the difference in lability of a Pt-Cl bond in contrast to a Pt-I bond.
6,8
 In similar 
investigations by Capape et al, phosphine substitutions were reported, interestingly, to 
displace nitrogen moieties and sulphur moieties in preference to chlorides (Figure 3.7).
11
  
These investigations further indicate the greater importance of the trans-effect and the 
strength of the platinum chloride bond, compared with the HSAB theory described in Section 
3.2.2. In Figure 3.7, the sulphur donor moiety on compounds 310 is substituted rather than 
the chloride because of the weak trans-effect found for imines relative to the carbon on the 
aryl ring. However, HSAB theory and the trans-effect are not the only concepts that are 
important here; relative bond strengths also play a significant role.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Reaction of triphenylphosphine with a cyclometallated Pt (II) complex where the 
nitrogen and sulphur moieties are substituted over chloride.
11
  
 
According to the theories put forward in the last part of Section 3.2.2, the chloride 
(being a hard Lewis base and platinum being a soft acid) should be substituted by a 
phosphine without any difficulty. Instead the chlorine (trans to a Pt-C bond to a phenyl 
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group) remains intact, even with two equivalents of triphenylphosphine present (312, Figure 
3.7). 
Also worthy of note in Figure 3.7 is the apparent strength of the organometallic bond 
of the platinum metal centre and the carbon of the aromatic ring system where a monodentate 
complex is the result of substitution with the introduction of two phosphine moieties.  
 
 
 
 
 
 
 
       313        314 
Figure 3.8: Direct substitution of Pt-N bonds resulting in ring opening of the 5-membered 
chelate structure. Again the Pt-Cl bond remains unsubstituted in contrast to the theories 
proposed by the HSAB theory.  
 
These types of unusual substitutions have also been reported by Albrecht et al for η3-
C,N,N pincer type complexes where again the nitrogen moieties were displaced over the 
chloride ligand even though the iminic nitrogen would be considered borderline (1:1 soft:hard 
base) according to the hard-soft acid base theory (HSAB), unlike the significantly harder 
chloride base, Figure 3.8. In the case of these η3-C,N,N systems, opening of the chelate ring 
is also observed on introduction of the new phosphine moiety like that seen for the complex 
in Figure 3.7.
12
 
Investigations undertaken by our research group have also revealed the increased 
lability of the platinum iodide bond over the platinum chloride bond of analogous complexes 
by way of achieving direct substitution for the metal-halide bond in the iodo complexes but 
not the previously reported PNO chloride complexes reported in Chapter 2.
7,6
  
In work reported by Fernandez et al, cyclometallated palladium complexes of the 
[C,N,O] and [C,N,N] type were initially treated with a silver(I) salt to remove the chloride 
ligand from the metal centre as silver chloride, resulting in the vacant co-ordination site being 
later occupied by the desired phosphine donor moiety, Figure 3.9. This is similar to the 
mechanism employed by the last part of the Dhara synthesis of cisplatin in 305, Figure 3.1.
13
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Figure 3.9: The use of silver (I) perchlorate to achieve substitution of a series of 
cyclometallated palladium CNN type complexes (315) to form the substituted complexes as  
perchlorate salts (316).
13
  
 
Interestingly, unlike previous examples in Figure 3.7 and 3.8, the cyclopalladated 
complex in Figure 3.9 reacts with numerous monophosphines, PR3 (including PPh3), to form 
the desired phosphine substituted complex by substitution of the Pd-Cl bond. Of particular 
interest in this reaction is the resulting geometry. The introduced monophosphine is located 
trans to the imino-nitrogen; the position occupied by the halide ligand in the starting material. 
Interestingly however, unlike that seen for the Pt-N bonds in Figure 3.8, the Pd-O bond is not 
broken here despite the oxygen being a hard base according to the HSAB theory. This is 
similar to previous work completed within our research group on PNO type complexes, 
Figure 3.10.
6 
 
 
 
 
 
 
 
 
Figure 3.10: The use of silver (I) perchlorate to achieve substitution of the PNO complex 
275/285,  previously reported by this research group and again in the current studies in 
Chapter 2 from a different synthesis method.
7
  
 
It can be seen therefore that the Pt (II) chloro complexes require the use of halide 
scavenger to achieve chloride abstraction, like AgCF3SO3 or AgClO4, in order to remove the 
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halide from the platinum centre. Direct substitution, like that observed for the previously 
reported iodo complexes, has proven very difficult to achieve for platinum-chloride bonds 
without the use of these perchlorate salt to initially remove the halide from the metal centre. 
Extensive work within our research group on platinum chloride iminophosphines of the η3-
P,N,O type has only yielded substitution with phosphines in the presence of silver 
perchlorate, Figure 3.10.
7
 
This method has been established to allow phosphine substitution without the loss of 
the tridentate ligand coordination or undesired displacement of a donor moiety from the metal 
centre, as reported by other research groups in Figure 3.8 and Figure 3.9. However, the 
properties of the phosphine were also found to be particularly significant when substituting 
with Pt (II) complexes. In particular reduced reactivity was found for the Pt (II) complexes in 
comparison to the analogous Pd (II) complexes due to the proposed reduced lability of the Pt-
Cl bond in comparison to the Pd-Cl bond. Also no reaction was observed for some of the 
platinum iodo complexes reported with certain phosphines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Direct phosphine substitution of tridentate CNS type platinum chloro complexes 
with mono and di-phosphine ligands.
14
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Reactions of reduced cone angle phosphines like tris(2-cyanoethyl)phosphine were 
found to be successful over sterically bulky phosphines such as triphenylphosphine in spite of 
the higher acidity of these ligands. Previous studies within our research group indicated that 
the use of a more labile halide group, such as iodide, within these complexes results in 
successful direct phosphine substitution however, direct substitution for chlorides did not 
occur.
6
 
 
Also worthy of note is the extensive work completed by Vila et al
 
into substitutions of 
η3-C,N,S complexes derived from thiosemicarbazones, Figure 3.11.14 For these complexes 
diphosphine substitution was achieved using diphenylphosphinoethane (dppe) in acetone as 
well as direct substitution (without a halide scavenger) using monophosphine ligands.  These 
phosphine-bidentates, 320, Figure 3.11, have also been a subject of interest in our research 
group
 
but have not yielded any significant success due to the insolubility of the products.
15
 
 
3.3.2 One-Step Phosphine Substitutions: 
 
 Within our research group direct phosphine substitution, i.e. without the use of a 
halide scavenger, has been achieved with moderate success primarily with iodo platinum 
PNC and PNO complexes 224 and 258 respectively, Figure 3.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Direct phosphine substitution of tridentate PNC and PNO type platinum iodo 
complexes with mono phosphine ligands previously reported by our research group.
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The success of these reactions has been attributed to the increased lability of the 
platinum iodide bond over the platinum chloride bond. The use of the above indicated mixed 
solvent system also plays a part in achieving direct substitution. The importance of solvent 
choice has been discussed in the previous section. From previous reports and from work in 
our research group, it was found that direct substitution of platinum chloride bonds without 
displacing the coordination of the tridentate iminophosphine ligand from the metal centre is 
very difficult to achieve without the use of a halide scavenger.
6,7
  
However, extensive work completed by Anderson et al
 
and work reported in Chapter 
2, has highlighted the importance of chlorinated solvents for chloride ion stabilisation. 
Anderson et al have reported that the presence of a silver (I) salt (or other halide scavengers) 
is not necessary for the formation of phosphine substituted complexes from chloro Pt (II) 
precursors Figure 3.13.
16
  
 
 
 
 
 
Figure 3.13: Direct phosphine substitution of platinum chloro complexes with  di-phosphine 
ligands with the loss of a chloride from the metal centre completed in chloroform.
16
  
 
 Following on from Figure 3.13, both chlorides by way of an associative mechanism, 
can be displaced by dppe again in the absence of a silver (I) salt. Anderson et al have also 
completed work in comparing perchlorate cationic platinum salts and cationic platinum 
complexes where the displaced chloride acts as the counter-ion instead of the perchlorate 
anion.
16
  
Interestingly, when the cationic platinum complex is not isolated as its perchlorate 
salt, that is when the counter-ion is chloride, the 
31
P{H} NMR spectra are somewhat broad at 
ambient temperature, but when the sample is cooled to -40
o
C the spectra become sharp. They 
propose that this observation is due to the interaction of the highly electronegative chloride 
ion with the metal complex through ligand exchange or ion-pair formation.
16
  
 Another point of interest in the work by Anderson et al, is that when the platinum-
dmpe complex was treated with PPh3, the triphenylphosphine displaces the other previously 
introduced phosphine ligands, Figure 3.13. It is generally considered that the PMePh2 (dmpe) 
is a better donor ligand than PPh3 because of the electron-donating methyl group present over 
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the electron-withdrawing phenyl group. However when [PtCl2(dmpe)] is treated with 
triphenylphosphine, displacement is seen to occur for the dmpe group.
16
  
 
3.4 Pt (IV) Anti-cancer Drugs: 
 
3.4.1 The Current Clinical Status of Pt (IV) Anti-cancer Drugs: 
 
 A large amount of Pt (II) and Pt (IV) anti-cancer drugs approved for clinical use 
around the world, including those in advanced clinical trials, have chloride ligands as part of 
their structure (see Chapter 1). Cisplatin, the first generation platinum anticancer drug, has 
chloride ligands as do some of the second and third generation platinum anti-cancer drugs 
such as Picoplatin, JM 11 and NSC 170898.
17
  
This is primarily due to the fact that it has been widely reported that chloro platinum 
complexes remain intact in the bloodstream due to the relatively high concentration of 
chloride ions present (~100 mM). They readily dissociate their chloride ligands when they 
enter a cell (due to the lower chloride concentration) to form reactive hydroxyl analogues 
ready for DNA binding.
18
 
Tetraplatin (also known as Ornaplatin) was the first Pt (IV) drug developed for anti-
cancer activity and its structure is mostly composed of chloride ligands, Figure 3.14. The 
method of action of these Pt (IV) pro-drugs has been covered in detail in Chapter 1, Section 
1.4.6 so instead here we will discuss their synthesis, stability and reactivity, along with their 
current progress within clinical trials. 
  
 
 
 
 
 
 
 
 
  323     324    325 
Figure 3.14: The three Pt (IV) anti-cancer drugs that have reached advanced clinical trials.  
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 Tetrachloro (1,2-cyclohexanediamine-N,N’) Pt (IV) or Tetraplatin, 323, is a pro-drug 
that undergoes reduction by proteins in tissue and blood plasma to its active Pt (II) analogue. 
Multiple Phase I clinical trials were conducted but severe neurotoxicity was observed at high 
doses and to date no Phase II trials have been reported in the literature.
19
  
cis, trans, cis-Dichlorodihydroxidobis (isopylamine) Pt (IV) or Iproplatin, 324, on the 
other hand has been extensively studied with multiple Phase I, Phase II and Phase III clinical 
trials. Its activity was examined for a variety of cancer types including ovarian, urothelial, 
malignant pleural mesothelioma, breast, squamous cell carcinoma and cervical cancer to 
name only a few. However, advancement of the drug was hindered by some toxic related 
deaths, dose reductions due to cumulative effects and its response rate being no different to 
cisplatin.
19
  
Developed over 16 years ago, bis(acetato-O)amminedichloro(cyclohexylamine) Pt 
(IV) or satraplatin (JM216), 325, was found to have the lowest IC50 value to date of any 
platinum anticancer drug (Pt (II) or Pt (IV)) coupled with dramatically decreased 
cytotoxicity. Recently, it was also found to be 2.8 times more effective against human 
ovarian carcinoma cell lines than cisplatin. Also, further studies by Ricart et al
 
have laid the 
foundation for the drug to progress into phase III of clinical trials.
20–22
  
Satraplatin is the first orally administered platinum anti-cancer drug where the 
patients can self administer the tablet over a five day basis. The advantages of this method of 
delivery are immense; including self administration for the patients in their own homes which 
is cost-effective over making frequent trips to a clinic. It was also reported again by Ricart et 
al that there was no cardiac, renal, hepatic or neurologic toxicity associated with this Pt (IV) 
chloride drug. It has reported to be very effective in particular against non-small cell lung 
cancer (NSCLC) and Hormone Refractory Prostate Cancer (HRPC).
20,23
  
 Current studies involving satraplatin are concerned with the dosage limits and 
response time for the drug by oral administration, along with the effect of food on diffusion 
of the drug from the stomach. Other studies include further in-vitro testing of satraplatin on 
new types of cancers along with extensive investigations into the pharmacokinetics of the 
drug after administration. In light of the ongoing research into this new generation of 
platinum anti-cancer drugs and the advanced stage of clinical trials at which satraplatin is 
currently in, it is hoped that further analogous Pt (IV) chloride complexes can be synthesised 
and brought to clinical trials.
21,23–25
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3.4.2 Stability and the Chelate Effect: 
 
 Unfortunately there are some reports of Pt (IV) complexes that suffer from greatly 
reduced stability over their Pt (II) analogues.
26
 However, it has been recognised for many 
years that ligands which form a ring structure that includes the metal ion, called a chelate 
ring, have exceptional thermodynamic stability. This increased stability, beyond which could 
achieved with a similar non-chelate system, is called The Chelate Effect.
5,9
  
Like the complexes reported in Chapter 2 (281-289), chelate rings that have a total of 
five or six atoms in the ring (including the metal ion) are more stable than rings with four or 
seven members. While the arrangement of chelate rings, the nature of the donor atoms and 
their charge, and the size of the rings all affect the stability of the complex, in general ligands 
which have multiple points of attachment to the metal ion produce the most stable 
complexes.
5
 
Therefore, it can be extrapolated that tridentate chelate platinum complexes would 
have increased stability over analogous bidentate chelate platinum complexes such as 
Tetraplatin, 323, Figure 3.14. Previous work by our research group on analogous iodo 
platinum complexes utilized this increased stability to isolate stable Pt (IV) iodo complexes, 
Figure 3.15.  
 
 
 
 
 
 
 
Figure 3.15: The previously reported oxidation of iodo Pt (II) complexes by our research 
group to form stable Pt (IV) complexes. 
 
The exceptional stability of the metal chelate ring, which will also be explored in this 
chapter for the complexes 281-289, implies that the binding constant of the ligand toward the 
metal ion is large. Also the increase in entropy going from left to right (with the loss of HCl 
from the complex because of cyclometallation as seen in Chapter 2) is often cited as the 
thermodynamic basis for the chelate effect.
5,3
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Although the Chelate Effect does enhance the stability of metal complexes, reductive 
elimination of the newly introduced axial ligands on some Pt (IV) complexes to produce the 
Pt (II) precursor have been reported, Figure 3.16. However, isolation and characterisation of 
the Pt (IV) complex 328 was achieved with the crystal structure showing a distorted 
octahedral geometry. For both complexes displayed in Figure 3.16; the interaction of the 
carbene ligands (neutral carbon with a valance of 2 and 2 unshared valence electrons) with 
the platinum metal centre trans to each other is considered a coordination bond, as confirmed 
by x-ray crystallography.
26
  
 
 
 
 
 
 
 
 
  327       328 
Figure 3.16: The oxidation of the CNC type chelate platinum complex 327 and the reductive 
elimination of the resulting Pt (IV) complex 328 due to instability.
26
 
 
3.4.3 Oxidation of Pt (II) Complexes Using Hydrogen Peroxide:  
 
 The most common oxidation reagent used in the synthesis of Pt (IV) complexes is 
hydrogen peroxide, H2O2. In general reactions with Pt (II) complexes involving hydrogen 
peroxide results in the trans oxidative addition of the HO-OH bond across the Pt (II) metal 
centre to form octahedral structures. To achieve oxidations of this type, aqueous solutions of 
30% (w/v) H2O2 have been added to varying solutions of the Pt (II) complex at room 
temperature primarily for short periods of time.  
Numerous examples of this method have been reported in the literature
27–29 
and 
moderate success has been achieved previously within our research group using peroxide on 
bidentate iodo iminophosphine Pt (II) complexes shown in Figure 3.17. These complexes 
were synthesised by stirring a dichloromethane solution of 329 with 30% H2O2 at room 
temperature for 16h to form the trans-dichloromethane Pt (IV) analogue 334 by picking up 
two solvent molecules during the oxidation process.
6
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Figure 3.17: The oxidation of the bidentate Pt (II) iminophosphine complex 329 using 
hydrogen peroxide to form the stable Pt (IV) complex 334.
6
  
 
 The proposed mechanism of the interaction occurring in Figure 3.17 involves 
oxidative addition of hydrogen peroxide (HO-OH) to the Pt (II) initially generating the Pt 
(IV) species HO-Pt
IV
-OH (332), Figure 3.18. The solvent, dichloromethane, is partially polar 
due to the electronegative atoms present within the molecule (Cl) (as previously discussed in 
detail in Chapter 1 and 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: The proposed solvent mediated mechanism  to generate the Pt (IV) species via 
an Sn2 mechanism.
6
 
 
The ionic species generated, [CHCl2]
-, due to abstraction of one of the δ+ hydrogens 
from the dichloromethane, attacks the Pt (IV) centre, thereby displacing water (an excellent 
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leaving group) to generate 332, Figure 3.18. This intermediate, 332, then reacts with another 
dichloromethane molecule to generate an ionic Pt (IV) species, 334, and another water anion. 
Subsequent attack by the [CHCl2]
-
 anion on the Pt (IV) centre liberates another water 
molecule and generates the final complex 334, Figure 3.18.
 
An alternative mechanism can be proposed for this reaction which involves the 
presence of free radicals. Two hydroxyl radicals are generated by irradiation of light, which 
then react with dichloromethane to yield water and the radical 
●
CHCl2. The subsequent 
interaction of the dichloro radical with the bidentate Pt (II) complex may form a highly 
reactive Pt (III) intermediate, which is similar to by-products found for other Pt (IV) forming 
reactions reported by Whitfield et al.
30
 
Further reports into methods to generate Pt (IV) complexes have shown hydrogen 
peroxide to be a very versatile oxidising agent. Ellis et al have demonstrated oxidative 
addition of various anhydrides to a Pt (IV) metal centre to generate a wide variety of 
analogues in addition to a trans axial chloro Pt (IV) complex 337, Figure 3.19.
31
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: The oxidation of the Pt (II) complex 335 by hydrogen peroxide, followed by a 
section of anhydrides to form a range of products 338-340. Of interest also is the formation 
of a chloro Pt (IV) complex using HCl, 337.
31
 
 
Pt
Cl
Cl
335
H2O2
H2
N
NH2
Pt
Cl
Cl
OH
OH
H2
N
N
H2
HCl
Pt
Cl
Cl
Cl
Cl
H2
N
N
H2
RT
Pt
Cl
Cl
OCCH3
OCCH3
H2
N
N
H2
Pt
Cl
Cl
OCCH2CH3
OCCH2CH3
H2
N
N
H2
Pt
Cl
Cl
OCCH2CH2CH3
OCCH2CH2CH3
H2
N
N
H2
O
O
O
O O
O
Acetic
Anhydride
Propionic
Anhydride
Butyric
Anhydride
337
336
338
339
340
Chapter 3  Substitutions and Oxidations 
 
Page | 202 
 
In Figure 3.19, the reaction of the Pt (II) complex 335 with hydrogen peroxide 
generates the Pt (IV) hydroxo analogue 336 via trans oxidative addition, which is consistent 
with the previously discussed oxidation in Figure 3.18. Further reaction of 336 with the 
appropriate anhydride generates the three Pt (IV) complexes 338-340. But of particular 
interest to this project, the reaction of the Pt (IV) hydroxo complex 336 with HCl generates 
the Pt(IV) tetrachloride complex 337 in good yields (circa 82%). 
 
In the literature there are few reports involving the oxidation of cyclometallated Pt (II) 
species using hydrogen peroxide, primarily because of the difficulties in obtaining pure Pt 
(IV) products. However, recent work by Newman et al reports the successful oxidation of 
phenylpyridine Pt (II) type complexes 341, Figure 3.20.
27
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20: The oxidation of the Pt (II) complex 341 to form the isomeric products 342-346 
using hydrogen peroxide.  
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and secondly, interestingly, it induced activation of a C-H bond to generate the bis-
cyclometallated species 342-346, which have the potential to exist in five isomeric forms.
30
  
Two possible reaction mechanisms are proposed: (i) oxidation to Pt (IV) followed by 
cyclometallation or (ii) cyclometallation followed by oxidation. As covered in detail in 
Chapter 2 of this report, cyclometallation is defined as primarily an electrophilic attack of 
the metal centre by a carbon centre. As Pt (IV) is more electrophilic than Pt (II), owing to its 
higher oxidation state, cyclometallation would be a more efficient and favourable process if 
oxidation to Pt (IV) occurred first, thus mechanism (i) is considered more probable.
30
  
 
3.4.4 Oxidation of Pt (II) Complexes Using Group 17 Elements: 
 
The oxidation of Pt (II) complexes to produce chlorinated Pt (IV) products has been 
explored in detail in the inorganic literature, traditionally using Cl2 as the oxidant. One of the 
earliest examples was provided by Rund et al, studying the oxidative addition of chlorine to 
dihalo (1,10-phenathroline) Pt (II) 346, Figure 3.21. Chlorine oxidation of this Pt (II) 
complex produced a new Pt (IV) species 347, with the chloride ligands in a cis orientation to 
one another at the axial positions of an octahedral structure.
32
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: The oxidation of the Pt (II) complex 349 using molecular chlorine gas, Cl2.  
 
The proposed mechanism for these transformations is an ionic pathway involving 
nucleophilic attack on the Pt (II) metal centre to generate a cationic five-coordinate Pt (IV) 
intermediate 349, Figure 3.22. This is similar to the associative mechanism proposed for the 
substitution reactions in Section 3.2.3.  
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The five-coordinate intermediate, 349, is then followed by coordination of an X
–
 
(halide anion) to produce the neutral Pt (IV) chloride product 351. This mechanism was first 
proposed by Skinner et al (specifically using bromine).
33
 Other investigations using Cl2 and I2 
have also confirmed a similar mechanism.
34–36
  
 
 
 
 
 
 
Figure 3.22: The oxidation of the Pt (II) complex 351 via oxidative addition of a halide to a 
Pt (II) metal centre with assistance from a donor solvent H2O.
33
  
 
 In previous work by our research group, Pt (IV) complexes were formed from 
reacting an excess of molecular iodine with the relevant Pt (II) complexes in an ethanolic 
solution over the course of five days at room temperature giving yields ranging from 30 % to 
60%. However, the crude products almost always contained some Pt (II) starting material.
6
  
Using molecular iodine is convenient due to the fact that it is a solid at room 
temperature, but in order to oxidise Pt (II) complexes using Cl2, a gas system is required in 
order to bubble the chlorine through the solution. This inconvenient set-up can be very 
hazardous so alternative methods to chlorinate these complexes have been developed by Liu 
et al and others and discussed further in the next section.
30,37 
  
 
 
 
 
 
 
 
 
 
Figure 3.23: Oxidation of a Pt (II) complex using an aqueous solution of sodium 
hypochlorite.
37
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3.4.5 Other Methods for Oxidising Pt (II) Complexes: 
 
Liu et al have reported chlorination (oxidation) of various Pt (II) complexes, 352, 
using sodium hypochlorite as the oxidising agent, Figure 3.23. Previously sodium 
hypochlorite has also proven to be a very convenient oxygen source for olefin epoxidation, 
catalysed by transition-metal complexes.
38
 Liu et al found that it can act as a chloride and 
hydroxyl anion source for the preparation of mixed (chloro)(hydroxo) Pt (IV) complexes 355, 
Figure 3.23. However, even though sodium hypochlorite is a cheap and widely available 
reagent, and eliminates the need for organic solvents, unfortunately unpredictable and 
varying results are a disadvantage.
37
 
While oxidations with Cl2 have been studied extensively, significantly less attention 
has focused on the oxidations of Pt (II) complexes with electrophilic chlorine oxidants such 
as PhICl2 and N-chlorosuccinimide (NCS). Baxter et al has shown that PhICl2 can react with 
Pt (II) metal centres such as that in Figure 3.24.
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
356     357       358 
Figure 3.24: Oxidation of a Pt (II) complex 356 using PhICl2 to initially form a stable Pt (III) 
complex 357 and finally a Pt (IV) complex 358.
39
  
 
This transformation has been proposed to proceed by a mechanism analogous to that 
of the chlorination reactions discussed in Figure 3.22. N-Chlorosuccinimide (NCS) has also 
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been used in limited instances for the oxidation of Pt
II
 species. For example, [Pt
II
Me2(α-
diimine)] 359 and [Pt
II
Me2(DPK)] 362 have  been shown to react with NCS in MeOH to 
afford Pt
IV
 products that incorporate 1 equiv of chloride and an OMe group from  the solvent, 
Figure 3.25.
40
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25: Formation of Pt (IV) products, 361 and 364 due to the oxidation of [Pt
II
Me2(α-
diamine)] 359 and [Pt
II
Me2(DPK)] 362 respectively with N-chlorosuccinimide (NCS) in 
methanol.    
 
As shown in Figure 3.25, the mechanism of these transformations are presumed to 
involve initial, two electron oxidation of the Pt
II
 complexes in order to form a cationic Pt (IV) 
intermediate, 360 and 363, which is then followed by trapping of the intermediate with the 
solvent to form the stable Pt (IV) complexes 361 and 364.
40
  
Sanford et al
 
have also produced similar results using NCS as an oxidant involving 
the phenylpyridine Pt
 
(II) complex 365, Figure 3.26. Also of significance in this work is the 
Pt (III) intermediate, 366, which for the first time was observed and isolated with NCS as an 
oxidant. Interestingly they have also reported similar palladium oxidations to form stable Pd
 
(IV) chloride complexes with the same phenylpyridine ligands. 
30
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Also worth noting for these series of reactions was the role of light in the reaction 
mechanism and the photophysical properties the complexes were seen to have. The Pt (IV) 
complexes (367 and 368) increased in yield while the oxidation reaction was carried out 
under intense light and as a result the yield of the Pt (III) complex 366 decreased. This was 
explained by way of photoexcitation of the Pt
 
(II) starting material 365, followed by Cl
●
 
radical abstraction from the solvent to form the Pt
 
(III) radical and finally radical cage 
recombination to afford the Pt
 
(IV) complexes, 367 and 368. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26: Formation of Pt (IV) products, 367 and 368 due to the oxidation of 
phenylpyridine Pt (II) complex 365 with N-chlorosuccinimide (NCS) in dichloromethane. 
Also of note is the formation of the Pt (III) complex 366 which under intense light also 
undergoes oxidation.
30
    
  
3.5 Summary and Conclusions: 
 
From the literature reviewed it is apparent that, although difficult, it is possible to 
achieve one-step substitution of platinum chloride bonds and the methods used have been 
seen to be dependent on solvent-ion stabilisation previously discussed in reference to 
chloroform in Chapter 2. From work completed previously by our research group, 
PtII
N
N
N
O
O
Cl
CH2Cl2
PtIV
N
N
PtIV
N
Cl
Cl
Cl
Cl
PtIII
N
Cl
PtIII
N
Cl
365
367 368
366
N
O
O
Cl
Photochemical
Effects
N
O
O
Cl
N- Chlorosuccinimide
Chapter 3  Substitutions and Oxidations 
 
Page | 208 
 
particularly in the case of group 10 metal-halide bonds, the lability of these bonds have been 
reported to increase down the group (F> Cl> Br> I). Generally, on substituting chloro ligands 
in tridentate complexes, if no chloride scavenger is present either no reaction occurs or 
displacement of one of the tridentate ligand donor moieties has been observed.  
Following on from work completed within our research group into iodo platinum 
substitutions, it is therefore the aim of the first part of this chapter to investigate the 
possibility of achieving direct substitution of chloride platinum iminophosphines using 
methods employed by Anderson et al which involves using mixed chlorinated solvent 
systems such as chloroform:methanol. Chlorinated solvent systems have already shown to be 
successful in this project as reported in Chapter 2 by stabilisation of the chloride anion to 
allow cyclometallation.  
Pt
 
(IV) chloride complexes on the other hand can be synthesised using a variety of 
means, affording varying stable and unstable products. Previous work in our research group 
and others has achieved stable Pt (IV)
 
iodo complexes using molecular iodine as the oxidising 
agent. Molecular chlorine is a possibility towards oxidising the Pt
 
(II) chloride analogues, but 
from the literature reviewed oxidising platinum complexes using various cheap alternative 
and less hazardous methods are a more desirable route. Oxidising agents such as sodium 
hypochlorite and electrophilic oxidising agents such as N-chlorosuccinimide have shown 
some success in recent studies by Sanford et al and others.  
With these reagents in mind oxidations of all the Pt (II) complexes reported in 
Chapter 2 will be attempted and reported in the second part of this chapter. It is also hoped 
that eventually these proposed Pt (IV)
 
chloride complexes may also have the potential to be 
precursors for the preparation of other Pt
 
(IV) complexes via displacement of chloride ligands 
using the methods developed in the first part of this chapter. It is also hoped that these 
proposed Pt
 
(IV) chloride complexes may hold potential anti-cancer activity as pro-drugs, as 
discussed in Chapter 1. 
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3.6 Syntheses: 
 
All the starting materials used in this chapter are prepared as per the procedures 
outlined in Chapter 2 for the synthesis of the cyclometallated Pt (II) complexes consisting of 
the cyclometallated iminophosphines 281-285 and the cyclometallated phosphinoamides 286-
288. All were characterised by NMR spectroscopy, X-Ray crystallography (in selected 
cases), IR spectroscopy and elemental analysis prior to being used in this chapter.  
Substitution and oxidation reactions of the insoluble proposed bidentate complexes 
271-273 were also attempted. It was hoped that the resulting products would be more soluble 
and agreeable to further characterisation. However all the products formed were also 
insoluble and therefore difficult to characterise. No further substitution or oxidation reactions 
were therefore attempted with these complexes and all further work was concentrated on the 
cyclometallated complexes 281-288. 
 
3.6.1 Synthesis of cationic triphenylphosphine (PPh3) substituted Pt (II) complexes of 
the general formula [Pt(η3-PNC/PNO-L1-4)PPh3]Cl 371-375: 
 
The synthesis utilised for the substitution reactions is a variation of a literature 
procedure previously utilised for iodo complexes both by this research group and others.
41
 
Previous reports by this research group into both chloro and iodo platinum substitution 
required a halide scavenger (silver perchlorate) to initially remove the halide from the metal 
centre before substitution with the required phosphine was undertaken.
8,6
  
Direct substitution (without the use of a halide scavenger) was, however, seen to 
occur for the iodo cyclometallates using a mixed solvent system of acetonitrile:methanol but 
it was never successfully applied to the analogous chloro palladium or platinum complexes. 
This may be due to the relative reactivity of the platinum iodide bond compared with the 
platinum chloride bond, discussed previously in Figure 3.6. 
The iminophosphine cycloplatinated PNC or PNO complexes 281-285 were stirred 
with 1.1 equivalents of triphenylphosphine (PPh3) at room temperature for 6 hours in a 1:1 
methanol:chlotoform mixed solvent system. 
The solution immediately changed from orange to a pale straw yellow colour on 
addition of the phosphine. After 6 hours it was then reduced to dryness in vacuo, and 
recrystallised from doubly distilled dichloromethane layered with diethyl ether, Figure 3.27. 
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Figure 3.27: Direct substitution of the cyclometallated platinum iminophosphine complexes, 
281-285, with triphenylphosphine (PPh3). 
 
This procedure involves the direct displacement of the chloride moiety owing to the 
stronger Pt-P (soft acid-soft base) interaction from the introduced phosphine over that of the 
weaker Pt-Cl (soft acid-hard base) bond, coupled with stabilisation of the liberated chloride 
anion. A summary of the complexes synthesised, their yields and physical appearances, are 
displayed in Table 3.1. 
  
Substituted Complex Precursor Physical appearance  % Yield 
371 281 Pale yellow metallic crystalline powder 88 
372 282 Dark yellow metallic crystals 71 
373 283 Pale yellow metallic crystals 69 
374 284 Orange metallic crystalline powder 89 
375 285 Yellow metallic crystalline powder 68 
 
Table 3.1: Yields and appearances for the cationic chloro Pt (II) phosphine substituted 
products, obtained by novel direct substitution methods. 
N
Pt
Ph2
P Cl
R'
Ph2
P
N O
Pt
Cl
N
Pt
Ph2
P PPh3
R'
Cl
Ph2
P
N O
Pt
PPh3
MeOH: CHCl3
MeOH: CHCl3
R' = 3-H 281
= 3-Br 282
= 3-Cl 283
= 2,3(OMe)2 284
= 3-OMe 285
OMe
Cl
OMe
PPh3
281-284 371-374
285 375
R' = 3-H 371
= 3-Br 372
= 3-Cl 373
= 2,3(OMe)2 374
= 3-OMe 375
PPh3
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N
Pt
PPh2
Cl
R
R = 3-OMe 286
3,4-(OMe)2 287
3-Br 288
HO
N
Pt
PPh2
PPh3
HO
PPh3
MeOH:CHCl3
Cl
R
R = 3-OMe 376
3,4-(OMe)2 377
3-Br 378
Non-mixed solvent systems consisting of just chloroform or just methanol proved to 
be unsuccessful in the case of methanol and gave reduced yields of up to 30% in the case of 
chloroform. It was also hoped that refluxing would increase the yield but in fact it reduced 
the yield due to decomposition identified by the appearance of an insoluble black material in 
the reaction vessel. Longer reaction times (i.e. greater than 6 hours) also did not increase the 
yield as the reaction itself was primarily quantitative with no starting material identified after 
5 hours stirring at room temperature.  
Previously our research group used a methanol:acetonitrile solution to achieve one-
step substitutions, but this was unsuccessful here as it only gave the starting material as the 
majority product even after 24 hours stirring at room temperature. Instead it was found that a 
1:1 mixture of dry methanol:chloroform gave much better yields of the desired phosphine 
substituted product. The importance of stabilisation of the displaced anion, chloride, by the 
solvent system (like that reported previously in Chapter 2) was again identified here by 
using chloroform. Therefore in order for direct substitution to occur, it is proposed that the 
liberated anion must be stabilised allowing for substitution of the metal centre by the bulky 
incoming triphenylphosphine (PPh3) ligand. 
These complexes were characterised and confirmed by IR and NMR spectroscopy as 
well as elemental analysis which are all consistent with the proposed structure of these 
compounds and compares well with previously reported analogous complexes.
8
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28: Proposed direct substitution of the cyclometallated platinum phosphinoamide 
complexes, 286-288, with triphenylphosphine (PPh3). 
 
Substitution of the cyclometallated phosphinoamide complexes 286-288 using the 
same method employed for the iminophosphine Pt (II) complexes 281-285 proved to give 
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multiple unidentifiable products, Figure 3.28. TLC analysis of the solution after 6 hours 
stirring at room temperature in a 1:1 methanol:chloroform system gave circa 5 products, all 
of which were very insoluble in all common solvents making characterisation unachievable at 
this time. Separation of the products also proved unsuccessful using a variety of 
chromatographic eluents and methods including silica gel, alumina and celite.  
It is proposed that substitution of the phosphinoamide complexes is occurring at not 
only the platinum chloride bond, but also at the platinum carbon and platinum nitrogen bond 
due to the previously identified unstable nature of these complexes in the presence of 
reagents.
7
 
 
3.6.2 Discussion of Factors Influencing the Substitution Reactions: 
 
Previous work within this research group with substitution reactions involving 
phosphines encountered various difficulties with and without the use of a silver perchlorate 
salt to remove the halide from the metal centre.
8,6,7
 Triphenylphosphine (PPh3) was reported 
to be one of the most difficult to achieve one-step substitution of platinum metal centres due 
to its steric bulk, while tris-cyanoethylphosphine was found to be one of the easiest. Because 
of this it was proposed that the potential influences that determine platinum halide 
substitution by monophosphines were the basicity of the phosphine being used and the space 
occupied or cone-angle of the phosphine ligands. 
Previously it was proposed by our research group that the greater lability of the iodo-
Pt (II) bond should allow direct substitution of the tridentate PNO and PNC complexes over 
any equivalent chloro complexes. However, here we find using an appropriate solvent to 
stabilise the smaller chloride ion can achieve one-step substitution. Also the chloride ligand, 
being less bulky compared to the iodide, allows the sterically bulky phosphine to get closer to 
the metal centre, allowing for substitution to occur. This is proposed to assist displacement in 
a concerted mechanism involving stabilisation by the solvent as described in Chapter 2, 
Figure 3.29.  
As discussed previously in Chapter 2, chloroform has the unique ability to stabilise 
liberated chloride anions. We have already seen how important this was to the 
cyclometallation mechanism for the parent Pt (II) complexes 281-284 but we can also see its 
influence here.  
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Figure 3.29: Proposed mechanism for direct substitution of the cyclometallated Pt (II) 
iminophosphine complexes, 281-284, with triphenylphosphine (PPh3). 
 
Chloroform, possessing three electron withdrawing groups in the form of chlorides, 
has a dipole. This allows the δ+ H to interact quite strongly with the halide on the platinum 
metal centre. This interaction between the hydrogen of the solvent molecule and the chloride 
of the complex weakens the platinum chloride bond. This elongates it, as the highly 
electronegative chloride on the metal centre and hydrogen of the chloroform molecule bond 
gets shorter. This would then make it easier for triphenylphosphine to cause direct 
displacement of the chloride moiety from the metal centre, Figure 3.29. 
It was found previously that the influence of basicity and steric factors was also 
particularly relevant to the substitution of Pt (II) tridentate PNO complexes.
 
Previous work by 
our research group, which focussed on the substitution of Pt (II) PNO chloro-complexes, 
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found that triphenylphosphine substitution of the chloride ligand could not be achieved and 
that substitution using tri-p-tolylphosphine (which is more basic but has the same steric 
parameters) was achieved, but only with certain substituents.
8
 
However, the experimental evidence obtained in this study for the previously reported 
PNO complex [Pt(η3-PNO-L4)Cl] 285 has shown that stabilising the liberated anion 
facilitates an important requirement in the reaction mechanism causing it to overcome one of 
the primary reasons stopping one-step substitution of chloro complexes. Phosphine 
substitution of [Pt(η3-PNO-L4)Cl] 285, which was previously reported by our research group 
as described in Chapter 2, was never successfully reported with or without the use of a silver 
perchlorate salt. Here it is reported via direct substitution with triphenylphosphine forming 
the cationic Pt (II) PNO complex 375, Figure 3.27. 
 
3.6.3 Attempted oxidation of Pt (II) complexes Using H2O2 and NaOCl: 
 
Initial attempts to form Pt (IV) analogues of the iminophosphine complexes reported 
in Chapter 2 involved the use of H2O2, Figure 3.30 (all proposed Pt (IV) products are based 
on previous reports). This procedure involved an adaptation of a previously reported method 
that was found to be very successful for both our research group and others.
27,6
 The Pt (II) 
complexes reported in Chapter 2 (271-273, 281-285 and 286-288) were suspended in a 
dichloromethane solution to which 30% (w/v) aqueous hydrogen peroxide was added slowly 
over one hour.  
The biphasic solution was stirred vigorously for 16 hours but no observable difference 
was noticed for the solution in terms of colour or consistency. The solution was transferred to 
a separating funnel where the organic layer was washed with de-ionised water, dried over 
MgSO4 and reduced to dryness in vacuo. In the case of the tridentate iminophosphine 
complexes 281-285, only the Ptm (II) starting materials were recovered with yields of greater 
than 90%, indicating little or no reaction with the peroxide.  
The insoluble bidentate iminophosphine complexes 271-273 were also found to have 
no reaction with peroxide as their IR spectra after the reaction was identical to what was 
obtained prior to the reaction. In contrast a reaction did take place between H2O2 and the 
tridentate phosphinoamide cyclometallated complexes 286-288. TLC showed several 
products had formed, however spectroscopic analysis showed that there were no longer any 
evidence of the starting materials or any Pt (IV) complexes. This indicated that, like that 
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found for the triphenylphosphine (PPh3) substitution reactions earlier, Section 3.6.1, 
decomposition of the complexes had again occurred.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.30: Proposed oxidation reaction of the Pt (II) iminophosphine and phosphinoamide 
complexes with hydrogen peroxide.  
 
Variations of the procedure with different solvents, refluxing and longer/shorter 
reaction times were also unsuccessful for the formation of Pt (IV) complexes, despite 
previous success by our research group and others with this method.
6,29
  
Further reports in the literature also cite sodium hypochlorite (NaOCl) as a potential 
oxidising agent for Pt (II) complexes giving mixed axial ligands of chloride and hydroxyl 
groups. The most stable Pt (II) complexes (Chapter 2), the cyclometallated iminophosphines 
281-284, were attempted initially with this method due to the higher chances of achieving 
characterisation upon completion, Figure 3.31.  
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The Pt (II) complexes were dissolved in chloroform and NaOCl was added slowly 
over one hour. The biphasic solution was then stirred at room temperature for a further 2 
hours after which the solution turned a very dark red. TLC analysis of the solution gave 4-5 
products and NMR spectra also displayed multiple imino-hydrogen signals and multiple 
phosphorus signals, indicating a mixture of products. Interestingly there was no evidence of 
the Pt (II) starting material present in the solution and separation of the products has proved 
impossible to date.  
Further work with the phosphinoamide complexes, 286-288, involving NaOCl, again 
only gave decomposition products for the reaction which further emphasised the difference in 
stability between the Pt (II) iminophosphine complexes 281-285, in comparison to the Pt (II) 
phosphinoamide complexes 286-288.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.31: Proposed oxidation reaction of the Pt (II) iminophosphine and phosphinoamide 
complexes with NaOCl was somewhat successful for the iminophosphine complexes, however 
the products could not be characterised at this time.  
 
3.6.4 Synthesis of Pt (IV) chloro complexes of the general formula [Pt(η3-PNC-L1-
4
)Cl3] 381-384: 
 
Synthesis of the chloro iminophosphine Pt (IV) complexes 381-384, via oxidative 
addition of chloride using N-chlorosuccinimide, was successful using a variation of a 
previously reported method, Figure 3.32.
30
 To a mixed solvent solution (1:1 
chloroform:methanol) of the appropriate Pt (II) iminophosphine complex (281-284), an 
excess of N-chlorosuccinimide was added as a solid.  
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The solution immediately changed from a bright orange colour to a dark orange/red 
upon addition of NCS. It was then left to stir at room temperature for 16 hours, after which 
the resulting orange solution was transferred to a separation funnel and washed with water 3 
times to remove the remaining N-chlorosuccinimide and the succinimide product, Figure 
3.33.  
The organic phase was then dried over magnesium sulphate and reduced to dryness in 
vacuo. The resulting red oil was crystallised from dichloromethane-hexane to give moderate 
yields of the Pt (IV) cyclometallates. Any residual starting material (i.e. the Pt (II) complex 
281-284) remained in the mother liquor after crystallisation. This was confirmed by TLC of 
the solution with a 98:2 CHCl3:MeOH elution. The Rf value obtained was identical to that 
established for the Pt (II) complexes (as previously identified in Chapter 2). Interestingly, in 
the case of [Pt(η3-PNC-L4)Cl3] 384, no residual Pt (II) complex was identified even though 
the yield was still significantly low. A summary of the yields and physical appearances of the 
Pt (IV) complexes 381-384 are summarised in Table 3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.32: Successful oxidative addition of two equivalents of chlorine to the 
iminophosphine Pt (II) complexes, 281-284 using N- chlorosuccinimide was successful in 
creating novel Pt (IV) complexes. 
         
Elemental analysis data agrees, within experimental error, with the proposed 
empirical formula for the complexes where solvent of crystallisation is included; this solvent 
is also apparent in the 
1
H NMR spectra. The mechanism of oxidative addition of Br2 has been 
previously investigated and identified in 1969 by Skinner and Jones, Figure 3.33.
33
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analogy with the results we propose a similar mechanism for oxidation of the Pt (II) 
iminophosphine cyclometallates 281-284 and is backed-up by a similarly proposed NCS 
oxidation mechanism reported by Sanford et al, Figure 3.33.
30
 
 
Pt (IV) complex Pt (II) Precursor Physical appearance Yield (%) 
381 281 Black-red crystalline solid 30 
382 282 Brown crystalline solid 11 
383 283 Brown crystalline solid 25 
384 284 Red crystalline solid 36 
 
Table 3.2: Physical appearances and yields obtained for the Pt (IV) iminophosphine 
complexes 481-484. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33: The mechanism for oxidative addition of two equivalents of chlorine to the 
iminophosphine Pt (II) complexes, 281-284 using N- chlorosuccinimide in the presence of a 
protic solvent – methanol (MeOH). 
 
The mechanism proposed in Figure 3.33 uses two equivalents of N-
chlorosuccinimide and a protic solvent in order to form the stable Pt (IV) iminophosphine 
complexes with two chloro axial ligands (given as Blue and Red in Figure 3.33). The last 
step of the mechanism is the rate determining step as the methoxy-chloro mixed axial 
intermediate, 386, has been isolated during shorter reaction times. Evidence for this 
mechanism in this work has also been identified with the isolation of the mixed axial 
N
P
C
ClPt
Cl
Cl
N
P
C
Cl
Pt
N
P
C
Cl
Pt
OMe
Cl
N
P
C
Cl
Pt + MeOH
381-384
281-284
NO
O
Cl
NO
O
N O
O
1st Equivalent NCS
2nd Equivalent NCS
Cl
Cl
NO
O
H
N
O
OMe
O
Succinimide
Methoxy-Succinimide
386
R.D.S
Chapter 3  Substitutions and Oxidations 
Page | 219  
 
intermediate 386, Figure 3.34 at shorter reaction times. This suggests that the reaction of the 
Pt (II) iminophosphines proceed via this mechanism to form the final Pt (IV) complexes 381-
384. 
Based on the work of Sanford et al, reactions of the Pt (II) complexes with NCS were 
initially undertaken in dichloromethane. Reaction times shorter than 1 hour did not go to 
completion and a significant amount of the parent Pt (II) starting materials were recovered. 
However, reaction times longer than 1 hour resulted in the solution turning green and the 
presence of no identifiable products due to proposed decomposition.
30
  
A protic solvent, methanol (MeOH), was found to be crucial for formation of stable Pt 
(IV) complexes with NCS, which has also been reported by Sanford et al as an important 
factor in the mechanism for oxidative addition, Figure 3.32.
30
 Reaction times of 16 hours 
were found to be ideal, as shorter reaction times resulted in the isolation of the photo-
sensitive Pt (IV) intermediate 386 with mixed chloro/methoxy axial ligands, Figure 3.34. 
These type of complexes have also been reported by Sanford et al and identified here by 
1
H 
NMR studies, Figure 3.34.
30
  
. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.34: Shorter reaction times gave mixed axial ligands of methoxy and chloride, but 
these Pt (IV) complexes proved to be unstable in light and serve as an intermediate to the 
reaction mechanism described in Figure 3.32.  
 
It was therefore decided, in order to stabilise the intermediate 386 and ensure 
formation of the final chloride Pt (IV) product, a mixed solvent system was required. A 
mixed solvent system of chloroform and methanol, like that employed for the substitution 
reactions Section 3.5.1, gave the best yields. The methanol was required as per the 
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mechanism described in Figure 3.33 and the chloroform, as detailed previously in Chapter 
2, has the unique ability of stabilising chloride anions necessary to increase the yield of the 
desired Pt (IV) complexes.  
The reaction products were also found to contain some Pt (II) starting material for the 
382 and 283 complexes as identified by TLC and NMR analysis. Attempts to force the 
reactions to completion by heating the reaction mixtures resulted in the formation of a black 
insoluble product. Identification of this material has at this time failed, but it is proposed to be 
platinum metal resulting from thermal decomposition.
6
 Hydrolysis of the ligands was also 
seen to occur on occasion when the reaction solution was stirred for longer than 24 hours. 
This was identified by the appearance of an aldehyde peak in the 
1
H NMR spectra. 
Having developed a successful route to cycloplatinated Pt (IV) chloride 
iminophosphine complexes for 381-384, attempts were then made to apply these 
methodologies to achieve oxidation of the tridentate P,N,O Pt (II) chloride complex 285, 
Figure 3.35. However, although some oxidation is thought to have occurred, the reactions 
did not go to completion and attempts to separate the Pt (II) starting material and proposed Pt 
(IV) complex via a variety of means has failed to date.  
 
 
 
 
 
 
 
 
 
 
Figure 3.35: Proposed oxidation of the PNO complex 285 to its analogous Pt (IV) complex 
385 via the same mechanism and intermediate described in Figure 3.32.  
 
Analogous to work previously reported by our research group, despite using a range 
of solvent systems, the Pt (II) and Pt (IV) PNO species had such similar Rf values that it was 
not possible to separate them by conventional means. The best separation at this time was 
found with 98:2 CHCl3:MeOH as the eluent where Rf of the Pt
 
(II) complex = 0.78 (from 
Chapter 2) and Rf of the Pt
 
(IV) = 0.81, Figure 3.36.   
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Figure 3.36: Illustration of a TLC separation of the PNO Pt (II) and PT (IV) complexes  
 
The products from attempted oxidations of the tridentate phosphinoamide 
cyclometallated complexes 286-288 with N-chlorosuccinimide, Figure 3.37, on the other 
hand did not provide any evidence indicating successful oxidation. There was also no longer 
evidence of the Pt (II) starting material in the solution but there was also no evidence to 
suggest Pt (IV) complexes had formed either. TLC and NMR analysis on the resulting green 
solution indicated that multiple complexes and decomposition products existed. 
This indicated that, like that found for the triphenylphosphine (PPh3) substitution 
reactions earlier and attempted oxidation with peroxide and sodium hypochlorite, 
decomposition of the complexes had once again occurred. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.37: Unsuccessful oxidation of the phosphinoamide Pt (II) complexes 286-288 to 
their analogous Pt (IV) complexes with N-chlorosuccinimide via the same mechanism and 
intermediates described in Figure 3.32.  
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3.7 Infra-red spectroscopic studies: 
 
3.7.1 Cationic triphenylphosphine (PPh3) substituted Pt (II) complexes of the general 
formula [Pt(η3-PNC/PNO-L1-4)PPh3]Cl 371-375: 
 
Like that seen for the parent Pt (II) chloro iminophosphine complexes 281-285 in 
Chapter 2, the most informative peak in the IR spectra of the triphenylphosphine substituted 
complexes is the imine stretching band, υ(C=N) at approx 1600cm-1. A comparison of the 
stretching frequencies of the parent complexes 281-285 with their analogous 
triphenylphosphine substituted complexes 371-375 are contained in Table 3.3, along with the 
stretching frequencies of the free iminophosphine ligands HL
1-4
 261-264. 
 
Free 
Ligands 
υ(C=N) 
cm
-1
 
Parent 
complex 
υ(C=N) 
cm
-1
 
Phosphine 
complex 
υ(C=N) 
cm
-1
 
HL
1
 261 1626 281 1585 371 1590 
HL
2
 262 1621 282 1587 372 1591 
HL
3
 263 1622 283 1576 373 1590 
HL
4
 264 1615 284 1578 374 1587 
HL
4
 265
 1615 285 1607 375 1589 
 
Table 3.3: IR data comparing the υ(C=N) of the triphenylphosphine substituted 
cyclometallated platinum complexes 371-375 with their parent complexes 281-285 and their 
free ligands 261-264. 
 
On substitution of these iminophosphine chloro complexes by triphenylphosphine, we 
see an increased υ(C=N) stretching frequency for the substituted cyclometallates 371-374 and 
a reduction for the PNO complex 375. In the case of the cyclometallated substituted products, 
this indicates a strengthening of, and hence shortening of, the imine C=N bond. This bond 
strengthening can be attributed to the weakening of the imino-nitrogen-platinum coordination 
bond. This is due to the strong trans effect exerted by the new phosphine donor ligand 
introduced trans to this coordination bond. These trends mirror those obtained previously by 
our research group for the analogous iodo cyclometallated phosphine substituted complexes. 
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The PNO tridentate complex 285 on the other hand gave a reduced stretching 
frequency when substituted by triphenylphosphine, complex 375, indicating a weakening, 
and hence lengthening, of the imine C=N.  
This trend has also been reported previously by our research and is in direct contrast 
to that observed for the tridentate cyclometallated triphenylphosphine substitutions 381-384. 
It has been proposed that this apparent weakening could be attributed to the steric strain on 
the six-membered fused ring system of the PNO complex interacting with the introduced 
triphenylphosphine moiety, causing repulsion and lengthening of the ligand bonds to 
accommodate the extra steric bulkiness.
7
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.38: The range of complexes described in this section with the types of rings involved 
in the structure of each complex as discussed previously in Chapter 2. 
 
3.7.1 Infra-red spectra of Pt (IV) chloro complexes of the general formula [Pt(η3-PNC-
L
1-4
)Cl3] 381-384: 
 
Chlorination of the Pt (II) cyclometallated complexes 281-284 yielded the 
corresponding Pt (IV) cycloplatinates 381-381. Like that seen for the parent Pt (II) chloro 
iminophosphine complexes 281-285 in Chapter 2 and the PPh3 substituted complexes in 
Section 3.6.1, the most informative peak in the IR spectra of the Pt (IV) chloro 
iminophosphine complexes is the imine stretching band, υ(C=N) at approx 1600cm-1. A 
comparison of the stretching frequencies of the parent complexes 281-285 with their Pt (IV) 
analogous complexes 381-384 are contained in Table 3.4, along with the stretching 
frequencies of the free iminophosphine ligands HL
1-4
 261-264. 
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Free 
Ligand 
υ(C=N) 
cm
-1
 
Pt (II) η3-chloro 
complex 
υ(C=N) 
cm
-1
 
Pt (IV) η3-chloro 
complex 
υ(C=N) 
cm
-1
 
HL
1
 261 1626 281 1585 381 1591 
HL
2
 262 1621 282 1587 382 1595 
HL
3
 263 1622 283 1576 383 1596 
HL
4
 264 1615 284 1578 484 1586 
 
Table 3.4: IR data comparing the υ(C=N) of the cyclometallated Pt (IV) chloro complexes 
381-384 with their parent complexes 281-285 and their free ligands 261-264. 
 
We again see the expected trend of lower stretching frequencies for the υ(C=N) bond 
on comparison of the Pt (IV) cycloplatinated complexes 381-384 with the free ligands 261-
264 due to continued successful coordination of the C=N group to the Pt (IV) metal centre. 
However, on comparison of the Pt (II) complexes 281-284 with their Pt (IV) cycloplatinated 
analogues 381-384 we see an increase in the imine stretching frequency representing an 
increase in imine bond strength for the Pt (IV) complex.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.39: The range of Pt (IV) complexes described in this section including the free 
ligands and Pt (II) complexes discussed previously in Chapter 2. 
 
This is due to the increased electrophilicity of the Pt (IV) metal centre. The increased 
electrophilicity arises because of the increased charge on the Pt (IV) centre relative to the Pt 
(II) centre due to the addition of electron withdrawing groups in the form of chlorides. This 
pulling of electron density away from the metal centre weakens the platinum-nitrogen bond 
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but strengthens the imine bond resulting in an increase in stretching frequencies. This is also 
similar to the analogous iodo Pt (IV) complexes previously reported by our research group.
6
 
 
3.8 NMR spectroscopic studies: 
 
3.8.1 NMR spectroscopy of the ionic, cyclometallated and PNO triphenylphosphine 
substituted complexes of the general formula Pt[η3-PNC-L1-4]PPh3(Cl) 371-375: 
 
Complex 
 δ (H-C=N) δ (H-Ar) δ (R=OCH3) δ (
31
P{
1
H}) δ (31P{1H}) 
3-H  
371 
11.02 (1H, d) 
JPt-H = 87 Hz 
JPt-Pb = 10Hz 
6.50-7.80 
(33H, m) 
- 33.3 (d) 
2
JPa-Pb = 15 
JPt-Pa = 1911 Hz 
18.4 (d) 
2
JPa-Pb = 16 
JPt-Pb = 3794 Hz 
3-Br  
372 
11.36 (1 H, d) 
JPt-H = 88 Hz 
JPt-Pb = 9Hz 
6.40-7.75 
(32 H, m) 
- 33.4 (d) 
2
JPa-Pb = 16 
JPt-Pa = 1945 Hz 
17.8 (d) 
2
JPa-Pb = 16 
JPt-Pb = 3732 Hz 
3-Cl  
373 
11.31 (1 H, d) 
JPt-H = 87 Hz 
JPt-Pb = 9Hz 
6.40-8.20 
(32 H, m) 
- 33.4 (d) 
2
JPa-Pb = 16 
JPt-Pa = 1949 Hz 
17.9 (d) 
2
JPa-Pb = 16 
JPt-Pb = 3737 Hz 
2,3-
(OMe)2  
374 
9.91 (1 H, d) 
JPt-H = 86 Hz 
JPt-Pb = 9Hz 
6.17-8.27 
(31 H, m) 
3.60 (3 H, s) 
4.14 (3 H, s) 
33.4 (d) 
2
JPa-Pb = 16 
JPt-Pa = 1956 Hz 
17.5 (d) 
2
JPa-Pb = 16 
JPt-Pb = 3815 Hz 
PNO 
3-OMe 
375 
10.06 (1 H, d) 
JPt-H = 61 Hz 
JPt-Pb = 14Hz 
6.59-7.90 
(31 H, m) 
3.20 (3 H, s) 19.0 (d) 
2
JPa-Pb = 22 
JPt-Pa = 3607 Hz 
9.1 (d) 
2
JPa-Pb = 22 
JPt-Pb = 3434 Hz 
7. Chemical shift values (δ) are expressed in ppm relative to the TMS standard for 1H and H3PO4 
for 
31
P. 
8. s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet.  
9. Coupling constants (J) are measured in Hz 
Table 3.5: 
1
H and 
31
P{
1
H} NMR data
1, 2, 3
 for the PPh3 substituted iminophosphine Pt (II) 
complexes 371-375. All ran in CDCl3 at 300MHz and 121.5 Hz respectively. 
The 
1
H and 
31
P{
1
H} NMR data of all the PPh3 substituted complexes 371-375 are 
summarised in Table 3.5. All of the complexes display doublet signals, integrating for 1H, in 
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the azomethine region of the 
1
H NMR spectra. The doublet arises from coupling between the 
newly introduced phosphine and the azomethine signal with 
4
JH-P of 9-10 Hz.  
As previously discussed in Chapter 2, the azomethine resonances of the parent 
cycloplatinated species appear as singlets, thus the appearance of a doublet here coupling to a 
second phosphorus signal supports the presence of the new phosphine ligand.  
The observed downfield shift in the NMR spectra correlates with this reduction in 
bond strength also seen in the IR data for these complexes, Section 3.7.1. The shifts for these 
complexes are also consistent with previously obtained results by our research group and 
others for analogous complexes.
42,6,8
 A comparison of the azomethine shifts for the PPh3 
substituted iminophosphine complexes and their respective parent Pt (II) chloro complexes is 
shown below in Table 3.6. 
 
Pt (II) parent 
complex 
δ(H-C=N) 
ppm 
PPh3 Substituted 
Complex 
δ(H-C=N) 
ppm 
Δδ 
ppm 
3-H 281 9.40 (1H, s) 371 11.02 (1 H, d) 1.26 
3-Br 282 9.40 (1H, s) 372 11.36 (1 H, d) 1.33 
3-Cl 283 9.41 (1H, s) 373 11.31 (1 H, d) 1.30 
2,3-(OMe)2 284 9.72 (1H, s) 374 9.91 (1 H, d) 1.18 
PNO 3-OMe 285 9.15 (1h, s) 375 10.06 (1 H, d) 0.61 
Table 3.6: Comparison of the 
1
H azomethine signals between the parent complexes 281-285 
and that recorded for the PPh3 substituted iminophosphine Pt (II) complexes 371-375. All ran 
in CDCl3 at 300MHz. 
There is a downfield shift of the azomethine signal on coordination of the introduced 
phosphine moiety trans to the nitrogen of between 0.20 and 1.6 ppm. These shifts are in 
general larger than the analogous iodo complexes, possibly due to the parent chloro 
complexes having a further upfield signal than the iodo complexes to begin with (Chapter 
2). Like that found for the parent Pt (II) complexes on donation of the lone pair of electrons 
on the imino-nitrogen into the metal centre, electron density is pulled towards the 
coordination bond (Pt-N), weakening the H-C=N bonds.  
Like the previously reported iodo complexes, the largest shift is noticed for the HL
1
 
ligand complexes 281/371 and the smallest shift is observed for substitution of 284 (complex 
374). We propose that this is attributed to the presence of electron-donating substituents 
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within the ligand affecting the electronic properties of the molecule in the complexes 
284/374. 
 
 
 
                                                
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40: Comparison of the 
1
H azomethine signal spectra for the parent cyclometallated 
Pt (II) complex 284 (left) and the analogous phosphine substituted complex 374 (right). 
 
As previously mentioned the azomethine signal is now displayed as a doublet 
complete with 
195
Pt satellites with a 
3
JH-Pt coupling of ca. 83-86 Hz, Figure 3.40. These Pt-H 
coupling constants are around 40 Hz less than that of the parent complexes. This reduction 
can be attributed to the decreased electrophilicity of the Pt (II) metal centre on successful 
coordination of the electron-rich triphenylphosphine moiety.  
In the case of the PNO complex 375, we see a significantly smaller downfield shift to 
that of the cyclometallated complexes on comparison to the parent Pt (II) complexes as well 
as a smaller 
3
JH-Pt coupling constant (61Hz) which is compared in Table 3.5 and 3.6. We can 
propose therefore, like that discussed in Chapter 2, that the PNO complex 375 has a stronger 
imine bond (C=N) than that of the cyclometallated complexes 271-274 which is also 
supported by the IR data obtained and reported in Section 2.6.1.  
The 
1
H NMR spectra of the dimethoxy cyclometallated complex 374 also displays 
two singlet resonances at δ 3.60 and δ 4.14 ppm respectively. These again correspond to the 
two electron donating methoxy (-OCH3) substituents present at the C-3 and C-2 position of 
the lower aryl ring and integrate for 3 hydrogens each. This also represents a slight shift 
downfield in comparison with the parent Pt (II) complex 284 and is due to the addition of the 
new electron-donating triphenylphosphine ligand, Table 3.5. For the PNO complex 375 only 
one methoxy signal is again present at δ 3.20 ppm and integrates for 3H.  
N
Pt
Ph2
P Cl
OMe
OMe
H
N
Pt
Ph2
P PPh3
OMe
OMe
Cl
H
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Aromatic signals appear as very complex multiplets with considerable overlap of 
signals in the range of δ 6.27 – 9.14 ppm, more so than that seen for the parent complexes 
281-285. However, the integration of these aromatic signals are as expected for each 
complex, detailed in Table 3.5.  
[
1
H-
1
H] COSY plots, Figure 3.41, unfortunately did not allow for full aromatic 
characterisation due to the large overlapping signals caused by the extra phenyl groups on the 
newly introduced triphenylphosphine ligand. Attempted [
13
C DEPT 45-
1
H] HETCOR plots 
are inconclusive at this time for further characterisation due to solubility issues for all the 
substituted complexes, but did provide some information on the azomethine signal and 
methoxy signals in the case of 374 and 375.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.41: The [
1
H-
1
H] COSY NMR plot of the 3-Cl triphenylphosphine substituted 
cyclometallated complex 373 tentatively showing the interactions between some aromatic 
hydrogens as well as the position of the azomethine group (He) H-C=N run at 300 Mhz.  
 
Unfortunately due to the large shift in the signals of all the aromatic hydrogens, 
making a direct comparison with the parent complex 283 is difficult. The coupling 
frequencies and spectral structure of some signals however do allow for some comparisons to 
be made. As can be seen from the [
1
H-
1
H] COSY plot, there are now more aromatic 
HaHb
Hc
Hd N
Pt
PPh2
He
PPh3
Hi Cl
Hh
Hg
Substituted PPh3 Complex 373
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Ha Hg 
Hc 
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He Hh 
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H
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H
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H
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H
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hydrogens in the phosphinophenyl region (δ 6.80 – 7.61 ppm) than the parent complex, as 
expected with the introduction of the triphenylphosphine ligand. 
 
δ(1H) ppm Peak Assignment Observed Correlations 
6.52 m (Hh) (Hg) 
6.76 t (Hg) (Hh, Hi) 
6.80-7.63 m (Hd), (Hi), Phosphinophenyl (Hc), (Hg), Phosphinophenyl 
7.77, q (Ha) (Hb, Hc) 
8.36 m (Hc) (Hb, Hd) 
9.14 q (Hb) (Hc, Ha) 
Table 3.7: Measured [
1
H-
1
H] COSY NMR correlations for the triphenylphosphine substituted 
3-Cl cyclometallated complex 373, Figure 3.41. 
As per the [
1
H-
1
H] COSY plot in Figure 2.74 of the substituted 3-Cl cyclometallated 
complex 373, the aromatic protons in the region of 6.80-7.63 ppm can be attributable to the 
phosphinophenyl protons from the complex (10 H) and the newly introduced 
triphenylphosphine ligand (15 H), which only couple to themselves.  
The rest of the aromatic hydrogens (7 H) are assigned from their [
1
H-
1
H] COSY plot 
correlations in Table 3.7, but the extensive overlaps make this a very tentative assignment. 
The azomethine signal (He) is easily assigned and reported previously in Table 3.5, and as is 
seen in the [
1
H-
1
H] COSY plot only couples to itself. The substituted 3-Cl cyclometallated 
complex 373 is the only complex with minimal overlapping aromatic signals, allowing for 
some assignment but its limited solubility prevents further detailed studies at this time. 
Unfortunately various attempts to collect useful 
13
C, DEPT NMR and [
13
C DEPT 45-
1
H] HETCOR plots were unsuccessful at this time due to the limited solubility of the 
complexes. 
13
C NMR data was also difficult to get for these complexes, with the goal being a 
comparison between the parent complexes 281-285 and the substituted complexes 371-375 to 
demonstrate any changes in the metallic Pt-C bond. In the 
13
C NMR spectra only strong 
multiple overlapping signals at 128.56-135.04 ppm were found and assigned to the 
phosphinophenyl carbons as per the spectra obtained for the parent complexes in outlined in 
Chapter 2.   
The 
31
P{
1
H} NMR data obtained for the triphenylphosphine substituted complexes 
371-375 display two sets of doublet signals. Each phosphorus signal represents one of the 
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two phosphorus environments now present due to the two phosphines (Pa and Pb) and 
doublet signals are observed due to cis 
2
JP-P coupling.  
 
Pt (II) parent 
complex 
δ 31P{1H} 
ppm 
Pt (II) PPh3 
Complex 
δ 31P{1H} 
ppm (Pa) 
δ 31P{1H} 
ppm (Pb) 
Δδ 
ppm (Pa) 
3-H 281 25.3 (s) 371 33.3 (d) 18.4 (d) 8.0 
3-Br 282 25.4 (s) 372 33.4 (d) 18.0 (d) 8.0 
3-Cl 283 25.5 (s) 373 33.4 (d) 17.9 (d) 7.9 
2,3-(OMe)2 284 25.2 (s) 374 33.4 (d) 17.5 (d) 8.2 
PNO 3-OMe 285 13.1 (s) 375 19.0 (d) 9.1 (d) 5.9 
 
Table 3.8: Comparison of the 
31
P{
1
H} signals between the parent Pt (II) complexes 281-285 
with the triphenylphosphine substituted Pt (II) complexes 271-275. 
 
The signal at circa δ 34 ppm seen for the substituted complexes (Pa, Figure 3.42 and 
3.43) is assigned to the phosphine group of the tridentate ligand i.e. for the cyclometallated 
complexes this is trans to the σ Pt-Caryl bond. This represents a shift downfield of circa δ 8 
ppm in comparison to the parent Pt (II) complexes which had a phosphine signal at circa δ 
25ppm, Table 3.8.  
 
 
 
 
 
 
 
 
Figure 3.42: A comparison of the single phosphine on the parent complexes 281-284 (left) 
with the two phosphine ligands on the substituted complexes 371-374 (right). 
In a similar fashion, two phosphine environments are also observed for the substituted 
PNO type complex 375 with the signal at δ 19.0 ppm assigned to the phosphine of the 
tridentate ligand Pa (P-Pt-O) and representing a shift of δ 5.9 ppm in comparison to its parent 
N
Pt
Ph2
Pa Cl
R
R = 3-H
3-Br
3-Cl
2,3-(OMe)2
281
282
283
284
N
Pt
Ph2
Pa PbPh3
Cl
R = 3-H
3-Br
3-Cl
2,3- (OMe)2
281
282
283
284
R
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complex, while the signal at δ 9.1 ppm is assigned to the newly introduced phosphine Pb (P-
Pt-N). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.43: A comparison of the 
31
P{
1
H} spectra data for the parent cyclometallated 
complexes 281-284 (left) and the triphenylphosphine substituted complexes 371-374 (right). 
This cis coupling between the two phosphine moieties was found to be in the order of 
15-16 Hz for the cyclometallated complexes which are analogous to previous work reported 
by this research group.
6
 For the PNO complex, the cis coupling between the two phosphine 
moieties was found to be slightly higher at 22 Hz due to the structural differences previously 
discussed in Chapter 2 in comparison to the cyclometallated complexes, Figure 3.43.  
195
Pt 
1
JP-Pt coupling is also observed again here as previously seen in Chapter 2 for 
the parent complexes 281-285, indicating coordination of both phosphorus moieties to the Pt 
(II) metal centre. The assignment of Pa and Pb is confirmed by the trans 
1
JP-Pt coupling 
constants, which are circa. 1950 Hz for the triphenylphosphine substituted cyclometallated 
complexes 371-374 in contrast to 2100 Hz for the parent complexes 281-284. This is 
consistent with other P-Pt-Caryl trans 
1
JP-Pt coupling constants previously reported in the 
literature and by this research group.
6,43
  
The second signal seen in the phosphorus NMR of the substituted complexes (Pb, 
Figure 3.43) arises from the newly introduced triphenylphosphine moiety trans to the imino-
nitrogen group. The 
1
JPt-P coupling observed here is much greater than for Pa at circa 3793 Hz 
and again is consistent with reported P-Pt-N trans 
1
JP-Pt coupling constants for analogous 
complexes.
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Figure 3.44: A structural comparison of the parent Pt (II) PNO complex (left) 275, the 
substituted cyclometallated PNC complexes (middle) 371-374 and the substituted PNO 
complex (right) 375. 
 The substituted PNO complex 375 has slightly different 
1
JPt-P coupling constants over 
the substituted cyclometallated complexes 371-374 due to the Pa phosphine being trans to an 
oxygen within the metal-fused ring system rather than a carbon, Figure 3.44. As previously 
mentioned two phosphine environments are observed here also and assigned Pa or Pb 
according to their coupling frequencies.   
Therefore Pa is assigned as δ 19.0 ppm which is the phosphine of the tridentate ligand 
with P-Pt-O trans coupling in the order of 3606.6 3Hz, and Pb is assigned as δ 9.1 ppm, the 
newly introduced phosphine with coupling to the 
195
Pt trans to the nitrogen moiety of the 
ligand  (P-Pt-N) in the order of 3434.43 Hz. These results are again consistent with 
previously studied complexes within this research group.
8 
 
3.8.2 NMR spectra of tridentate, cycloplatinated Pt (IV) chloro iminophosphine 
complexes [Pt(η3-PNC-L1-4)Cl3] 381-384: 
 
1
H and 
31
P{
1
H} NMR data for the Pt (IV) cycloplatinated species 381-384 is 
displayed in Table 3.9. As seen for all other platinum complexes reported here, the 
azomethine signal is again observed with 
195
Pt satellites, but this time it was found to be 
further upfield when compared to the parent Pt (II) complexes 281-284.  
 
 
N
Pt
PaPh2
PbPh3
PPh3 substituted Cyclometallated
PNC Complexes
Parent Pt (II) PNO Complex
275
R
R = 3-H 371
3-Br 372
3-Cl 373
2,3-(OMe)2 374
PPh3 Substituted Cyclometallated
PNO Complex 375
N Pt
PaPh2
O
PbPh3
OMe
5
5
5
6
Cl Cl
N
Pt
PaPh2
O
Cl
OMe
5
6
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Complex 
 δ (H-C=N) δ (H-Ar) δ 
(R=OCH3) 
δ (31P{1H}) 
3-H  
381 
9.11 (1 H, s) 
JPt-H = 81 Hz 
7.30-8.24 (18 H, m) - -2.1 (s) 
JPt-P = 1326 Hz 
3-Br  
382 
9.20 (1 H, s) 
JPt-H = 83 Hz 
7.40-8.20 (17 H, m) - -1.7 (s) 
JPt-P = 1345 Hz 
3-Cl  
383 
9.21 (1 H, s) 
JPt-H = 84 Hz 
6.40-8.20 (17 H, m) - -1.4 (s) 
JPt-P = 1350 Hz 
2,3-(OMe)2  
384 
9.34 (1 H, s) 
JPt-H = 84 Hz 
7.23-7.90 (14 H, m) 
8.07-8.16 (2 H, m) 
3.91 (3H, s) 
4.10 (3H, s) 
-2.1 (s) 
JPt-P = 1334 Hz 
1. Chemical shift values (δ) are expressed in ppm relative to the TMS standard for 1H and H3PO4 
for 
31
P. 
2. s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet.  
3. Coupling constants (J) are measured in Hz 
Table 3.9: The 
1
H and 
31
P{
1
H} NMR spectra
1, 2, 3
 recorded for the chloro iminophosphine Pt 
(IV) complexes 381-384. All ran in CDCl3 at 300MHz. 
As previously discussed in Chapter 2 and for the PPh3 substituted complexes 371-
374 in Section 3.8.1, the azomethine resonances of the parent Pt (II) species appear as 
singlets, which is also found here for the Pt (IV) products here. Like that seen for the parent 
Pt (II) complexes, changes in the electron density of the azomethine H-C=N bond causes a 
shift in the 
1
H NMR spectra. As discussed previously, this is due to donation of the lone pair 
of electrons from the imino-nitrogen donor moiety into the metal centre to stabilise the Pt-N 
bond. 
For the PPh3 substituted Pt (II) complexes, Section 3.7.1, this shift was observed to be 
large and downfield in the 
1
H NMR spectra due to the introduction of another electron 
donating ligand trans to the imino-nitrogen donor moiety. This resulted in an increase in bond 
strength for the C=N bond, also noted by IR spectroscopy, since the imino-nitrogen bond is 
donating less electron density into the metal centre due to the presence of the new PPh3 
ligand.  
In the present case of the Pt (IV) complexes 381-384, the IR spectra also noted an 
increase in bond strength for the C=N bond like that of the PPh3 substituted complexes. 
However, the azomethine H-C=N signal in the 
1
H NMR is shifted upfield in comparison to 
the parent Pt (II) cyclometallates 281-284 and the triphenylphosphine substituted Pt (II) 
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complexes 371-374. Therefore, although the C=N bond itself has increased in strength, the 
effect of the newly introduced electron withdrawing chloride ligands at the axial positions of 
the metal centre is to pull electron density away from the metal centre, weakening the Pt-N 
bond. This in turn pulls electron density away from the C=N bond and conversely from the 
azomethine H-C=N bond as well, Figure 3.45. This causes electron density from the 
azomethine bond to be pulled into the C=N bond increasing its strength to cope with the new 
electron withdrawing chlorides present and is displayed as an upfield shift for the azomethine 
signal in the 
1
H NMR spectra. 
 
 
 
 
 
 
 
 
 
Figure 3.45: A comparison of the parent Pt (II) complexes 281-284 (left) with the oxidised Pt 
(IV) complexes 381-384 (right). Both have their azomethine H-C=N-Pt system highlighted. 
Table 3.10 contains a comparison of the azomethine signals and coupling between the 
Pt (II) chloro parent complexes and the newly formed Pt (IV) chloro complexes 381-384. As 
discussed, the upfield shift can be directly related to the increased electrophilicity of the d
6
 Pt 
(IV) metal centre, compared to d
8
 Pt (II) metal centre, which influences the electronic 
properties of the imino-nitrogen bond of the tridentate ligand. The average upfield shift, in 
comparison to the Pt (II) complexes, for these complexes is ca. 0.30 ppm which is 
significantly less than previous reports by our research group. The largest shift was again 
found to be for the 2,3-(OMe)2 complex 384, due to the presence of the methoxy groups as 
previously discussed.  
Previous reports by our research group and others on iodo Pt (IV) complexes have 
found upfeld shifts of circa 0.7 ppm in comparison to their Pt (II) precursors.
6,30 
This is 
proposed to be caused by the stronger withdrawing effect chloride possesses over iodide due 
to the difference in electronegativity between the two halides, as discussed in Chapter 2. 
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Pt (II) parent 
complexes 
δ (H-C=N) 
ppm 
Pt (IV) Oxidised 
complexes 
δ (H-C=N) 
ppm 
Δδ 
ppm 
3-H 281 9.40 (1 H, s) 
JH-Pt = 123 Hz 
381 9.11 (1 H, s) 
JH-Pt = 81 Hz 
0.29 
3-Br 282 9.40 (1 H, s) 
JH-Pt = 123 Hz 
382 9.20 (1 H, s) 
JH-Pt = 83 Hz 
0.20 
3-Cl 283 9.41 (1 H, s) 
JH-Pt = 123 Hz 
383 9.21 (1 H, s) 
JH-Pt = 84 Hz 
0.20 
2,3-(OMe)2 284 9.72 (1 H, s) 
JH-Pt = 126 Hz 
384 9.34 (1 H, s) 
JH-Pt = 84 Hz 
0.38 
Figure 3.10: A comparison of the azomethine signal for the parent Pt (II) complexes 281-284 
and the oxidised Pt (IV) complexes 381-384. 
195
Pt satellites were also observed for the Pt (IV) complex due to 
3
JH-Pt coupling 
similar to the parent Pt (II) complexes, but the coupling constants are circa 40 Hz lower than 
their Pt (II) analogues Table 3.10. Figure 3.46. They are, however, almost identical to the Pt 
(IV) iodo analogous reported previously by this research group.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.46: Comparison of the azomethine signal from the 
1
H NMR spectra for the parent 
cyclometallated Pt (II) complex 284 (left) and the equivalent Pt (IV) complex 384 (right). 
 
This is proposed to be as a result of the increased electrophilicity of the Pt (IV) metal 
centre and the resulting increased ligand-metal bond strength on comparison to the parent Pt 
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(II) parent complexes and appear as complex, overlapping multiplets. The aromatic ranges for 
each complex (and their respective integrations) are contained in Table 3.9.  
The 
1
H NMR spectra of the Pt (IV) complex 384 also displayed two singlet 
resonances, both integrating for 3H, at δ 3.91 and δ 4.10 ppm. As expected these 
corresponding to the two methoxy groups present on the ligand of the complex. On 
comparison with the parent Pt (II) chloro complex 284, the methoxy resonances were found 
to be shifted slightly upfield. This could potentially be attributed to the increased interaction 
of these substituents with the newly introduced axial chloride ligands, causing lengthening of 
the bonds due to repulsion. It’s also possibly due to the increased electron withdrawing effect 
of the newly introduced chlorides which may pull away electron density away from the 
substituents. 
[
1
H-
1
H] COSY plots unfortunately did not allow for any significant aromatic 
characterisation due to the large overlapping signals caused by the shifting of the signals due 
to the new chloride ligands. Attempted [
13
C DEPT 45-
1
H] HETCOR plots and other 
13
C 
NMR spectra were also inconclusive at this time so no further characterisation is reported due 
to extensive solubility issues for all the Pt (IV) complexes.  
 
Pt (II) parent 
complex 
δ 31P{1H} 
ppm 
Pt (IV) 
Complex 
δ 31P{1H} 
ppm 
Δδ 
ppm 
3-H 281 25.3 (s) 
JPt-P = 2083 Hz 
381 -2.3 (s) 
JPt-P = 1326 Hz 
27.6 
3-Br 282 25.4 (s) 
JH-Pt = 2100 Hz 
382 -1.7 (s) 
JPt-P =1349 Hz 
27.1 
3-Cl 283 25.5 (s) 
JH-Pt = 2123 Hz 
383 -1.4 (s) 
JH-Pt = 1350 Hz 
26.9 
2,3-(OMe)2 284 25.2 (s) 
JH-Pt = 2102 Hz 
384 -2.1 (s) 
JH-Pt = 1344 Hz 
27.3 
Table 3.11: A comparison of the phosphorus signal for the parent Pt (II) complexes 281-284 
and the oxidised Pt (IV) complexes 381-384. 
The 
31
P{
1
H} NMR spectra on the other hand displayed a single resonance for each 
complex indicating only one phosphorus environment, like the parent Pt (II) complexes 281-
284, Table 3.9. A comparison of the Pt (IV) complexes 381-384 with their respective Pt (II) 
analogues 281-384 are contained in Table 3.11. There is a significant upfield shift observed 
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for the phosphorus donor moiety due to the introduction of the two new axial chloride ligands 
of circa δ 27 ppm.  
Interestingly, analogous Pt (IV) iodo complexes previously reported by our research 
group displayed singlet resonances in the range of δ -15.5 to δ -16.1 ppm whereas the novel 
chloro Pt (IV) complexes reported here, 381-284, give resonances in the range of δ -1.4 to -
2.3 ppm. This is a significant difference cause by the axial chloride ligands in comparison to 
the iodide ligands seen previously.
 
The higher electronegativity of the chloride ligands cause 
a stronger electron withdrawing effect on the phosphorus donor moiety, exhibited by the 
further upfield shift compared to the Pt (IV) iodo complexes reported previously.
6
  
Evidence for the continued coordination of the Pt-P bond was again provided by the 
presence of 
195
Pt satellites generated as a result of 
1
JP-Pt coupling Figure 3.47. The coupling 
constants for the Pt (IV) complexes 381-384 were found to be circa 600 Hz lower than the 
parent Pt (II) chloro complexes 281-284, again as a direct consequence of the increased 
electrophilicity of the Pt (IV) centre. These reduced coupling constants, compared to their 
respective Pt (II) analogues, are characteristic of Pt (IV) complexes previously identified by 
our research group and others.
30,6
 
 
2 
 
 
 
 
 
 
 
 
 
 
Figure 3.47: A comparison of the phosphorus signal from the 
31
P{
1
H} NMR Spectra for the 
parent Pt (II) complexes 281-284 (left) and the oxidised Pt (IV) complexes 381-384 (right). 
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3.8.3 NMR studies of the proposed mixed axial Pt (IV) intermediates, 386 and the 
PNO type Pt (IV) complex 385: 
 
1
H and 
31
P{
1
H} NMR data was also collected, where possible due to insolubility, for 
the mixed chloro-methoxy Pt (IV) intermediates, 386, as described in Figure 3.34. As seen 
for all other platinum complexes reported here, the azomethine signal is again observed with 
195
Pt satellites and found to be further upfield when compared to the parent Pt (II) complexes 
281-284. However, the upfield shift observed for the mixed axial complex, 386,  is slightly 
less than the final Pt (IV) complexes 381-384, and the 
195
Pt coupling frequency is only 42 Hz 
in comparison to 84 Hz for the final priducts, Table 3.12. 
 
Pt (II) parent 
complex 
δ (H-C=N) 
ppm 
Pt (IV) products δ (H-C=N) 
ppm 
Δδ 
ppm 
2,3-(OMe)2 284 9.72 
JH-Pt = 126 Hz 
384 
Final Pt (IV) product 
9.34 (1 H, s) 
JH-Pt = 84 Hz 
0.38 
2,3-(OMe)2 284 9.72 
JH-Pt = 126 Hz 
386  
Intermediate (OMe) 
9.38 (1 H, s) 
JH-Pt = 42 Hz 
0.34 
Table 3.12: A comparison of the azomethine signal for the parent Pt (II) complex 284 and the 
Pt (IV) methoxy-chloro mixed axial intermediate, 386, and the final oxidised Pt (IV) complex 
384. 
The 
1
H NMR spectra of the mixed axial ligands gave very similar azomethine signals 
but the reduced coupling frequencies in comparison to the final Pt (IV) complexes 381-384, 
is probably due to the presence of one electron donating group at the axial position. However, 
there was also a slightly broad signal with 
195Pt satellites at circa δ 2.30 ppm. This is 
proposed to be representing the axial methoxy ligand coordinated to the platinum metal 
centre and was found to have a coupling frequency of 54 Hz, Figure 3.48. 
These values correspond very well to previous reports by Sanford et al who also 
found a methoxy signal at circa δ 2.50 ppm for Pt (IV) products completed in methanol. It is 
proposed that the upfield shift from the usual signal found in 
1
H NMR spectra for methoxy 
signals (δ 3.00 – 4.00 ppm) is due to the chloride ligands present.30 However, unlike other 
reported Pt (IV) complexes these proposed Pt (IV) complexes were found to be 
photosensitive which caused decomposition of the complexes. The decomposition products 
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P Cl
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H
were insoluble in all common solvents and determination of their structure is inconclusive at 
this time.  
 
 
 
 
 
 
 
 
Figure 3.48: The slightly broad methoxy signal complete with 
195
Pt satellites found for the Pt 
(IV) intermediate 386. Please note the structure may also have the axial methoxy group on 
the opposite side of the metal centre, but only one isomer is shown here for clarity. 
The 
31
P{
1
H} NMR spectra also gave similar results in comparison to the final chloro 
Pt (IV) complexes 381-384 with an upfield signal at circa δ -2.0 ppm and 195Pt satellites with 
coupling frequencies of circa 1300 Hz.  
Oxidation studies on the PNO type complex 285, reported previously by our research 
group and here also in Chapter 2, gave inconsistent results as deduced from NMR studies. 
1
H and 
31
P{
1
H} NMR data was obtained, but insolubility and varying reaction products from 
time to time make structural proposals tentative.  
 
 
 
 
 
 
 
 
 
Figure 3.49: The azomethine signal complete with 
195
Pt satellites and proposed structure for 
the Pt (IV) PNO complex 385. 
An azomethine signal is observed with 
195
Pt satellites in the 
1
H NMR spectra and 
found to be further upfield when compared to the parent Pt (II) complex, 285, Figure 3.49, 
N
Pt
Cl
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and represents the most upfield signal observed for all the platinum complexes reported by 
our research group to date 
It was generally found to be present at δ 8.55 ppm and in comparison to δ 9.15 ppm 
for the parent Pt (II) PNO complex this represents a shift upfield of δ 0.60 ppm . The 
coupling frequency of the 
195
Pt satellites was calculated to be 27 Hz in comparison to 76 Hz 
for the parent Pt (II) PNO complex 285. These values are generally consistent with the 
signals and coupling frequencies shifts observed for the cyclometallated Pt (IV) complexes 
381-384 reported in Section 3.7.2.  
The 
31
P{
1
H} NMR spectra of the proposed PNO Pt (IV) complex 385 on the other 
hand gave a single phosphorus resonance with only a slight upfield shift of circa δ 1.4 ppm in 
comparison to the parent Pt (II) PNO complex 285. The signal for the proposed Pt (IV) PNO 
complex was found to be present at δ 11.30 ppm compared to δ 13.1 ppm for the parent Pt 
(II) complex and 
195
Pt satellites were found to be present complete with a coupling frequency 
of 2343 Hz. This represents a reduction of 1474 Hz in comparison to the parent Pt (II) 
complex which has a coupling frequency of 3816 Hz, Figure 3.50.  
 
 
 
 
 
 
 
 
 
Figure 3.50: The signal found in the 
31
P{
1
H} NMR spectra complete with 
195
Pt satellites and 
again the proposed structure for the Pt (IV) PNO complex 385. 
Again these values are consistent with those found for the other cyclometallated Pt 
(IV) complexes 381-384. Unfortunately mixtures of products, that we are currently unable to 
separate, along with varying results found for signals and coupling frequencies, means this 
complex remains a proposed structure at this time with further extensive work needed to fully 
characterise it. Elemental analysis and IR spectra also gave varying results. The C=N stretch 
in the IR spectra for this complex ranged from 1590 cm
-1
 to 1602 cm
-1
.   
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However, from the spectra recorded to date we are confident that we have 
successfully oxidised the Pt (II) PNO complex 285 to its Pt (IV) analogue 385 using N-
chlorosuccinimide. 
 
3.9 Chapter 3 Summary and Conclusions: 
 
3.9.1 The Triphenylphosphine Substituted Pt (II) Complexes: 
 
The synthesis of the triphenylphosphine substituted chloro Pt (II) complexes was 
achieved using a novel procedure based on the success of employing chloroform in the 
cyclometallation reactions as discussed previously in Chapter 2. Previous methods used to 
remove a chloride from a platinum metal centre of analogous complexes, reported by our 
research group, involved a reaction of the parent Pt (II) complex with a one molar equivalent 
of silver (I) perchlorate.
8
 The removal of the halide from the metal centre then generated a 
cationic, solvated intermediate and a silver (I) chloride precipitate which was filtered through 
celite. Addition of the appropriate monophosphine, PR3 (R = Ph, p-tolyl, EtCN), then yielded 
the cationic, substituted complexes. 
In this Chapter we have developed a novel one-step method for synthesis of cationic 
phosphine substituted Pt (II) iminophosphine complexes, without the need for silver (I) 
perchlorate. The one-pot synthesis of 371-375 is based on the success of employing 
chloroform for the reactions in Chapter 2. In this chapter it is used as part of a mixed solvent 
system similar to methods previously employed by our research group and others, with 
chloroform instead of acetonitrile.
16,6
 
Substitution of the parent Pt (II) iminophosphine complexes from Chapter 2 was 
achieved in a 1:1 methanol:chloroform solution and a slight excess of the appropriate 
monophosphine, PR3 (R = Ph, EtCN), which were stirred at room temperature for 6 hours.  
The yields obtained for the substituted complexes are much higher than previously 
obtained for analogous iodo based complexes at circa 70-90%, and so far have been 
successful for all the cyclometallates 281-284. Phosphine substitution of [Pt(η3-PNO-L4)Cl] 
275 was never successfully substituted with or without the use of the silver perchlorate salt 
by our research group. It has been successfully substituted here with triphenylphosphine by a 
new direct method for the first time yielding the cationic P,N,O complex 375 in a 70% yield.  
The triphenylphosphine substitutions, previously reported by our research group, were 
the most difficult to achieve by both direct methods and by use of silver (I) perchlorate. This 
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research has found that this particular phosphine posed no difficulties primarily due to the 
novel solvent system employed i.e. via stabilisation of the liberated chloride anion. Despite 
the reduced lability of the platinum chloride bond on comparison to the platinum iodine bond 
reported previously, it was successfully substituted for the first time as a one-step process 
within this research.  
All the cationic substituted complexes 371-375 were fully characterised by IR, 
1
H and 
31
P{
1
H} NMR and elemental analysis. Other NMR techniques including [
1
H-
1
H] COSY and 
[
13
C DEPT 45-
1
H] HETCOR plots but solubility limitations prevented full use of these 
methods including 
13
C NMR as previously employed in Chapter 2.  
There is a downfield shift of the azomethine signal found in the 
1
H NMR spectra on 
coordination of the introduced phosphine moiety trans to the nitrogen of between 0.20 and 
1.6 ppm. The azomethine signal is also now displayed as a doublet complete with 
195
Pt 
satellites and 
3
JH-Pt coupling of ca. 83-86 Hz. These Pt-H coupling constants are around 40 Hz 
less than that of the parent Pt (II) complexes. This reduction can be attributed to the 
decreased electrophilicity of the Pt (II) metal centre due to the successful coordination of the 
electron-rich triphenylphosphine moiety.  
Aromatic signals for all the complexes appear as overlapping multiplets due to the 
addition of three more phenyl groups in the form of triphenylphosphine. Integration of these 
aromatic signals, however, are as expected for each complex and [
1
H-
1
H] COSY plots did 
provide some detail but did not allow for full aromatic characterisation due to the large 
overlapping signals caused by the extra phenyl groups.  
13
C NMR data was particularly difficult to get for all the complexes reported in this 
chapter and unfortunately various attempts to collect useful 
13
C, DEPT NMR and [
13
C DEPT 
45-
1
H] HETCOR plots were unsuccessful at this time due to the limited solubility of the 
complexes. In the 
13
C NMR spectra only strong multiple overlapping signals at 128.56-
135.04 ppm were found and assigned to the phosphinophenyl carbons as per the spectra 
obtained for the parent complexes in Chapter 2.   
The 
31
P{
1
H} NMR data obtained for the triphenylphosphine substituted complexes 
371-375 display two sets of doublet signals. Each phosphorus signal represents one of the 
two phosphorus environments now present due to the two phosphines and doublet signals are 
observed due to cis 
2
JP-P coupling. The signal at circa δ 34 ppm seen for the substituted 
complexes corresponds to the phosphine group of the tridentate ligand i.e. for the 
cyclometallated complexes this is trans to the σ Pt-Caryl bond. This represents a shift 
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downfield of circa δ 8 ppm in comparison to the parent Pt (II) complexes which had a 
phosphine signal at circa δ 25ppm.  
 The presence of solvent of crystallisation was also noted in the 
1
H NMR spectra of the 
complexes (dichloromethane and chloroform) and was therefore including for successful 
elemental analysis. This was also noted previously by our research group and others where 
most of the analogous iodo complexes also contained solvent of crystallisation.
44,45,6,7,46
  
 
3.9.2 Synthesis of the Pt (IV) Complexes: 
 
In this chapter we also describe the synthesis and characterisation of a series of novel 
tridentate Pt (IV) chloro cycloplatinated complexes of the general formula [Pt(η3-PNC-L1-
4
)Cl3] 381-384. All of the Pt (IV) complexes 381-384 were synthesised by oxidising the 
appropriate tridentate Pt (II) complexes 281-284 reported in Chapter 2, with N-
chlorosuccinimide.  
Initial attempts to achieve successful oxidation of the Pt (II) complexes involved the 
use of hydrogen peroxide (H2O2) and sodium hypochlorate (NaOCl) as well as hydrochloric 
acid. All of these attempts failed. However, the reaction solution did return the parent 
iminophosphine Pt (II) complexes in almost quantitative yields suggest immense stability for 
these complexes.  
The successful preparation of cyclometallated chloro-Pt (IV) iminophosphine 
complexes 381-384 was based on a previously reported method by Sanford et al.
30
 A mixed 
solution of chloroform and methanol was again employed like that used for the substitution 
reactions for complexes 371-375. The appropriate parent Pt (II) cyclometallated complex 
281-284 was reacted with 2.1 equivalents (an excess) of N-chlorosuccinimide to give the Pt 
(IV) chloro complexes 381-384 in yields ranging from 11-36% at present with significant 
parent Pt (II) starting material remaining even after 48 hours stirring. 
 The Pt (IV) complexes 381-384 were analysed by infra-red spectroscopy which, as 
expected, shows an imine υ(C=N) stretching band at 1586cm-1. On comparison with the 
respective parent Pt (II) cyclometallated complex, a decrease in the imine stretching 
frequency was found. This indicated a weaker imine C=N bond in the Pt (IV) complexes in 
comparison to their parent Pt (II) complexes. This trend was also found to be evident 
previously in our research group for the Pt (IV) iodo complexes and are proposed to indicate 
successful oxidation of the Pt (II) parent complex.  
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1
H NMR spectra of cycloplatinated Pt (IV) chloro complexes [Pt(η3-PNC-L1-4)Cl3] 
481-384 all display singlet 1H resonances in the range δ 9.10-9.34 ppm corresponding to the 
azomethine signal. On comparison with the parent Pt (II) complexes resonances, we see an 
upfield shift of the resonance frequency for these novel complexes. Further evidence to 
support the evidence of successful oxidation of the Pt (II) complex comes in the form of 
195
Pt 
satellites which were again seen on the azomethine resonances similar to that seen for the 
parent Pt (II) complexes in Chapter 2. The coupling frequencies of the azomethine proton 
here however with the NMR active 
195
Pt nucleus produces coupling constants in the order of 
3
JH-Pt = 81-84 Hz, a change of circa 40 Hz in comparison to the parent Pt (II) complexes.  
31
P{
1
H} NMR spectra for the Pt (IV) cycloplatinates 381-384 again show a single 
resonance identifying the single phosphorus environment of the Pt (IV) complex. However, 
the resonances have shifted significantly to be in the range of δ -1.4 to  -2.4ppm. This upfield 
shift, on comparison with the corresponding Pt (II) complex, also identifies coordination of 
the phosphorus to the more electrophilic Pt (IV) metal centre. 
195
Pt satellites are again present 
with 
1
JP-Pt coupling in the order of 1344-1350 Hz which is also a reduction of circa 700 Hz in 
comparison to the Pt (II) complexes 281-284. Interestingly, however, is the significant 
difference of the resonances in comparison to the previously reported Pt (IV)  iodo complexes 
which is proposed to be due to the more electronegative chloride axial ligands in  comparison 
to iodide.  
Attempts to oxidise the phosphinoamide Pt (II) complexes reported in Chapter 2, 286-
288 by all the reagents reported in this chapter has proved to be unsuccessful at this time and 
only decomposition was found to occur rather than a return of the parent complexes seen for 
the iminophosphine complexes 281-284. Also oxidation of the iminophosphine PNO 
complex, 275, proved to be unsuccessful at this time with further work required to understand 
the process of this particular complex. It is proposed that steric bulk around the metal centre 
due to the presence of an oxygen coordinated to the metal centre is hindering successful 
oxidation via N-chlorosuccinimide.  
 
3.9.3 Overall Summary and Conclusion: 
 
 The introduction of an electron rich triphenylphosphine ligand, by removing all 
electron-withdrawing ligands, causes the Pt (II) metal centre to decease in electrophilicity. 
This is seen as a downfield shift of the ligands attached directly to the metal centre, the 
azomethine and phosphorus signals, in both the 
1
H NMR and the 
31
P{
1
H}NMR spectra.  
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 When the more electron withdrawing ligands (chlorides) are coordinated to the metal 
centre due to oxidation, we see the Pt (IV) metal centre increase in electrophilicity. This 
results in upfield shifts for the signals related to ligands attached directly to the platinum 
centre, the azomethine and phosphorus signals, in both the 
1
H NMR and the 
31
P{
1
H}NMR 
spectra. In conclusion this chapter has explored the stability, flexibility and potential for the 
parent complexes reported in Chapter 2.  
 
3.10 Chapter 3 Experimental: 
 
3.10.1 Background: 
 
All reaction solvents were distilled prior to use, unless purchased as analytical grade 
(all from Sigma Aldrich Chemical Co. Ltd.). Toluene and thf were distilled directly before 
use from sodium-benzophenone. Methanol was distilled over magnesium/iodine according to 
Perrin et al
47 
and hexane was distilled over phosphorus pentoxide. O-
diphenylphosphinoaniline was synthesized according to a variation of a method by M. K. 
Cooper et al.
48
  
The following reagents were used as supplied; N-Chlorosuccinimide (Aldrich 
Chemical Co. Ltd), triphenylphosphine (Aldrich Chemical Co. Ltd); tri-p-tolylphosphine, 
triscyanoethylphosphine (both Strem chemicals), H2O2 and NaOCl. Elemental analyses 
(Perkin-Elmer 2400 CHN elemental analyser) were performed by the microanalytical 
laboratory, University College Cork.  
The 
1
H and 
31
P{
1
H} NMR spectra were recorded on a Bruker Advance 300 MHz, 400 
MHz or 600 MHz NMR spectrometer (where specified). Chemical shifts (δ) are expressed in 
parts per million (ppm) and referenced to external tetramethylsilane (δ0) for 1H and 85% 
phosphoric acid (δ0) for 31P{1H} NMR using the high frequency positive convention.  
Infrared spectra were recorded as KBr disks on a Perkin-Elmer Paragon 1000 FT 
spectrometer. Relative intensities are designated (s), strong; (m), medium; (w), weak; (b), 
broad.  
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3.10.2 Synthesis of the substituted Pt (II) complexes [Pt
II
( 3–PNC–L1-4)PPh3]Cl 371-375: 
 
 A stirred solution of [Pt
II
(η3–PNC/PNO–L1-4)Cl] in 1:1 chloroform/methanol 
(10ml:10ml) was reacted with 1.1 equivalents of triphenylphosphine at room temperature for 
6 hours. The resulting pale yellow solution was reduced to dryness in vacuo and crystallised 
from doubly distilled DCM-diethyl ether to yield the substituted cationic chloro complexes 
371-375. The diethyl ether removes the remaining triphenylphosphine and there are no traces 
of remaining Pt (II) starting material via TLC analysis of the filtrate.  
 
 
371: [Pt
II
(η3–PNC–L1)Cl] (0.040 g, 0.07 mmol) 281 and 
PPh3 (0.020 g, 0.08 mmol) gave [Pt( 
3–PNC-L1)PPh3]Cl 
371 as a pale yellow metallic crystalline powder.  
Yield: 0.050 g (88 %) 
Found (required for C43H34ClNP2Pt.0.5CH2Cl2): C, 
57.52 (57.54); H, 3.89 (3.95); N, 1.21 (1.53). 
IR vmax (KBr): 3378 (b), 3048 (w), 1624 (w), 
N
Pt
PPh2
PPh3
Cl-+
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1590(m)(C=N), 1568(w), 1542(m), 1480(m), 1436(s), 1363 (w), 1303 (w), 1249 (m), 1190 
(w), 1160 (w), 1097 (s), 1066 (w), 997 (m), 918 (w), 840 (w), 745 (m), 722 (w), 692 (s), 571 
(m), 543 (s), 519 (s), 503 (s). 
1H NMR δ ppm: 11.02 (1 H, d) (JPt-H = 87 Hz, JPt-Pb = 10 Hz), 6.50-7.80 (33H, m), 5.30 
(CH2Cl2). 
31P NMR δ ppm: 33.3 (d) (2JPa-Pb = 15, JPt-Pa = 1911 Hz), 18.4 (d) (
2
JPa-Pb = 16, JPt-Pb 
= 3794 Hz) 
 
 
372:
 
[Pt
II
(η3–PNC–L2)Cl] (0.047 g, 0.07 mmol) 282 and 
PPh3 (0.020 g, 0.08 mmol) gave  [Pt( 
3–PNC-L3)PPh3]Cl 
303 as a dark yellow metallic crystalline powder.  
Yield: 0.024 g (35 %) 
Found (required for C43H33BrClNP2Pt.0.5CH2Cl2): C, 53.11 
(52.99); H, 3.42 (3.54); N, 1.27 (1.40). 
IR vmax (KBr): 3309 (b), 2978 (w), 2863 (w), 2330 (w), 
1735 (w), 1627 (w), 1591 (m)(C=N), 1568 (m), 1532 (m), 
1480 (m), 1435 (s), 1347 (w), 1295 (m), 1241 (m), 1190 (m), 1168 (w), 1096 (s), 1070 (m), 
1027 (w), 997 (m), 928 (w), 878 (w), 811 (m), 771 (w), 754 (m), 736 (m), 703 (m), 609 (m), 
573 (m), 548 (s), 512 (s), 509 (m). 
1H NMR δ ppm: 11.36 (1 H, d) (JPt-H = 88 Hz, JPt-Pb = 9 Hz), 6.40-7.75 (32 H, m), 5.30 
(CH2Cl2). 
31P NMR δ ppm: 33.4 (d) (2JPa-Pb = 16, JPt-Pa = 1945 Hz), 17.8 (d) (
2
JPa-Pb = 16, JPt-Pb 
= 3732 Hz) 
 
 
373: [Pt
II
(η3–PNC–L3)Cl] (0.044 g, 0.07 mmol) 283 and 
PPh3 (0.020 g, 0.08 mmol) gave  [Pt( 
3–PNC-L3)PPh3]Cl 
373 as a dark yellow metallic crystalline powder.  
Yield: 0.046 g (69 %) 
Found (required for C43H33ClNP2Pt.2CH2Cl2 ): C, 50.92 
(50.92); H, 3.47 (3.51); N, 1.10 (1.32). 
IR vmax (KBr): 3307 (b), 3039 (w), 2976 (w), 2863 (w), 
2330 (w), 1735 (w), 1717 (w), 1627 (w), 1590 (m)(C=N), 
1568 (m), 1532 (m), 1480 (m), 1435 (s), 1347 (w), 1291 (m), 1241 (m), 1190 (m), 1168 (w), 
1095 (s), 1070 (m), 1027 (w), 997 (m), 928 (w), 878 (w), 810 (m), 771 (w), 757 (m), 736 (m), 
703 (m), 692 (s), 611 (m), 573 (m), 543 (s), 517 (s), 506 (m), 497 (s). 
N
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+
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1H NMR δ ppm: 11.31 (1H, d) (JPt-H = 87 Hz, JPt-Pb = 9 Hz), 6.40-8.20 (32 H, m), 5.30 
(CH2Cl2). 
31P NMR δ ppm: 33.4 (d) (2Jp-pa = 16, JPt-Pa = 1949 Hz), 17.9 (d) (
2
Jp-pb = 16, JPt-Pb = 
3737 Hz) 
 
 
374: [Pt
II
(η3–PNC–L4)Cl] (0.046 g, 0.07 mmol) 284 and 
PPh3 (0.020 g, 0.08 mmol) gave  [Pt( 
3–PNC-L4)PPh3]Cl 
374 as an orange/yellow metallic crystalline powder.  
Yield: 0.062 g (89 %) 
Found (required for C45H38ClNO2P2Pt.2CH2Cl2): C, 51.80 
(51.93); H, 4.14 (3.89); N, 1.18 (1.29). 
IR vmax (KBr): 3317 (b), 3052 (w), 2932 (w), 1628 (w), 
1587 (w) (C=N), 1545 (s), 1478 (s), 1437 (s), 1415 (m), 
1340 (w), 1261 (s), 1207 (m), 1184 (w), 1129 (w), 1097 (s), 1025 (m), 997 (m), 955 (w), 835 
(w), 809 (w), 753 (m), 729 (m), 694 (s), 581 (w), 563 (w), 544 (s), 517 (s), 507 (s). 
1
H NMR δ ppm: 9.91 (1 H, d) (JPt-H = 86 Hz, JPt-Pb = 9 Hz), 6.17-78.27 (31 H, m), 5.30 
(CH2Cl2), 3.60 (3 H, s), 4.14 (3 H, s). 
31P NMR δ ppm: 33.4 (d) (2JPa-Pb = 16, JPt-Pa = 1956 
Hz), 17.5 (d) (
2
JPa-Pb = 16, JPt-Pb = 3815 Hz) 
 
 
375: [Pt
II
(η3–PNO–L4)Cl] (0.045 g, 0.07 mmol) 275 
and PPh3 (0.021 g, 0.08 mmol) gave  [Pt( 
3–PNO-
L
4
)PPh3]Cl 375 as an orange/yellow metallic 
crystalline powder.  
Yield: 0.048 g (69 %) 
Found (required for C44H38ClNO2P2Pt.CH2Cl2): C, 
54.53 (54.70); H, 4.06 (3.88); N, 2.41 (1.43). 
IR vmax (KBr): 3637 (w), 3572 (w), 3368 (b), 3040 
(m), 3000 (m), 2346 (w), 1734 (w), 1604 (s), 1589 (s)(C=N), 1571 (s), 1541 (s), 1481 (m), 
1458 (w), 1435 (s), 1396 (s), 1330 (m), 1279 (w), 1256 (s), 1230 (s), 1179 (s), 1099 (s), 1065 
(m), 997 (m), 983 (m), 874 (w), 857 (w), 777 (w), 743 (s), 711 (m), 691 (s), 618 (w), 566 
(m), 549 (w), 530 (s), 510 (s), 502 (s), 455 (w). 
1H NMR δ ppm: 10.06 (1 H, d) (JPt-H = 61 Hz, JPt-Pb = 14 Hz), 6.59-7.90 (31 H, m), 5.30 
(CH2Cl2), 3.20 (3 H, s). 
31P NMR δ ppm: 19.0 (d) (2JPa-Pb = 22, JPt-Pa = 3607 Hz), 9.1 (d) (
2
JPa-
Pb = 22, JPt-Pb = 3434 Hz) 
N
Pt
PPh2
PPh3
Cl-
OMe
MeO
+
N
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O
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+
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N-ChlorosuccinimideN
Pt
PPh2
Cl
N
Pt
Ph2
P Cl
Cl
R
CHCl3:MeOH R
Cl
Parent Platinum (II) Complexes
R = 3-H
3-Br
3-Cl
2,3-(OMe)2
281
282
283
284
R = 3-H
3-Br
3-Cl
2,3-(OMe)2
381
382
383
384
Platinum (IV) Complexes
3.10.3 Synthesis of the Pt (IV) complexes [Pt
IV
( 3–PNC-L1-4)Cl3] 381-384: 
 
 
 
 
 
 
 
 
 
 
 
 
 To a solution of [Pt
II
(η3–PNC-L1-4)Cl] 281-284 in 10 ml of a 1:1 solution of 
chloroform:methanol, an excess of N-chlorosuccinimide (2.1 equivalents) was added and the 
reaction mixture was stirred at room temperature for 16 hours. It was then reduced to dryness 
in vacuo. The residue was taken up in dichloromethane and washed with water (3x10 ml) in a 
separation funnel to remove the succinimide formed during the reaction. The final product 
mixture was then reduced to dryness in vacuo and re-crystallised from dichloromethane-
hexane to yield compounds 281-384. 
 
381: Pt
II
( 3–PNC–L1)Cl] 281 (0.021 g, 0.035 mmol) and 
N-Chlorosuccinimide (0.011 g, 0.082 mmol) gave [Pt
IV
( 3–
PNC-L
1
)Cl3] 381 as a dark brown, crystalline solid.  
Yield: 0.007 g (30 %) 
Found (required for C25H21Cl3NP.CH2Cl2): C, 41.48 
(41.59); H, 2.80 (2.82); N, 1.79 (1.87). 
IR vmax (KBr): 3051 (b), 1591 (s) (C=N), 1565 (s), 1478 (s), 1434 (s), 1254 (s), 1188 (m), 
1099 (s), 1068 (m), 997 (m), 970 (w), 844 (w), 767 (s), 720 (m), 693 (s), 570 (w), 528 (s), 
502 (s). 
1H NMR δ ppm: 9.11 (1 H, s) (JPt-H = 81 Hz), 7.30-8.24 (18 H, m), 5.30 (CH2Cl2). 
31P NMR δ 
ppm: -2.1 (s) (JPt-P = 1326 Hz). 
 
N
Pt
Cl
Cl
Cl
Ph2
P
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382: [Pt
II
( 3–PNC–L2)Cl] 282 (0.022 g, 0.033 mmol) 
and N-Chlorosuccinimide (0.012 g, 0.82 mmol) gave 
[Pt
IV
( 3–PNC-L3)Cl3] 283 as a light yellow solid.  
Yield: 0.003 g (11 %) 
Found (required for C25H18BRCl3NPPt) C, 40.12 
(40.42); H, 2.40 (2.44); N, 1.78 (1.88) 
IR vmax (KBr): 3317 (b), 1595 (w)(C=N), 1565 (s), 1478 (s), 1437 (s), 1415 (m), 1390 (w), 
1261 (s), 1207 (m), 1189 (m), 1129 (w), 1097 (s), 1025 (m), 835 (s), 809 (w), 750 (s), 729 
(m), 694 (s), 581 (w), 511 (s), 504 (s). 
1H NMR δ ppm: 9.20 (1 H, s) (JPt-H = 83 Hz), 7.40-8.20 (17 H, m). 
31P NMR δ ppm: -1.7 (s) 
(JPt-P = 1345 Hz). 
383: [Pt
II
( 3–PNC–L3)Cl] 283 (0.021 g, 0.033 mmol) 
and N-Chlorosuccinimide (0.013 g, 0.83 mmol) gave 
[Pt
IV
( 3–PNC-L3)Cl3] 383 as a light yellow solid.  
Yield: 0.006 g (25 %) 
Found (required for C25H21Cl4NP.CH2Cl2): C, 39.65 
(39.77); H, 2.49 (2.57); N, 1.65 (1.78). 
IR vmax (KBr): 3052(w), 1596(w)(C=N), 1541 (s), 1478 (s), 1437 (s), 1415 (m), 1340 (w), 
1261 (s), 1207 (m), 1184 (w), 1129 (w), 1097 (s), 1025 (m), 997 (m), 955 (w), 835 (w), 809 
(w), 753 (m), 729 (m), 694 (s), 581 (w), 563 (w), 544 (s), 517 (s), 507 (s). 
1H NMR δ ppm: 9.21 (1 H, s) (JPt-H = 84 Hz), 6.40-8.20 (17 H, m). 
31P NMR δ ppm: -1.4 (s) 
(JPt-P = 1350 Hz). 
384: [Pt
II
( 3–PNC–L4)Cl] 284 (0.025 g, 0.038 mmol) 
and N-Chlorosuccinimide (0.013 g, 0.084 mmol) gave 
[Pt
IV
( 3–PNC–L4)Cl3] 384 as a dark red powder.  
Yield: 0.010 g (36 %) 
Found (required for C27H23Cl3NO2PPt.0.1CH2Cl2): C, 
43.95 (44.32); H, 3.17 (3.18); N, 1.80 (1.91) 
IR  max (KBr): 3392 (w), 2932 (w), 1586 (m)(C=N), 1538 (s), 1477 (m), 1436 (m), 1410 (w), 
1336 (w), 1266 (s), 1206 (w), 1134 (w), 1096 (w), 1081 (w), 1002 (m), 817 (w), 743 (m), 690 
(m), 563 (w), 527 (m), 498 (m). 
1H NMR δ ppm: 9.34 (1 H, s) (JPt-H = 84 Hz), 7.23-7.90 (14H, m), 8.07-8.16 (2H, m), 3.91 
(3H, s), 4.10 (3H, s). 
31P NMR δ ppm: -2.1 (s) (JPt-P = 1334 Hz). 
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4.1 Chapter 4 Background: 
 
The biological role of metal ions and metal based drugs was discussed extensively in 
Chapter 1. In particular platinum based metallo-drugs were discussed in terms of their 
pharmacokinetics and their mechanism of action in-vitro and in-vivo. Chapter 2 then went on 
to discuss the design and synthesis of a new range of Pt (II) complexes, while Chapter 3 
discussed substitution and oxidation reactions of these complexes to form cationic 
triphenylphosphine Pt (II) complexes and Pt (IV) complexes respectively. This chapter on the 
other hand aims to focus on the applications and potential biological activity of the most 
stable complexes reported in Chapter 2 and 3.  
 
4.2 The Role of Sulphur in Platinum Anti-cancer Therapy: 
 
4.2.1 Sulphur biomolecules: 
 
 Sulphur containing biomolecules such as cysteine (Cys), methionine (Met), 
glutathione (GSH), metallothionein (MT) and albumin play a significant role in the 
metabolism of platinum anti-cancer drugs due to their high affinity to the Pt (II) metal 
centre.
1
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Examples of some biomolecules involved in the metabolism of Pt (II) drugs; 
cysteine 401, methionine 402 and glutathione 403 
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Sulphur is involved in the entire metabolic process of platinum drugs, including 
reactions prior to cell uptake, deactivation prior to DNA binding, and formation of DNA 
adducts.
2
 Sulphur containing amino acids such as cysteine and methionine, 401 and 402, 
Figure 4.1, play an important role in maintaining the integrity of cellular systems by 
influencing the cellular redox state and can detoxify unwanted compounds, free radicals and 
reactive oxygen species.  
Sulphur containing peptides such as glutathione, 403, Figure 4.1, also act as 
important antioxidants and play key roles in the detoxification of a variety of electrophilic 
compounds and peroxides. Finally, large proteins such as albumin and metallothionein are 
very abundant thiol rich biomolecules found in humans and have a strong affinity for certain 
metal ions (“soft” acids as described by the HSAB theory).2–4 
However, the role of sulphur in platinum based chemotherapy has been controversial 
with arguments claiming that these biomolecules can hinder therapeutic efficacy as well as 
assist in the biological activity of platinum complexes.
5–8
 Carboplatin for instance is much 
less chemically reactive than cisplatin, meaning fewer side effects, but it still has potent anti-
tumour properties. This has prompted investigators to focus on ways in which it reacts with 
biomolecules that are normally found in the body.  
 Platinum-sulphur interactions are ubiquitous in the human body and many 
occurrences encountered during platinum chemotherapy such as uptake, excretion, resistance 
and toxicity are related to them. Therefore sulphur containing biomolecules play a significant 
role in the anti-cancer mechanism of current platinum drugs and determine the design of 
future analogues. Studies involving the reaction of both new platinum complexes and 
currently approved drugs with these biomolecules are therefore necessary to establish 
structure activity relationships (SAR) and determine potential anti-cancer activity. 
 
4.2.2 Sulphur biomolecules hindering the mechanism of action of Pt (II) drugs: 
 
 Sulphur manifests its negative influence on platinum anti-cancer chemotheraphy in 
two aspects. Firstly endogenous sulphur containing biomolecules such as cysteine, 
methionine and glutathione affect the metabolism of platinum drugs and exert adverse effects 
on the therapeutic efficacy while exogenous congeners such as amifostine and dimesna 
mitigate the toxic side effects of platinum drugs and serve as chemoprotectants.  
 It is commonly accepted that the most platinum drugs in the clinic exert their anti-
cancer effect by interacting with DNA, however, these drugs will inevitably meet a variety of 
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sulphur containing biomolecules before reaching this target. The major platinum-sulphur 
interactions inside and outside the cell are highlighted in Figure 4.2, some of which lead to 
“deactivation” of the platinum anti-cancer drug by preventing entry to the cell (exogenous) 
while others prevent interaction with the target DNA within the cell (endogenous).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: A summary of the major platinum-sulphur interactions inside (endogenous) and 
outside (exogenous) the cell.
2
 
 
Comparisons between the three FDA approved platinum anti-cancer drugs; cisplatin, 
carboplatin and oxaliplatin, have revealed vastly different reactivity with certain 
biomolecules. Cisplatin in water is about four and a half times more reactive towards 
methionine than carboplatin for instance, while the higher stability of the 1,2-
diaminocyclohexane (DACH)-platinum moiety in oxaliplatin leads to a reaction behaviour 
significantly different to that of the other two.
9,10
 
The formation of mixed-ligand adducts with biomolecules in the case of cisplatin and 
carboplatin is prevented in oxaliplatin due to the high stability of the Pt (II)-DACH moiety, 
Figure 4.3. However, methionine has a major influence on the binding behaviour of 
oxaliplatin and it has been suggested that the non-leaving group (DACH in the case of 
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oxaliplatin) (discussed in Chapter 1) may affect the formation and stability of platinum-
DNA adducts in the presence of methionine.
9,11
  
To further investigate this, Lippard et al on the solid-state (crystal) structure of the 
oxaliplatin-DNA adduct found hydrogen bonding between the pseudo-equatorial NH 
hydrogen atom of the DACH ligand, Figure 4.3, and the O6 atom of guanine at the site of 
platination. The investigators suggested that this feature of the structure shows the 
importance of chirality in the DACH ligand (the non-leaving group) of oxaliplatin despite 
any interactions with biomolecules such as methionine.
12
  
 
 
 
 
 
 
 
Figure 4.3: Carboplatin 404 and Oxaliplatin 405, both of which have vastly different 
reactivity with biomolecules in-vivo due to the 1,2-diaminocyclohexane ligand on 
Oxaliplatin.  
 
 As discussed in Chapter 1, cisplatin enters the cell from the blood via passive 
diffusion or through metal transporters, Figure 4.2. After hydrolysis the active species of 
cisplatin then enters the nuclear envelope and binds to DNA, which triggers apoptosis. 
However, biomolecules within the cell compete for cisplatin with DNA and have therefore 
been associated with increased inactivation and drug resistance (endogenous).
13,14
 
The most important non-DNA target of cisplatin has been identified as glutathione, as 
it is present in cells at high concentrations. In cell cytoplasm approximately 60% of cisplatin 
that has entered the cell is conjugated to glutathione, leaving only a small fraction to bind 
with target DNA. The glutathione in cells reacts with cisplatin to form a platinum-glutathione 
complex that is active in the inhibition of cell-free protein synthesis and can quench DNA-
platinum adducts before cross linking can occur.
15
  
 This interaction of glutathione with cisplatin reduces the amount of intracellular 
platinum available for interaction with DNA. Also, it has been proposed that the GS-X pump 
present on the cell membrane is active in the excretion of glutathione adducts from the cell 
due to cellular protection from “toxins”.16 
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  As highlighted in Chapter 1, platinum anti-cancer drugs also cause severe toxicity 
such as nephro- and neurotoxicity during chemotherapy, which have also been related to their 
interactions with exogenous sulphur continuing biomolecules such as glutathione. By 
forming adducts with the platinum anti-cancer complexes, protein bound thiol groups are 
depleted in renal cells and in respiratory enzymes particularly for cisplatin.
17,18
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: The proposed metabolism of cisplatin 406 with glutathione 403 to form the 
highly reactive thiol nephrotoxin 410.
19
 
 
Nephrotoxicity is one of the major toxicities induced by platinum anti-cancer drugs 
and starts with the formation of a platinum-glutathione complex within the cell. After the Pt-
GS adduct is transported out of the cell it undergoes cleavage into a highly reactive thiol (a 
nephrotoxin), Figure 4.4, which then binds to essential proteins.
19
  
The enzymes involved in the cleavage and shown in Figure 4.4 are, γ-glutamyl 
transpeptidase (GGT) which cleaves the Pt-GS adduct into 408, aminodipeptidase N which 
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forms the adduct 409 and Cys-S-conjugate β-lyase which cleaves the adduct into the highly 
reactive thiol nephrotoxin 410.
19
  
 
4.2.3 Sulphur biomolecules assisting the mechanism of action of Pt (II) drugs: 
 
 It has been proposed by a number of investigators that biomolecules can also cause 
opening of the 1,1-cyclobutanedicarboxylato (CBDCA) chelate ring in carboplatin, thus 
producing a reactive platinum fragment that could readily interact with DNA and protein 
targets in the cell.
7,8
 This therefore implies that carboplatin is in fact a prodrug, which, 
although not reactive in the body as it is, is activated by some substance in the biological 
system to form the reactive entity, Figure 4.4. However, although the biomolecules can 
activate the drug, they can also render the same drug inactive as outlined in Section 4.2.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: The reaction of carboplatin 411 with L (S)-methionine 402 in water at pH 7 to 
give the  monomethionine adduct 412 and eventually the chelate structure 413.
7
 
 
Sadler et al have used various NMR studies to show that carboplatin reacts in-vitro 
with the amino acid L-Methionine (Met), which is present in blood, to produce the 
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monomethionine adduct, cis-[Pt(CBDCA-O)(NH3)2(L-HMet-S) 412, Figure 4.4. This 
monoadduct, was found to be quite stable toward elimination of the CBDCA ligand. It is 
suggested that this stability is due to intramolecular hydrogen bonding, which prevents the 
CBDCA ligand from being completely displaced from the platinum.
7
  
However, eventually the CBDCA ligand is displaced to produce [Pt(L-Met-
S,N)(NH3)2] 413, Figure 4.4, which contains a methionine chelate. Due to the trans effect, 
discussed in detail in Chapter 2 and 3, entry of a sulphur atom into the coordination sphere 
of the platinum metal centre of carboplatin labilises the group that is trans to the sulphur i.e. 
ammonia. This allows the methionine chelate adduct [Pt(L-Met-S,N)(NH3)2] 412 to further 
react with nucleophiles, ultimately resulting in the loss of an ammonia molecule.
7
  
In a comparison with cisplatin Sadler et al have identified the presence of the CBDCA 
ligand in carboplatin as core to the dramatic difference in reactivity. In reactions with other 
sulphur containing biomolecules, such as N-acetyl-L-cysteine and L-glutathione, they have 
reported low reactivity towards carboplatin for these biomolecules.
7
 In addition to binding to 
amino acids and other small molecules, carboplatin also interacts with proteins in blood 
where some research groups have reported platinum-albumin and γ-globulin adducts in blood 
samples from carboplatin treated patients. Opening the chelate ring of carboplatin or 
removing it entirely results in platinum complexes that are much more toxic to cells than the 
intact drug.
20
  
 
 
 
 
 
 
Figure 4.5: A comparison of the leaving groups (highlighted in red) for carboplatin 411 and 
cisplatin 406. 
 
Other interesting aspects relating to the mechanism of action of carboplatin were 
identified by Overbeck et al and others who reported that carboplatin which aged in media 
containing chloride ions was much more toxic to E.Coli bacteria than freshly prepared 
aqueous solutions of the drug. It was found that cisplatin was present in the chloride-aged 
solutions of carboplatin which suggested that the antitumour effects of carboplatin could be 
in part due to the conversion of some of the drug to cisplatin.
21–23
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As seen for cisplatin, carboplatin also forms intrastrand DNA crosslinks as its primary 
mode of action towards cancer cells. However, various studies have found that the 
concentration of carboplatin required to reach a DNA-unwinding state comparable to that of 
cisplatin was about 100 times greater than that of cisplatin, meaning carboplatin is much less 
reactive towards DNA than cisplatin presumably because of the better leaving group(s) 
present on cisplatin, Figure 4.5.
24,25
  
Interestingly though, work by Holler et al showed that mixing carboplatin with 
purified calf thymus DNA in the presence of either methionine, glutathione or thiourea cause 
more platinum to be bound to DNA than if these sulphur-containing molecules were not 
present in the reaction medium. This indicates that sulphur nucleophiles could play an 
important role in activating carboplatin and allow the product to react with its primary 
cellular target; DNA as proposed by Sadler et al, Figure 4.4.
24
 Further work by Van Boom et 
al, in contrast to the investigations discussed in Section 4.2.2, has shown that the platinum 
adducts formed, which result in inactivation and increased toxic side-effects, due to the 
interactions of platinum anti-cancer drugs with sulphur based biomolecules, can in fact still 
coordinate to DNA, Figure 4.6.
26
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: The reaction of 5’-GMP (through the N7 position of guanine) with a platinum 
biomolecule adduct (S-methyl-glutathione GSMe) [Pt(dien)(GSMe)]
2+
 414 demonstrating the 
reversible nature of some platinum-GS adducts.
26
  
  
Monofunctional [Pt(dien)Cl]
-
 was chosen by Van Boom et al for their study as this 
species has only one leaving group, chloride, which therefore mimics the first binding step of 
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cisplatin to biomolecules. Also, amine release as a possible consequence of the trans-effect of 
S-donor ligands is avoided because of the stability of the dien chelate.
26
 The [Pt(dien)Cl]
-
 
complex is also similar to the structure of the complexes described in Chapter 2 and 3 
reported here by our research group, giving a good basis for comparison with the current 
work. Both structures feature a single chloride leaving group and stable tridentate chelate 
ligand, Figure 4.7. 
Previous work by Lempers et al into the reactivity of [Pt(dien)Cl]
-
 towards 
glutathione and S-methyl-glutathione found that there was no intermolecular substitution of 
GSMe by 5’-GMP at room temperature.27 However, ligand exchange reactions were found to 
occur successfully in later work by Van Boom et al at 37
o
C and pH 7, Figure 4.6.  
 
 
 
 
 
 
 
Figure 4.7: A comparison of the tridentate [Pt(dien)Cl]
-
 complex 416 used by Van Boom and 
Lempers et al and the complexes described by our research group Pt[η3-PNC-L1-4]Cl.  
 
Van Boom et al used 
1
H NMR spectroscopy to study the characteristic signals for N7 
coordination, previously reported by Reedijk et al, and found that substitution by 5’-GMP in 
[Pt(dien)(GSMe)]
2+
 414 was slow at ambient temperature but had a half-life of 31 hours at 
35
o
C. It is proposed that this intermolecular rearrangement supports the hypothesis of a drug 
reservoir mechanism for platinum anti-cancer drugs, Figure 4.8, particularly for mono-
adducts such as those described by our research group, Figure 4.7.  
A drug reservoir mechanism is similar to that previously discussed for carboplatin in 
which the platinum-sulphur adducts act as an intermediate for platinum binding to DNA. In-
vivo, such a mechanism could operate under circumstances that reduce the role of the 
aquation pathway usually found for cisplatin. A favourable orientation is likely to occur when 
proteins are located in close vicinity of, or even bind to DNA. Rearrangement is then possible 
where the platinum-sulphur adduct could react with the N7 position of guanine, Figure 4.8.
28
 
Earlier studies also by Van Boom et al on the competition in platinum binding 
between sulphur donor atoms and reactive nucleobases using S-guanosyl-L-homocysteine 
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(SGH) as a model compound, also revealed that the N7 position of guanine can replace a 
sulphur donor atom in a platinum-thioether adduct as well as those studied with 
gluthathione.
29,30
 
 
 
 
 
 
417           418 
 
 
 
 
Figure 4.8: Possible structures with a favourable orientation of the thioether function and 
the N7 of guanine in (417) DNA-binding proteins and (418) the cis-platinum cross-link with 
DNA and a protein.
26
  
 
 
4.2.4 Sulphur Biomolecules Assisting Pt (IV) Pro-drugs: 
 
 As discussed in detail in Chapter 1, the new third generation of platinum anti-cancer 
drugs, primarily Pt (IV), are pro-drugs where in-vivo they are reduced to their active Pt (II) 
analogue. The reducing agent employed to “activate” Pt (IV) drugs has been identified most 
often as glutathione, which can exchange with the axial ligands forming part of the octahedral 
structure of the Pt (IV) pro-drug.
31
  
The kinetic stability of the Pt (IV) axial ligand bonds in particular has been found to 
strongly influence the reactions and reduction potential of Pt (IV) complexes and, therefore, 
can be expected to exert an influence on their biological activity. The majority of Pt (IV) 
complexes studied as potential anti-cancer agents have either chloro or hydroxo ligands in the 
axial positions, with some newer drugs, such as satraplatin, having carboxylato ligands in 
these positions.
31,32
 
Extensive work by Hambley et al, Hall et al and others found that in the absence of 
glutathione, none of the Pt (IV) complexes caused complete inhibition of cancer cell lines 
tested, even up to high concentrations of the drug. It was also reported that the most readily 
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reduced complexes bind to DNA the most, while the least readily reduced complexes binds 
the least. Pt (IV) complexes that were incubated with glutathione prior to reacting with DNA 
however showed substantially increased inhibition over the glutathione-free 
experiments.
31,33,32,34,35
   
Previous work by our research group into the reduction of cyclometallated iodo Pt (II) 
iminophosphine complexes using sulphur based biomolecules has seen some success, Figure 
4.9. The Pt (IV) complexes were reacted with sulphur based biomolecules (glutathione and 
N-acetyl-L-cysteine) at 37
o
C and investigated for evidence of reduction at specific time 
periods over 48 hours.  
After 6 hours of incubation with glutathione the resulting solution contained 61 % of 
the Pt (II) reduced analogue, with only 9 % of the starting Pt (IV) complex remaining. 
Interestingly, there was also significant decomposition of the Pt (IV) complex and its ligands 
with a peak appearing in the aldehyde region of the 
1
H NMR and accounting for almost 30 % 
of the final solution after 6 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Proposed pathway for Pt (IV) iminophosphine reduction by sulphur containing 
biomolecules previously reported by our research group.
36
 
 
After 48 hours the major product found in the solution was the benzaldehyde 
decomposition product occupying 87 % (relative NMR intensities), while the Pt (II) reduced 
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analogue, 420, was present at 13%. There was no longer any evidence of the Pt (IV) complex, 
419, after 48 hours, indicating that it had all been reduced or suffered decomposition.
36
 
In summary our research group has previously identified that the use of thiolates like 
glutathione (GSH) and N-acetyl-L-cysteine (RSH) reduce Pt (IV) iodo complexes, 419, to 
their Pt (II) analogues, 420. However, further decomposition of the reduced Pt (II) species 
occurs via acid catalysed hydrolysis. Products formed include an aldehyde (proposed to be 
similar to the starting material for the synthesis of the ligand) and the insoluble P(O)N 2-
diphenylphosphinoaniline oxide, Figure 4.9.
36
  
 
4.3 In-Vitro Cell Testing of Cyclometallated Platinum Anti-Cancer Drugs: 
 
4.3.1 Monofunctional Complexes: 
 
 The development of second and third generation platinum anti-cancer drugs has been 
driven by the attempts to broaden the spectrum of activity, overcome resistance, and obviate 
toxic side effects. Over the past forty years some general principles emerged as a guide to the 
design of new bioactive platinum based anti-cancer therapeutics, and several successful 
platinum anti-cancer drugs were developed as a result of this and confirmed by in-vitro and 
in-vivo testing as outlined in Chapter 1.  
 
 
 
 
 
 
 
 
 
Figure 4.10: The structures of some complexes tested by Webster et al. The monofunctional 
complex 422 was found to be very active in-vitro and in-vivo. Cisplatin 406 is shown for 
comparison purposes.
37
   
 
The formation of bifunctional lesions upon the binding of cisplatin to DNA has been 
linked strongly to its activity and the vast majority of complexes tested to date have 
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bifunctional leaving groups as part of their structure. There has been much less success 
reported for monofunctional platinum complexes on the other hand, with many of those 
reported to date being charged which can cause issues with cell membrane permeability. 
However, interesting exceptions have been found for some small monofunctional 
platinum complexes, particularly in relation to a class of organoamidoplatinum (II) 
complexes complete with trans-amine ligands reported by Webster et al. These complexes 
were found to have excellent activity across in-vitro, cellular, and animal studies, and 
comparable in size and function to that of cisplatin, Figure 4.10.
37
  
Further reports by Edwards et al on neutral cyclometallated complexes have also seen 
success with their complexes acting as monofunctional DNA binding agents. The low 
chloride concentration of intracellular fluid leads to hydrolysis, which then forms a reactive 
cationic species ready to bind covalently to DNA.
38
  
 
 
 
 
 
 
 
 
Figure 4.11: Neutral monofunctional cyclometallated Pt (II) 423 and palladium (II) 424 
complexes reported as very active in-vitro with low IC50 values of circa 1.1 µmol/L 
 
As the complexes reported by Edwards et al are neutral and therefore are insoluble in 
water. Therefore ethanol, ethanol-dimethyl sulfoxide, or dimethyl sulfoxide was used to 
prepare the stock solutions and serial dilutions required for testing. The complexes in Figure 
4.11 have an IC50 comparable to that of cisplatin for the same cell lines of approximately 0.9 
µmol/L. They also found that the introduction of steric crowding around the metal ion with 
successive α-substituents on the pyridine ring, for example complex 423, leads to greatly 
enhanced cytotoxicity, 423, Figure 4.10.
38
  
They also noted that the presence of unidentate phosphorus donor ligands in general 
also greatly inhibited cell growth at low concentrations with some complexes showing IC50 
values approaching that of cisplatin, 424, Figure 4.11. The nature of the cyclometallated 
ligand also appears to be crucial for activity particularly if an intercalative mode of binding is 
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involved in the mechanism of action for these complexes. The increased surface area of the 
pyrazolylphenyl ligands along with the addition of methyl groups and an extra phenyl ring 
resulted in enhanced activity, confirming intercalation as part of the biological function of 
these complexes.
38
  
Further work by Edwards et al and Kodaka and co-workers into the biological activity 
of cyclometallated platinum complexes such as 423, Figure 4.12 have seen promising results 
in-vivo also. The platinum cyclometallates were tested against the P388 leukaemia cell line 
and found to have significant anti-cancer activity at relatively low doses comparable to the 
widely used anti-cancer agent 5-fluorouracil.
38,39
  
In other work by Kodaka et al it was found that similar sterically bulky platinum anti-
cancer drugs also showed activity against the cisplatin resistant mouse sarcoma 180 cell lines. 
This has since lead to further investigations into development of new sterically bulky 
platinum cyclometallated anti-cancer complexes. Interestingly, Edwards et al also reported 
that the palladium complex 424, Figure 4.11, despite being highly active in-vitro, showed no 
antitumour activity in-vivo and was found to be toxic at relatively low doses.
38,39
  
 
4.3.2 Tridentate Pt (II) Anti-cancer Drugs and Intercalation: 
 
 Over the past decade, intercalation of Pt (II) and (IV) complexes with DNA has 
gained significant traction as a biologically viable function for anti-cancer activity, 
particularly for complexes that employ one leaving group (monofunctional). Lippard et al 
pioneered studies on DNA-metallointercalators using square-planar d
8
 Pt (II) complexes, 
while Barton et al subsequently extended the scope to octahedral d
6
 metal complexes with 
aromatic diamine ligands.
40,41
 
Recently a number of research groups have reported various biologically active 
platinum complexes whose mechanism of action is proposed to be primarily intercalation into 
the strands of the DNA double helix structure.
42–44
  Frassineti et al have reported extensively 
on their complex, 425, Figure 4.12, which has shown antiproliferative activity towards both a 
cisplatin-sensitive human ovarian carcinoma cell line as well as its resistant counterpart. 
Ligand bulkiness and hydrophobicity of the substituents on the thiourea moiety were cited as 
important for increased biological activity.
44
  
As in most DNA-intercalating agents, DNA damage is promoted by the inhibition of 
topoisomerase II (topo II) activity, an enzyme with the role of maintaining the correct 
topological properties of DNA which is usually over expressed in cisplatin-resistant cells. 
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The concentration of Mg
2+
 ions is also an essential cofactor of topo II activity and it has been 
shown that decreased magnesium availability leads to the inhibition of topo II enzyme 
activity, resulting in cell growth arrest.
45
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: A biologically active DNA intercalating Pt (II) complex, 425.
44
 
 
Frassineti et al have shown that not only does compound 425 greatly accumulate into 
cells and intercalate into calf thymus DNA, but it also targets topo II activity which affects 
DNA integrity. It forms and stabilises a ternary drug-DNA-topo II complex. 
As discussed in Chapter 2, the presence of a strong platinum carbon bond(s) in a Pt 
(II) anti-cancer complex can also be beneficial for increased anti-cancer activity. It renders Pt 
(II) cyclometallated complexes to display enhanced stability against biological reduction and 
ligand exchange reactions. Tridentate chelate complexes offer further stability in the form of 
the chelate effect and recent work by Che et al on a range of bulky platinum cyclometallates 
has seen induced apoptosis in cancer cells through in-vitro and in-vivo testing, Figure 
4.13.
46,47
 
Che et al initially tested complex 426 with glutathione and found that ligand exchange 
only occurred for less than 5% of the complex, even after 72 hours. They report that the 
presence of bulky substituents around the metal centre prevents interaction of sulphur 
biomolecules with the platinum metal centre, therefore vastly reducing potential side effects 
of these complexes in-vivo.
47
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Figure 4.13: Bulky cationic monofunctional cyclometallated Pt (II) complexes reported as 
being very active in-vitro and in-vivo with low IC50 values of circa 0.49 µmol/L.
47
 
 
 The in-vitro studies were carried out on human cancer cell lines of cervical epithelioid 
carcinoma (HeLa), hepatocellular carcinoma (HepG2), and nasopharyngeal carcinoma, and a 
normal cell derived human lung fibroblast cell line (CCD-19Lu). IC50 values for compound 
426 in particular was found to be between 0.057 to 0.77 µM, which is significantly less than 
the IC50 values for cisplatin on the same cell lines ( between 2.4 and 15 µM). Most of the 
complexes tested were found to be more cytotoxic than cisplatin with up to 300 fold increases 
in potency found for the HeLa cell line.
47
  
 Compound 426 was later carried forward for in-vivo testing where it was found that 
the drug significantly inhibited the growth of NCH-H460 non-small cell lung carcinoma cells 
by over 55% at 30 mg kg
-1
. It was also noted that the mice did not die during the treatment 
and regular body weight measurement of the mice showed no significant weight loss.
47
  
DNA binding studies of compound 426 with calf-thymus DNA in cell free conditions 
also revealed that intercalation is the primary interaction the drug has with the double 
stranded biomolecule. It was also found that this complex preferentially accumulates in the 
cytoplasmic structure of the cells instead of covalently binding to DNA. Che et al cite the 
strongly coordinating tridentate structure and platinum carbon bond as responsible for the 
stability of these Pt (II) complexes towards glutathione reduction/substitution within the 
cell.
47
  
As well as antitumoral properties, tridentate cyclometallated platinum complexes have 
also shown promise as antiparasitics and antibacterial agents. Work by Smith et al on 
cycloplatinated thiosemicarbazones, Figure 4.14, have revealed significant antitumour 
activity in-vitro for these compounds. The complexes in Figure 4.14 were evaluated against 
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the cisplatin sensitive and cisplatin resistant ovarian cell lines, A2780 and A2780cisR 
respectively.
48
   
 
 
 
 
 
 
 
 
 
Figure 4.14: Tridentate cyclometallated Pt (II) complexes reported as being very active in-
vitro for antitumour and antiparasitic activity.
48
  
 
 While none of the compounds tested showed activity comparable to that of cisplatin 
against the cisplatin sensitive cell line (A2780), they did however give markedly better results 
than cisplatin for the cisplatin resistant cell line (A2780cisR) suggesting perhaps that they 
have a different mechanism of action to cisplatin. As well as antitumour activity these 
complexes also show moderate antiparasitic activity in-vitro against Plasmodium falciparum 
strains, D10 (chloroguine sensitive), Dd2 (chloroquine-resistant), and the parasite 
Trichomonas vaginalis.
48
  
 It was found that the presence of triphenylphosphine as the ancillary ligand gave the 
complex better activity as an antiparasitic. Although none of the compounds tested gave 
activities comparable to that of chloroquine, some of the complexes showed significant 
percentage inhibition of up to 93%, which is very close to the current FDA approved drug; 
Metronidazole, which exhibits 100% inhibition at the same concentration. Furthermore it was 
again found that the presence of an aromatic ring enhanced the cytotoxicity of these 
complexes in comparison to the clinical drugs cisplatin and carboplatin.
48
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4.4 Photophysical Studies of Platinum Complexes and Mixed Donor Ligands: 
 
4.4.1 Factors Influencing Luminescence of Pt (II) Complexes: 
 
 Around 30 years ago, much of the research into platinum coordination chemistry 
orientated around the unprecedented success of cisplatin and its activity towards cancer cells. 
However, a small number of simple Pt (II) compounds were beginning to emerge with 
photoluminescent properties at low temperatures or in solid state.  In Chapter 1 we discussed 
platinum complex luminescence in detail, as well as the background to luminescence itself. 
Here we are discussing some of the factors influencing luminescent platinum compounds, 
their applications and recent advances in the area that may be relevant to current work.  
 Over the past decade studies on the factors that influence the efficiencies of Pt (II) 
complexes have been spurred on by the potential application of triplet-emitting metal 
complexes as phosphors in organic light-emitting devices (OLEDs). These devices are 
proposed to have the ability to trap otherwise wasted triplet states, which can lead to large 
gains in efficiency.
49
  
 Many luminescent active Pt (II) complexes reported to date consist of bidentate 
diimine ligands such as bipyridine or phenanthroline and the emission depends significantly 
on concentration and solvent choice, Figure 4.15. Compound 430 for instance displays green 
emission in dilute dichloromethane (10
-5
 M), however, red emission becomes the dominant 
band at higher concentrations at the expense of the green band, but the complex retains an 
identical excitation spectra.
50
  
 
 
 
 
 
 
 
 
 
Figure 4.15: Luminescent Pt (II) complex with the ability to switch its colour of emission in 
dilute dichloromethane 430, and a complex which is solvent dependant for excimer emission 
431.
50,51
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Kato et al have also found a solvent dependence, as well as concentration 
dependence, for the type of emission of Pt (II) complexes such as compound 431. In polar 
solvents such as methanol and acetonitrile, exclusively monomer emission is observed over a 
wide concentration range (10
-5
 to 10
-3
 M). However, over the same concentration range in 
chloroform, the emission switches from monomer to excimer and in toluene the excimer is 
observed even at very dilute concentrations of 10
-5
 M (excimer emission generally only 
happens in concentrated solutions).
51
  
When the electrons in a molecule are excited from the HOMO to the LUMO, it forms 
a monomer and can emit the energy absorbed as light when the electron(s) return to the 
ground state. If a monomer meets either a ground state molecule or another monomer they 
can form an excimer. An excimer
 
(short for excited dimer) is a short-lived dimeric or 
heterodimeric molecule formed from two species where at least one of which has a 
completely filled valence shell. It usually involves the formation of a molecule that is only 
possible in an excited state, as a bond is formed between atoms that don’t normally bind in 
the ground state. The lifetime of an excimer is very short, generally in the order of 
nanoseconds. However, binding of a larger number of excited atoms can increase the lifetime 
of an excimer emission to many seconds.
52
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Luminescent Pt (II) complexes with platinum carbon bonds, 432 and 433. The 
complex 434 is not luminescent however due to the methyl groups present.
53,54
  
 
It is proposed that the reorganisation of the molecules in Figure 4.16 to form the 
excimer is favoured by solvents of low polarity. As discussed in Chapter 1, slight structural 
differences in the complex can also play an important role in the potential luminescence of Pt 
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(II) complexes. Platinum carbon complexes and cyclometallated compounds (discussed in 
Chapter 1) have recently gained significant promise as variable emitters.
55–58
  
 Work by Dungey et al has seen the bis-mesityl complex 432, Figure 4.16 emit in a 
toluene solution at room temperature where the strongly σ-donating aryl groups serve to 
lower the energy of the excited state.
53
 Nishida and coworkers have also found emission from 
a similar complex where the hydrogens on the aryl rings have been replaced by fluorine, 433, 
Figure 4.16. Emission was however substantially shifted towards the blue region instead due 
to the electron withdrawing effects of the fluorine substitutions.
54
  
Interestingly though, no emission was found to occur by Nishida et al for complex 
434, despite the strong emission found for its analogue 433. The incorporation of methyl 
substituents at the 2 and 9 position of the dpphen ligand resulted in slightly longer Pt-N bonds 
due to the steric hindrance caused by the two groups.
54
 The solid state X-ray structure also 
revealed that this structure is “bent” more dramatically out of the plane in comparison to its 
analogue 433, resulting in reduced rigidity which is unfavourable for luminescence. Both the 
reduced rigidity and the increase of the Pt-N bond lengths promote unwanted non-radiative 
decay.
54
 
 
4.4.2 Luminescence of Small Organic Molecules (Ligands): 
 
 Organic LED’s are of immense interest to various industries because of their mixed 
properties, versatility and inexpensive nature. They are generally thin, emit in the visible 
region, rugged and very power efficient. They generally consist of a thin sandwich of one or 
more specially designed organic molecules between two electrodes.  
One electrode must be transparent to let the light out and a battery voltage across the 
electrodes generates holes and electrons in the respective layers which upon recombination 
emit energy in the form of light. The color (energy) of the light depends upon the choice of 
the organic molecule and can be tuned using well-defined organic synthetic methods.
59
  
 Usually the organic molecule used is polymeric in nature and incorporates into a 
single functional group such as sulphur or nitrogen. Some research groups however have 
found success with mixed phosphorus and nitrogen type functional groups within the 
polymeric structure, Figure 4.17, including those with imines and phosphines.
59,60
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Figure 4.17: Mixed phosphorus and nitrogen type luminescent organic polymers.
59
  
 
Recently, work by a number of research groups into small conjugated organic 
luminescent molecules has also seen banana’s of success with nitrogen and phosphorus donor 
type ligands. Though blue-, green-, and red-emitting materials are all needed for OLED 
applications, currently the development of deep-blue emitters with good stability and high 
luminescence efficiency is deemed most critical in effectively reducing the power 
consumption of OLEDS and generating emission of different colors (including white 
light).
61–63
 
 
 
 
 
 
 
 
 
Figure 4.18: Examples of blue band emitting luminescent complexes via Excited State 
Intramolecular Proton Transfer (ESIPT).
63,62
  
 
Organic molecules exhibiting Excited State Intramolecular Proton Transfer (ESIPT) 
processes have also been reported by a number of research groups with structures similar to 
compound 436, Figure 4.18.
63,64
 Sanghyuk and coworkers in particular have reported a novel 
class of blue-light emitting imidazole-based ESIPT molecules with hydroxyl-substituted 
tetraphenylimidazole (HPI) and its acetylated derivative HPI-Ac ligands, 437 Figure 4.18.
62
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Figure 4.19: Schematic representation of the ESIPT photocycle reported for small 
luminescent molecules.
62
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: The photophysical and photochemical processes of a phototautomerizable 
quinoline unit resulting in blue band emission.
64
 
 
These compounds readily form large single crystals exhibiting intense blue 
fluorescence at 460 nm and low-threshold amplified spontaneous emission (ASE). The steric 
crowding of the four phenyl groups substituted into the imidazole ring limit the excessive 
tight-stacking responsible for intermolecular vibrational coupling and relevant non-radiative 
relaxation, resulting in strong fluorescence emission in the crystal state, Figure 4.19 and 
Figure 4.20.
62
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4.5 Summary and Conclusions: 
 
From the literature reviewed it is clear that sulphur based biomolecules are integral to 
the biological activity of Pt (II) and (IV) anti-cancer complexes. It has been found that in 
particular methionine and glutathione play an important role in helping the biological activity 
of currently approved Pt (II) drugs such as carboplatin. However, it has also been noted by a 
number of research groups that glutathione also deactivates Pt (II) drugs and in some cases 
even cause a decrease in cellular accumulation due to efflux of the platinum-glutathione 
adduct out of the cell.  
In the case of the Pt (IV) anti-cancer complexes studied by our research group and 
others, glutathione was seen as essential for reduction of the complex to its active Pt (II) 
analogue in-vivo. It was found that without reduction to the Pt (II) analogue, the Pt (IV) 
complexes have very little or no activity towards cancer cells. Therefore it was seen that 
glutathione and other sulphur biomolecules are necessary for these pro-drugs to be 
biologically active.  
Successful in-vitro cell testing has been reported for various Pt (II) neutral complexes 
even though water proved to be an unsuitable solvent for preparation of the stock solutions. 
Therefore, preparation and serial dilutions of a number of compounds were carried out in 
ethanol, ethanol-dimethyl sulfoxide, or dimethyl sulfoxide. These compounds were found to 
have biological functionality comparable to that of cisplatin in some cases. Successful in-
vitro cell testing used cisplatin as the control to compare IC50 values and overall activity.  
The vast majority of approved platinum anti-cancer drugs are bifunctional, i.e. they 
have two leaving groups; which are chlorides in the case of cisplatin. However, 
monofunctional complexes, i.e. those that employ one leaving group, have recently also been 
reported capable of biological functionality via intercalation of the Pt (II) and (IV) complexes 
with DNA. Flat planar structures with multiple aryl rings have proven to have biological 
activity comparable to that of cisplatin but employ more stable molecular structures ensuring 
longer survival in-vivo. 
The potential application of triplet-emitting metal complexes as phosphors in organic 
light-emitting devices (OLEDs) has spurred extensive research into possible Pt (II) 
luminescent complexes. These devices are proposed to have the ability to trap otherwise 
wasted triplet states, which can lead to large gains in efficiency 
It has been reported that rigid platinum complexes with nitrogen donor moieties and 
organometallic bonds can successful emit light across a range of light bands. However, even 
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slight differences in the complex structure can prevent luminescence even in analogues of 
very successful luminescent complexes.  
Until recently, the use of ligands containing donor moieties such as nitrogen and 
phosphorus was dominated by research into new polymeric compounds for organic LEDs. 
However, in the past decade researchers have found extensive success with small organic 
molecules as blue-band emitters via Excited State Intramolecular Proton Transfer (ESIPT) 
where tautomerism from a keto form to an enol form can facilitate potential luminescence.  
 
4.6 Synthesis of Cyclometallated Pt (II) Bio-Adducts: 
 
All the starting materials used in this chapter are prepared as per the procedures 
outlined for the ligands, platinum complexes, substitution products and oxidation products in 
Chapter 2 and 3. Only the Pt (II) iminophosphine cyclometallates 281 and 284 (3-H and 2,3-
(OMe)2) were used for biological studies towards sulphur containing biomolecules and in-
vitro cell testing due to their superior yields, solubility and stability over all other compounds 
reported. Both complexes were purified by re-crystallisation and characterised by NMR and 
IR spectroscopy along with elemental analysis prior to all biological studies to ensure no 
impurities were present.  
The ligand HL
1
 261 and the complexes derived from it, reported in Chapter 2 and 3, 
were also the subject of UV visible and luminescent studies to investigate their photophysical 
properties.  
 
4.6.1 Synthesis of the Pt (II) N-acetyl-L-cysteine bio-adducts of the general formula 
[Pt(η3-PNC-L1/4)N-Acetyl-L-Cys] 440-441: 
 
The synthetic method utilised for reactions with N-acetyl-L-cysteine is a variation of 
the procedure outlined previously in Chapter 3 for the triphenylphosphine (PPh3) 
substitution reactions involving the Pt (II) cyclometallates 281-284.
65
 Previous reports by this 
research group into the reactivity of iodo Pt (II) cyclometallates with biomolecules also used 
a variation of this procedure (90:10 chloroform:methanol mixture).
36
  
Non-mixed solvent systems consisting of just chloroform or just methanol proved to 
be unsuccessful, as did aqueous systems due to the insolubility of the platinum complexes in 
water and the biomolecules being insoluble in chloroform. Therefore a 1:1 mixture of dry 
methanol:chloroform was found to be an ideal solvent system for dissolving both the Pt (II) 
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complex and the biomolecule compound. A methanolic solution of N-acetyl-L-cysteine was 
added dropwise to a stirred solution of the iminophosphine cycloplatinated complexes 281 
and 284 in a 1:1 methanol:chloroform solvent system over one hour.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Formation of the Pt (II) iminophosphine biomolecule adducts with N-acetyl-L-
cysteine to form 440-441. 
 
The solution immediately changed from orange to a dark red colour on addition of the 
N-acetyl-L-cysteine. After 20 hours it became a pale yellow colour and TLC analysis 
confirmed that the platinum (II) starting material was no longer present. The reaction mixture 
was then reduced to dryness in vacuo and then taken up in dichloromethane (where it again 
turned dark red) and washed once with a small portion of distilled water to remove any 
remaining N-acetyl-L-cysteine and HCl formed during the reaction. The organic layer was 
dried over MgSO4, reduced to dryness in vacuo again and the resulting dark red solution was 
crystallised from distilled methanol layered with hexane to form the neutral Pt (II) N-acetyl-
L-cysteine bio-adducts 440-441, Figure 4.21. 
 
Bio-Adduct Precursor Physical appearance  % Yield 
440 281 Dark red powder 78 
441 284 Dark red powder 85 
 
Table 4.1: Yields and appearances for the iminophosphine Pt (II) N-acetyl-L-cysteine bio-
adducts 440 and 441. 
 
The reaction gave good yields, however increasing the temperature to 37
o
C had little 
or no impact on the final yield. Interestingly, however, it was found that the final platinum 
bio-adducts 440-441 were slightly water soluble with some of the yield being lost to the 
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water layer during the washing procedure to remove the remaining N-acetyl-L-cysteine. This 
was confirmed by TLC analysis of the water layer after the washing.  
The importance of stabilisation of the displaced anion, chloride, by the solvent 
system, like that reported previously in Chapter 3 for the triphenylphosphine substitutions, 
was again identified here. The proposed mechanism for the reaction of these platinum 
complexes with biomolecules therefore involves the direct displacement of the chloride 
moiety owing to the stronger Pt-S (soft acid-soft base) interaction formed with the newly 
introduced N-acetyl-L-cysteine (or L-glutathione in Section 4.6.2) over that of the weaker Pt-
Cl (soft acid-hard base) bond, coupled with solvent assisted stabilisation of the liberated 
chloride as discussed in Chapter 3. A summary of the complexes synthesised, their yields 
and physical appearances, are displayed in Table 4.1. 
These complexes were characterised and their identities confirmed by IR and NMR 
spectroscopy as well as elemental analysis which are all consistent with the proposed 
structure of these compounds and compare well with previously reported analogous 
complexes.
66
 It was noted, however, that unlike previous work with PNC and PNO type 
complexes by our research group, both Pt (II) N-acetyl-L-cysteine bio-adducts 440-441 are 
air and light sensitive. The solid form decays and changes colour from dark red to 
yellow/orange over 16 hours in sunlight and over 48 hours without sunlight. In a solution of 
dimethylsulfoxide this is roughly increased to 20 hours in sunlight and 72 hours without 
sunlight.  
After this time there is no longer any evidence for the Pt (II) bio adduct or its Pt (II) 
starting material. No identifiable decomposition products, like an aldehyde peak, have been 
identified from these reactions, implying formation of alternative products.  
Photo decomposition has been reported previously for other sulphur based Pt (II) 
complexes and is proposed to consist of a photo-oxidation process.
67
 Although the resulting 
products are currently unidentifiable at this time for the N-acetyl-L-cysteine Pt (II) bio-
adducts 440-441, having photo sensitive properties may also have positive implications for 
uses in photo-dynamic therapy (PDT) if the products formed have greater cytotoxicity over 
the platinum bio-adducts, as discussed in Chapter 1. However, further research into the 
mechanisms employed here and products formed are required to better understand the 
process.  
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4.6.2 Synthesis of the Pt (II) L-glutathione bio-adducts of the general formula [Pt(η3-
PNC-L
1/4
)Glu] 442-443: 
 
The synthetic method utilised for reactions with L-glutathione is also a variation of 
the procedure outlined previously in Chapter 3 for the triphenylphosphine (PPh3) 
substitution reactions involving the Pt (II) cyclometallates 281-284, and is similar to that used 
to that used in Section 4.6.1 for N-acetyl-L-cysteine.
65
  
A 1:1 mixture of dry methanol:chloroform was again found to be an ideal solvent 
system for dissolving both the Pt (II) complex and the biomolecule compound since an 
aqueous system could not be employed due to the neutral nature of the Pt (II) complexes. A 
methanolic solution of L-glutathione was added dropwise to a stirred solution of the 
iminophosphine cycloplatinated complexes 281 and 284 in a 1:1 methanol:chloroform 
solvent system over one hour.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: Formation of the Pt (II) iminophosphine biomolecule adducts with L-
glutathione to form 442-443. 
 
The solution immediately changed from orange to a dark red colour on addition of the 
L-glutathione. After 48 hours it became a pale yellow colour and completion was confirmed 
by TLC analysis. The reaction mixture was then reduced to dryness in vacuo and taken up in 
dichloromethane (where it again turned dark red) and washed once with a small portion of 
distilled water to remove any remaining L-glutathione and HCl formed during the reaction. 
The organic layer was dried over MgSO4, reduced to dryness in vacuo again and the resulting 
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dark red solution was crystallised from distilled methanol layered with hexane to form the 
neutral Pt (II) L-glutathione bio-adducts 442-443, Figure 4.22. 
Like that found for the N-acetyl-L-cysteine, increasing the temperature to 37
o
C had 
little or no impact on the final yield of the reaction with L-glutathione, however, reaction 
time was decreased to circa 36 hours. Also it was found again here that the final platinum 
bio-adducts 442-443 were quite water soluble with some of the yield being lost to the water 
layer during the washing procedure. It was also found that these adducts were much more 
water soluble in comparison to the N-acetyl-L-cysteine Pt (II) adducts, Section 4.6.1. This 
was confirmed by TLC analysis of the water layer after the washing. A summary of the 
complexes synthesised, their yields and physical appearances, are displayed in Table 4.2. 
 
Bio-Adduct Precursor Physical appearance  % Yield 
442 281 Dark red powder 72 
443 284 Dark red powder 77 
 
Table 4.2: Yields and appearances for the iminophosphine Pt (II) L-glutathione bio-adducts 
442 and 443. 
 
These complexes were characterised and confirmed by IR and NMR spectroscopy as 
well as elemental analysis which are all consistent with the proposed structure of these 
compounds. It was also found that both Pt (II) L-glutathione bio-adducts are air and light 
sensitive, unlike previous work by our research group with chloro PNO type complexes.
68
 
Both the solid form and dimethylsulfoxide solution decay from dark red to yellow/orange 
over 6 hours in sunlight and over 24 hours without sunlight. This represents a shorter reaction 
time in comparison to the Pt (II) N-acetyl-L-cysteine bio-adducts.  
After this time there is no longer evidence for the Pt (II) L-glutathione bio adduct or 
its Pt (II) starting material. Like that found for N-acetyl-L-cysteine no identifiable 
decomposition products have been identified from these reactions, although having photo 
sensitive properties may have positive implications for possible uses in photo-dynamic 
therapy (PDT) as discussed in Chapter 1. Of interest for this platinum bio-adduct also is its 
increased water solubility over the Pt (II) N-acetyl-L-cysteine bio-adduct, which is hugely 
beneficial for biological applications in terms of administration as an anti-cancer drug.  
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4.6.3 Other reactions involving biomolecules and platinum complexes: 
 
Some reactions with the other cyclometallated iminophosphine Pt (II) complexes 282-
283 and the Pt (II) phosphinoamides 286-288 as well as the bidentate iminophosphine 
complexes 271-273 were attempted. Reactions were found to occur however characterisation 
is currently inconclusive due to solubility issues and the formation of a complicated mixture 
of products. 
The PNO complex 285 was also reacted with L-Glutathione but it was found that after 
24 hours stirring at room temperature, the Pt (II) starting material was recovered. However, it 
was returned in a low yield of circa 40%, along with an unidentifiable yellow solid. However, 
there was no evidence of a platinum bio-adduct from IR or NMR studies and the products 
formed are insoluble in a variety of solvents, Figure 4.23.  
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Proposed pathway for the reaction of Pt (II) PNO iminophosphine complex with 
L-glutathione, which was unsuccessful. 
 
 It is proposed that the steric crowding around the metal centre caused by the oxygen 
moiety of the iminophosphine ligand reduces possible interaction of the PNO complex, 285, 
with L-glutathione. However, when the PNO complex was reacted with N-acetyl-L-cysteine 
a reaction did occur with no Pt (II) starting material remaining after 24 hours. The Pt (II) N-
acetyl-L-cysteine bio-adduct could not be characterised however as the product formed was 
insoluble. 
The iminophosphine Pt (IV) complexes 381-384 reported in Chapter 3 were also 
reacted with L-glutathione with the objective of inducing biological reduction of the 
octahedral Pt (IV) structures to their Pt (II) square-planar analogues, Figure 4.24. Previously 
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within our research group successful reduction was observed for the analogous Pt (IV) iodo 
complexes where after 24 hours reduction to the Pt (II) analogue was observed.
36
  
 
  
 
 
 
 
 
 
 
 
Figure 4.24: Proposed pathway for the reaction of the Pt (IV) iminophosphine complexes 
381-384 with L-glutathione, which remains inconclusive. 
 
The Pt (IV) complexes 381-384 were stirred with L-glutathione in a 1:1 
methanol:chloroform solvent system for circa 16 hours. However, unlike previous reports by 
our research group, there was no evidence of reduction of the Pt (IV) complexes observed by 
NMR or IR. Currently, characterisation of the final products remains inconclusive with only 
some of the Pt (IV) starting material identified in the final products by 
1
H NMR. 
Decomposition was also identified by 
1
H NMR with the appearance of an aldehyde peak after 
extended reaction times of 48 hours. Further work is required for these reactions in order to 
better understand the mechanisms employed and obtain any potential reduction products.  
 
4.6.4 Infra-red spectroscopic studies of the platinum bio-adducts [Pt(η3-PNC-
L
1
/
4
)Glu/NaLCys]: 
 
Like that seen for the complexes reported in Chapter 2 and 3, one of the most 
informative peaks in the IR spectra of the platinum bio-adducts is the imine stretching band, 
υ(C=N) at circa 1600cm-1. A comparison of the stretching frequencies of the parent 
complexes 281 and 284 with their analogous platinum bio-adducts 441-443 are contained in 
Table 4.3, along with the stretching frequencies of the free iminophosphine ligands HL
1-4
 
261-264. 
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Free 
Ligands 
υ(C=N) 
cm
-1
 
Parent 
complex 
υ(C=N) 
cm
-1
 
Platinum 
Bio-adducts 
υ(C=N) 
cm
-1
 
HL
1
 261 1626 281 1585 440 1586 
HL
4
 264 1615 284 1578 441 1600 
HL
1
 261 1626 281 1585 442 1590 
HL
4
 264 1615 284 1578 443 1602 
 
Table 4.3: IR data comparing the υ(C=N) of the platinum bio-adducts 440-443 with their 
parent complexes 281-285 and their free ligands 261-264. 
 
On substitution of the iminophosphine chloro complexes by N-acetyl-L-cysteine and 
L-glutathione, we see a slight increase observed for the υ(C=N) stretching frequency in the Pt 
(II) bio-adducts 440-443. This increase is also slightly larger than that previously found for 
the triphenylphosphine (PPh3) substituted complexes reported in Chapter 3, 371-375 by circa 
10 cm
-1
. This indicates a strengthening of, and hence shortening of, the imine C=N bond, but 
also weakening of the Pt-N bond due to lengthening in order to accommodate the large 
biomolecule trans to the nitrogen donor moiety. This is primarily due to the strong trans 
effect, as discussed in Chapter 3, exerted by the new biomolecule ligand introduced trans to 
this coordination bond.  
Steric effects of the newly introduced biomolecule on the Pt (II) complex can also 
exert a significant influence on the bond trans to the Pt-S bond and therefore could also be a 
factor here. These trends mirror those obtained previously by our research group for the 
analogous iodo Pt (II) cyclometallated bio-adducts.
36
 
Other stretching frequencies corresponding to the newly introduced biomolecule were 
also observed and compared to an IR spectrum obtained for N-acetyl-L-cysteine and L-
glutathione prior to reaction with the platinum complexes. A shift was observed 
corresponding to the ν(C=O) stretching frequency in the Pt (II) N-acetyl-L-cysteine bio-
adduct at 1728 cm
-1
, which represents a slight increase from 1717 cm
-1
 observed in the free 
N-acetyl-L-cysteine.  
This was also observed for the Pt (II) L-glutathione bio-adduct where a ν(C=O) 
stretching frequency was found at 1726 cm
-1
, which is again an increase from 1713 cm
-1
 
found for the free L-glutathione biomolecule. In addition to that, ν(O-H) stretching 
frequencies were also found for all Pt (II) bio-adducts and the free biomolecules at circa 3415 
cm
-1
 as well as extra ν(C=C) stretching frequencies at circa 1440 cm-1.  
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The most significant stretching frequency in relation to the biomolecules, however, is 
ν(S-H), observed at 2548 cm-1 for the free N-acetyl-L-cysteine biomolecule and 2525 cm-1 for 
the free L-glutathione biomolecule. For the platinum bio-adducts this stretching frequency is 
not observed in the IR spectra, indicating successful coordination of the sulphur biomolecules 
to the metal centre due to the loss of the hydrogen from the sulphur group to form HCl with 
the chloride from the platinum complex.  
 
4.6.5 NMR spectroscopic studies for the platinum bio-adducts Pt(η3-PNC-
L
1
/
4
)Glu/NaLCys]: 
 
Complex 
 δ (H-C=N) δ (H-Ar) δ (R=OCH3) δ (CH3,CH2, CH) δ (
31
P{
1
H}) 
3-H  
440 
9.68 (1H, s) 
3
JPt-H = 91 Hz 
7.22-7.98 
(18H, m) 
- 1.92 (3 H, s) 
2.90-3.41 (2 H, m) 
4.32 (1 H, s) 
31.4 (s) 
1
JPt-P = 2184 Hz 
2,3-(OMe)2  
441 
9.94 (1 H, s) 
3
JPt-H = 96 Hz 
7.19-7.96 
(16 H, m) 
3.87 (3 H, s) 
4.01 (3 H, s) 
1.93 (3 H, s) 
2.96-3.31 (2 H, m) 
4.10 (1 H, s) 
31.1 (s) 
1
JPt-P = 2195 Hz 
3-H  
442 
10.19 (1H, s) 
3
JPt-H = 84 Hz 
7.37-8.24 
(18H, m) 
- 1.75-1.87 (2 H, m) 
2.05-2.98 (6 H, m) 
4.10-4.16 (2 H, m) 
31.4 (s) 
1
JPt-P = 2188 Hz 
2,3-(OMe)2  
443 
10.51 (1 H, s) 
3
JPt-H = 86 Hz 
7.41-8.27 
(16 H, m) 
3.98 (3 H, s) 
4.05 (3 H, s) 
1.25-2.18 (4 H, m) 
2.20-3.58 (4 H, m) 
4.63-4.67 (2 H, m) 
32.2 (s) 
1
JPt-P = 2198 Hz 
10. Chemical shift values (δ) are expressed in ppm relative to the TMS standard for 1H and H3PO4 
for 
31
P. 
11. s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet.  
12. Coupling constants (J) are measured in Hz 
Table 4.5: The 
1
H and 
31
P{
1
H} NMR spectra
1, 2, 3
 recorded for the iminophosphine Pt (II) bio-
adducts 440-443. All ran in DMSO-d6 at 300 MHz for 
1
H NMR and 121.5 Hz for 
31
P{
1
H} 
NMR. 
The 
1
H and 
31
P{
1
H} NMR data of the platinum bio-adduct complexes 440-443 are 
summarised in Table 4.5. All of the complexes display the characteristic single resonance 
Chapter 4  Biological Activity & Photophysical Studies 
 
Page | 290 
 
integrating for 1H in the azomethine region of the 
1
H NMR spectra, as well as extra signals 
for the newly introduced ligands (N-acetyl-L-cysteine and L-glutathione).  
There is a downfield shift found for these azomethine resonances of between δ 0.22 
and 0.79 ppm, which is a smaller shift than that found for the triphenylphosphine substituted 
Pt (II) complexes reported in Chapter 3 (circa δ 1.20 ppm). Like that found for the parent Pt 
(II) complexes 281-285 and PPh3 substituted complexes 371-375, on donation of the lone pair 
of electrons from the imino-nitrogen moiety into the metal centre, electron density is pulled 
towards the metal-donor coordination bond (Pt-N), weakening the H-C=N bonds.  
The observed downfield shift in the NMR spectra correlates with this reduction in 
bond strength also seen in the IR data for these complexes, Section 4.6.4. The shifts for these 
complexes are also consistent with previously obtained results by our research group and 
others for analogous complexes.
36
 These shifts indicate successful coordination of the sulphur 
moiety of N-acetyl-L-cysteine and L-glutathione to the metal centre. A comparison of the 
azomethine shifts for the Pt (II) bio-adducts 440-443 and their respective parent Pt (II) chloro 
complexes 281 and 284 is shown below in Table 4.6. 
 
Pt (II) parent 
complex 
δ(H-C=N) 
ppm 
Pt (II) 
Bio-adducts 
δ(H-C=N) 
ppm 
Δδ 
ppm 
3-H 281 9.40 (1H, s) 
3
JPt-H = 123 Hz 
440 9.68 (1H, s) 
3
JPt-H = 91 Hz 
0.28 
2,3-(OMe)2 284 9.72 
3
JPt-H = 126 Hz 
441 9.94 (1 H, s) 
3
JPt-H = 96 Hz 
0.22 
3-H 281 9.40 
3
JPt-H = 123 Hz 
442 10.19 (1H, s) 
3
JPt-H = 84 Hz 
0.79 
2,3-(OMe)2 284 9.72 
3
JPt-H = 126 Hz 
443 10.51 (1 H, s) 
3
JPt-H = 86 Hz 
0.78 
Table 4.6: Comparison of the 
1
H azomethine signals between the parent complexes 281 and 
284 with that recorded for the Pt (II) bio-adducts 440-443. 
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Figure 4.25: Comparison of the 
1
H azomethine signal spectra for the parent cyclometallated 
Pt (II) complex 284 (left) and the N-acetyl-L-cysteine Pt (II) bio-adduct 441 (right). 
 
The azomethine signals for the Pt (II) bio-adducts are displayed as a singlet resonance 
complete with 
195
Pt satellites and a 
3
JPt-H coupling of ca. 84-96 Hz, Figure 4.25. Compared to 
the parent Pt (II) complexes there is a reduced coupling constant for 
3
JPt-H  observed due to the 
strong trans effect and decreased electrophilicity of the Pt (II) metal centre due to successful 
coordination of the electron-rich sulphur biomolecule, Table 4.6.  The coupling constants of 
84-96 Hz found here are quite similar to those found for the PPh3 substituted complexes 
reported in Chapter 3, which were found to be between 86 and 88 Hz.  
The 
1
H NMR spectra of the dimethoxy Pt (II) bio-adducts 441 and 443 (Figure 4.26) 
also display two singlet resonances at circa δ 3.87 and δ 4.01 ppm respectively. Like the 
parent Pt (II) complexes and PPh3 substituted complexes these correspond to the two electron 
donating methoxy (-OCH3) substituents present at the C-3 and C-2 position of the lower aryl 
ring and integrate for 3 hydrogens each. This also represents a slight shift downfield in 
comparison with the parent Pt (II) complex 284 and is due to the addition of the new 
electron-rich sulphur biomolecule, Table 4.5.  
Aromatic signals appear as very complex multiplets with extensive overlapping of 
signals in the range of δ 7.19 – 8.27 ppm, more so than that seen for the parent complexes 
281-285. However, the integration of these aromatic signals are as expected for each 
complex, detailed in Table 4.5. Limited solubility and extensive overlapping of signals 
unfortunately did not allow for full aromatic characterisation using [
1
H-
1
H] COSY plots and 
[
13
C DEPT 45-
1
H] HETCOR plots at this time.  
N
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Figure 4.26: Illustration of the positions of the corresponding proton signals for N-acetyl-L-
cysteine, as well as the α and β positions.  
 
Additional signals are also observed for the proton signals present in the coordinated 
N-acetyl-L-cysteine or L-glutathione confirming their presence in the Pt (II) complexes. For 
the N-acetyl-L-cysteine Pt (II) bio-adducts 440-441 a singlet resonance is observed 
integrating for three protons in the range of δ 1.92-1.93 ppm. These are characteristic for the 
amide methyl group, indicated in red in Figure 4.26. Two 1H multiplet signals are also 
observed in the range δ 2.90-3.41 ppm which represents the β-CH2 group indicated in red in 
Figure 4.26. Finally a multiplet was also observed in the range δ 4.10-4.32 ppm and 
integrated for 1H, which corresponds to the α-CH group also indicated in red in Figure 4.26. 
The N-H resonances for these ligands are obscured by the aromatic signals present in 
the spectra of both Pt (II) bio-adducts 440-441. The signals integrate for ten protons in total, 
which corresponds with the expected signals. The L-glutathione Pt (II) bio-adducts 442-443 
also gave multiple signals corresponding to the proton signals on the biomolecule ligand. 
Unfortunately due to extensive overlapping and very broad signals obtained individual 
assignment is currently not possible for these complexes.  
The 
31
P{
1
H} NMR data obtained for all the Pt (II) bio-adducts 440-443 gave a single 
phosphorus resonance shifted downfield in comparison to the parent Pt (II) cyclometallates 
281 and 284, Table 4.7. The signal range of δ 31.1-32.2 ppm is similar to that observed for 
the iminophosphine phosphorus signal obtained for the PPh3 substituted Pt (II) complexes 
371-375 which gave a range of δ 33.3-33.4 ppm. This signal represents a downfield shift of 
circa δ 6 ppm in comparison with the parent Pt (II) complexes which had a phosphine signal 
at circa δ 25 ppm, Table 4.7. 
 
N
Pt
PPh2
S OH
HN
CH3
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MeO
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Pt (II) parent 
complex 
δ 31P{1H} 
ppm 
Pt (II)  
Bio-adducts 
δ 31P{1H} 
ppm 
Δδ 
ppm  
3-H 281 25.3 (s) 
1
JPt-P = 2083 Hz 
440 31.4 (s) 
1
JPt-P = 2184 Hz 
6.1 
2,3-(OMe)2 284 25.2 (s) 
1
JPt-P = 2102 Hz 
441 31.1 (s) 
1
JPt-P = 2195 Hz 
5.9 
3-H 281 25.3 (s) 
1
JPt-P = 2083 Hz 
442 31.4 (s) 
1
JPt-P = 2188 Hz 
6.1 
2,3-(OMe)2 284 25.2 (s) 
1
JPt-P = 2102 Hz 
443 32.2 (s) 
1
JPt-P = 2198 Hz 
7.0 
 
Table 4.7: Comparison of the 
31
P{
1
H} signals between the parent Pt (II) complexes 281 and 
284 with the Pt (II) bio-adducts 440-443. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27: A comparison of the 
31
P{
1
H} spectra for the parent cyclometallated complexes 
281 an 284 (left) and Pt (II) bio-adducts 440-443 (right). 
Evidence for the Pt-P bond was again provided by the presence of 
195
Pt satellites 
generated as a result of 
1
JP-Pt coupling Figure 4.27. The coupling constants for all the Pt (II) 
bio-adducts 440-443 were found to be circa 100 Hz higher than the parent Pt (II) chloro 
complexes 281-284, again as a direct consequence of the decreased electrophilicity of the 
metal centre due to the presence of the  electron rich sulphur biomolecule. This would 
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identify that the sulphur moiety, even in a cis geometry, influences the bond strength of all 
the platinum-ligand group interactions. 
 
4.7 In-Vitro Cancer Cell Testing with Pt (II) Cyclometallates: 
 
4.7.1 Background on the cell culture used: 
 
Due to their solubility, stability and good yield, the Pt (II) cyclometallated complexes 
281 and 284 were selected for in-vitro cancer cell testing against squamous human 
esophageal cancer cells (OE21), Figure 4.28. Cancers of the esophagogastric region consist 
of highly malignant tumours with five-year survival rates of less than 16% and many research 
groups have shown that 88% of esophagogastric cancer patients who have received 
successful treatment are susceptible to the dormant cancer re-emerging as an aggressive drug-
resistant metastases.
69
  
 
 
 
 
 
 
Figure 4.28: The two Pt (II) cyclometallated iminophosphine complexes tested on human 
esophageal cancer cells, 281 and 284. 
Successful chemotherapeutic regimes must therefore effectively induce Programmed 
Cell Death (PCD) in cancer cells to overcome drug resistance and recurrence. Until recently 
apoptosis (Type I PCD) was regarded as the central mediator of PCD in response to 
chemotherapeutic agents and is generally characterised by loss of the nuclear membrane, 
fragmentation of the chromatin and cell shrinkage.
70
  
However, other cell death programs have been identified more recently with both 
platinum based anti-cancer drugs and non-platinum based anti-cancer drugs.
43,70
 Type II 
Programmed Cell Death (PCD) is characterised by the formation of vesicles in the cytoplasm 
of the cell and results in loss of the cytoplasmic structure and pyknosis of nuclear material 
within an intact nuclear membrane i.e. the nucleus is the only remnant of the dead cell.
71
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Evidence suggests that Type II PCD is a consequence of excessive autophagy and a 
number of studies have reported autophagic cell death in cultured mammalian cells. 
Autophagy is a cell’s survival response to growth limiting conditions in which non-vital 
cellular components are sequestered, degraded and recycled to ensure the cell survives. 
Although autophagy can help cancer cells survive in response to growth-limiting conditions, 
the induction of excessive autophagy and Type II PCD may also be a major cell death 
mechanism that takes over when apoptosis is unavailable.
72,73
  
Previous work by McKenna et al in the Cork Cancer Research Centre has 
concentrated on cell death programs initiated in esophageal cancer cells in response to the 
chemotherapeutic agents 5-fluorouracil (5-FU) and cisplatin. They have recently reported that 
treated cells which do not undergo apoptosis instead opt for cell death via autophagy. 
However, it has been shown that this can also cause some cell populations to recover when 
the cytotoxic drugs are withdrawn.
70
  
As the more drug sensitive cell line, it was found that OE21 induced a predominantly 
apoptotic cell death morphology (Type I PCD) in response to 5-FU and cisplatin, with low 
levels of non-apoptotic cell death morphology found (Type II PCD). Interestingly, the more 
drug resistant cell lines (OE19 and KYSE450) instead displayed predominantly non-apoptotic 
morphology, or Type II PCD. The OE21 cells displayed 31 % apoptotic cell death (Type I 
PCD) and 3 % non-apoptotic cell death (Type II PCD) in response to cisplatin at a 
concentration of 40 µM, whereas the OE19 cell line showed only 0.5 % apoptosis (Type I 
PCD)  and 38 % non-apoptotic cell death (Type II PCD) with cisplatin.
70
  
Based on this work by McKenna and co-workers, the OE21 cell line was chosen as an 
ideal candidate to compare the established biological activity of cisplatin with the potential 
biological activity of the cyclometallated Pt (II) complexes 281 and 284. Propidium iodide 
(PI) uptake and morphological analysis were used to compare the response of human 
oesophageal cancer cells (OE21) to a 24 hour treatment with cisplatin, the conventional 
chemotherapeutic, and the two novel Pt (II) cyclometallates 281 and 284. Each compound 
was made up in a solution of dimethylsulfoxide prior to treatment, as the complexes 281 and 
284 were insoluble in water. 
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4.7.2 Propidium iodide (PI) uptake and flow cytometry: 
 
Propidium iodide (PI) is used as a DNA stain for flow cytometry, to evaluate cell 
viability or DNA content in cell cycle analysis,
 
and microscopy to visualise the nucleus and 
other DNA containing organelles. It can also be used to differentiate necrotic, apoptotic and 
normal cells. It is only taken up and bound by non-viable cells or cells that have been 
compromised i.e. cells that are undergoing or have undergone Type I or Type II PCD.  
Figure 4.29 shows Propidium Iodide (PI) uptake in human oesophageal cancer cells 
(OE21) following 24 hours treatment with cisplatin, the 3-H complex 281 or the 2,3-(OMe)2 
complex 284 in concentrations of 5 µM to 30 µM as determined by Flow Cytometric 
analysis. The scatter plots show the size and granularity of the cells (in the FSC-A/SSC-A 
panels) and PI uptake is measured on the 488 1A channel. 
 
         Cisplatin             3-H Complex 281  2,3-(OMe)2 Complex 284 
 
 
0 µM 
 
 
 
 
5 µM 
 
 
 
 
10 µM  
 
 
 
Figure 4.29 (Part A): Propidium Iodide (PI) uptake in OE21 cancer cells after 24 hours 
treatment. 
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Cisplatin      3-H Complex 281  2,3-(OMe)2 Complex 284 
 
 
 
15 µM 
 
 
 
 
20 µM  
 
 
 
 
30 µM 
 
 
Figure 4.29 (Part B): Propidium Iodide (PI) uptake in OE21 cancer cells after 24 hours 
treatment. 
Cells debris is excluded from analysis (shown in red), all other cells are analysed to 
determine whether or not they will take up PI. Cells excluding PI (viable) are shown in 
green, while those that take up and bind PI (PI positive, non-viable) are shown in the box 
labelled “P3” and are displayed in blue. A comparison of the percentage of cells taking up PI 
(non-viable, blue population) following treatment is presented in Figure 4.30.  
From the graph in Figure 4.30 it is clearly evident that there is a significant increase 
in the percentage of non-viable cancer cells (cells that take up PI) after 24 hours treatment 
found for the 2,3-(OMe)2 cyclometallate 284, in comparison to similar concentrations of 
cisplatin and the 3-H cyclometallate 281. For example, at a concentration of 20 µM, cisplatin 
caused circa 7 % of cells to undergo cell death (take up PI) while the 2,3-(OMe)2 
cyclometallate 284, at the same concentration, induced cell death in over 50% of the OE21 
cells. The five bars for each test substance represent progressively higher concentrations of 
each compound used in this experiment.  
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Figure 4.30: Graphical representation of the percentage of cells taking up PI (non-viable, 
blue population) for each compound at each concentration after 24 hours. 
Using a linear regression model in conjunction with the percentages and 
concentrations obtained for the treated cell lines, gives the 2,3-(OMe)2 cyclometallate 284 an 
IC50 value of 14.3 µM, the 3-H cyclometallate 281 an IC50 value of 88.1 µM and cisplatin an 
IC50 value of 98.2 µM for the OE21 squamous human esophageal cancer line.  
 
4.7.3 Analysis of morphological features: 
 
 Following treatment with cisplatin, compound 281 or compound 284, the OE21 
cancer cells were removed from the culture and cytospun onto glass slides, fixed in methanol 
and stained with Rapi-Diff. The morphological features of the cells following treatment were 
examined to determine whether Type I PCD or Type II PCD had occurred, Figure 4.31.  
Cells that underwent apoptotic cell death (Type I PCD) were found to have clearly 
fragmented nuclei within an intact cell membrane. as expected, and are highlighted in Figure 
4.31 with red circles. Alternatively, cells that underwent a Type II PCD mechanism 
(through autophagy or otherwise), which is characterised by an intact nuclear membrane and 
N
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N Pt
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H3N Cl
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a severely compromised cytoplasm/cell membrane, are highlighted with green circles in 
Figure 4.31.  
To determine Type I vs Type II PCD, typical markers of apoptotic cell death, such as 
activation of caspase-3 and mitochondrial depolarisation, were assessed. All cell images are 
shown at a 40X magnification. The cisplatin treated cell lines were found to undergo mainly 
Type I PCD across all concentrations, while the novel cyclometallates 281 and 284 induced 
Type I PCD at low concentrations and primarily Type II PCD at higher concentrations.  
 
  Cisplatin           3-H Complex 281          2,3-(OMe)2 Complex 284 
 
 
 
 
 
 
  
0 µM    0 µM    0 µM 
 
 
 
 
 
 
5 µM    5 µM    5 µM 
 
 
 
 
 
 
10 µM     10 µM    10 µM 
Figure 4.31 (Part A): Analysis of the morphological features of the OE21 cancer cells after 
treatment, shown here at 40X magnification. 
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Cisplatin            3-H Complex 281          2,3-(OMe)2 Complex 284 
  
 
 
 
 
 
 
15 µM     15 µM    15 µM 
 
 
 
 
 
 
20 µM     20 µM    20 µM 
 
 
 
 
 
 
30 µM     30 µM    30 µM 
Figure 4.31 (Part B): Analysis of the morphological features of the OE21 cancer cells after 
treatment, shown here at 40X magnification. 
For the 3-H cyclometallate 281 the limited solubility became a dose limiting issue at 
higher concentrations. This was particularly evident for the 20 µM and 30 µM solutions, 
where the growth of long yellow crystals in the cell culture after 24 hours was observed, 
Figure 4.31. The 2,3-(OMe)2 cyclometallate 284 on the other hand was found to have much 
better solubility and did not form crystals. It is therefore possible that the increased biological 
activity of the 2,3-(OMe)2 cyclometallate 284 over the 3-H cyclometallate 281 is also due to 
the significant difference in solubility.  
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For the novel cyclometallates 281 and 284, the presence of controlled apoptosis 
(Type I PCD) as a method for biological activity which is similar to that found for cisplatin, 
gives further evidence for the proposed interaction of these complexes with DNA outlined in 
Chapter 1 and Section 4.3 of this chapter. We propose that these complexes bind to the N7 
position of guanine monofunctionally through hydrolysis of the chloride ligand within the 
cell, as well as intercalate between the base pairs of DNA to induce cell apoptosis. However, 
these complexes also induce significantly greater Type II PCD in comparison to cisplatin in 
the OE21 cell line, implying further biological targets and mechanisms for these complexes.  
If the Type II PCD is primarily caused by autophagy (rather than necrosis), this 
would imply that these complexes are inducing cell death by targeting cytoplasmic structures, 
forcing the cell to undergo extensive autophagy. However, further in-vitro studies as well as 
studies involving binding to nucleotide bases are required to confirm the biological 
mechanisms and potential cytoplasmic targets for these complexes.  
 
4.8 Photophysical Studies of the Platinum Complexes and their Ligands: 
 
4.8.1 UV-visible spectroscopy: 
 
  UV-visible (and subsequently luminescence) spectroscopy was performed on the best 
yielding platinum complexes and ligand, reported in Chapter 2 and 3, which consisted of the 
3-H 261 ligand and the platinum complexes derived from it to form a “family”, Figure 4.32. 
Each compound was tested while in a solution of chloroform which was diluted to a 
concentration of 10
-5
 M before being measured using a Carey 50 Scan, UV-visible 
Spectrophotometer at ambient temperature.  
 
 
 
 
 
 
 
Figure 4.32: The HL
1
 ligand 264 and the platinum complexes 281, 371 and 381 derived from 
it making up the “family” of compounds tested for photophysical properties. 
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Figure 4.33: UV-vis spectroscopy of the 3-H HL
1
 ligand 261 and the derived platinum 
complex family 281, 371 and 381. 
 
The free HL
1
 ligand displayed a shifted, weaker band at 320 nm. All the platinum 
complexes on the other hand gave a weak shoulder band at circa 450 nm, as well as a modest 
peak at circa 350 nm. The strong peaks observed for the Pt (II) 281, Pt (II) PPh3 371 and Pt 
(IV) 381 complexes between 320 and 350 nm are assigned to metal perturbed ligand-centred 
transitions (π      π*) and the bands near them, observed between 370 and 380 nm, are 
attributed to metal-ligand charge transfer (MLCT) (5d(Pt)       π* (HL1)) transitions as 
reported previously by Fuertes et al and others. Finally, all the high energy intense absorption 
bands found below 300 nm - some of which were observed to be quite strong for the platinum 
complexes, Figure 4.33 - are attributed to excitations from the singlet ground state to singlet 
excited states of ligand centred transitions (π     π*).74–76  
The maximum absorption wavelength (λmax) common to all the compounds tested was 
therefore determined to be 270 nm, which was used as the excitation wavelength for the 
luminescence studies outlined in Section 4.8.2. 
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There were no visible bands found higher than 350 nm for the HL
1
 ligand 261. 
However, the platinum complexes 281, 371 and 381 were found to have absorptions in the 
lower energy, higher wavelength region above 350 nm. Further studies on the remaining 
platinum iminophosphine and phosphinoamide complexes, as well as their ligands, is 
required to propose further transitions and functionality.  
 
4.8.2 Luminescence studies on platinum complexes and mixed donor ligands: 
 
 None of the complexes or ligands tested were found to be photoluminescent in the 
solid state, despite extensive recent reports of such activity by other research groups.
74,77,67
 
This is proposed to be due to non-radiative processes concerning low-lying d-d excited states 
and fast decay rates.
74
 Therefore, solutions of each compound were made up using 
chloroform to concentrations of 10
-5 
M and excited at a wavelength of 270 nm as per the 
maximum absorption wavelength (λmax) obtained from the UV-vis absorption spectra in 
Section 4.8.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.34: Emission spectra for the HL
1
 ligand 261 and Pt (II) complexes 281 and 371 
along with the Pt (IV) complex 381. 
 
Interestingly, the free ligand HL
1
 261 was found to have the highest intensity 
emission spectra of all the compounds tested at this time. The strongest band was found to 
occur in the blue region at 320 nm and represented a 6-fold increase over similar bands found 
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for the platinum complexes, Figure 4.34. An intense band was also found at 460 nm for the 
ligand and all the compounds displayed a band in the low energy region of 580 nm.  
Also found for the ligand were bands in the very low energy (red) region of 670 nm, 
700 nm and 850 nm. The ligand is proposed to undergo an Excited State Intramolecular 
Proton Transfer (ESIPT) process in the chloroform solution similar to previous reports by 
other research groups, Figure 4.35.
62
 
 
 
 
 
 
 
 
 
Figure 4.35: The proposed Excited State Intramolecular Proton Transfer (ESIPT) for the 
HL
1
 ligand which causes the bands found in the red region of the luminescence spectra. 
 
Despite having a lower emission intensity in comparison to the free ligand HL
1
 261, 
the Pt (II) cyclometallate 281, cationic Pt (II) PPh3 substituted complex 371 and the Pt (IV) 
cyclometallate 381 were all found to have emission intensities greater than or equal to that 
reported by other research groups for similar tridentate platinum complexes, Figure 4.36.
74,77
 
It is proposed that the rigid square planar structures reported here, and confirmed by X-ray 
crystallography in Chapter 2, favour increased luminescent emission over less rigid 
structures discussed in Chapter 1 and Section 4.4.1 of this chapter. 
Interestingly, in addition to the high energy bands observed for all the compounds 
between 300 nm and 500 nm, low energy bands were also found at 580 nm and circa 650 nm 
for all the platinum complexes tested, as well as the HL
1
 ligand. These low energy emissions 
(circa 700 nm) are frequently encountered for other platinum complexes, primarily Pt (II), 
and are usually attributed to excimers or aggregates.
74
  
Excimers are formed from Pt−Pt bimetallic interactions and interligand π−π 
interactions during the formation of excimer structures. While the Pt−Pt interactions are 
critical for excimer formation, the interligand π−π interactions also play a significant role in 
determining the optimal excimer geometry and the magnitude of the phosphorescence energy 
lowering in going from the monomer to the aggregated dimer. There have been frequent 
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reports by various research groups of planar platinum complexes forming dimers through the 
axial ligands of the metal centre and this is tentatively proposed to be occurring here also.
74,78
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36: The emission spectra obtained, using a luminescence spectrophotometer, for the 
3-H Pt (II) complexes 281 and 371, as well as the Pt (II) complex 381 
 
 Further work involving the remaining ligands and platinum complexes reported in 
Chapter 2 and 3 is required before any further proposals and structure activity relationships 
can be established. From the work to date it can be seen that the emission type and intensity 
of the free ligand HL
1
 261 differs significantly in comparison to the platinum complexes 281, 
371 and 381. 
 
4.9 Chapter 4 Summary and Conclusions: 
 
The synthesis of the Pt (II) bio-adducts was successfully achieved using a 
combination of a similar procedure that was used previously by our research group and the 
method that was employed to achieve successful substitution of the Pt (II) cyclometallates in 
Chapter 3, with triphenylphosphine (PPh3).  
Each bio-adduct synthesised from the Pt (II) cyclometallates 281 and 284 and was 
fully characterised by IR, 
1
H NMR, 
31
P{
1
H} NMR and elemental analysis, which together 
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confirmed the structure of the N-acetyl-L-cysteine and L-glutathione Pt (II) bio-adducts. 
Interestingly both sets of bio-adducts were found to be water soluble, but more so in the case 
of the L-glutathione platinum complexes. Also, all the Pt (II) bio-adducts were found to 
display photophysical properties and reacted to both light and air over a number of days to 
form unidentifiable decomposition products.  
The presence of solvent of crystallisation was also noted in the 
1
H NMR spectra of the 
bio-adduct complexes (chloroform) and was therefore included for successful assignment of 
the elemental analysis. This was also noted previously by our research group and others 
where most of the analogous iodo Pt (II) complexes previously reported also contained 
solvent of crystallisation.
79,80,36,68,81
  
The 3-H Pt (II) cyclometallated complex 281 and the 2,3-(OMe)2 cyclometallated 
complex 284 were chosen as the best candidates for biological testing due to their high yield, 
obtained during their synthesis reported in Chapter 2, which allowed for further purification 
techniques such as re-crystallisation. It was necessary to have highly pure samples of both 
complexes to ensure only the platinum complex was responsible for any observed biological 
activity. Also, both complexes were found to have the best solubility in a wide variety of 
solvents needed to conduct biological studies.  
 In-vitro testing was conducted using the aggressive OE21 esophageal cancer cell line. 
The cancer cell line was treated for 24 hours with the 3-H Pt (II) cyclometallated complex 
281, the 2,3-(OMe)2 cyclometallated complex 284 and the well established platinum anti-
cancer therapeutic; cisplatin, as a comparison.   
 Interestingly, both novel Pt (II) cyclometallates were found to have extensive 
biological activity towards the OE21 esophageal cancer cell line despite having only one 
ligand to hydrolysis and bind to DNA. Controlled cell death in the form of apoptosis was 
observed for both complexes, leading to a proposed mechanism of action involving a 
combination of monofunctional DNA binding coupled with intercalation of the planar aryl 
ring structure between the nucleotide bases of DNA.   
 In comparison to cisplatin on the same cell line, the 3-H Pt (II) cyclometallated 
complex 281 was found to have a similar biological activity profile over the 24 hour period. 
However, the 2,3-(OMe)2 cyclometallated complex 284 was found to have a 7-fold increase 
in activity over the well established anti-cancer drug cisplatin on this cell line which can be 
seen as a very positive result for Pt (II) cyclometallated anti-cancer complexes. 
 Both the platinum complexes and the free ligand for the 3-H 261 family of 
compounds were also tested for UV-vis absorption and luminescent emission. The Pt (II) 
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complexes 281 and 371, as well as the Pt (IV) complex 381 were all found to have emission 
in the blue region.  
However, the free ligand 261 was found to have a 5-fold higher emission intensity 
over the platinum complexes with strong bands found in the blue and green region, but also 
having bands in the low energy red region. These initial tests have now opened the door to 
future studies into the analysis of potential luminescence of all the ligands and platinum 
complexes reported in Chapter 2 and 3 to establish structure activity relationships.  
 
4.10 Chapter 4 Experimental: 
 
4.10.1 Background: 
 
All reaction solvents were distilled prior to use, unless purchased as analytical grade 
(all from Sigma Aldrich Chemical Co. Ltd.). Toluene and thf were distilled directly before 
use from sodium-benzophenone. Methanol was distilled over magnesium/iodine according to 
Perrin et al
82 
and hexane was distilled over phosphorus pentoxide.  
The following reagents were used as supplied; N-acetyl-L-cysteine (Sigma-Aldrich 
Chemical Co. Ltd), L-glutathione (Sigma-Aldrich Chemical Co. Ltd), cisplatin (Sigma-
Aldrich Chemical Co. Ltd), propidium iodide (Sigma-Aldrich Chemical Co. Ltd), rapi-diff 
(Braidwood Laboratories). Elemental analyses (Perkin-Elmer 2400 CHN elemental analyser) 
were performed by the microanalytical laboratory, University College Cork.  
The 
1
H and 
31
P{
1
H} NMR spectra were recorded on a Bruker Advance 300 MHz, 400 
MHz or 600 MHz NMR spectrometer (where specified). Chemical shifts (δ) are expressed in 
parts per million (ppm) and referenced to external tetramethylsilane (δ0) for 1H and 85% 
phosphoric acid (δ0) for 31P{1H} NMR using the high frequency positive convention.  
Infrared spectra were recorded as KBr disks on a Perkin-Elmer Paragon 1000 FT 
spectrometer for the Pt (II) bio-adducts. Relative intensities are designated (s), strong; (m), 
medium; (w), weak; (b), broad.  
The OE21 esophageal cancer cell line was obtained from the European Collection of 
Cell Cultures (96062201). They were maintained in RPMI 1640 medium and supplemented 
with 1% penicillin/streptomycin, 10% (v/v) fetal calf serum (Gibco, 21875-034, 15070-063, 
10270) at 37
o
C, 5% CO2. 
The UV-visible absorption spectra were recorded using optical grade quartz cuvettes 
on a Carey 50 scan UV-visible spectrophotometer and the emission spectra were recorded on 
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a LS 50 B Perkin Elmer luminescence spectrophotometer using dilute chloroform solutions of 
the compounds.  
 
4.10.2 Synthesis of the Pt (II) bio-adducts [Pt
II
( 3–PNC–L1/4)N-acetyl-L-cys/L Glu]Cl 
440-443: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Two equivalents of the biomolecule (N-acetyl-L-cysteine or L-glutathione) in a 
methanolic solution was added slowly over one hour to a stirred solution of [Pt
II
(η3–PNC–
L
1/4
)Cl] 281 or 284 in a 1:1 chloroform/methanol (10 ml:10 ml) solution. The solution was 
then stirred at ambient temperature for 24 hours in the case of N-acetyl-L-cysteine and 48 
hours in the case of L-glutathione.  
After 24 hours (N-acetyl-L-cysteine) or 48 hours (L-glutathione) the solution became 
a pale yellow colour which was then reduced to dryness in vacuo. It was then taken up in 
dichloromethane (where it again turned dark red) and washed once with a small portion of 
distilled water to remove any remaining N-acetyl-L-cysteine or L-glutathione and HCl 
formed during the reaction.  
N
Pt
Ph2
P Cl
R
N
Pt
Ph2
P S
R
MeOH: CHCl3
R = 3-H 281
= 2,3(OMe)2 284
N-acetyl-L-cysteine
R = 3-H 440
= 2,3-(OMe)2 441
- HCl
OH
HN
CH3
O
O
N
Pt
Ph2
P Cl
R
N
Pt
PPh2
S
R
MeOH: CHCl3
R = 3-H 281
= 2,3(OMe)2 284
L-glutathione
R = 3-H 442
= 2,3-(OMe)2 443
- HCl
NH
O
HN
O
NH2
HOOC
HOOC
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The organic layer was dried over MgSO4, reduced to dryness in vacuo again and the 
resulting dark red solution was crystallised from distilled methanol layered with hexane to 
form the neutral Pt (II) bio-adducts 440-441. 
 
 
440: [Pt
II
(η3–PNC–L1)Cl] (0.020 g, 0.03 mmol) 281 and 
N-acetyl-L-cysteine (0.011 g, 0.07 mmol) gave [Pt( 3–
PNC-L
1
)N-acetyl-L-cys] 440 as a dark red powder.  
Yield: 0.019 g (78 %) 
Found (required for C30H27N2O3PPtS.0.3CHCl3): C, 48.10 
(48.04); H, 3.91 (3.63); N, 3.79 (3.70). 
IR vmax (KBr): 3415 (b), 2923 (w), 1728 (w), 1626 (m), 
1586(m)(C=N), 1529 (w), 1436 (m), 1396 (w), 1240 (m), 1187 (w), 1118 (w), 911 (w), 840 
(w), 745 (m), 719 (w), 692 (s), 571 (m). 
 
1H NMR δ ppm: 9.68 (1 H, s) (3JPt-H = 91 Hz), 7.22-7.98 (18 H, m), 1.92 (3 H, s), 2.90-3.41 
(2 H, m), 4.32 (1 H, s). 
31P NMR δ ppm: 31.4 (s) (1Jp-p = 2184 Hz). 
 
 
441:
 
[Pt
II
(η3–PNC–L4)Cl] (0.020 g, 0.03 mmol) 284 and N-
acetyl-L-cysteine (0.011 g, 0.07 mmol) gave  [Pt( 3–PNC-
L
4
)N-acetyl-L-cys] 441 as a dark red powder.  
Yield: 0.020 g (85 %) 
Found (required for C32H31N4O5PPtS.0.3CHCl3): C, 47.29 
(47.45); H, 4.16 (3.86); N, 3.31 (3.43). 
IR vmax (KBr): 3366 (b), 3056 (w), 2934 (w), 2346 (w), 
1718 (w), 1704 (w), 1634 (s), 1600 (m)(C=N), 1529 (m), 
1477 (m), 1463 (m), 1439 (s), 1426 (w), 1409 (m), 1374 (m), 1331 (m), 1297 (w), 1267, (m), 
1243 (m), 1185 (w), 1098 (s), 1084 (m), 1012 (w), 958 (m), 827 (w), 811 (m), 799 (w), 748 
(m), 701 (m), 664 (m), 584 (m), 524 (s), 512 (s), 499 (m). 
 
1H NMR δ ppm: 9.94 (1 H, s) (3JPt-H = 96 Hz), 7.19-7.96 (16 H, m), 5.30 (CH2Cl2), 3.87 (3 H, 
s), 4.01 (3 H, s), 1.93 (3 H, s), 2.96-3.31 (2 H, m), 4.10 (1 H, s). 
31P NMR δ ppm: 31.1 (s) 
(
1
Jp-p = 2195 Hz). 
 
N
Pt
PPh2
S
OH
HN CH3
O
O
N
Pt
PPh2
S
OH
HN CH3
O
O
MeO
OMe
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442: [Pt
II
(η3–PNC–L1)Cl] (0.020 g, 0.03 mmol) 281 and 
L-glutathione (0.021 g, 0.07 mmol) gave  [Pt( 3–PNC-L1) 
L-Glu] 442 as a dark red powder.  
Yield: 0.021 g (72 %) 
Found (required for C35H35N4O6PPtS): C, 48.20 (48.55); 
H, 4.40 (4.07); N, 6.05 (6.47). 
IR vmax (KBr): 3401 (b), 2922 (w), 1967 (w), 1726 (m), 
1645 (w), 1590 (m)(C=N), 1527 (m), 1435 (m), 1402 (m), 
1239 (m), 1187 (w), 1096 (m), 1027 (s),  912 (m), 865 (w), 762 (m), 619 (m), 567 (m), 526 
(m), 419 (w). 
 
1H NMR δ ppm: 10.19 (1 H, s) (3JPt-H = 84 Hz), 7.37-8.24 (18 H, m), 1.75-187 (2 H, m), 2.05-
2.98 (6 H, m), 4.10-4.16 (2 H, m). 
31P NMR δ ppm: 31.4 (s) (1Jp-p = 2188 Hz). 
 
 
443: [Pt
II
(η3–PNC–L4)Cl] (0.020 g, 0.03 mmol) 284 and 
L-glutathione (0.019 g, 0.07 mmol) gave  [Pt( 3–PNC-L4) 
L-Glu] 443 as a dark red powder.  
Yield: 0.022 g (77 %) 
Found (required for C37H39N4O8PPtS): C, 48.10 (48.00); 
H, 4.18 (4.25); N, 6.12 (6.05). 
IR vmax (KBr): 3365 (b), 3056 (w), 2934 (w), 1718 (w), 
1704 (w), 1635 (m), 1602 (w) (C=N), 1529 (s), 1477 (m), 
1463 (s), 1439 (m), 1426 (w), 1374 (w), 1331 (s), 1098 (m), 1084 (w), 1012 (w), 958 (w), 
827 (w), 798 (m), 748 (m), 700 (s), 667 (m), 585 (w), 565 (w), 525 (s), 509 (s), 499 (s). 
 
1H NMR δ ppm: 10.51 (1 H, s) (3JPt-H = 86 Hz), 7.41-8.27 (16 H, m), 3.98 (3 H, s), 4.05 (3 H, 
s), 1.25-2.18 (4 H, s), 2.20-3.58 (4 H, m), 4.63 (2 H, m). 
31P NMR δ ppm: 32.2 (s) (1Jp-p = 
2198 Hz). 
 
 
 
 
 
N
Pt
PPh2
S NH
O
HN
O
NH2
HOOC
HOOC
N
Pt
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S NH
O
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4.10.3 In-vitro Cell Testing on the Pt (II) cyclometallates 281 and 284: 
 
 Cisplatin, compound 281 and 284 were all dissolved up into solutions using 
dimethylsulfoxide prior to treatment. Each solution was then diluted to the desired 
concentrations of 5 µM, 10 µM, 15 µM, 20 µM and 30 µM. The OE21 cell cultures present in 
agar plates were treated with each solution and left to incubate for 24 hours.  
Morphology of the cell treated with cisplatin, complex 281 and 284 were examined by 
light microscopy. Aliquots of vehicle control and drug treated cells were cytospun onto glass 
slides and stained with Rapi-Diff. The extent of apoptotic and non-apoptotic cell death was 
determined by counting the cells in at least three fields of view per slide, with an average of 
circa 100 cells per field. Apoptotic cell death was characterised by the presence of two or 
more of the following morphological features: cell shrinkage, chromatin condensation, DNA 
degradation and fragmentation into “apoptotic bodies”, within an intact membrane.  
Type II programmed cell death was defined as follows: absence of a discernable 
plasma membrane, with a highly vesicular cytoplasm which is often associated with 
extensive loss of cytoplasmic material. The nucleus remains intact, with clear pyknosis 
(condensed regions). 
 
4.10.3 Photophysical studies on the 3-H ligand 261 and platinum complexes 281, 371 
and 381: 
 
Each compound was made up by weighing the samples and dissolving them using 
chloroform to a concentration of 10
-3
 M. Each solution was then subsequently diluted down 
to 10
-5
 M for UV-vis spectroscopy and luminescent testing.  Each solution was placed in a 
quartz cuvette, which was cleaned with chloroform between each sample test, and placed in 
the machine. For the luminescence spectrophotometer the samples were excited at a 
wavelength of 270 nm as this was the maximum absorption wavelength identified for all the 
compounds from the UV-visible spectra.  
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5.1 Final Conclusions and Summary: 
 
5.1.1 Aims of the Project: 
 
 This work began with the aim of producing a series of novel chloro analogues of the 
iodo platinum complexes reported previously by our research group, 501, Figure 5.1. 
Previously, the ONíD group reported some success for chloro based PNO type platinum (II) 
complexes for example Figure 5.1, but all previous attempts to synthesis and isolate chloro 
based platinum cyclometallates were unsuccessful.  
 
 
 
 
 
 
 
Figure 5.1: Iodo-PNC type platinum (II) cyclometallates 501 and chloro-PNO type platinum 
(II) cyclometallates 502 previously reported by our research group.   
 
 From the literature reviewed in Chapter 1, chloro based platinum complexes have 
been identified as having greater potential for anti-cancer activity over complexes with iodide 
or bromide as the leaving group. This is due to the natural concentration of chloride ions in 
the blood and within cells. Also, cisplatin’s established mode of action involves hydrolysis of 
the chloride ligands within the cell in order for it to bind to DNA and induce cell apoptosis.
1
 
Therefore, the presence of the Pt-chloride bond is seen as very important to the biological 
activity of platinum complexes. 
Also found in the literature was the interesting feature of double-stranded DNA in that 
flat planar molecules (usually containing aromatic groups) that are hydrophobic, can insert 
themselves between the base pairs of DNA through a process known as intercalation. This 
acceptance of an intercalating molecule increases the length of the DNA helix, which affects 
the template function of DNA in terms of replicating.
2,3
  
 Therefore, aside from simply binding a metal centre to a donor atom on a DNA 
strand, certain metal complexes that contain flat aromatic residues can also bind to DNA by 
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intercalation. Therefore a further aim of this work was to synthesis novel planar chloro 
platinum complexes capable of binding monofunctionally with DNA, as well as having 
intercalating properties due to the planar structure of aromatic rings. Forming tridentate 
complexes was therefore seen as desirable to increase stability through the chelate effect as 
well as ensuring the complex remains planar in order to achieve intercalation.  
 
5.1.2 Synthesis of Chloro Platinum (II) Cyclometallated Complexes: 
 
  Initial work was centred on the synthesis of the iminophosphine ligands HL
1-4
 261-
264 which required that the 2-diphenylphosphinoaniline (2-DPPA) starting material be 
synthesised. To store the 2-diphenylphosphinoaniline for long periods of time, it was stored 
in a freezer which prevented the previously reported photophysical interactions as well as 
ensuring a fresh batch was readily available at all times.
4
  
 Coordination studies with the iminophosphine ligands were initially undertaken with 
PtCl2 as a starting material as this was used previously within our research group to 
successfully produce the chloro platinum (II) PNO complexes. However, the reactions of 
PtCl2 with the iminophosphine ligands gave insoluble bidentate platinum (II) complexes 271-
273 which were characterised by IR spectroscopy and elemental analysis. All attempts to 
further react these insoluble bidentate complexes with external bases such as NaOAc, in order 
to achieve cyclometallation, proved unsuccessful.  
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Synthesis of the novel platinum (II) tridentate iminophosphine complexes 281-
284 via direct thermal and solvent assisted cyclometallation.   
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However, changing the starting material from PtCl2 to PtCl2(cod) and reacting it with 
the appropriate iminophosphine ligand HL
1-4
 261-264 in dichloromethane afforded a series of 
soluble products. Evidence of a shifted imine signal in the 
1
H NMR spectra complete with 
195
Pt satellites gave the first evidence of successful coordination.  
Subsequent “fine-tuning” of the reaction conditions including; changing the solvent 
from dichloromethane to chloroform to help thermal cyclometallation, adding the ligand 
slowly over a long period of time to allow time for coordination and dilution of the solution 
to prevent dimerisation of the bidentate intermediates, gave good reproducible yields of circa 
60% for most of the complexes, Figure 5.2. Also formed from the reaction of PtCl2(cod) and 
the HL
4
 ligand 264 was the previously reported PNO tridentate complex 285 as a minor 
product due to the interesting reactivity of the platinum metal centre towards on of the 
methoxy groups. 
Once the series of platinum (II) iminophosphine cyclometallates were isolated and 
fully characterised 281-284, attention was then directed to the phosphinoamide ligands 265-
267 and their potential complexes, Figure 5.3. The ligands were synthesised from a novel 
method in good yields of circa 60% and for the first time, extensive NMR analysis revealed 
two isomers were present in solution. The phosphinoamide ligands were found to tautomerise 
in solution to form two iminol isomers with the E-isomer being the major of the two.  
   
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5.3: Synthesis of the novel platinum (II) tridentate phosphinoiminol complexes 286-
288 via direct thermal and solvent assisted cyclometallation.   
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 Initial attempts to produce an identifiable product from the reaction of the 
phosphinoamide ligands with PtCl2(cod) proved to be very difficult with solubility issues, 
multiple products formed and decomposition identified by NMR spectroscopy. However, by 
using a bulky external base called Dabco resulted in the removal of the HCl formed during 
the cyclometallation which reduced decomposition of the ligand prior to coordination to the 
PtCl2(cod).  
Novel platinum (II) phosphinoiminol complexes 286-288 where therefore 
successfully isolated and characterised by NMR and IR spectroscopy as well as elemental 
analysis. Due to the tautomerism of the ligands in solution, the yields of these complexes 
were found to be very low, Figure 5.3. As well as cyclometallated complexes, a novel 
tridentate PNO phosphinoiminol complex 289 was also identified from the reaction of 
PtCl2(cod) with the HL
6
 ligand 266. This is formed in a similar way to the iminophosphine 
PNO complex discussed earlier, however, it was found to be too unstable for full 
characterisation and isolation.  
As well as the PNO complex 289, the cyclometallates formed, 286-288, were also 
found to be significantly less stable than their iminophosphine counterparts 281-284. 
Therefore, these complexes were deemed suitable for further studies and applications, in 
particular for oxidation and substitution reactions where all initial reactions with them proved 
to be unsuccessful.  
 
5.1.3 Substitution of the Platinum (II) Complexes 281-284 [Pt(η3-PNC-L1-4)Cl]: 
 
 One of the most important influences on the biological function required of platinum 
anticancer compounds is the lability of the leaving group(s), in this case the Pt-Cl bond. To 
investigate this for the platinum (II) cyclometallates 281-284, substitution of the chloride 
ligand with a bulky phosphine (triphenylphosphine - PPh3) was attempted. In Chapter 2 it 
was found that solvents can stabilise chloride ions, which can assist in the cyclometallation 
reactions.  
Here similar solvent systems are used to stabilise the chloride ion in solution, which 
allows for novel one-step phosphine substitution of chloro iminophosphine complexes. The 
iminophosphine platinum (II) complexes 281-284 were reacted with triphenylphosphine to  
successfully form the novel cationic platinum (II) substituted PPh3 tridentate PNC and PNO 
complexes which were isolated and characterised by IR and NMR spectroscopy along with 
elemental analysis, Figure 5.4.  
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Figure 5.4: Direct substitution of the platinum (II) iminophosphine complexes, 281-285, with 
triphenylphosphine (PPh3). 
Achieving one-step phosphine substitution in short reaction times is a significant 
improvement on previous work by our research group and others. These relied on halide 
scavengers to initially remove the chloride ligand prior to the addition of the new phosphine 
ligand.
5
    
 
5.1.4 Oxidation of the Platinum (II) Complexes 281-284 [Pt(η3-PNC-L1-4)Cl]: 
 
The ongoing success of the platinum (IV) complex Satraplatin, as well as the limited 
past success of Tetraplatin, has increased research interest into novel platinum (IV) 
complexes. As an oral based drug, Satraplatin has convenient dosing and so far has not been 
associated with the same level of toxicity as the currently approved platinum based anti-
cancer compounds. At the time of writing, it remains in clinical trials in the United States but 
given the lack of an overall survival benefit, satraplatin has not received approval by any 
regulatory authority.
6
 
After the success of the substitution reactions, Section 5.1.3, oxidations were 
attempted on the platinum (II) cyclometallates 281-284 in the hope of forming stable chloro 
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platinum (IV) complexes for biological applications. However, all initial attempts of 
oxidising the platinum (II) cyclometallates 281-284 using methods previously found 
successful for our research group and others, proved to be unsuccessful. Interestingly, even at 
excessive concentrations of hydrogen peroxide, the platinum (II) iminophosphine complexes 
281-284 were returned from the reaction quantitatively with no signs of decomposition.  
After an extensive literature search, a select number of papers identified the use of N-
chlorosuccinimide (NCS) as a successful reagent for oxidising platinum complexes via the 
addition of chloride ligands at the axial positions. In these papers, the researchers reported 
fast reaction time, good yields and stable platinum (IV) complexes formed from NCS.
7
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Successful oxidative addition of two equivalents of chlorine to the 
iminophosphine platinum (II) complexes, 281-284 using N- chlorosuccinimide to form the 
novel platinum (IV) complexes 381-384. 
 
These methods and reagents were successfully applied to the platinum (II) 
cyclometallated complexes 281-284, but the novel series of platinum (IV) complexes formed, 
381-384, proved to be significantly less stable than their parent platinum (II) analogues. 
Sensitivity to acids, bases and light were noted in varying amounts while trying to remove the 
excess N-chlorosuccinimide from the reaction solution. Nonetheless, low yields of the 
octahedral platinum (IV) complexes were isolated and characterised by IR and NMR 
spectroscopy as well as elemental analysis, Figure 5.5.  
Oxidation reactions were also attempted with the platinum (II) phosphinoiminol 
complexes 286-288, however the products formed were insoluble in all common solvents and 
evidence of decomposition was noted in the NMR spectra. 
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5.1.5 Platinum Bio-adducts with N-acetyl-L-cysteine and L-glutathione: 
 
 From the literature reviewed it was identified that sulphur based biomolecules can 
have both a detrimental and beneficial effect on the biological activity of platinum 
complexes, so reactions involving biomolecules was a necessary step in the evaluation of the 
potential biological activity of these novel complexes.  
 It was determined that the most stable complexes formed in this work, which also had 
the highest yields of all the platinum (II) complexes reported, were the unsubstituted 3-H 
platinum (II) iminophosphine 281 and the 2,3-(OMe)2 platinum (II) iminophosphine 284 
complexes. It was therefore decided that these two complexes would be ideal candidates for 
extensive biological testing. The platinum (II) cyclometallates 281 and 284 were reacted with 
with N-acetyl-L-cysteine and L-glutathione to form novel platinum bio-adduct complexes, 
Figure 5.6. 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Formation of the platinum (II) iminophosphine biomolecule adducts with 
N-acetyl-L-cysteine and L-glutathione to form 440-441. 
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Both platinum (II) cyclometallates tested were found to react quite readily with N-
acetyl-L-cysteine and formed slightly water soluble platinum (II) bio-adducts. More 
interestingly however was that they also reacted very readily with the large sulphur based 
biomolecule; L-glutathione, which produced water soluble platinum (II) bio-adduct 
complexes with greater water solubility in comparison to the N-acetyl-L-cysteine bio-adduct 
complexes, Figure 5.6. 
All the bio-adducts were isolated in good yields and characterised by IR and NMR 
spectroscopy as well as elemental analysis, but further investigation into the reactivity of 
these platinum complexes with other biomolecules is required to successfully established a 
full biological reactivity profile.  
 
5.1.6 In-vitro cancer cell testing: 
 
 To fully investigate the biological activity of the platinum complexes, in-vitro cancer 
cell testing was required. Through Dr. Sharon McKenna, the Cork Cancer Research Centre 
was contacted to facilitate the testing; which is an independent foundation whose research 
activity is based in the Leslie C. Quick Jnr. Laboratory in the BioSciences Institute, UCC.  
 After extensive discussions the best candidate platinum complexes were chosen to be 
those which gave the best yield in order to provide a sufficient supply for the tests as well as 
having the best solubility in a medium that could be utilised with cells. The platinum (II) 
complexes 281 and 284 were chosen as having the greatest potential to display biological 
activity from the 24 novel complexes reported in this project.   
Under the supervision of professional cancer cell biologists and biochemists, the 
solutions of each complex, as well as cisplatin, were made up in dimethylsulfoxide and each 
cell line was treated for 24 hours with one of the three platinum (II) complexes. It is also 
worth noting that the cell cultures were kept away from light during the incubation period to 
prevent any possible photophysical effects for this test.  
 Interestingly the 2,3-(OMe)2 platinum (II) cyclometallated complex 284 was found to 
be significantly more active than both the unsubstituted platinum (II) cyclometallate 281 and 
the well established anticancer therapeutic, cisplatin. These results are a testament to the 
ongoing research into the biological potential of cyclometallated platinum complexes where 
both Type I and Type II programmed cell death (PCD) was observed, Figure 5.7.  
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Figure 5.7: OE21 Cancer cells after treatment with the novel platinum (II) complex 284 over 
24 hours, which induced Type I PCD (red circle) and Type II PCD (green circle). 
 
5.1.7 Photophysical Studies: 
 
 Throughout this project, photophysical effects were observed for nearly every type of 
complex and ligand reported. When left in direct sunlight, all the ligands were found to have 
undergone oxidation processes with a signal appearing at circa δ 30 ppm in the 31P{1H} NMR 
spectra corresponding to the oxidised phosphine group. This was particularly evident in 
chlorinated solutions and usually took a number of days where the solution would gradually 
turn from yellow to orange. Also, the initial coordination studies attempted with the PtCl2 and 
iminophosphine ligands uncovered some very unusual colour changes with samples left in 
NMR tubes changing to bright pink, red and even green after a number of days. However, 
NMR spectra only identified decomposition produces such as aldehyde peaks.  
 After a literature investigation it was found that a number of rigid, stable tridentate 
platinum (II) complexes with mixed donor ligands have been reported over the past decade 
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with luminescent properties. These types of complexes in particular have found applications 
in OLEDS alongside traditional purely organic molecules.  
 Initial studies on the luminescence properties of the iminophosphine ligands and 
complexes proved to be unsuccessful due low concentrations, solvent choice and issues with 
the luminescent spectrophotometer. After consulting colleagues in the Centre for Research 
into Atmospheric Conditions (CRAC), also based in UCC, a study was undertaken with UV-
visible spectroscopy to identify the ideal solvent, concentration (10
-5
M) and ideal wavelength 
for excitation to investigate any possible luminescence for the compounds in this project.  
 The highest yielding ligand and complexes were chosen for the study i.e. the 3-H 
ligand HL
1
 261 and the platinum complexes derived from it.  Emission spectra were found 
for all tridentate platinum complexes tested 281, 371 and 381, where significant 
luminescence was observed. However, the 3-H ligand 261 was found to have over five times 
greater emission intensity in comparison to the platinum complexes. This work has opened 
the door to the possibilities of using iminophosphine, and possibly phosphinoamide, ligands 
as organic molecules for organic LED applications as well as spurring further investigations 
into luminescence of cyclometallated platinum complexes.  
 
5.2 Future Work: 
 
5.2.1 Novel Synthetic Methods: 
 
 To date all reactions completed have been achieved using solvents, in particular 
chloroform. Initial work in this project for the coordination of PtCl2 to the iminophosphine 
ligands 261-264 in Chapter 2, involved some solid state reactions. Solid state reactions are 
desirable for green chemistry synthetic routes to novel products as it reduces the current 
reliance on solvents which are harmful to the environment and saves money on purchase of 
solvents. 
As identified in Chapter 2, the reaction between PtCl2 and the iminophosphine 
ligands HL
1-4
 initially form platinum (II) bidentate complexes 271-273. These complexes 
then undergo an intramolecular reaction (cyclometallation) which occurs via thermal means. 
Therefore the bidentate complexes were heated as a solid for a number of hours to induce 
cyclometallation with the hope of forming the cyclometallated platinum (II) complexes 281-
284 using a solid state reaction mechanism.  
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 During the course of the reaction, using pH paper and a pH meter, HCl gas was 
identified from the solid, which implied successful cyclometallation since HCl is the 
expected by-product of the cyclometallation reaction. However, despite several attempts, 
only barely detectable amounts of the cyclometallated complexes 281-284 were identified by 
NMR spectroscopy. Unfortunately, thermal decomposition was also found to occur with a 
black solid forming after 2-3 hours, which we propose is metallic platinum.  
 The observation of HCl and some NMR results pointed to some successful 
cyclometallation which gives this method some promise. Further work into fine-tuning of 
these solid state reactions may lead to increased yields, with the added bonus of reducing 
solvent usage for a novel green chemistry route to platinum (II) cyclometallation of 
iminophosphines. Some research groups have already identified solid state thermal 
cyclometallation of platinum complexes, which gives this proposed method even more 
potential.
8,9
 
 The formation of the platinum (IV) complexes via the reaction of the platinum (II) 
cyclometallates with N-chlorosuccinimide, although successful, gave very low yields. One 
possible solution to this would be the use of chlorine gas generated in-situ to oxidise the 
platinum (II) cyclometallates (and also maybe the PNO type complexes) by bubbling the 
halogen through a solution of the platinum (II) complex. This method has been cited by a 
number of research groups as being a primary method for platinum (II) oxidation and a test 
reaction within this project using in-situ generation of chlorine gas also proved to be 
successful, Figure 5.8.
7,10
  
 
 
 
 
 
 
 
 
 
Figure 5.8: A test reaction using this method proved to be successful, possibly providing a 
method to increase the yield of the platinum (IV) complexes allowing for reactivity studies 
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The test method involved the slow addition of dilute hydrochloric acid onto solid N-
chlorosuccinimide, which produced the green chlorine gas in a sealed vessel. This sealed 
vessel was fed through to another vessel where it was bubbled through a solution of the 
platinum (II) cyclometallate 281, which itself was kept under a continuous flow of N2. After 
an hour, the solution turned pale yellow and evidence was found in the NMR spectra for the 
platinum (IV) complex previously reported in Chapter 3, 381. However, other unidentifiable 
products were also found so further work on this method is required.  
 Further work could also be completed on the platinum (II) interactions with sulphur 
based biomolecules, reported in Chapter 4. The reactivity of the rest of the platinum (II) 
complexes reported in this work could be established, which would then give a basis for 
structure activity relationships. Also the reactivity of the platinum (IV) complexes towards 
biomolecules could be investigated further to see if they can be reduced by other 
biomolecules such as L-methionine or if they are active in their Pt (IV) form.  
 
5.2.2 In-vitro cell testing and photophysical studies: 
 
 The success of the 2,3-(OMe)2 platinum (II) cyclometallate towards the OE21 cancer 
cell line gives significant weight to justifying further testing of the platinum complexes 
reported in this work. Also, of particular interest is the potential reactivity of the platinum 
bio-adduct complexes towards cancer cells, in order to investigate whether the complexes are 
still active as bio-adducts or whether the addition of the biomolecule prevents biological 
activity. The water solubility of the platinum bio-adducts may also provide further test 
methods currently unavailable to the platinum (II) and platinum (IV) cyclometallates.  
 Also, other cisplatin sensitive and cisplatin resistant cell lines could be tested in order 
to compare activity profiles and types of cell death induced in cancer cells by these 
complexes. The impact of light on the activity of the complexes undergoing in-vitro testing, 
in particular the platinum (II) bi-adducts, could also be of significant interest in terms of 
potential Photo-Dynamic Therapy (PDT).  
 Finally, in terms of photophysical studies, the remaining “families” of platinum 
complexes and ligands, of which there are 7 in total from this work, could yield extensive 
structure activity relationships for all the complexes. The high intensity emission observed 
for the ligands in particular should be investigated further with all the ligands reported in this 
project, as well as ligands previously reported within our research group which may also have 
high intensity emission spectra.
5
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